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Abstract 
The main aims of this research were to evaluate the use and efficacy of 
analgesics in the management of chronic pain in the community and to investigate 
the role of the pharmacist in optimising health outcomes relating to chronic pain by 
assessing the effect of pharmacist intervention on pain control and activities of life. 
Cluster samples of patients with chronic non-malignant pain living at home were identified 
from 3 medical practices in 2 Scottish Health Board areas, using diagnosis of rheumatoid 
arthritis (RA) and repeat prescription of non-steroidal anti-inflammatory drugs (NSAIDs) 
and other analgesics as selection criteria. Structured interviews determined patients' use of 
prescription and non-prescription therapies for pain relief, attitude to medication and 
perceived side effects. 
Outcomes measured were pain relief, influence of pain on activities using a 
quality of life (QOL) scale and side effects experienced. Pain relief was assessed 
using the McGill Pain Questionnaire (MPQ) and horizontal visual analogue scales 
(VAS). Poor outcomes were defmed as at least one of the following: poor pain 
control (VAS average pain greater than 75), total QOL score greater than 35, signs 
or symptoms of an adverse drug reaction, deliberate therapy change by patient due 
to lack of awareness of rationale of therapy or patient dissatisfaction. Patients with 
poor outcomes were given information or advice, referred to their GP and 
interviewed after 4 to 6 weeks to determine any changes in outcomes. 
A total of 109 patients were identified of whom 96 agreed to participate; 42 
had RA, 22 had osteoarthritis (OA), 25 had both OA and RA and 7 had low back 
pain. Seventy-one patients were prescribed NSAIDs, 15 disease-modifiying agents 
(DMARDs) , 49 combination analgesics and 27 paracetamol. The majority of OA 
patients prescribed NSAIDs had no inflammation. Use of other therapies for pain 
e.g. anticonvulsants, hypnotics and herbal products was significantly higher in RA 
patients. Documentation of biochemical and haematological parameters in GP 
records was very limited. 
Twenty-eight patients had poor outcomes requiring GP referral, but also had 
significantly higher expectations of pain relief, higher pain and QOL scores 
compared to the 68 patients with satisfactory outcomes. Suggestions for changing 
· 
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therapy in 24 of the 28 patients were discussed with the GP, the other 4 requiring 
surgery. Although the phannacist's recommendations were accepted and acted on in 
22 of the 24 patients, 7 were unwilling and 3 were too ill to be re-interviewed during 
the study period. The phannacist's recommendations were implemented in 12 of the 
14 patients who had a follow-up interview. Pain scores and QOL scores improved in 
9 and 8 patients respectively after phannacist intervention. Twenty-four and 38 
patients respectively with satisfactory outcomes required advice to improve 
concordance and to minimise the risk of side effects. Sixty-four patients reported 
side effects, 5 of whom required GP referral. Although there was a need for referral 
advice and information, the small number of patients followed up did not allow 
estimation of the outcome measures' sensitivity to phannacist intervention, thus the 
second aim was not fully achieved. 
Potential pharmacist role(s) within a primary care chronic pain team were 
identified using questionnaires sent to a random selection of GPs, community 
phannacists and physiotherapists. Most phannacists wanted to provide more 
analgesic advice, a rmding supported by most GPs and physiotherapists. This study 
has demonstrated both a need for phannacist input into chronic pain management 
and evidence that such input would be welcomed. 
-v-
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Chapter 1 
Chronic pain 
1.1 Definitions of chronic pain 
Pain is defmed as 'an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in tenns of such damage' 
(Merskey 1986). Chronic pain is defmed as pain that persists for longer than 3 
months which recurs on a regular basis or is ongoing on a daily basis, and can be 
classified into recurrent, malignant or non-malignant pain (O'Hara 1996). 
Recurrent pain is episodic with a predicted end, but can recur frequently after 
pain-free episodes e.g. migraine. Chronic malignant pain is pain which lasts for 
months or years but does have a fmite time span e.g. cancer pain. Chronic non-
malignant pain or chronic 'benign' pain recurs daily with variable intensity, where 
the pain has no predictable end and often does not respond to treatment e.g. 
peripheral neuropathy, low back pain, rheumatoid arthritis, osteoarthritis. The tenn 
'benign' is a misnomer, because patients with such pain suffer significant physical 
and psychological trauma (O'Hara 1996). 
1.2 Types and locations of pain 
Pain can be categorised by its source. Superficial pain occurs when the surface 
tissue receptors are stimulated and is often sharp whereas deep pain can occur deep 
in the viscera or within muscles or tendons, the latter often poorly localised. 
Localised pain comes directly from a site of injury whereas referred pain is pain felt 
in an area remote from site of injury. Projected pain occurs when pain messages are 
set up at a point along the pain pathway beyond peripheral pain receptors e.g. 
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phantom limb pain. Patients with psychogenic pain have no detectable organic 
lesion or stimulation, although the pain is very real to the patient and is thought to be 
a physical manifestation of a psychological disturbance (O'Hara 1996). 
Intractable pain refers to any chronic pain which cannot be controlled 
effectively by medication. Most patients with chronic pain have pain due to a 
physical cause, with emotional and behavioural factors influencing their perception 
and expression of the pain. Such psychological factors have been shown to diminish 
on appropriate pain management (Sternbach and Timmermans 1975). 
1.3 Physiology of pain 
There are a number of different components involved in pain processing and 
response, which affect both pain perception and behavioural outcome i.e. reflex 
motor/autonomic, sensory-discriminative, cognitive-evaluative and motivational-
affective components. 
When a painful or noxious stimulus is applied to sensitive tissues in skin, 
muscle and around joints, specialised afferent nerves called nociceptors are 
activated. These nociceptors respond to noxious stimuli, which do not always elicit 
pain. Moroever, pain can arise without nociceptor stimulation (Jones 1997). Non-
nociceptive pain is that experienced in neuropathic or psychogenic pain whereas 
nociceptive pain usually describes inflammatory pain. 
Receptor activation translates the heat, chemical or mechanical stimulus into a 
nerve impulse along the primary afferent nerve. These nerve impulses are then 
'coded' and their messages transmitted via synapses with neurones largely within 
the dorsal hom (specific nociceptor and multi-modal non-specific neurones) and the 
ventral root of the spinal cord. 
When trauma frrst occurs, the initial sharp, localised pain (epicritic) is quickly 
transmitted by A -delta fibres after which, the second pain, (protopathic) a more 
diffuse, dull and throbbing sensation is C-fibre mediated. Activation of the A-beta 
fibres occurs when rubbing of the skin (cutaneous stimulation) is initiated (Jones 
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1997). In patients with chronic pain, these components of pain perception may not 
be readily defmed. 
Thereafter, some impulses pass directly to motor neurones to initiate a reflex 
response, while the majority of pain impulses cross to the opposite side of the spinal 
cord and ascend via the anterolateral spinothalamic tract and the brain stem to the 
medial and lateral thalamic nuclei of the brain. These spinothalamic tracts project to 
the somatosensory cortex and are thought to serve the discriminative and sensory 
aspects of pain providing information about the location and quality of the painful 
impulse. A less specific pathway, involving the spinoreticular tract, makes 
widespread and diffuse connections with areas of the forebrain especially the limbic 
system, and is involved in the affective aspects of pain (Jones 1997). 
Jones (1997) has defmed central pain transmission in terms of a pain matrix to 
process both acute and chronic pain. The more frontal cortical structures of the brain 
are sensitive to the suffering component of chronic pain and may be involved in 
processing the affective and attentional components of pain (Jones et al 1993). 
Investigations in cortex responses to pain in controlled studies of patients with 
rheumatoid arthritis and atypical facial pain suggest that response patterns in 
different types of chronic pain may reflect differences in affective and attentional 
responses to acute pain (Jones et a/1993). 
Several chemical compounds have been shown to accumulate near nociceptors 
after tissue injury has taken place and may either activate nociceptors directly e.g. 
histamine, bradykinin and potassium or are potent mediators of the pain response 
e.g. prostaglandins and leukotrienes. Histamine also causes vasodilation, while 
bradykinin both directly and indirectly stimulates nociceptors causing hyperalgesia 
(enhanced pain). Prostaglandin E2 (pGE2), prostacyclin (PGI2) and prostaglandin 
E 1 are potent pain inducers and cause hyperalgesia either directly e.g. PGE2 or 
indirectly via cyclic -AMP activation or via interaction with bradykinin or histamine 
e.g.PGE 1. Leukotrienes also produce hyperalgesia directly and indirectly (Levine et 
aI1984). 
Nociceptors have also been shown to release their own pain producing 
substances e.g. substance P and N-methyl-D-aspartate (NMDA). Substance P, a 
peptide, released from C fibres excites pain transmission pathways in the dorsal hom 
and is also a potent vasodilator, releasing histamine which stimulates nociceptors 
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further (Levine et al 1988). Prolonged release of substance P and NMDA probably 
have a role to play in primary and secondary sensitisation to pain, the latter 
occurring when both noxious and originally non-noxious stimuli give rise to pain. 
The importance of neuromodulation of pain in both inflammatory and neurogenic 
pain is well reviewed by Woolf (1994). 
1.4 Pain control mechanisms 
Gate control mechanisms, central descending control pathways, opioid 
receptors and endogenous analgesics all have roles to play in pain control (Reisner-
Keller 1992, O'Hara 1996, Jones 1997). 
The 'gate-control' mechanism postulated by Melzack and Wall (1965) is still 
widely accepted to explain how pain signals are obtained, transmitted and 
interpreted within the central nervous system. The basic concept is that 
transmissions of stimulated afferent pathways are blocked or filtered by a synaptic 
gate in the substantia gelatinosa in the dorsal hom of the spinal cord, which contains 
both inhibitory and excitatory interneurones. The extent to which the gate is opened 
or closed is controlled by the activity of other afferent inputs to the spinal cord and 
the descending pathways from the brain stem including the descending noxious 
inhibitory control (DNIC), located in the periaqueductal grey matter (P AGM). The 
precise roles of the DNIC are unclear, but it seems to be more involved in increasing 
pain discrimination rather than painful stimulus suppression (Jones 1997) and 
inhibits the nociceptive responses at dorsal hom level, possibly stimulating the gate 
control mechanism (O'Hara 1996). 
The role of opioid receptors (mu, delta, kappa and sigma) in pain control is 
well reviewed by Reisner-Keller (1992) and Yaksh (1984). 
Endogenous opioids (enkephalins and dynorphins) help regulate the pain 
response and appear to act as excitatory transmitter substances which inhibit the 
nociceptive pathway and close the pain gate. The enkephalins and dynorphins 
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regulate pain perception largely within the medulla, while the endorphins and 
enkephalins act within the dorsal hom and the substantia gelatinosa. 
Enkephalins and beta-endorphins are potent mu and delta agonists, while 
dynorphins bind preferentially to kappa receptors (Cannody 1987). Such systems 
are activated by stress responses to increase enkephalin or endorphin release e.g. 
eating, drinking, exercise, acupuncture, but such release can be inhibited by 
prolonged pain and alcohol. 
1.5 Physical and psychosocial consequences of chronic non-
malignant pain 
Chronic non-malignant pain continues beyond the expected healing time of a 
specific insult and is seldom accompanied by autonomic symptoms including 
tachycardia and sweating which occur in acute pain. Patients with chronic pain often 
do not show any underlying pathophysiology, but the pain can arise from viscera, 
muscle and connective tissue (musculoskelatal disease) or from neurological sites 
e.g. peripheral neuropathy. 
Chronic pain causes significant lifestyle changes e.g. giving up work due to 
pain, inability to perform everyday tasks such as bathing or cooking and can lead to 
loss of role and self-esteem (Yelin et al 1987). The complex problems faced by 
patients with chronic pain can be described in terms of a chronic pain model, 
consisting of physical disability, depression, side effects of medication and 
dependence on family and the medical profession (O'Hara 1996). 
Such patients with chronic pain often have had their pain treated in the 
traditional 'medical model' where diagnosis of the cause of the pain is expected, the 
doctor is regarded as the expert, therapy is very 'cure' orientated and patients 
consequently can feel out of control. People with chronic pain tend to have a 
lifestyle which consists of times of over-activity and under-activity. When pain has 
improved, efforts are made to catch up with activities left undone due to pain. When 
pain exacerbates, patients require rest, medication and consequently become 
frustrated and depressed (O'Hara 1996). 
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Pain - related behaviour in patients with chronic pain depends not only on the 
patient's perception of their own pain, but also the duration of pain and other 
people's reaction to their pain behaviours. Patients may become absorbed by their 
pain and this behaviour can become a habit even when pain is less severe, resulting 
in isolation from family and friends (Skevington 1990). 
Skevington (1990) identified psychosocial problems of patients with arthritis 
which included uncertainty, loss of control of life events and lack of family support. 
Although depression has been shown to arise as a consequence of arthritis or as a 
separate psychological problem (Newman et al 1989), its prevalence in rheumatoid 
arthritis may have been overestimated due to the use of self-report questionnaires 
(Ash 1990). Indeed, Ash (1990) has identified psychosocial factors including social 
isolation, long term illness of family, and consulting behaviours of patients such as 
disproportionately frequent or early attendance at clinic, associated with depression 
in rheumatoid arthritis. 
1.6 Assessment of chronic pain 
The difficulties associated with pain assessment arise from its subjectivity, 
multidimensional nature and the numerous personal, psychological, cultural and 
environmental factors which influence different peoples' perception and response to 
the same pain stimulus (Tursky et al1982). 
A wide variety of subjective and objective methods of pain measurement exist. 
Subjective methods tend to assess the sensory aspects of pain and the patient's 
emotional response to that painful experience using intensity scales, while objective 
methods may try to differentiate the strength of the painful stimulus from the 
patient's subjective response. The latter technique has been used in clinical studies 
to determine whether analgesics reduce the pain experience itself or make the patient 
less likely to call the stimulus painful (McDowell and Newell 1996). 
Assessment of pain may involve the use of pain questionnaires, observation of 
pain behaviour or use of analogue methods. Pain questionnaires tend to concentrate 
on measuring pain intensity and duration e.g. visual analogue scales and numerical 
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rating scales (Jensen et al 1986) but can also provide a more qualitative description 
of pain and a measure of the patient's affective response e.g. McGill Pain 
Questionnaire (Melzack 1975). Behavioural rating scales are also used to assess 
pain, since pain often causes involuntary or voluntary change in behaviour e.g. 
reduction in physical function or an involuntary body movement (McDaniel et al 
1986). Analogue methods try to correlate a patient's 'typical' pain with pain 
experimentally induced in an attempt to assess individual patients' maximum 
tolerance level. However, it has been suggested that the results obtained using 
analogue methods may not mimic what would happen in reality (McDowell and 
Newell 1996). 
McDowell and Newell (1996) have extensively reviewed the most widely used 
and validated pain scales in terms of their purpose, description, applicability, 
reliability and validity. Pain scales which are commonly used in clinical practice for 
the assessment of chronic pain include the Visual Analogue Rating Scale (Scott and 
Huskisson 1976), the McGill Pain Questionnaire (Melzack 1975), the Brief Pain 
Inventory (formerly the Wisconsin Brief Pain Questionnaire) (Daut et aI1983), the 
Oswestry Low Back Pain Disability Questionnaire (Fairbank et al 1980) and the 
Pain Perception Profile (Tursky 1982). 
Visual Analogue scales (VAS) are simple, sensitive methods to assess 
subjectively not only pain intensity, but also pain frequency, and have been 
incorporated into health-related quality of life instruments (McCormack et al 1988). 
Initial and subsequent VAS pain ratings correlate well and the scale can be 
descriptive (none, slight, moderate or complete reliet) or a VAS scale ranging from 
no to complete pain relief (Scott and Huskisson 1976). An advantage of the pain 
relief VAS is that each patient has the same extent of potential response whatever 
his initial pain (Sriwatanakul et aI1983). Downie et al (1978) suggested that a 10 
point numerical rating scale was more reliable than the VAS due to the risk of user 
error especially those with literacy problems. 
Reliability of the VAS when printed horizontally or vertically is good, but 
correlation of horizontal scores can be slightly less than vertical scores (Scott and 
Huskisson 1976). However, horizontal scales may have a reduced failure rate, 
provide less distortion and are generally preferable (McCormack et al 1988). The 
validity of VAS has been investigated and found to be high when compared with a 
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four-point descriptive pain rating scale (Downie et al 1978). The VAS correlated 
well with a verbal rating scale and was more sensitive than the latter, hence useful in 
small sample studies. Since both the 10 point numerical rating scale and VAS have 
similar responsiveness, Guyatt et al (1987) have suggested that numerical rating 
scales should be recommended in small sample studies. 
Good correlations have been found between VAS and the McGill Pain 
Questionnaire (MPQ) scores (McCormack et al 1988), the results of which have 
varied with the type of patient interviewed and scoring used (perry et alI988). 
1.7 Rheumatoid arthritis 
1.7.1 Aetiology, epidemiology, pathogenesis, diagnosis and clinical 
findings of rheumatoid arthritis 
Rheumatoid arthritis (RA) is the commonest form of inflammatory arthritis 
which affects about 1 % of the population, affecting more females than males (3: 1) 
and has a peak onset between the ages of 30-50 years, although age of onset is now 
increasing and incidence is declining, especially among women (Silman 1997). 
In RA extensive morbidity is associated with joint destruction and patients 
have an increased rate of mortality due to cardiovascular, respiratory, renal diseases, 
infection and medication with estimates of loss of life expectancy varying from 3-18 
years (Scott and Symmons 1986). In primary health care, rheumatic symptoms are 
the most common problems seen by most general practitioners (GPs), representing 
15% of all GP consultations i.e. more than 8 million consultations per year (Ashcroft 
1997). 
The aetiology of the disease is still unclear, but research does suggest that 
genetic, environmental, hormonal, viral, autoimmune and other factors have a role in 
causing RA, all of which have been well reviewed (panayi and Welsh 1988, Yaron 
1995). 
A genetic predisposition may reside in the major histocompatibility complex 
molecule (MHC) which binds antigen and presents it to T cells, especially in severe 
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RA (Emery et al 1992). This MHC marker may be able to predict those patients 
most at risk of severe disease and thus who require early aggressive management 
(Bensen et al1997), although some studies have found poor predictability (Emery et 
al 1992). No joint specific antigens have yet been found but research suggests that 
immune mechanisms against 'self break down to cause joint- specific diseases such 
as RA. Intracellular signalling pathways regulating DNA sequence-specific 
transcription factors which turn genes off or on and play a key role in joint erosion 
and inflammation have been found in patients with RA (Lewis 1997). 
Rheumatoid arthritis is characterised by infiltration of the synovium with 
lymphoid cells such as B and T lymphocytes and macrophages, proliferation of the 
synovial membrane and joint destruction. Macrophages and fibroblasts dominate the 
chronic phase of the disease by production of cytokines (small protein messengers 
that mediate inflammatory and immune responses). They maintain the chronic 
synovitis and induce matrix metalloproteinases (Buckley 1997) which play a 
significant role in joint destruction. Genes for cytokine production are over-
expressed in patients with RA. 
The most pro-inflammatory cytokines released by macrophages are Interleukin 
1 (IL-l) and tumour necrosis factor (TNF-a) and are well reviewed by Maini (1996). 
IL-l and TNF -a encourage chemotaxis and stimulate the release of other 
immunological, enzymatic or inflammatory mediators such as Interleukin 6 (IL-6), 
granulocyte-macrophage colony stimulating factor (GM-CSF), prostagandin E2 
(PGE2), collagenase and substance P. Synovial fibroblasts, after stimulation by IL-l 
and TNF- a, produce collagenase, PGE2 and plasminogen activator. Hyperactivity 
of T lymphocytes in peripheral blood and synovial fluid develops, which encourages 
further cartilage degradation and synovial tissue proliferation (Buckley 1997). This 
destruction ultimately causes limitation of movement, pain and joint destabilisation. 
Criteria for classification of RA, such as those developed by the American 
College of Rheumatology (Arnett et al 1988) were originally developed to act as a 
standard for purposes of investigation. These criteria are not helpful in making an 
early diagnosis of the disease, which is vital to identify those most at risk of 
debilitating disease and to optimise therapy (prouse 1998). Long-term studies of 
patient groups from arthritis clinics have demonstrated that polyarthritis of the small 
joints and the presence of serum rheumatoid factor can predict the development of 
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persistent rheumatoid disease (Emery et al 1992). Other features predictive of RA 
are early morning joint stiffness and fatigue. In individuals, recent studies suggest 
that accurate and early diagnosis is best achieved by a rheumatological team (panush 
et aI1995). 
There are as yet, no simple and reliable markers of disease severity to help 
clinicians titrate therapy to each individual and target those patients most in need of 
aggressive therapy. While studies have demonstrated variable abilities in the 
presence of rheumatoid factor and the HLA-DRJ3 epitope to predict disease severity 
(Emery et aI1992), longer prospective studies have shown that female gender, early 
development of erosions, greater disability and older age at initial presentation are 
more reliable predictors of poor functional outcome (Zwillich 1997, Akil and Amos 
1995(A». 
Mild to moderate RA is characterised by tenderness on palpation or pain on 
movement of involved joints usually those of hands, feet, wrists and/or ankles. In 
patients with moderate to severe arthritis, signs will be more severe with swelling 
due to synovial proliferation, while progressive disease is characterised by joint 
malformations and instability with disabling deformity particularly damage to 
weight bearing joints. Extra-articular consequences of RA, usually indicating more 
severe disease, are rheumatoid nodules in the lungs and heart, renal problems, 
anaemia, depression, pericarditis and ocular problems. 
1.7.2 Management of rheumatoid arthritis 
The aims of rheumatoid arthritis treatment are to improve or maintain existing 
function, prevent the development of the patient's joint and extra-articular disease 
and to minimise side effects of therapy. Since there are no disease-specific clinical, 
immunological or radiological features with which RA can be identified, diagnosis 
and hence the initiation of appropriate therapy can be delayed (platt 1997, Prouse 
1998). Such a delay is worrying, especially since research has found that the rate of 
RA progression is greatest in the frrst 2 years of the disease and during this phase, 
the inflammatory features are more easily controlled (platt 1997). 
Management of RA can involve both drug and non-drug management 
strategies. Drug management of RA includes simple analgesics (Boyce 1992), non-
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steroidal anti-inflammatory drugs (NSAIDs) (Anon 1994), disease-modifying 
antirheumatic drugs (DMARDs) (Anon 1998, Medicines Resource Centre 1996), 
immunosuppressants, corticosteroids, homeopathic and herbal products (Watson and 
Dieppe 1998, Mills et al 1996). Other experimental therapies include minocycline, 
gene therapies, CD4 antibodies and antibodies to TNF -alpha (Watson and Dieppe 
1998, Breedveld 1997). 
Non-drug management generally involves patient education, rest, exercise and 
surgery (Akil and Amos 1995(B), Boyce 1992). Donovan et al (1989) demonstrated 
that patient beliefs very much influenced their concordance with RA drug therapy, 
while Stenstrom et al (1997) identified specific patient factors which promoted 
compliance with home exercise programmes. Indeed, recent guidelines have 
recommended that 'all arthritis patients should receive enough information to 
understand the type of arthritis they have and its likely process together with 
information on enabling them to learn how to manage their arthritis' (Rowan et al 
1997). Cognitive behavioural programmes encourage a multidisciplinary input from 
health care professionals such as physiotherapists, occupational therapists and 
psychologists, and include muscle relaxation, distraction and imagery techniques to 
help the individual regain control over his / her life. Such programmes have been 
shown to increase work, social and leisure activities in patients with RA as well as 
decrease chronic pain behaviour and anxiety (Anderson et aI1985). 
Surgery is useful in repairing or replacing damaged joints, correcting ligament 
or tendon instability, reducing compression of the spinal nerves and the spinal cord. 
Its applications in RA are well reviewed by Oliver (1997). 
Traditionally, the therapeutic management of rheumatoid arthritis has been a 
'pyramid approach' whereby NSAIDs were initially used as baseline symptomatic 
therapy, after which individual DMARDs were prescribed as patients' disease 
progressed, usually hydroxychloroquine or sulphasalazine frrst line followed by gold 
or penicillamine depending on efficacy and side effects (Bensen et al 1997). If the 
disease deteriorated further, third line agents were used including oral 
corticosteroids and other immunosuppressants (Platt 1997). 
This model has been criticised for providing a simplistic approach to a 
complex disease (Bensen et aI1997), assuming that DMARDs were more toxic than 
NSAIDs and that RA was a 'benign' disease, resulting in DMARDs being initiated 
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once radiological evidence of damage had occurred. The use of DMARDs in this 
way, suppressed disease activity and improved function, slowing joint deterioration, 
but long-term improvements in disability were not frequently obtained (Anon 1993). 
Fries et al (1996) followed up 2888 RA patients prospectively between 1980-90 and 
found that patients who were more extensively treated with DMARDs showed 
disability levels which were 40% lower than those of the group who had little 
DMARD exposure. 
New therapeutic pyramids have now been proposed to ensure early, aggressive 
management of RA such that NSAIDs, DMARDs and steroids as well as health 
professionals' input are used early in combination, depending on initial severity of 
disease (Bensen et aI1997). Since erosive changes are late markers of RA indicating 
joint damage, and such joint damage and functional disability occur commonly 
within the frrst 2 years of the disease (Egsmose et al 1995), DMARDs are now 
started shortly after a diagnosis of RA has been established to improve long-term 
outcomes (Anon 1998). Patients with moderate disease may benefit from a 
combination of DMARDs to improve efficacy and limit drug toxicity (pratt 1997, 
Anon 1998). However, much of the clinical evidence for this use has come from 
small, uncontrolled trials. Some results from random is ed, double blind trials suggest 
that combinations of methotrexate and sulphasalazine or methotrexate with 
cyclosporin can improve outcomes with no increase in toxicity (Boers et al 1997, 
Tugwell et aI1995). 
NSAIDs, unlike DMARDs, only provide symptomatic relief by inhibition of 
prostaglandin synthesis in inflammed tissues and do not influence the acute-phase 
response or reduce the development of joint erosions. The hypothesis that NSAIDs 
which inhibit the cyclo-oxygenase enzyme 2 (COX-2) more selectively than COX-l 
enzyme may be more effective anti-inflammatory agents with minimal 
gastrotoxicity than non-selective agents is still under investigation (De Brum-
Fernandes 1997). The COX-2 enzyme is thought to be more involved with 
prostaglandins involved in the inflammatory response, while the COX-l enzyme 
controls those participating in gastric mucosa function. Recent evidence using 
selective COX-2 inhibitors in RA have demonstrated significant improvements in 
the signs and symptoms of RA (Lipsky and Isakson 1997). 
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Guidelines for the appropriate choice, use and monitoring of NSAIDs in RA 
have been developed to maximise efficacy and minimise the toxicity of NSAIDs 
(Anon 1994, Scottish Medicines Resource Centre 1995, Committee on Safety of 
Medicines 1994). Pharmacists have adopted strategies to help review NSAID 
prescribing to ensure that such prescribing is cost effective (Hampal 1997). 
The choice of DMARD depends initially on each drug's efficacy and toxicity 
profile and ease of monitoring (platt 1997, Anon 1998). The American College of 
Rheumatology (ACR) has now recommended specific criteria for assessing positive 
outcomes in terms of joint inflammation, overall disease activity, pain and disability 
(Felson et aI1995). An improvement of at least 50% on the ACR criteria has been 
recommended as a valid indicator towards achieving complete suppression of the 
active disease (Anon 1998). Studies have demonstrated that a good response with an 
NSAID in mild disease is suggestive of a good response with a DMARD (platt 
1997). 
In the UK, sulphasalazine and methotrexate tend to be the DMARDs of fIrSt 
choice now (Medicines Resource Centre 1996), with gold use declining due to its 
toxicity profile (Watson and Dieppe 1997, Anon 1998). Analysis of pooled data 
suggest that sulphasalazine, methotrexate, intramuscular gold and penicillamine are 
similar in efficacy but more effective than auranofm or the antimalarials. However, 
the response to methotrexate seems to occur much earlier than with other DMARDs 
(Anon 1998). The efficacy of all DMARDs has been recently reviewed (platt 1997, 
Anon 1998, Medicines Resource Centre 1996). 
Discontinuation of DMARDs is quite common due to their toxicity profile, 
lack of sustained effect or limited efficacy (Felson et al 1990). The toxicity of 
methotrexate and sulphasalazine is much lower than that of intramuscular gold and 
their discontinuation rate is lower than that for other DMARDs (Felson et aI1990). 
Other researchers have suggested that patients' psychological wellbeing prior to 
DMARD use and disease activity are important predictors of discontinuation of 
initial DMARD treatment (Listing et aI1997). 
With the increasing early use of DMARDs and thus the need for accurate 
diagnosis and effective monitoring of therapy, the resources in hospital 
rheumatology units are increasingly overstretched to meet demands (platt 1997). 
Unfortunately, recent studies are indicating that GPs are increasingly unwilling to 
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initiate DMARD therapy, provide essential information about DMARD therapy and 
/ or are unable to monitor therapy effectively (Anon 1996(A), Anekwe et al 1997), 
thus rheumatology nurses and pharmacists are increasingly required to adopt these 
roles (Kay 1997, Hill et aI1997). 
Immunosuppressants such as cyclosporin and cyclophosphamide have until 
recently been restricted to management of RA which was unresponsive to other 
treatments (Watson and Dieppe 1998, Anon 1993). Recently, cyclosporin has been 
licensed for RA use and is suggested to be as efficacious as sulphasalazine when 
used early in the disease, despite its use being limited by its side effects (platt 1997). 
No clear indications and guidelines have been developed for the use of steroids 
in RA. They can be given orally, as intravenous pulse therapy and as intramuscular 
or intra-articular injections (Coombes and Bax 1996). Low dose oral corticosteroids 
(i.e. 5-10mg prednisolone daily) are used in about 20-30% of RA patients, 
particularly those refractory to other treatments and in the elderly, in whom steroids 
may be safer than NSAIDs (Platt 1997, Coombes and Blax 1996). Studies are still 
inconclusive as to whether steroids have a disease-modifying effect. Although some 
patients benefit from the addition of low dose oral corticosteroids to existing 
DMARD therapy, the effect is only sustained for 6-9 months. Moreover, a 
significant rebound of disease activity can result as the dose is tapered down, 
making discontinuation difficult and long-term toxicity a potential problem 
(~oombes and Blax 1996). A recent meta-analysis (Saag et a11996) and a low dose 
prednisolone study (Kirwan 1995) suggest that low dose corticosteroids do slow 
down erosions as evidenced by radiological examination, but it is unclear if these 
benefits are sustained after the treatment period or outweigh long-term side effects. 
Intravenous pulse therapy with, for example, methylprednisolone has been 
used to induce remissions in severe disease prior to onset of activity of a DMARD 
and to limit the side effects of oral steroids, however cardiac arrhythmias can occur. 
Intramuscular methylprednisolone or triamcinolone have been used to control acute 
RA exacerbations and as induction agents with DMARDs (platt 1997). 
Intra-articular steroids have no disease-modifying effect, but provide 
symptomatic relief by reducing joint inflammation with minimal side effects, but 
good injection technique is required and the frequency of injections per joint is 
limited (Coombes and Blax 1996). 
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1.8 Osteoarthritis 
1.S.1 Aetiology, epidemiology, pathogenesis, diagnosis and clinical 
fmdings of osteoarthritis 
Osteoarthritis (OA) , a degenerative disease, is the most common rheumatic 
disease, although its precise incidence is hard to defme due to discrepancies in 
diagnosis and the low correlation between clinical symptoms and radiological 
evidence of the disease. Approximately 12% of the general population aged 65 years 
or older are affected by OA (Watson 1997). The onset of OA begins around middle 
age and is more common in men before age 45 but more common in women after 
age 45. 
In many people, the disease occurs spontaneously and no previous cause is 
identified (primary osteoarthritis), and is a generalised arthritis involving multiple 
joints usually those of knee, hand, hip or spine. In other patients, especially middle 
aged women, osteoarthritis may start with inflamed Heberden' s nodes. Secondary 
osteoarthritis may demonstrate unusual patterns of joint involvement and may co-
exist with rheumatoid arthritis (Hutton 1995). 
Researchers suggest that the aetiology of OA is multifactorial with age, 
genetic, patient-specific and environmental risk factors identified (Mahoney et al 
1992). 
In osteoarthritis, unlike RA, the effects are limited to the joints and result from 
changes in the biochemical composition of articular cartilage. The articular matrix 
becomes poorly regulated, associated with cartilage hydration, loss of elasticity and 
cartilage breakdown. Underlying bone then becomes exposed, sclerotic and prone to 
hypertrophy, leading to fracture, subchondral cyst and osteophyte development. 
These osteophytes can then cause joint enlargement, spinal compression and joint 
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immobility. Chronic inflammation of the synovium is caused by collagen fragments 
and proteoglycan subsequent to proteolysis of collagen (Mahoney et aI1992). 
The diagnosis of OA is based primarily on clinical symptoms and 
radiographical fmdings. Clinical symptoms may include intermittent pain, the 
pattern of which depends on the affected joint( s), limited range of movement of an 
affected joint, stiflhess after inactivity, crepitus (where the joint 'crackles' due to 
bone and cartilage rubbing together) and disability. Radiographical changes 
diagnostic of OA include the narrowing of joint space, sclerosis of subchondral bone 
and the presence of subchondral cysts and osteophytes (Hutton 1995). 
Recent guidelines from the Primary Care Rheumatology Society 1995, suggest 
that localised pain, restricted movement, joint stiffuess and tenderness and 
radiographical changes are required to confmn the diagnosis. 
1.8.2 Management of osteoarthritis 
The aims of OA management are to relieve symptoms, reduce disability, limit 
further joint damage, preserve existing joint function and maintain a good quality of 
life (Mahoney et al 1992, Primary Care Rheumatology Society 1995). Thus OA 
treatment programmes include non-pharmacological therapy, pharmacological 
therapy and surgical intervention, depending on disease severity and patient 
concordance (Watson 1997). 
Non-pharmacological therapy has a very important part to play in OA 
management and includes patient education, physiotherapy, weight reduction, 
occupational therapy and use of appropriate aids. Surgical intervention is indicated 
when pain and joint stiflhess and deformity is uncontrolled, performed most 
frequently on the hip and knee joints via arthroplasty (Anon 1996(B)). 
A randomised, controlled trial by Weinberger and colleagues in 1989 
demonstrated the importance of ensuring patients are well informed about and agree 
with the specifc management plan for their own OA to maximise outcomes of 
therapy. Some evidence exists regarding the importance of self-management courses 
in improving health outcomes and reducing consultations, but this was an 
uncontrolled study (Lorig et a/1993). National management guidelines for both OA 
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and RA now recommend that patients should be given access to the whole primary 
care team, primarily the GP, to encourage the development of an individual 
management plan and to discuss the importance of self-help, physiotherapy, 
exercise, aids and the benefits and limitations of medication (primary Care 
Rheumatology Society 1995, Rowan et aI1997). 
Randomised controlled studies have demonstrated the benefit of physiotherapy 
and exercise to improve function, pain and gait pattern in OA patients (Kovar et al 
1992). Puett et al (1994) have reviewed the benefits of specific aids such as walking 
frames to stabilise joints and compensate for joint length inequalities. 
Pharmacological therapy is aimed at alleviating pain and improving joint 
function and may include the use of topical therapies such as rubefacients, NSAIDs, 
capsaicin or intra-articular corticosteroids or systemic treatments such as simple 
analgesics e.g. paracetamol or combination analgesics, oral NSAIDs and low dose 
antidepressants (Anon 1996(B)). 
Topical analgesic preparations in current use can be classified in 3 groups: (1) 
rubefacients, (2) formulations based on NSAIDs including diclofenac, ibuprofen and 
piroxicam and (3) a miscellaneous group including benzydamine and capsaicin (Li 
Wan Po 1997). 
Rubefacients, benzydamine and capsaicin are thought to mediate their pain 
relief by counter-irritancy, depressing the activity of T cells in the spinal cord, but 
this theory does not help to explain their prolonged effect. Among the latter drugs, 
only capsaicin has demonstrated clinical effectiveness in randomised controlled 
trials in OA (Schnitzer et a11995, McQuay et aI1997). Capsaicin causes analgesia 
by depleting sensory neurones of substance P, has been recently marketed for the 
treatment of osteoarthritis as a 0.025% cream and has been recommended as a useful 
second line treatment in OA after simple analgesics (primary Care Rheumatology 
Society 1995). 
Until recently, there was considerable doubt of the superiority of topical 
NSAIDs over simple rubefacients, despite their wide use in sports injuries, acute soft 
tissue injuries, rheumatoid arthritis, osteoarthritis and back pain (Anon 1994, 
Medicines Resource Centre 1997). Well conducted placebo-controlled, double blind 
studies used to assess topical NSAID efficacy have often had many difficulties 
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including lack of sensitive and specific outcome measures, lack of consistency of 
use of the same pain measurement and high placebo responses in patients (Buchanan 
1997, McQuay et al 1997). Both felbinac and piroxicam gels have been studied in 
OA of the knee compared to oral ibuprofen, with only limited improvement in 
efficacy with piroxicam as compared to placebo (McQuay et aI1997). 
A large recent systematic review comparing topical NSAIDs with placebo, or 
with oral or other topical NSAIDs on the basis of number needed to treat (NNT), 
demonstrated that 7 of the 13 placebo-controlled trials involving patients with 
chronic arthritis showed NSAIDs to be more effective than placebo (NNT=3.1) 
(Moore et aI1998). Moreover, there was no significant difference in the incidence 
of side effects with topical NSAIDs as compared to placebo in the chronic groups. 
When 5 studies comparing topical with oral NSAIDs were reviewed, oral therapy 
did not confer any additional benefit over topical therapy. Such fmdings may 
encourage topical therapy to be used in preference to oral NSAIDs especially in high 
risk groups such as the elderly. At least one large, 2 phase, randomised, controlled 
trial of a topical NSAID is still needed e.g. ibuprofen, incorporating an early phase 
to determine effectiveness and a longer phase to establish the efficacy / toxicity 
profile (McQuay et aI1997). 
Intra-articular steroids such as methylprednisolone or triamcinolone are 
commonly used to treat knee and thumb joint synovitis in OA (Anon 1996(B)). 
Limited trial data exists regarding the efficacy and optimal frequency of 
administration of such injections (Anon 1995). 
Systemic treatments for OA may be required if non-pharmacological and / or 
topical therapies fail to control symptoms. Paracetamol should be used fIrSt line, 
since the few studies which have compared paracetamol against either NSAID or 
placebo in OA suggest that paracetamol is as effective as NSAIDs in OA, is cheaper 
and has an improved side effect profile (Dieppe et aI1993(B), Bradley et aI1991). 
However, a 2 year comparative study of naproxen and paracetamol in patients with 
OA suggested that some patients may require reintroduction of their NSAID in 
combination with paracetamol to control symptoms (Dieppe et aI1993(A)). Some 
GP prescribing initiatives have suggested that switching patients with OA from 
NSAIDs to paracetamol is possible without compromising patient outcome 
(Helliwell et a11994, Swift and Rhodes 1992). Indeed, one recent randomised study 
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investigating patient satisfaction with NSAIDs in OA identified that less than 60% 
of patients reported having used paracetamol as fITst line therapy and only 50% of 
patients aged 75 or less could recall if they had been provided with information 
about their NSAID therapy (Long and Wynne 1996). 
Oral NSAIDs should only be initiated if inflammation (often a minor 
component of OA) as well as pain is present, no contraindications to their use exist 
and NSAID use is reviewed regularly (primary Care Rheumatology Society 1995). 
The choice of NSAID should be one least likely to cause gastrointestinal toxicity 
e.g. ibuprofen or diclofenac, initiated at lowest effective dose to minimise toxicity 
and with appropriate renal and gastrointestinal monitoring (Anon 1994, Committee 
on Safety of Medicines 1994). 
Many GPs and hospital clinicians prescribe combination analgesics for patients 
often inappropriately (Hulme et al 1996, Dixon et al 1995), due to habit (Haigh 
1996), preferred patient preference (Sykes et al 1996) or when patients fail to 
respond to paracetamol and / or NSAIDs. Few trials in OA show that combination 
analgesics confer any clinical advantage over paracetamol alone (Anon 1996(B)}. Li 
Wan Po and colleagues (1997) recently conducted an overview of 26 randomised 
trials of paracetamol and coproxamol involving 2231 patients including patients 
with OA and found that there was little objective evidence to suggest that the 
combination of paracetamol with dextropropoxyphene was more efficacious than 
paracetamol alone in treating moderate pain. 
Evaluation of the use of opioids in chronic non-malignant pain such as OA has 
largely been via published surveys and open-label clinical trials. Resistance to 
opioid use in such patients has been due to perceived lack of efficacy, concerns 
about addiction, side effects and analgesic tolerance (portenoy 1990). However, a 
recent, small, but randomised, placebo-controlled trial in arthritis patients suggests 
that controlled release opioid formulations significantly improve pain scores and 
functional ability, although constipation is a long-term problem (Arkinstall et al 
1995). 
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1.9 Low back pain 
1.9.1 Aetiology, epidemiology, pathogenesis, diagnosis and clinical 
findings of low back pain 
Back pain is an increasing problem in the UK with a 7% prevalence in 
Scotland as estimated by general practice data (Department of General Practice and 
Primary Care 1998). The peak incidence of back pain occurs at about 40-60 years 
with chronic back pain more frequent with increasing age. Surveys show that 6% of 
employed people lost at least 1 working day because of back pain in the past month, 
which represents about 52 million working days lost in Britain. Back pain is 
estimated to cost the NHS about £481 million a year, such that a typical GP practice 
with 5 GPs and 10,000 patients would have consultation and drug costs around 
£88,000 (Clinical Standards Advisory Group 1994). 
Diagnosis of low back pain requires an understanding of back pain syndromes 
and is made on the basis of a patient's history and examination. Back pain 
syndromes include mechanical back pain or prolapsed lumbar disc and systemic 
back pain which may indicate a tumour, spinal stenosis, postural or referred pain. 
Bad posture is probably the commonest cause of persistent back pain but unequal 
leg length can also be a contributory factor causing a scoliosis (Jenner and Barry 
1995). 
Investigations of low back pain may include haematological and biochemical 
tests (to rule out systemic causes), radiography and other imaging techniques to 
investigate disc lesions. Electromyography can help identify nerve root 
degeneration. 
Most acute episodes of back pain arise from degeneration of the nucleus 
pulposus in the lumbar disc, but the pain source may not be the disc itself but facet 
joints and / or surrounding ligaments which become stressed as a result of the 
degeneration of the disc. This factor may explain why removal of the disc will not 
always cure the pain. Acute low back pain is often due to accidents or injuries and 
pain intensity often relates to the degree of tissue damage experienced. Pain and 
associated functional disability may last up to 3 months. 
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True sciatica, where pain and numbness occur via a single lumbar root, may be 
accompanied by motor, sensory or reflex changes and is most commonly caused by 
a posterolateral protrusion of a disc impinging on the nerve root. 
Chronic low back pain, where pain has been established for more than 3 
months (Berman and Singh 1997), has a poor prognosis. Degenerative lumbar 
disease, osteoporosis, ankylosing spondylitis or neoplasia (Porter and Ralston 1994) 
may cause chronic back pain. However, there is often little physical evidence of 
injury, with no radiological evidence and patients experience hyperalgesia i.e. an 
exaggerated response to a stimulus. Chronic pain has a strong psychological 
component, often expressed as depression and a lack of coping strategy (Berman 
and Singh 1997). 
1.9.2 Management of acute and chronic low back pain 
Management of acute low back pain in primary care has been reviewed· 
(Clinical Standards Advisory Group 1994). Current guidelines now aim to relieve 
pain and disability. The main aim of treatment of chronic back pain is to help 
patients come to terms with their pain and for them to accept that they can do much 
themselves to relieve their own symptoms. 
Acute back pain management includes the use of physical therapies 
(manipulation, early active exercise and physical activity), drug therapy, and 
psychosocial management (patient ownership of disease, coping strategies) within a 
multidisciplinary environment. Bed rest should not be recommended for simple low 
back pain (Clinical Standards Advisory Group 1994). If needed, bed rest should be 
restricted to a few days, which is as effective as 2 weeks (Deyo et aI1986). 
Drug therapy for acute back pain should be limited to the use of simple 
analgesics such as paracetamol, then NSAIDs if necessary and ultimately a 
combination analgesic. If opioids or muscle relaxants are needed, a short course is 
recommended (Royal College of General Practitioners 1996). 
Recent randomised controlled studies in chronic back pain have demonstrated 
that appropriate exercise programmes are more effective in relieving and lessening 
pain intensity than bed rest (Timm 1994). Since negative life experiences including 
stress affect low back pain, pain management programmes encourage patients to 
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learn coping strategies e.g. problem solving techniques and relaxation to help 
patients regain control over their own lives. Indeed, combinations of methods 
including combined mind-body interventions have significantly improved pain, 
function and mood of patients with chronic back pain (Berman and Singh 1997, 
McQuay et al 1997). More recently, a meta-analysis of 9 randomised, controlled 
trials of acupuncture used in back pain has suggested that acupuncture may have 
more than just placebo effects (Barnes and White 1998). 
Pharmacological management of chronic back pain has been reviewed by 
Porter and Ralston (1994) and includes the use of simple analgesics, NSAIDs, 
opioids, muscle relaxants and tricyclic depressants. 
There has been general reluctance to prescribe opioids in chronic non-
malignant back pain due to clinician concerns about addiction, side effects and lack 
of efficacy (Portenoy 1990). Guidelines in the management of chronic pain with 
opioids have been proposed by Portenoy (1990) to maximise outcomes and to 
identify those patients in whom opioid therapy would be inappropriate. 
Tricyclic anti-depressants particularly amitriptyline can elevate mood and 
increase pain tolerance in depressed patients reducing chronic back pain (McQuay et 
al 1997). The analgesic effect of an antidepressant occurs usually within one week, 
but may be delayed for up to 3 months, occurring at a much lower dose than that for 
an anti-depressant effect i.e. 10-25mg at night increasing to 100-150mg according to 
symptoms and/or side effects. Non-tricyclic antidepressants have been shown to be 
less effective in the management of chronic pain (McQuay et alI997). 
1.10 Patient outcome measures 
1.10.1 Health outcomes 
Various defmitions of health outcomes have been proposed by researchers to 
identify the influence of health care on overall health status (McCallum 1993, 
Shanks and Frater 1993). McCallum (1993) defmed a health outcome as " a natural 
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or artificially designated point in the care of an individual or population suitable for 
assessing the effect of an intervention, or the natural history of a condition". Shanks 
and Frater (1993) thereafter sub-classified outcomes in terms of outcomes, health 
outcomes, health care outcomes and health outcomes of health care in an attempt to 
recognise the variety of desired outcomes identified. The latter researchers defmed a 
health outcome as "an effect manifest as a change in health status", but the cause of 
the change may not be known i.e. social, economic or environmental factors, 
whereas an outcome was a result in any sphere of life. The term health outcome is 
still the most widely used. 
Health outcomes are being increasingly used to objectively monitor the 
progress of patients, evaluate the cost-effectiveness of treatment options by 
managers, clinicians and other health professionals and to develop research 
strategies (Shanks and Frater 1993). The most frequently reported health outcome 
measures include morbidity and mortality rates, adverse reactions to drug therapy, 
physiological changes, hospital admission and re-admission rates and economic 
changes, all of which are well reviewed (Bowling 1997, McCallum 1993). 
Health outcomes are influenced by many factors such as type of disease state 
or intervention, and factors not generally considered as 'health', making assessment 
of health outcomes per se difficult. Moreover, health outcomes of patients with 
chronic disease in primary care need to be realistic and centred on the patient. 
Consequently, researchers have suggested that health-related quality of life is the 
most important outcome measurement and should be patient-assessed (Guyatt et al 
1993, Carr et a11996, Ruta et aI1994). 
1.10.2 Health related quality of life 
Health related quality of life or quality of life is a multidimensional concept 
which measures not just aspects of physical, mental and social functioning, but also 
areas such as the patient's well being and life satisfaction including housing and 
occupation (McDowell and Newell 1996). The WHOQOL Group (1993) consider 
this measure in their defmition of quality of life i.e. " an individual's perception of 
their position in life in the context of the culture and value systems in which they 
live in relation to their goals, expectations, standards and concerns". Bowling (1995) 
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thereafter, defmed health related quality of life as "the optimum level of mental, 
physical, role and social functioning, including relationships, perceptions of health, 
fitness, life satisfaction and well being". Comprehensive reviews of health related 
quality of life have been recently published (McDowell and Newell 1996, Bowling 
1997, Guyatt et aI1993). 
There is no clear differentiation between quality of life, health status or 
functional status, hence the terms are used often interchangeably (McDowell and 
Newell 1996) although, MacKeigan and Pathak (1992) have suggested that the 
concepts should be considered separately. 
Health related quality of life measurement provides a large number of benefits 
all of which have been discussed by a number of researchers (McDowell and Newell 
1996, Bowling 1997, Carr et al 1996) including their use in medical audit, 
population surveys of perceived health problems and outcome measures and 
evaluation of clinical trials. In terms of patient outcomes, quality of life assessment 
encourages the monitoring of patients' progress and screening for particular 
problems using a more extensive number of outcome measures rather than just 
clinical indicators. Patients' views on the factors which influence their quality of life 
and on the efficacy of treatment are also investigated (Ruta et al 1994). Moreover, 
the influence of any intervention on patients' physical, social and psychological 
status can be assessed. However, outcomes using clinical indicators often do not 
correlate with quality of life outcomes as perceived by either clinicians or patients 
(Fitzpatrick et a11992, Guyatt et aI1993). 
1.10.3 Health related quality of life instruments 
Health related quality of life instruments contain a number of items or 
questions grouped in domains or dimensions, which represent specific aspects of a 
person's state of health e.g. social or physical status. 
These instruments can be classified in terms of health profiles or health 
indices. Health profiles provide separate scores for each domain to be measured and 
allow the researcher to identify factors and the extent to which they are influenced 
by ill health. Health indices describe quality of life in terms of a single global score 
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for well-being and are used to analyse the cost-effectiveness of treatment in 
economic studies. 
Researchers have also classified quality of health instruments as generic, 
disease specific or domain specific (Fletcher et a11992(A) and (B), McDowell and 
Newell 1996). 
Generic instruments cover a broad range of quality of life dimensions in one 
instrument commonly mental, physical and social health. Such instruments permit 
comparisons between different disease groups but may be less responsive than 
disease or domain specific instruments and thus fail to identify small but significant 
changes in quality of health. The most commonly used generic instruments of health 
related quality of life used in primary care include Sickness Impact Profile (SIP) (De 
Bruin et al 1992), Nottingham Health profile (NHP) (Hunt et al 1985) and Short 
Form 36 (SF-36) (Brazier et aI1992). 
Disease specific instruments include domains specific for one particular 
disease state e.g. the Arthritis Impact Measurement Scales, AIMS 1 and AIMS2, 
(Meenan et al 1980, 1992). Such scales have greater patient acceptability and are 
more sensitive. Domain specific measures contain only items within one domain, 
usually severity of symptoms or psychological status, which, like disease specific 
scales could exclude necessary dimensions or may be too narrow an assessment. 
Consequently, most researchers advocate the use of an appropriate domain or 
disease specific instrument in conjunction with a generic instrument to investigate 
broader measures of quality of life while maintaining responsiveness (Fitzpatrick et 
a11992, Malek 1997). 
Quality of life outcomes can be assessed from both the physician's and 
patient's point of view, assessment of which can differ significantly between groups 
(Donovan 1991). The importance of different aspects of quality of life varies among 
and within individuals over time, thus tools which are too structured may be 
insensitive. 
Quality of life measurement scales have been based largely on concepts 
devised by health professionals. Patient-focused scales should be encouraged to 
obtain a more accurate assessment of patients' quality of life. In such scales, the 
patient may be asked to (1) identify and rank the areas of life which they consider 
most important to their quality of life (Schedule for the Evaluation of Individualised 
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Quality of Life, SEIQoL, O'Boyle et aI 1992) or (2) identify their own experience of 
a disease state and its influence on their outcome expectations as in the Disease 
Repercussion Profile (Carr et al 1996) or both, as in the Patient Generated Index, 
PGI, (Ruta et al 1994) and the Measure Yourself Medical Outcome Profile, 
MYMOP (paterson 1996). As more QOL measures are defmed by patients, then 
treatment outcomes will be able to be predicted and assessed with improved validity 
and reliability. 
Almost all QOL scales measure the negative aspects of health, which does not 
reflect a person's realistic assessment of his / her quality of life in terms of its 
advantages and disadvantages. It is hoped that new scales such as that devised by the 
World Health Organisation, the World Health Organisation Quality of Life 
instrument, (WHOQOL 1993), will help to identify patients' perceptions of the 
positive aspects of life such as positive feelings, self esteem and body image, and 
relate quality of life measures to life satisfaction. 
Appropriateness of any new health related quality of life instrument is now 
measured against defmed scientific review criteria consisting of 8 qualities 
developed by the Scientific Advisory Committee of the United States Medical 
Outcomes Trust which are validity, reliability, responsiveness, interpretability, a 
conceptual and measurement model, alternative forms, cultural and language 
adaptations and respondent and administrative burden (Lohr et al 1996). Such 
attributes have been recommended by other investigators (Fletcher et al 1992(B), 
McDowell and Newell 1996). 
Validity and reliability measures have been described extensively by other 
investigators (Deyo et a11991, Bowling 1995, McDowell and Newell 1996). 
Validity is defmed as the extent to which an instrument actually measures what 
it is supposed to measure and can be defmed in terms of face, content, criterion and 
construct validity. Face validity is a subjective measurement of whether the 
instrument seems appropriate and unambiguous. Content validity considers 
subjectively the extent to which questions within an instrument actually reflect its 
aims and are usually determined by panels of experts and appropriate lay people. 
Criterion validity tests how an instrument compares with the 'gold standard' of the 
area under research. Since health-related quality of life lacks such a standard, 
criterion validity is rarely carried out thus making it necessary for construct validity 
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to be investigated. Construct validity relies on linking the attribute we are 
investigating to other attributes by separate hypotheses and then testing the resultant 
constructs using the test instrument in different test samples i.e. multiple validity 
indicators are created by correlating individual domains of the instrument with other 
validated instruments. Convergent and discriminant validity should also be 
demonstrated, the former testing for high levels of correlation between health 
outcome indicators and the latter testing for limited correlation between indicators 
which are unrelated. 
Reliability is the extent to which an instrument will produce consistent results 
on different occasions when no change has occurred, and is assessed by internal 
consistency and test-retest methods. Internal consistency investigates how well 
individual items are inter-correlated and the extent with which they correlate with 
overall scores, usually determined by calculating Cronbach's alpha statistic. A 
minimum score of 0.7 and a maximum score of 0.9 is recommended for group 
comparisons for all reliability tests (Nunally 1978). Test-retest is the relationship 
between scores obtained by the same person on 2 or more occasions and is 
determined for continuous data with a normal distribution by using the Pearson 
correlation coefficient or intraclass correlation coefficient. Test-retest for continuous 
data without a normal distribution is determined using Spearman's rank correlation 
coefficient (Altman 1991). 
Responsiveness has been defmed as 'the ability of an instrument to detect 
minimal clinically important differences' by Guyatt et a11987. However, in health 
outcomes research, minimal clinically important differences are often not well 
defmed. Many health profiles produce individual domain or dimension scores rather 
than a total summary score and clinically important differences can vary among the 
domains. 
Investigation of clinically important differences can help sample size 
calculations in clinical trials. laeschke et al (1989) defmed such a difference as 'the 
smallest difference in score in the domain of interest which patients perceive as 
beneficial', using small sample studies, while Deyo et al (1991) defmed the minimal 
clinically important difference as the improvement in score after an intervention of 
predetermined efficacy. The claims of laeschke et al (1989) have not been 
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demonstrated in studies with large patient numbers and may be disease-specific. 
Indeed, responsiveness depends on the extent of floor or ceiling effects of the 
instrument under investigation (Fletcher 1992(B)). 
1.11 Roles of the pharmacist in primary care 
1.11.1 Pharmaceutical care and pharmaceutical needs assessment 
Phannaceutical care has been defmed by Hepler and Strand 1990, as 'the 
responsible provision of drug therapy for the purpose of achieving defmite outcomes 
that improve the patient's quality of life'. In 1997, Hepler redefmed pharmaceutical 
care as a practice in which the pharmacist takes responsibility for a patient's drug-
related needs and also holds him or herself accountable for meeting those needs. The 
outcomes may include cure of a disease, reduction or elimination of symptoms, 
slowing or stopping the disease process or preventing symptoms or development of 
a disease. Pharmaceutical care should be integrated within other health care systems 
and should be negotiated with patients and members of the primary health care team 
(Hepler and Strand 1990, Hepler 1997). Frameworks for accurate documentation of 
such pharmaceutical care are vital to be provided to optimise pharmaceutical input 
(Briggs et al 1996), encourage effective communication with clinicians (Wood et al 
1998), minimise the risk of side effects and lor adverse drug interactions (Rogers et 
al 1994, Whittlesea and Walker 1996) and accurately evaluate the outcome(s) of 
pharmaceutical care (Lipowski 1996). 
A pharmaceutical need is defmed by Scottish Clinical Pharmacy guidelines 
(1997) as 'a patient's requirement for a pharmaceutical product or service'. 
Pharmaceutical needs can be determined by identifying pharmaceutical risk factors 
and potential care issues. Pharmaceutical care issues should be identified for both 
individuals and populations to enable cost-effective use of health care resources 
available (Krska 1998). As increasing pressure is placed on health boards and 
authorities to achieve measurable improvements in health care, practical and 
achievable frameworks for health needs assessment such as pharmaceutical needs 
assessment, should be used to help purchasers decide on what services they require. 
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1.11.2 Emerging roles of the pharmacist in primary care 
There is currently extensive encouragement to develop the roles of the 
pharmacist within many different primary care settings to encourage cost-effective 
prescribing, promote the under-utilised skills of pharmacists and help reduce the 
ever increasing workload of GPs within a primary care-led NHS (Royal 
Pharmaceutical Society of Great Britain 1995, Scottish Office Department of Health 
(SODoR) 1996 (A) and (B), SODoH 1997). Moreover, recent NHS changes 
including greater emphasis on health promotion, encouragement of GPs to take on 
more specialised roles, promotion of evidence-based medicine, expansion of the 
primary health care team and movement of chronic disease management to 
community care, all further encourage the development of pharmacists' roles in 
primary care (SODoH 1998). 
There is now a 'window of opportunity' for pharmacists to become more fully 
integrated into the primary health care teams not only as advisers but also as 
providers of pharmaceutical care to individual patients within Primary Care Groups 
(PCGs), a multi-disciplinary health care team. Pharmacists are now being 
encouraged to become members of their local Primary Care Groups to help to 
'contribute to health improvement programmes, promote the health of the local 
population, commission health services, monitor performance and develop primary 
care' (SODoH 1998). 
1.11.3 Models of pharmaceutical input to primary care prescribing 
Recent white papers on primary care have encouraged initiatives to improve 
primary care prescribing, inter-professional co-operation in service provision and 
greater skill mixing (SODoH 1996 (A) and (B)). The types of prescribing review 
initiatives which have been implemented by pharmacists have been reviewed by 
Bradley et al (1997) and include review of repeat prescnoing (Davidson et aI1998), 
total medication review (Beech and Brackley 1996) and the analysis of PACT data 
(Bevan 1996). Other collaborative training activities involving pharmacists and GPs 
have in uncontrolled studies been shown to improve prescribing (Wood et a11997, 
Roberts et al 1997). 
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Other initiatives include the development, monitoring and updating of practice 
formularies (Jenkins 1994), the development of prescribing policies (Fisher and 
Dunning 1998) and prescribing audit by disease (Moorhouse et al 1996). As more 
medicines are re-regulated / deregulated, pharmacists have also developed their 
advisory role to improve the appropriate use of medicines and the treatment of 
minor ailments (Whitaker et al 1995) and in health promotion (Ghalamkhari et al 
1997(A)). 
Pharmacists are increasingly employed full time or on a contractual basis 
within GP practices to aid in the control of prescribing budgets by providing 
appropriate drug information and developing prescribing policies (Mason 1996). 
Such pharmacists have then been able to establish disease-specific clinics including 
pain control (MacGregor 1996), anticoagulation (MacGregor et al 1996) and 
Helicobacter pylori (H Pylori) eradication (Moorhouse et aI1996). 
Many of these models however, have been small pilot studies, lacking controls 
with outcome data limited to specific objectives with minimal evaluation of the 
impact of pharmaceutical care and the cost-effectiveness of such schemes (Lipowski 
1996). However, some models have utilised controls (Thompson et aI1984). 
Pharmaceutical outcome data in primary care research has tended to include 
process outcomes such as the extent of uptake of pharmacists' recommendations by 
GPs (Naylor and Oxley 1997) and the number and type of clinical interventions 
made (Beech and Brackely 1996). The latter have often been evaluated by a clinical 
expert panel (Caleo et al 1996, Begley et al 1996). Financial outcome data has 
included the consequences of medication changes on prescribing costs (Beech and 
Brackley 1996), fmancial implications of improved stock control (Dixon et al 1995) 
and the implications of medication changes in preventing hospital admissions or 
readmissions (Thompson et aI1984). 
As more primary care pharmacists are getting involved in medicines' 
management via disease-specific clinics, the impact of pharmaceutical intervention 
on patient outcome is increasingly being evaluated in terms of validated quantitative 
clinical indicators. Pharmacists have utilised INR control in anticoagulant clinics 
(MacGregor et al 1996), eradication of H Pylori (Moorhouse et al 1996) and other 
biochemical parameters (Broderick et al 1992) to evaluate pharmaceutical 
interventions. Qualitative outcomes are also being investigated such as patient 
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concordance with medication (Fairbrother et a/1993, Naylor and Oxley 1997) and 
patient satisfaction (Long and Wynne 1996), but few pharmacists have utilised 
validated tools to assess patients' health related quality of life. Some pharmacists 
have used validated QOL tools to evaluate the impact of their interventions, but 
most studies have been using small sample sizes or have questioned the validity of 
such tools when applied to pharmaceutical care (Stewart 1997,Tully and Cantrill 
1998). 
1.11.4 Medication review and the role of domiciliary visits 
Medication review can be described as 'the systematic evaluation of 
medication therapy' (Sommerville 1996). Such a review has been effectively 
undertaken within patients' homes, domiciliary medication review, (Dixon et ai, 
1995, Beech and Brackley 1996, Naylor et al 1997), community pharmacies 
(Goodyer et a/1996) and other care environments such as nursing homes, residential 
homes or care centres (Somerville 1996, Rees et a/1995, Goldstein et a/1995). 
Pilot projects have, over the last 10 years, evaluated the model of domiciliary 
medication review as a strategy to identify medication, compliance and storage 
problems, to provide appropriate drug information or other health advice to patients 
and carers, and to refer to other health professionals as appropriate (Royal 
Pharmaceutical Society of Great Britian 1988, Fairbrother et a11993, Goldstein et al 
1995, Naylor and Oxley 1997). 
Patients who have been targeted for such a review have usually been frail, 
elderly, confused or have special needs (SODoH 1996, The Royal College of 
Physicians 1997, Thompson et al 1984). Such patients are often on multiple 
medication, are left to manage their medication unaided or often have carers with 
limited drug information (Goldstein et al 1995), whose therapy is poorly monitored 
leading to hospitalisation (Col et aI1990). Other researchers have targeted a specific 
patient group by identifying those patients on selected repeat medicines (Dixon et al 
1995). 
Controlled studies have assessed the influence of domiciliary medication 
review by phannacists on elderly patients recently discharged from hospital (Begley 
et al 1996), or in residential or nursing homes (Rees et al 1995, Thompson et al 
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1984). Such studies suggest that pharmacists have a very important role in 
maximising the efficacy and minimise the toxicity of medication in such patients 
and reducing hospital admission rates. 
The cost-effectiveness of domiciliary intervention has been assessed in terms 
of reducing costs due to hoarding of medicines (Dixon et al 1995), minimising 
inappropriate prescribing (Mackie 1997, Beech and Bracldey 1996) or adverse drug 
reactions (Begley et al 1996) and improving quality of life (Krska 1998). The 
studies of Begley et ai, 1996, Krska 1998 and Mackie 1997 were randomised and 
controlled, the two latter studies using large patient groups. 
1.11.5 Roles of the pharmacist in the management of chronic pain in 
primary care 
Many patients with chronic pain have benefited from management by a 
hospital-based multidisciplinary pain team (Hardy and Hill 1996). 
The role of the pharmacist within a hospital chronic pain clinic (Reisner-Keller 
1992) or a rheumatology clinic (Kay 1997) is well established. Such pharmacists 
provide appropriate drug information to patients, nurses and clinicians, ensure 
patient compliance with and understanding of their medication prior to discharge 
and that appropriate therapy is provided and monitored for each patient (Snell 1993). 
This role is not unique to pharmacists since a recent randomised controlled 
trial has demonstrated that nurse practitioners can effectively manage chronic pain 
using drug therapy, referral to other health professionals and patient education (Hill 
et a/1997). However, this was a small study, which did not identify pharmaceutical 
needs. 
It has been estimated that 50% of the population suffer from chronic pain, (C 
Smith, personal communication). The majority of these patients are managed in 
primary care using analgesic and NSAID therapy, often inappropriately and use non-
prescription medicines and alternative therapies to improve pain control (Long and 
Wynne 1996). There would therefore appear to be a need to investigate further the 
management of patients with chronic pain in primary care, perhaps as part of a 
chronic pain team (MacGregor 1996). Although pharmacists have encouraged the 
development of guidelines for the management of chronic pain (MacGregor 1996), 
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there has been no evaluation of the outcomes of patients with chronic pain in tenus 
of pain control and quality of life using validated measurement scales before and 
after pharmacist intervention. This study was designed to determine the potential for 
pharmacist input into the management of such patients, using appropriate outcome 
measures. 
General practitioners and community pharmacists previously expressed mixed 
views about pharmacist involvement in chronic pain management (Begley et al 
1994). However more recent work has shown that medication review and the 
development of pain clinics by pharmacists was rated favourably by GPs (Weir et al 
1997). In this study, the attitudes of not only GPs and community pharmacists but 
also physiotherapists towards pharmacists working within a chronic pain team were 
evaluated to identify the extent of support for the pharmacist's developing role in 
chronic pain management. 
1.12 Aims of the Study 
The aims of this research were: 
• To evaluate the use and efficacy of analgesics in the management of 
chronic pain in the community 
• To identify the potential role(s} of a pharmacist in the management of 
chronic pain in the community. 
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1.13 Objectives of the Study 
The objectives of this research were: 
• To determine the prescribing patterns for analgesics and other pain-related 
therapies in a cluster sample of patients with chronic pain living in their 
own homes 
• To determine the extent of patient adherence to prescribed therapy, the 
influence of patient attitude to pain, medicines and prescribers on this 
adherence 
• To investigate the pain experienced by patients and the differences, if any, 
between those with different pain diagnoses in terms of intensity, quality 
and description, using VAS and the McGill pain questionnaire 
• To investigate any effect of diagnosis and pain on quality of life 
• To investigate the reliability, validity, and sensitivity of the QOL scale used 
• To measure any differences between pain experienced at initial and follow-
up interview by the patients who had poor outcomes and were referred for 
. 
reVIew 
• To investigate the overall influence of pain on activities of daily living and 
mood, as experienced by patients, quality of life and the differences 
between those with satisfactory and poor overall outcomes in pain and 
quality of life scores 
• To identify side effects reported by the study patients and the extent of 
documentation of monitoring parameters for efficacy and toxicity 
• To quantify the types of pharmaceutical input needed by patients with 
chronic pain in primary care 
• To evaluate the attitudes of community pharmacists, GPs and 
physiotherapists towards the perceived role( s), if any, for the pharmacist 
within a chronic pain team 
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Chapter 2 
Methods 
2.1 Evaluation of chronic pain management in the community 
2.1.1 Ethical Committee and GP sub-committee approval 
Ethical Committee approval was sought and obtained from the Ethics 
Committee of Lanarkshire Health Board and by the Joint Ethical Committee of 
Grampian Health Board and the University of Aberdeen. Copies of both letters are 
included in Appendices 2 and 3. 
Approval was sought and obtained from all the general practitioners in the 
Oldmachar Medical Practice, Burnbank and Strathaven Health Centres, to allow the 
study pharmacist to access appropriate medical notes and to interview patients in 
their homes. A copy of the letter which was completed by all selected practices is 
included in Appendix 1. 
2.1.2 GP Practice selection 
Three GP practices were selected for inclusion in the study to investigate 
analgesic prescribing patterns, patient perception of pain and pain management 
Cluster sampling was carried out involving one GP practice in Aberdeen and two 
practices in Lanarkshire with whom the researcher had previous contact. 
One GP within each practice liaised regularly with the study pharmacist during 
the developmental stages of the project. Wherever possible, the liaison GP was the 
GP whom the researcher had previously worked with or knew personally. 
A synopsis of the demographic and clinical details of each of the 3 GP 
practices is provided in Table 2.1 
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Demographic Practice 1 Practice 2 Practice 3 
details (Aberdeen) (Strathaven) (Hamilton) 
Number ofGPs 7 3 5 
Number of patients 11345 5211 8494 
Number of 74 30 20 
documented RA 
patients 
Number of 647 194 382 
documented patients 
on repeat Rx NSAIDs 
and / or combination 
analgesics 
Table 2.1: A synopsis of demographic details of the 3 GP practices in 1994 
2.1.3 Criteria for poor outcome 
Patient outcomes were defmed in terms of pain control, quality of life, 
experience of side effects and patient attitude. The criteria for a poor outcome were 
defmed as at least one of the following: 
• Poor pain control (VAS average greater than 75) (Read 1989) and / or poor 
quality of life (total QOL score greater than 35) (Williamson et a11993) 
• Signs and / or symptoms described by a patient on interview which were 
suggestive of a significant adverse drug reaction 
• Deliberate change in therapy by patient due to lack of awareness of rationale for 
therapy 
• Patient who was dissatisfied with current medication at time of interview and 
requested alternative management 
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2.1.4 Criteria for DMARD monitoring 
Appendix 4 details the general protocol with which DMARD monitoring was 
compared in this study (Medicines Resource Centre 1996), since variations in 
protocols between practices were very limited. 
2.1.5 Patient sample size and patient selection 
A power calculation was made to estimate the sample size required to 
demonstrate a statistically significant difference in patients' pain or QOL (quality of 
life) scores after an intervention. It was found that a sample size of 13 patients 
would be required to achieve a difference of 10 units between pre and post 
intervention for VAS (mm), QOL or total PRI scores, at a power of 80%, p = 0.05. 
All patients in each practice in whom a defmitive diagnosis of rheumatoid 
arthritis had been made were included in the study. In addition, in each of the 3 
practices, every eighth patient from each practice list who was documented as 
receiving repeat prescriptions for combination analgesics, NSAIDs or any other 
analgesics was included in the study to provide a random sample of 60 patients from 
each practice. Patient information was retrieved using the practice computer system 
(General Practice Administrative System for Scotland, GPASS). Patients who were 
excluded were those under 18 years of age, patients unwilling to participate or who 
had malignant pain and those patients considered by their general practitioner to be 
unsuitable for inclusion e.g. significant mental impairment. 
All patients who were eligible for inclusion were sent a patient information 
leaflet about the project (Appendix 5) and asked to give written consent prior to 
being interviewed (Appendix 6). All of the patients who did consent to participate 
were either telephoned or written to by the study pharmacist to arrange a mutually 
convenient date and time for the frrst interview. 
Wherever possible, the study pharmacist telephoned or wrote a second letter to 
all patients who were potentially eligible, but who had not replied after the frrst 
mailing. 
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One hundred and nine out of the total 180 patients who were initially 
sampled from the three practices were identified. Fifteen of the 180 patients were 
unwilling to participate, 24 were dead, 17 could not be contacted using the address 
and I or telephone number noted in the respective medical notes and 15 were no 
longer taking any painkillers. 
Initial patient interviews in all three sites took place between July 1993 and 
June 1994. 
2.1.6 Development of data collection tools 
2.1.6.1 Information retrieval from medical records 
A data collection form was devised to permit retrieval of relevant information 
from the medical notes of all patients who gave written consent (Appendix 7). The 
data collection form included: 
1. Demographic information: age, sex, marital status and occupation - factors 
which can directly or indirectly influence pain. 
2. Medical information: diagnosis of type(s) of chronic pain, duration of the pain 
state(s), concurrent disease states, biochemical and haematological data. 
3. Drug information: current medication prescribed for chronic pain and any other 
concurrent disease states and medication history details. 
4. Other information relating to the management of chronic pain: present and past 
use of exercise, physiotherapy and use of aids for daily living. 
The form was piloted on 10 hospital inpatients with a diagnosis of RA. Very 
slight modifications were made to the data collection form in terms of layout i.e. 
tabulation of biochemical, haematological and other data in one rather than separate 
tables. 
2.1.6.2 Development of attitude statements 
Twenty attitude statements in total were developed by the study pharmacist, 
based on patient, physical and psychological factors which were known to influence 
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both patient concordance with medication (Britten 1996) and chronic pain 
management (Reisner-Keller 1992): 
Ten attitude statements related to patient concordance with medication 
including statements which aimed to identify patient attitude to and trust in his I her 
GP, attitude to prescribed and self-medication, patient health beliefs and awareness 
of side effects associated with long-term analgesic use. Ten attitude statements 
related to the management of chronic pain including statements which aimed to 
identify patient perception of chronic pain, patient understanding of the 
consequences of chronic pain (depression, lack of complete pain relief, side effects 
associated with chronic analgesic use), patient perception of the role of medication, 
exercise and self-management techniques in the management of chronic pain. 
2.1.6.3 Development of the pain questionnaire 
A pain questionnaire (Appendix 8) was developed for use by the study 
pharmacist to assess: 
• patients' pain perception in terms of quality and intensity using the McGill Pain 
Questionnaire (MPQ) and visual analogue scales 
• the influence of pain on patients' quality of life, particularly on activities of daily 
living using verbal descriptors 
• patients' attitude to pain, pain management and awareness of the implications of 
chronic pain (see section 2.1.6.2) 
The pain questionnaire included 2 visual analogue scales used to assess each 
patient's assessment of their 'ideal' analgesic and perceived efficacy of prescribed 
analgesia (questions 24 and 35). 
To assess the impact of chronic pain on patients' behaviour, mood and 
activities of daily living, statements which had been included within a previously 
validated questionnaire were used (Williamson et af 1993). The whole of the 
questionnaire could not be used in this study, due to its original length (69 items) 
and inappropriateness of some of the statements i.e. some statements related 
specifically to patient perception of chemotherapy. 
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Thus 14 of the 50 statements used by Williamson et al1993 were incorporated 
into the pain questionnaire (questions 9-22) covering 4 dimensions of physical, 
social, occupational and psychological status. The 14 statements were chosen 
because their individual scores had the highest correlations with their respective 
dimension scores in that study as compared to the scores of the other 36 statements. 
This rmding suggested that these 14 statements well reflected specific dimensions 
and could be utilised in an abbreviated form of the original questionnaire. 
The 14 statements used to derme the 4 dimensions (physical, social, 
occupational, psychological) were: 
• mobility, sleep and appetite (statements 9,11,12 and 19) - physical status 
• enjoyment of life, support of friends and planning of activities (statements 17,20 
and 21) - social status 
• ability to do household chores and any other activities and change in work 
circumstances, (statements 10,18 and 22) - occupational status 
• anxiety, depression, loneliness and frustration (statements 13-16) - psychological 
status 
A Likert descriptive rating scale was used to score each statement, where 
patients were asked to rate the extent to which each statement applied to them at the 
time of interview (Williamson et aI1993). The ratings were such that 0 = not at all, 
1 = a little, 2 = a fair amount, 3 = a lot, 4 = very much indeed. All patients 
completed their own appraisals independently, and could ask the study pharmacist to 
clarify any statements if necessary. 
The questionnaire also included open questions to assess each patient's 
analgesic usage and understanding of their analgesic therapy to identify: 
• what medication they were receiving for their pain (question 25) 
• when and how often they used their medication (questions 26 and 30) 
• patients' use of OTe or alternative therapies either instead of or in addition to 
their prescribed analgesics (questions 32-34) 
• patient awareness of side effects with long-term analgesic use (question 37) 
• patient concordance with prescribed medication (questions 27-29) 
- 41 -
2.1.6.4 Piloting of the attitude statements and pain questionnaire 
In June 1993, the attitude statements were initially piloted on 10 hospital 
pharmacists, 10 inpatients with a diagnosis of RA in a rheumatology ward in 
Aberdeen City Hospital and 10 family and friends prior to inclusion into the pain 
questionnaire. All were asked to identify how well the statements could be 
understood and read. Responders were also asked to indicate whether they strongly 
agreed, agreed, were uncertain, disagreed or strongly disagreed with each statement 
and whether they perceived the statement to be positive or negative. Any ambiguous 
statements or statements with which responders were consistently 'uncertain' were 
discarded. 
Eleven of the original 20 statements were both clearly understood and 
described by the majority of responders (at least 24 out of the 30 responders) as 
positive or negative statements. Four of the 11 statements were related more to 
knowledge than attitude, with no responders strongly agreeing or disagreeing with 
the statements. Thus these 4 statements were incorporated within the pain 
questionnaire with true / false / uncertain options (questions 37-40 of Appendix 8) 
instead of the graded Likert scale (strongly agreed, agreed, were uncertain, disagreed 
or strongly disagreed) (questions 2-8 of Appendix 8). Questions 2,3,5,6,7,39 were 
defmed as positive statements whereas questions 4,8,37 and 38 were defmed as 
negative statements. 
For questions 2-8, the highest score for positive statements was attributed to 
those who strongly agreed with the statement, whereas the highest score for a 
negative statement was attributed to those who strongly disagreed. For questions 37-
40, the highest score was given to those responders who answered the statement 
correctly e.g. for question 38 (persistent pain can make you depressed), the highest 
score was given to those responders who indicated 'true'. 
At least 60% of responders were uncertain regarding their response to 7 of the 
18 statements which were concerned with specific side effects and less well known 
consequences of chronic pain, thus the statements were discarded. 
The pain questionnaire was initially piloted for face and content validity on 10 
inpatients with a diagnosis of RA in a rheumatology ward in Aberdeen City 
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Hospital, a multidisciplinary group of 4 researchers in chronic pain and 10 family 
and friends. All participants were asked to comment on the relevance and clarity of 
the questions and the extent to which they perceived the questionnaire's content 
appeared to examine and include the full scope of chronic pain issues. A few 
modifications to the sequence of questions and wording of the attitude statements 
were carried out as a result. 
The original questionnaire started with questions relating to medication-taking 
(questions 4-8) which may have biased the response to question 2 'Doctors know 
what is right for their patients'. After the pilot, the more general questions about 
attitude to prescriber and outcome as a result of taking painkillers (questions 2 and 
3) preceded questions 4 to 8. The word 'medication' in statements 4 and 5 was 
changed to medicine after piloting to improve readability. 
2.1.7 Data collection 
All relevant information from each patient's medical notes was collected 1 -
2 days prior to an interview in the patient's home using the questionnaire. Data 
collection prior to frrst interviews in all three sites took place between July 1993 and 
June 1994. 
Assessment of chronic pain was carried out during each interview using the 
MPQ and visual analogue scales. 
The McGill Pain Questionnaire defmes pain in terms of three major 
dimensions i.e. sensory, affective and evaluative, such that the questionnaire consists 
of 20 categories of words to describe the pain experience (MeIzack 1975). Patients 
were asked to select the categories which they recognised as relevant to their pain at 
time of interview, and to circle the most appropriate word within each category. If 
none of the words within a category applied, none were chosen. 
Within the MPQ, patients were also asked to rate present pain intensity (PPI) 
on a 0 to 5 verbal descriptor scale where 0 = no pain to 5 = pain is horrible. All 
patients were also asked to mark on a body drawing, the areas where he I she 
actually felt pain to assess the correlation between a patient's perceived pain and the 
established pain diagnosis. 
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Visual analogue scales (VAS) were used to record (1) each patient's subjective 
assessment of pain intensity and (2) each patient's subjective assessment of their 
'ideal' analgesic and their perceived efficacy of prescribed analgesia. All VAS 
scales used were horizontal lines of 10cm. 
Appendix 9 details the 3 visual analogue scales used to assess pain intensity at 
its worst over the past month (VAS worst), pain on average (VAS average) and pain 
at time of interview (VAS now). Each VAS was marked at one end by zero (no 
pain) and at the opposite end by 10 (pain as bad as you can imagine). Patients were 
asked to place a mark on each of the 3 lines at a point which represented the severity 
of their pain. 
Each VAS used to assess pain relief was marked at one end by 0 (no relief) to 
1 00 (complete relief). Patients were asked to place a mark on each of the 2 lines at a 
point which represented respectively, their 'ideal' pain relief (question 24) and the 
pain relief achieved with medication (question 35). 
During each interview, all patients could discuss more fully the impact of their 
pain on activities of daily living, if they felt so prompted. The study pharmacist 
transcribed the patients' verbal accounts of their experiences and feelings 
immediately after the interview. 
For seven of the 11 attitude statements, all patients were asked to indicate 
whether they strongly agreed, agreed, were uncertain, disagreed or strongly 
disagreed with each statement. The statements aimed to assess patient attitude to his 
/ her GP (questions 2 and 5), patient attitude to and concordance with medication 
especially analgesia (questions 3,4,7,8) and patient attitude to pain control (question 
6). 
The four other statements which were used in the pain questionnaire 
considered patients' knowledge of chronic pain rather than attitude, in terms of the 
problems associated with the long-term use of analgesic medication (questions 36) 
and long-term pain (questions 37-39). For each of the 4 statements, all patients were 
asked whether the answer was true, false or they were uncertain. 
If a discrepancy was found between the medication identified by the patient as 
currently being taken (analgesic or any other medication), with that documented in 
the medical notes prior to interview, the pharmacist asked open questions to identify 
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if the patient had deliberately made changes to his / her therapy, and if so, whether 
these changes had been discussed with his / her GP. 
During the interviews, the patients were asked if they had ever experienced 
any problems, which they thought could be attributed to their medication. Some 
prompt words to help defme the word 'problem' i.e. stomach upset, constipation, 
were written in the questionnaire for the benefit of the study pharmacist, but the 
study pharmacist did not convey these prompt words to any of the patients. Patients 
could report on side effects attributed to any of their past or current medication. 
All patients were given an opportunity to ask any questions relating to their 
past or current medical problems, past or current drug therapy or any other 
pharmaceutical query. The study pharmacist provided verbal advice, a 
manufacturer's patient information leaflet, information leaflets from Aberdeen City 
Hospital or compliance charts, wherever possible. Referral of patients to any other 
health care team member was also made where the pharmacist deemed it 
appropriate. 
2.1.8 Intervention procedures 
All poor outcomes were referred to the respective GP of each patient. GP 
referrals included those patients in whom a particular problem had already been 
identified by the GP, but was not documented in the patient's medical notes prior to 
the pharmacist's interview with the patient. These problems were acknowledged by 
each GP verbally by telephone or interview with the study pharmacist. 
2.1.9 Follow-up of patients with poor outcomes 
A further assessment was made, where possible, during a second interview if 
patients had had poor outcomes on the fast interview. This second interview 
occurred 4 to 6 weeks after action was taken following the pharmacist's 
recommendations or 4 to 6 weeks after the fast interview if GP did not act on 
advice. This second interview occurred between September 1993 and September 
1994 and was performed by the same study pharmacist using the same assessment 
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tools i.e. pain questionnaire, data collection form to obtain information from notes, 
and MPQ and VAS scales as were used during the fIrst interview. 
2.2 Role of the pharmacist in chronic pain management 
2.2.1 Development of attitude statements 
Twelve attitude statements were initially developed by the study pharmacist in 
November 1995 to identify factors which influenced the attitude of health 
professionals towards the management of chronic pain such as patient factors and 
management strategies. The statements were developed from present knowledge 
concerning patient compliance (Stockwell Morris and Schulz 1992), chronic pain 
and its management (O'Hara 1996) and attitudes to the developing role of 
pharmacists in primary care particularly in chronic pain management ( Begley et al 
1994). The attitude statements were incorporated into a postal questionnaire. 
2.2.2 Development of questionnaires 
Postal questionnaires were developed in November 1995 to determine 
professional details and practice relating to chronic pain management for 
distribution to GPs, community pharmacists and physiotherapists. 
The questionnaires asked responders to identify factors from a specified list 
within the questionnaire which they believed influenced the management of chronic 
pain. All responders were also asked to state whether they strongly agreed, agreed, 
disagreed or strongly disagreed with the list of attitude statements relating to chronic 
pain management. Attitudes to pain management were assessed to determine 
whether any differences existed between OP, pharmacist or physiotherapist groups. 
All groups were asked to identify the potential role(s) of the pharmacist, if any, 
within a multidisciplinary team and more specifically, in the management of chronic 
. pam. 
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In addition, the questionnaires sent to GPs were designed to obtain: 
(1) practice details: number of patients in the practice, number of GPs per 
practice. 
(2) information to assess the current extent of clinical interaction with 
pharmacists 
Questionnaires sent to pharmacists were designed to obtain: 
(1) professional details e.g. work experience, number of pharmacists 
employed per pharmacy, information about current clinical services provided 
and those which the pharmacist would be keen to initiate and / or develop. 
(2) information concerning communication with GPs e.g. the type and 
frequency of queries which they conveyed to GPs, modes of communication 
employed and the extent of feedback received. 
Physiotherapists' questionnaires included professional details such as the main 
site and source of employment and work experience. 
2.2.3 Piloting of the questionnaire 
Five general practitioners, 5 community pharmacists and 5 physiotherapists in 
an area outwith the research areas, were recruited between December 1995 and 
January 1996 as a pilot group to investigate the questionnaire in terms of clarity, 
readability and content. All the pilot group completed the initial postal 
questionnaire. All responders were asked to indicate whether they strongly agreed, 
agreed, were uncertain, disagreed or strongly disagreed with each statement. 
After feedback from the pilot group, some changes were made to the number 
of attitude statements, wording and layout of the questionnaire. Two of the attitude 
statements were omitted from the fmal questionnaire. The majority of the pilot 
group (11 out of 15) regarded one of the 2 statements 'A patient with chronic pain 
exaggerates the pain which he / she feels' as ambiguous , while another statement 
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'Pharmacists should provide appropriate drug information to help optimise pain 
control' was regarded by 10 of the 15 as too leading a question. 
The wording of the instructions for completion of Section B of Appendices 12 
and 13 was modified to improve readability i.e. the instruction 'From the list below, 
decide which, if any of the factors, can prevent optimum control of chronic pain' 
was modified to 'Please tick any of the factors listed below which you feel are 
preventing you from optimising control of chronic pain'. 
Each of the 3 questionnaires was modified to improve its layout in terms of 
clarity and readability. Each of the section headings A, B and C of each 
questionnaire was bolded and enlarged to be more distinctive and additional space 
was provided within tables. 
2.2.4 Selection of study sample 
GPs, community pharmacists and physiotherapists were selected since they 
have important roles in pain management (Hardy and Hill 1990, Briggs et al 1996). 
Lists of the names of GPs and their respective practices, names of community 
pharmacies and their respective proprietors and names of community 
physiotherapists and their work bases were obtained from the Health Boards, Chief 
Area Pharmaceutical Officers and Senior Community Physiotherapists of the 
Lanarkshire and Grampian regions of Scotland. 
Thereafter, 100 GP practices, 100 community pharmacies and 50 
physiotherapy work bases were randomly selected in Aberdeen and Lanarkshire, 
which represented 60% and 63% of the total number of GP practices and 62% and 
60% of community pharmacies in Aberdeen and Lanarkshire respectively. Random 
selection of 50 physiotherapy work bases represented 69% and 92% of the 
physiotherapy work bases in Aberdeen and Lanarkshire respectively. Every eighth 
health care professional from each of the lists was selected. Only one practitioner 
was identified from each of the selected surgeries, pharmacies or physiotherapy 
sites. 
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2.2.5 Mailing procedures 
A revised questionnaire was then sent to each GP practice, phannacy and 
physiotherapy work base (see Appendices 11,12 and 13 respectively), accompanied 
by a covering letter (Appendix 10). 
The postal questionnaire study was run over a 3 month period from January to 
March 1996 and all health care professionals were given a 4 week deadline for 
completion and return of questionnaire in the stamped-addressed envelope provided. 
One further follow up letter was sent to non-responders in April 1996. The initial 
response rate was 60 out of 100 GP practices, 57 out of 100 community phannacies 
and 30 out of 50 community physiotherapist bases. Subsequent response rate 
improved the fmal response to 63 GP practices, 59 community phannacies and 33 
physiotherapy work bases. 
2.3 Data analysis 
2.3.1 Analysis of data from medical records 
The data collection forms were used to provide background clinical 
information and to identify any types and frequencies of discrepancies between 
documented drug histories in medical records and drug histories obtained at time of 
each patient interview. 
The appropriateness of biochemical and haematological monitoring which was 
actually documented by the practices, was assessed in terms of each patient's 
concurrent disease states, current therapy and any local protocols e.g. monitoring of 
DMARDs. Comparison was made of the documented monitoring of the DMARDs 
used in the study patients with our criteria as shown in Appendix 4. 
2.3.2 Patient Groupings 
Patients were categorised in terms of pain diagnoses (RA, OA, OA and RA or 
back pain). Patients were also grouped in terms of outcome at frrst interview i.e. 
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satisfactory or poor outcomes. Data for patients with poor outcomes was further 
evaluated in terms of those who had high VAS pain scores (greater than 75) and 
those who were interviewed after pharmacist intervention, to investigate the 
contribution of VAS scores to the assessment of poor outcomes. 
2.3.3 Analysis of MPQ data 
Pain scores for each patient were calculated in 4 ways, as described by 
Melzack (1975). 
• The sum of the scale values for all the words chosen across all categories, a total 
Pain Rating Index Score or PRI (S) score, or a PRI (S) score within a category 
e.g. (PRI (S) evaluative), could be calculated. The median and 95% confidence 
interval of the median PRI (S) were also calculated for all 96 patients at 
Interview 1 
• Similar Pain Rating Index Scores using rank values instead of weighted scale 
values were calculated e.g. a total PRI ® score, or a PRI ® score within a 
category e.g. (PRI ® evaluative). The median and 95% confidence interval of the 
median PRI ® were also calculated for all 96 patients at Interview 1 
• By totalling the number of words chosen (NWC) from the 20 categories within 
the MPQ, a NWC score was calculated at each interview. The median NWC and 
95% confidence interval of the median NWC were also calculated 
• The Present Pain Intensity Score (PPI) from 0 to 5 was also determined. The 
median PPI and 95% confidence interval of the median were also calculated 
All patients were given every opportunity to ask the study pharmacist if they 
were unsure of the meaning of any of the words. Each patient completed the 
questionnaire only in the presence of the study pharmacist. 
The Wilcoxon matched pairs signed rank sum test was used to investigate the 
within patient differences in NWC, total PRI® and PRI (S) and PPI scores in 
patients who were interviewed on a second occasion after the study pharmacist's 
recommendations were carried out. Differences were significant ifp < 0.05. 
2.3.4 Analysis of VAS data 
VAS scores were calculated by measuring the distance of each patient's mark 
from the lower end of the scale, measured in millimetres, ranging from 0 to 100. 
Individual VAS scores were presented as mUltiples of5. 
Since the distribution of VAS scores is not normal, non-parametric statistical 
analyses are generally considered more appropriate than parametric analyses 
(McDowell and Newell 1996). Thus medians and 95% confidence intervals of the 
medians were calculated to defme the average value and explicit uncertainty of the 
median respectively, of each VAS scale which was used instead of means. 
Differences were significant ifP < 0.05. 
The Wilcoxon matched pairs signed rank sum test was used to investigate the 
within patient differences in VAS scores in patients who were interviewed on a 
second occasion after the study pharmacist's recommendations were carried out. 
Any tied ranks within each set of patients were accounted for. Differences were 
significant ifP < 0.05. 
Reliability of the MPQ and VAS pain scales was assessed by determination of 
Pearson correlation coefficients for all patients after Interview 1 (n-96). 
Correlations were calculated between VAS average scores and total PRI (S) or PRI 
® scores and between NWC and VAS average scores. 
Chi-squared tests (2x2) were used to compare any differences in VAS pain and 
pain relief, NWC, PPI and total PRI rank and scale scores between those patients 
with satisfactory and those with poor outcomes. Differences were significant if P < 
0.05. 
- 51 -
2.3.5 Analysis of QOL statements 
Two quality of life scores were created as discussed by Williamson et al 1993 
to assess sensitivity and reliability of the scale: 
• A total QOL score - the sum of the individual scores achieved for each statement 
which was appropriate for each patient, divided by each patient's maximum 
possible score. This score was then calculated as a percentage. (Not all 
statements were always relevant to all patients i.e. retired patients could not rate 
the influence of pain on work, thus the maximum possible score varied between 
patients). A high score indicated poor quality of life. The median total QOL 
score and 95% confidence interval of the median were calculated 
• A dimension score (physical, social, occupational and psychological) - the sum 
of individual scores achieved for each statement within a specific dimension 
divided by each patient's maximum possible score. This score was then 
calculated as a percentage. A high score indicated poor quality of life. The 
median score and 95% confidence interval of the median were calculated for 
each dimension 
• When the sample size was small, the range was used instead of the 95% 
confidence intervals for the above QOL scores 
Reliability of the quality of life scales was assessed by determination of 
Pearson correlation coefficients, split-half reliability using the Spearman-Brown 
'prophesy' formula and by calculation of Cronbach's alpha (Streiner and Norman 
1995). The Spearman-Brown 'prophesy' formula was used to correct for any 
underestimation of the scale's true reliability when split into 2 sub-scales. 
Correlations were calculated between: 
(1) the total QOL score and each dimension score (physical, social, occupational 
and psychological) for all patients 
(2) each individual QOL statement score within a dimension and the appropriate 
dimension score 
(3) each individual QOL statement score within a dimension and total quality of 
life scores 
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(4) total quality of life scores and total PRI(S) or PRI ® scores and VAS average 
. pam scores 
The Wilcoxon matched pairs signed rank sum test was used to investigate the 
within patient differences in quality of life scores in patients who were interviewed 
on a second occasion after the study pharmacist's recommendations were carried 
out. Any tied ranks within each set of patients were accounted for. Differences were 
significant ifP < 0.05. 
Chi-squared tests (2x2) were used to compare any differences in QOL scores 
between those patients with satisfactory and those with poor outcomes. Differences 
were significant if P < 0.05. Yates' correction was used to minimise any bias 
associated with analysis. 
2.3.6 Analysis of patient attitude 
A score between 1 to 5 was assigned to each of the 5 potential responses (i.e. 
strongly agree, agree, uncertain, disagree, strongly disagree) for each of the 7 
attitude statements described in questions 2 to 8 of the pain questionnaire (section 
2.1.7). A high score implied a positive attitude. The total score achieved was divided 
by the maximal score for all 7 statements to create a percentage score. This score 
was then compared to pain control and quality of life scores using correlation 
coefficients. 
2.3.7 Analysis of questionnaires 
The Kruskal-Wallis and Mann-Whitney U tests (if appropriate) were used to 
compare differences, if any, in response to attitude statements to pain management 
between GPs, community pharmacists and physiotherapists. The same tests were 
applied to compare differences, if any, in response to attitude statements between 
patients with RA, OA, RA and OA and back pain. Analysis accounted for tied 
rankings. 
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2.3.8 Analysis of advice provided 
All patient information requests and advice provided by the study pharmacist 
were collated in terms of types and frequencies of query according to disease state 
. I.e.: 
1. Information concerning management of chronic pain. This category included 
drug information relating to patients' past or current therapy for chronic pain 
(excluding side effects). 
2. Specific side effects associated with patients' therapy. 
3. Drug information concerning any other current medical problem of a patient 
(excluding chronic pain). 
4. General drug information requests from patients e.g. compliance aids. 
Patient information requests and advice provided by the study pharmacist 
were also classified as reinforcement, clarification, correction or follow up with the 
prescriber. The pharmacist'S proposed solution to a patient's problem could involve 
more than one of these categories e.g. A patient may have required clarification and 
correction if he / she was not only confused about how to take the medication, but 
had also admitted to taking it inappropriately. 
1. Reinforcement- the pharmacist needed to reassure the patient that he / she was 
taking her medication correctly and that the therapy prescribed was appropriate. 
2. Clarification .. the pharmacist provided relevant information to solve any 
patient confusion about his / her therapy. 
3. Correction- the pharmacist needed to provide advice to prevent a problem 
from occurring or solve an existing problem. 
4. Follow up with prescriber - the pharmacist deemed a problem sufficiently 
serious to refer to the patient's GP. Referrals concerning chronic pain problems 
were considered separately from any other medical problem which required 
referral, but all were referred to the patient's GP. 
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2.3.9 Use of computer packages 
Epi-Info 5 software (Dean et a11990) was used to create the pain questionnaire 
(Appendix 8) and health professional assessment questionnaires (Appendices 11-13) 
and to analyse their respective results. All 3 main programmes of EPI were used. 
A Microsoft Excel spreadsheet was used to calculate medians and confidence 
intervals of non .. parametric data and correlation coefficients between VAS scales, 
MPQ pain scores and QOL scores. 
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Chapter 3 
Use of prescribed and alternative therapies in patients with chronic 
pain in the community 
3.1 Introduction 
Adherence to guidelines for the management of patients with chronic pain 
associated with rheumatoid arthritis, osteoarthritis and back pain should encourage 
more cost-effective prescribing (Anon 1994, 1996 (A) and (B), Clinical Standards 
Advisory Group 1994). 
As mentioned previously, the therapeutic drug management of rheumatoid 
arthritis has changed recently with rheumatologists now using DMARDs much 
earlier in the disease. 
However, NSAIDs continue to be extensively used and are probably over-
prescribed (Audit Commission 1994, Steele et al 1987). In addition, Donovan et al 
(1989) and McElnay and McCallion (1996) found that patients were increasingly 
buying OTC analgesics in addition to or in preference to their prescribed analgesic 
therapy, suggesting that pain relief and / or patient satisfaction was sub-optimal. 
This practice may be potentially hazardous if patients, especially those who are 
elderly, are using multiple analgesics with significant separate or additive toxicities 
(e.g. prescribed steroid with OTC ibuprofen) or are using duplicate therapies of one 
analgesic e.g. mUltiple products containing paracetamol (Whitaker et aI1995). 
Minor analgesics are the most extensively used over-the counter remedies in 
Europe, contributing about 20% of the OTC market (Li Wan Po 1990, Roins et al 
1998) and are widely used by elderly patients (greater than 65 years) who suffer 
pain. Patient-reported usage rates of OTC analgesics have varied from 18% 
(McElnay and McCallion 1996), 40% (Chrischilles et al1990) and 96% (Whitaker 
et al 1995) depending on sample size and methodology used. Most studies were 
retrospective in nature, where the defmitive diagnosis, if any, as to the cause of the 
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patients' pain was either not known or not validated by the investigators, so no 
evaluation of OTC therapy efficacy could be made. 
McElnay and McCallion (1996) recruited 16 community phannacies to assess 
prospectively the extent, type of and reasons for purchase of non-prescription 
medicines which were bought by elderly patients visiting their phannacy. The study 
was carried out over 2 periods of 6 and 10 weeks' duration using semi-structured 
interviews. Chrischilles et al (1990) studied a similar age group but a much larger 
sample of patients in a prospective epidemiological study, which investigated the 
influence of various social and environmental factors on mUltiple analgesic drug use. 
Whitaker et al (1995) used pharmacies and semi-structured interviews like those of 
McElnay and McCallion, but distributed questionnaires to any customers at 
specified time intervals, rather than just those who were elderly and / or purchased 
OTC analgesics. 
Hanlon et al (1996) and Chrischilles et al (1990) have investigated factors 
influencing analgesic use, in large cross-sectional surveys. Analgesic use was more 
likely in those patients who were female, had a physical, functional problem or had a 
history of cardiovascular disease, the latter perhaps reflecting the use of aspirin in 
thrombotic disease. White women, depressed people and those who visited their GP 
frequently were more likely to be taking three or more analgesics at one time. 
Depressed patients or those who needed help with basic daily activities were more 
likely to be using more than 1 analgesic within a therapeutic class. 
Various researchers have investigated the prescribed and OTC drug usage 
patterns in patients with chronic pain who are referred to pain clinics (Leavitt and 
Sweet 1986, Turner et al 1982, Ready et al 1982). Such patients often under-
reported their drug consumption, especially narcotic analgesics (Ready et al 1982) 
and had problems associated with drug misuse, side effects, drug interactions and 
dependency. The type(s) of analgesic(s) used were related to social, physical and 
psychological factors (Turner et aI1982). 
Drug usage patterns of patients with arthritis in the community have also been 
investigated. Long and Wynne (1996) studied the use of NSAIDs and alternative 
therapies in 153 patients with osteoarthritis and found that younger patients were 
more likely to report using alternative therapies for pain management with 75% 
reporting at least moderate pain relief with their NSAID. Some patients with 
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rheumatoid arthritis have reported improved perceived benefit with alternative 
therapies, even although good evidence of their efficacy is lacking (Pullar et al 
1982). 
One potential reason for the use of both OTe and alternative therapies is 
failure to use prescribed medication appropriately. The factors which influence the 
extent of and the methodologies used to assess patient compliance have been well 
reviewed by Stockwell Morris and Schultz (1992). Researchers who have 
investigated adherence of patients to their arthritis medication are now aware of the 
need to understand and appreciate patients' beliefs and attitudes to their disease, its 
management and implications to their daily lives, before an appropriate patient 
education programme can be developed (Donovan et a/1989, Donovan and Blake 
1992). 
3.2 Objectives 
The objectives of this part of the study were: 
1. To identify a cluster sample of patients with chronic pain living in 
their own homes, using the diagnosis of RA or repeat prescriptions ofNSAIDs 
and I or other analgesics. 
2. To determine the prescribing patterns for analgesics and other pain-
related therapies in this sample related to diagnosis of chronic pain. 
3. To determine the patterns of OTe and alternative therapies used by the 
study sample for relief of chronic pain. 
4. To determine the extent of patient adherence to prescribed therapy and 
the influence of patient attitude to medication and to prescribers on this 
adherence. 
S. To determine the extent and type of discrepancies, if any, between 
documented medication histories in patients' medical records and information 
supplied by the patients. 
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3.3 Methods 
A data collection form (Appendix 7) as described in Chapter 2, Section 2.1.6.1 
was used to document relevant demographic, medical, drug, and other patient 
information from each patient's medical notes prior to interview for comparison at 
time of interview. 
A pain questionnaire (Appendix 8) as described in Chapter 2, Section 2.1.6.3, 
was used to identify patients' self-reported concordance with their prescribed 
analgesia and other medication and usage of OTe or alternative therapies either 
instead of or in addition to their prescribed analgesia. 
Duration of each patient interview was between 1 and 1.5 hours. 
3.4 Results 
3.4.1 Demographic details 
A total of 96 patients were identified from the three practices, who agreed to 
participate in the study. Thirteen patients refused to participate, who showed no 
differences in terms of number of disease states or drugs prescribed. All thirteen 
patients refused because they did not want to be interviewed by a pharmacist in their 
own home. 
Of these 96 patients, 42 had RA, 22 had OA, 25 had both OA and RA and 7 
had low back pain. The mean age of the 96 patients was 60.4 years (SD 13.8 years, 
range 29-84 years). Twenty-eight of the 96 patients (29%) were male and 68 (71 %) 
were female. There was no significant difference in age between pain groups. The 
mean number of medications currently prescribed for patients was 4.9 (SD: 2.8) and 
the mean number of concurrent disease states (excluding the chronic pain diagnosis) 
was 3.0 (SD: 1.9). Forty-seven patients had concurrent problems which could 
exacerbate chronic pain, 21 with documented gastrointestinal problems and 4 with 
documented chronic headaches or migraine. 
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There were no significant differences between the mean number of 
medications which each group of patients were taking. The mean number of 
medications taken by each patient group were; RA 5.0 (range 0-12), OA 5.2 (range 
2-9), back pain 4.3 (range 2-9) and group with RA and OA 4.9 (range 0-12). 
3.4.2 Drugs used by study patients in the management of chronic pain 
Table 3.1 illustrates the types and frequencies of analgesic therapies prescribed 
for the study patients by pain diagnosis. There were no significant differences 
between the 4 groups' prescribed use of NSAIDs, paracetamol or combination 
analgesics. However, significantly more patients in the RA group were prescribed 
other therapies (X: =9.45, df = 3, P < 0.05). Thirty-three patients (34%) were 
prescribed other therapies which included cyclosporin, steroids, alternative therapy, 
hypnotics and anticonvulsants. Cyclosporin was prescribed concurrently with 
prednisolone for one patient with ankylosing spondylosis. Steroid therapy was 
prescribed in 10 patients, all of whom suffered RA, nine of whom were prescribed 
prednisolone therapy. Two of the 10 patients taking steroid therapy were prescribed 
intra-articular triamcinolone, one of whom was prescribed oral prednisolone 
concurrently. 
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Number of patients for whom drug was prescribed 
Type of drug Patients Patients Patients with RA Patients with Total 
prescribed withRA withOA andOA Back pain 
(0/0) (0/0) (%) (0/0) (%) 
n=42 n=22 0=25 0=7 0=96 
NSAID 35 i83) 17 (77) 15 (60) 4 (57) 71 (74) 
DMARD 11 (26) 0 4 (16) 0 15 (16) 
Combination 18 (43) 13 (59) 12 (48) 5 (71) 48 (50) 
anal!esic 
Paracetamol 15 (36) 4 (18) 8 (32) 0 27 (28) 
Dihydrocodeine 2 (10) 2 (10) 3 (12) 1 (14) 8 (8) 
Other 18 (43) 4 (16) 6 (24) 5 (71) 33 (34) 
Table 3.1: Types and frequencies of analgesic and DMARD therapies 
prescribed for the 96 study patients 
Alternative therapy was only prescribed for 2 RA patients. One of the 2 
patients was prescribed a combination of rhus tox and evening primrose oil and the 
other was prescribed Efamast. Both patients were taking NSAIDs concurrently. 
Although only 2 patients were taking prescribed alternative therapies at the time of 
study, 40 patients had documented evidence of previous use of alternative drug 
therapies and / or use of other treatment strategies such as heat. Moreover, 26 of the 
96 study patients (27%) reported on interview that they were actually using 
alternative therapies. Although, more patients with RA as compared to patients with 
OA or back pain used alternative therapies, this difference was not of statistical 
significance (x.2 = 4.67, df= 2, p < 0.1). 
No records of any present or past aTe medication were found in the medical 
notes of 92 out of the 96 study patients. Documented aTe analgesics were Anadin 
Extra (2 patients), diclofenac gel (1 patient) and garlic capsules, all of which were 
being taken in preference to the patients' prescribed analgesic therapy. Although 
only 4 patient records had any documentation of aTe analgesics, 25 of the study 
group (26%) during interview reported that they bought aTe preparations to 
alleviate pain. 
Slightly more RA patients used aTe analgesics than patients in the other 3 
groups, although this was not statistically significant (X2 = 1.76, df= 3, p > 0.2). 
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Tables 3.2 and 3.3 detail respectively, the types and frequency of use of 
alternative and OTC analgesics treatment used by patients to self-medicate at the 
time of interview. 
Number of patients using alternative therapy 
Type of Patients Patients Patients Patients Frequency of Total 
alternative withRA withOA withRA with back usage of therapy 
therapy andOA pain Regularly Pm 
Cod-liver oil 2 1 4 0 5 2 7 
Evening 2 0 1 0 3 0 3 
primrose oil 
Homoeopathy 4 1 1 0 2 4 6 
/Herbal 
Hot bath! 0 0 1 0 0 1 1 
shower/wax 
Combination 3 0 2 0 4 1 5 
of above 
Acupuncture 0 1 0 0 0 1 1 
Faith-healer 1 0 0 0 1 0 1 
Other 0 1 1 0 1 1 2 
alternative Rx 
Total 12 4 10 0 16 10 26 
Table 3.2: Types, frequencies and usage patterns of alternative therapies in the 4 
different patient groups 
Number of patients using OTC therapy 
TypeofOTC Patients Patients Patients Patients Frequency of Total 
analgesic withRA with OA withRA with back usa2e of therapy 
therapy andOA pain Regularly Pm 
orc paracetamol 6 0 1 0 0 7 7 
orc combination 0 1 0 0 0 1 1 
analgesic 
orc paracetamol 1 0 0 0 1 0 1 
/ Solpadeine 
Rubefacient 1 1 1 0 0 3 3 
Anadin Extra 1 1 1 0 2 1 3 
OrCNSAID 0 0 1 0 1 0 1 
OtherOrC 4 1 3 1 3 6 9 
Total 13 4 7 1 7 18 2S 
Table 3.3: Types, frequencies and usage patterns of OTC analgesic therapies in the 
4 different patient groups 
Other prescribed co-analgesic therapy included hypnotics (4 patients) and in 2 
patients, diazepam was used as a muscle relaxant. 
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Out of the 71 patients who were prescribed NSAIDs, 55 reported that they 
were using them regularly as prescribed by their GP. Seven patients were prescribed 
2 NSAIDs concurrently, four of whom were using oral combinations with 3 using a 
combination of oral and topical NSAID preparations. One of the latter 3 patients was 
prescribed a combination of 2 oral and 2 topical preparations. Table 3.4 illustrates 
the range of 17 NSAIDs prescribed in the study. 
Type of NSAID Number of patients Type of NSAID Number of 
prescribed NSAID patients 
prescribed NSAID 
Naproxen 21 Mefenamic Acid 3 
Ibuprofen 11 Azapropazone 3 
Fenbufen 7 Sulindac 2 
Diclofenac 5 Movelat gel 2 
Piroxicam 5 Tiaprofenic 1 
Acid 
Indomethacin 5 Benorylate 1 
Aspirin 4 Felbinac 1 
Nabumetone 4 Ketoprofen 1 
Etodolac 1 
Table 3.4: Types and frequencies ofNSAIDs prescribed 
Twenty-six patients were prescribed prophylactic therapy to prevent 
gastrointestinal (GI) ulceration which included misoprostol (3 patients), omeprazole 
( 5 patients), ranitidine ( 6 patients), cimetidine ( 5 patients), antacids ( 5 patients) and 
ranitidine plus antacid (2 patients). 
In terms of prophylaxis against NSAID- induced gastrointestinal ulceration, 
therapy was inappropriate in 9 of these patients (Scottish Medicines Resource 
Centre 1995(B)). The daily dose ofH2 antagonist was too low in 4 patients, antacids 
were used as sole prophylaxis in 4 patients and the omeprazole daily dose in 1 
patient was a treatment dose. A further 8 patients, six of whom were taking NSAIDs 
regularly or as required, had a previous history of gastrointestinal problems, but 
were not prescribed any prophylactic therapy. In addition, 3 patients prescribed GI 
prophylaxis were not taking their therapy at time of interview, despite 2 of the 
patients continuing to take 2 NSAIDs concurrently. 
Out of the 48 patients prescribed combination therapy, 30 patients had RA. 
Fourteen patients were using combination analgesics regularly with one patient 
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taking 2 prescribed combination analgesics concurrently. The 3 combination 
analgesics which were most commonly prescribed were coproxamol (30 patients), 
cocodamol (13 patients) and codydramol (4 patients). Solpadol was prescribed for 
one patient. 
Only 6 of the 8 patients reported to take dihydrocodeine regularly. Three of the 
patients prescribed dihydrocodeine were also taking combination analgesics 
concurrently, two of whom were taking combination analgesics regularly. 
Only 15 of the 67 patients (22%) in the study with RA, were prescribed 
disease-modifying antirheumatic drugs (DMARDs). The DMARDs prescribed were 
sulphasalazine ( 6 patients), intramuscular gold (4 patients), penicillamine (3 
patients), auranofm (1 patient) and hydroxychloroquine (1 patient). All 15 patients 
reported that they took their DMARD therapy regularly, although one patient did 
remark that she had lowered her dose of sulphasalazine while on holiday on one 
occasion. All DMARDs were initiated and monitored by rheumatologists. 
None of the 15 patients were prescribed a DMARD as sole therapy. Thirteen 
of the 15 were taking NSAIDS concurrently with 9 of the 13 prescribed a 
combination analgesic or paracetamol for background pain in addition. The other 2 
patients on DMARDs were prescribed dihydrocodeine and paracetamol (1 patient) 
and cocodamol (1 patient) due to NSAID intolerance in both patients. 
3.4.3 Pharmacist assessment of patients' knowledge of and adherence to 
prescribed medication and attitude to prescriber 
3.4.3.1 Patient awareness of indication for therapy 
Eighty-seven of the 96 study patients (91 %) identified all prescribed 
medications which were being taken by them at the time of interview and could 
identify their indications. 
Two patients had problems identifying their medication and its indication. One 
of these had no idea of the names and indications of 3 of her prescribed medications, 
while the other identified Sudafed tablets as being used to treat his constipation. The 
other seven patients could identify all their medication, but wrongly identified at 
least one of their therapies for the relief of pain i.e. low dose aspirin (3 patients), 
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antacid I proton-pump inhibitor (1 patient), choral hydrate (1 patient) and 
cardiovascular agents (2 patients). Six patients also identified that their anti-
rheumatic therapy aided sleep and I or mood. 
3.4.3.2 Patient awareness of drug administration details 
Ninety-four out of the 96 patients (98%) could identify how many dosage units 
of all their medications they took per dose, without being prompted or looking at 
their medication during interview. 
Patient awareness of strength of medication was not so encouraging, especially 
concerning their analgesic therapy. Thirty-eight out of the 96 study patients (40%) 
i.e.16 RA patients, 16 patients with RA and OA, 5 OA patients and 1 back pain 
patient could not identify the correct dosage of their analgesic therapy. None of the 
patients who were taking combination analgesics could identify the dosage of 
paracetamol or any other component within each tablet, but all could identify the 
maximum prescribed daily dosage of their combination analgesic. 
3.4.3.3 Pharmacist assessment of patient adherence to prescribed analgesic 
therapy and attitude to prescriber 
During the patient interview, patients were asked whether they always took 
their analgesic medication as prescribed or, if not, how their current regime differed 
from that prescribed by their GP. 
Table 3.5 compares the number of patients who were prescribed regular 
analgesic therapy by their GP as documented in each patient's medical records with 
the number of patients who reported taking their analgesic medication regularly at 
the time of interview. All patients prescribed DMARDs took them regularly as 
prescribed, but only 5 out of 14 patients prescribed paracetamol regularly actually 
took it as prescribed. Moreover, slightly fewer patients than predicted from medical 
records were actually taking their NSAIDs regularly. In total, 60 patients (62%) said 
that they always took their medication as prescribed, but 36 patients (38%) said that 
they had recently altered the dose and I or frequency of their current analgesic 
medication. The reasons patients gave for amending therapy are detailed in Table 
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3.6. When patients were asked about specific adherence to prescribed individual 
drug therapies, 46 patients (48%) actually admitted that they did not adhere to the 
prescribed regimes with 41 reporting that they used a lower dose than prescribed and 
5 a higher dose than prescribed. 
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Patient RA OA RAand Back Total 
group OA pain 
.. .. I. I. 
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-
=.- =.- • =.- .:! ~r ~lt. .~ ~lt. ~~ ~lt. • :I - • :I ~ a:; ~ f ~r .~~ ~r ~~ 
NSAID 32 29 12 11 14 12 3 3 61 55 
(35) (17) (15) (4) (71) 
DMARD 11 11 0 0 4 4 0 0 15 15 
(11) (4) (IS) 
Combination 4 5 0 4 5 2 1 2 10 13 
analgesic (18) (13) (12) (5) (48) 
Paracetamol 11 2 1 2 2 1 0 0 14 5 
(15) (4) (8) (O) (27) 
Dihydrocodeine 2 1 0 2 2 3 0 0 4 6 
(2) (2) (3) (1) (8) 
Other 13 14 4 3 5 5 4 3 26 25 
(18) (4) (6) (5) (33) 
Table 3.5: Self - reported patient concordance with prescribed medication 
'N' in each column refers to the total number of patients prescribed each type of 
analgesic within each disease category, including those for whom the medicine was 
prescribed as required. 
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Reasons for amending RA OA Back pain RAand Total 
dose(s) of analgesics group group group OAgroup 
n=42 n 22 n=7 n-25 n=96 
Reduced pain 1 2 0 2 5 
Only took what was needed 4 1 2 3 10 
Thought that I did not need 2 1 0 1 4 
them 
Side effects limit the dosage 2 2 0 1 5 
I can take 
Combination of reduced 1 0 0 1 2 
pain! only take what I need 
Pregnancy 1 0 0 0 1 
Increased pain 4 1 0 0 5 
Symptoms of another 0 1 3 1 4 
problem worsened 
Total 15 8 5 9 36 
(36%) (36%) (71%) (360/0) (38%) 
Table 3.6: Types and frequencies of reasons for patients amending the dose of 
analgesia currently prescribed 
Most of the 36 patients who had recently altered their current daily dosage of 
analgesic therapy, were taking a reduced dosage of analgesic compared to that 
prescribed. Doses were reduced by 15 patients prescribed NSAIDs (21 % of those 
prescribed NSAIDs), 10 prescribed combination analgesics (21 %), 9 prescribed 
other therapy (27%), 3 prescribed dihydrocodeine (38%) and 3 prescribed 
paracetamol (11%). Four of the 36 patients altered the daily dosage of more than 1 
currently prescribed analgesic. 
Although 28 patients were assessed by the study pharmacist as having poor 
pain outcomes, only five patients admitted to currently taking a higher dose of their 
analgesic therapy than their normal daily dose due to a recent increase in pain (see 
Table 3.6). 
Thirty-three patients (34%), identified that they had required a higher dose 
than currently prescribed at least once during their disease, largely due to decrease in 
pain control at the time. Significantly more patients with RA reported such a need 
than any other pain group (X2 = 8.26, df= 3, p < 0.04). Three patients identified that 
analgesic requirements had to be increased due to an exacerbation of a concomitant 
problem. 
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Patients were also asked if they had ever forgotten to take their analgesia at 
any time, and if so what had been the perceived consequences. Forty-six patients 
( 48%) admitted to having forgotten to take their medication at some time. 
Consequently, 15 out of the 46 patients recognised that the pain and stifihess got 
worse. Twenty-four patients found no problems and either took it as soon as they 
remembered or forgot that day's dose and continued as normal thereafter, while 7 
patients suggested that other disease state(s) became aggravated. 
Patients were asked when they took their analgesia in relation to food or times 
of the day. Although 62 patients identified that they took their NSAID with or after 
food, 7 patients admitted to taking their NSAID before food on an empty stomach, at 
any time or just with fluid, one of whom was taking two oral NSAIDs concurrently. 
Eleven out of the 15 patients taking DMARDs took their medication with or 
after food, two of whom were taking penicillamine. Only one of the 3 patients taking 
penicillamine was taking the medication before food as recommended. Three of the 
4 patients on intramuscular gold identified that administration of their DMARD 
depended on their clinic appointment time. Twenty-five out of 48 patients and nine 
of 25 patients who were prescribed combination analgesics or paracetamol 
respectively took their medications with or after food. The other 39 patients 
prescribed combination analgesics or paracetamol took them 'as required' or at 
times as GP had prescribed. Six out of the 8 patients taking dihydrocodeine took it 
with or after food. 
Case Study 1 (Appendix 14) illustrates changes in the use of prescribed 
medication and use of alternative therapy. 
When patients' responses to the attitude statements 2 to 8 of the pain 
questionnaire (Appendix 8) were compared to their self-reported adherence to 
medication, only one significant difference in attitude was found between those who 
adhered completely to their GP's advice and those who altered their medication. 
Patients who agreed or strongly agreed with the statement 'Doctors know what is 
right for their patients' were more likely to be compliant with their GP's 
recommendations compared to those who disagreed or strongly disagreed with the 
statement (X2 = 10.70, df= 1, P < 0.01). 
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3.4.3.4 Pharmacist assessment of patients' awareness of and attitude to drug 
information leaflets 
Patients were asked if they had ever received an information leaflet about their 
medication when it was dispensed. Patients who had received an information leaflet 
were then asked if they read it and if so, in what ways they found it useful. Fifty-
seven patients (59%) identified that they had received an information leaflet, 55 of 
whom, had read it. Twenty-eight of the 55 patients said the leaflets were useful to 
help explain how the drug worked and 39 that they were useful in aiding 
identification of potential side effects of their prescribed medication. Nine of these 
also suggested that leaflets could advise on the action to take if a side effect was 
experienced. Ten of the 55 patients suggested that the information leaflet clarified 
dosing and / or administration directions. 
Analysis of attitude statements showed that 71 patients (74%) agreed or 
strongly agreed that doctors knew what was right for their patients, while 23 (24%) 
disagreed or strongly disagreed and 2 (2%) were uncertain. Although, 84 patients 
(88%) felt that patients should try to control their own pain, 87 (91 %) believed that 
most patients benefit from taking painkillers for pain. There were largely 2 groups of 
thought regarding medicine taking. Forty-six patients (48%) thought that taking 
medicines was unnatural, while 44 (46%) disagreed with the statement. 
3.4.4 Discrepancies between documented medication histories in patient 
medical records and information supplied by patients 
3.4.4.1 Discrepancies in prescribed medication for chronic pain 
Table 3.7 details the types and frequencies of discrepancies in prescribed 
medication for chronic pain. 
Seventy-two out of the 96 (75%) patients interviewed had at least one 
discrepancy present between their documented drug history in their medical record 
and that obtained by interview concerning therapy for chronic pain. All 72 patients 
who described the 183 analgesic changes claimed at interview that the changes had 
actually been recommended or agreed by their GP, but the amendments had not been 
made in the patients' records (see Case Study 2 in Appendix 15). There were 
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discrepancies in 54 patients with RA (81 %), 15 with OA (68%) and 3 patients with 
back pain (43%). 
Forty-five of the discrepancies involved chronic pain therapies which had been 
discontinued without a documentation of the change made in the patient's medical 
notes. Twenty-five of these were for NSAID therapy, the rest for paracetamol or 
combination analgesics (6), steroids or DMARDs (7), rhus tox( 5) and others (2). 
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Type of discrepancy Drugs for chronic Other drugs Total number 
between records and . pain of 
information from (No. of patients) (No. of patients) discrepancies 
interview 
Change in dosage of 32 (23) 8 (8) 40 
currently prescribed 
medication 
Change in frequency of 48 (39) 14 (13) 62 
currently prescribed 
medication 
Change in formulation 9 (9) 0 9 
Addition( s) to treatment 49 (36) 31 (26) 80 
regimen 
Discontinued treatment 45 (43) 49 (35) 94 
Total 183 102 285 
Table 3.7: Types and frequencies of prescribed medication discrepancies 
Twenty-eight of the 48 discrepancies in dosing frequency between records and 
information from the patient were for paracetamol or combination analgesics,12 for 
NSAIDS and 8 others involving dihydrocodeine. Thirty-six of these 48 differences 
involved a decrease in dosing frequency. 
Additional therapy was prescribed for patients on 49 occasions but not 
recorded in the notes. Sixteen of these were related to NSAID therapy (10 changes 
in drug, 4 changes in formulation and 2 cases where an NSAID was added to 
existing NSAID therapy), 10 additions to combination analgesics where a 
combination was either added to an analgesic regime (6 patients) or changed (4 
patients). Nine and 10 additions respectively, concerned paracetamol and other 
therapies. Four additions related to OTC preparations. 
3.4.4.2 Discrepancies in over-the-counter (OTC) medication 
Only 4 patients had any OTC medication documented in medical notes. Two 
of these patients attributed greater efficacy to Anadin Extra as compared to their 
prescribed combination analgesics, thus used the fonner in preference to the latter. 
The two other patients were using garlic capsules and Diclofenac gel respectively. 
The patient taking garlic had actually been recommended cod-liver oil by his GP, 
-72 -
but the patient preferred garlic in conjunction with an NSAID. Diclofenac gel was 
being used by the fourth patient to reduce his daily dose of coproxamol from that 
prescribed. All patients stated that their GP was aware of the changes in medication. 
No further follow up was made to verify GP awareness since none of these 
patients had a poor pain outcome and thus according to study protocol, did not 
require GP referral. 
3.4.4.3 Discrepancies in other medication 
Table 3.7 details the actual number and type of discrepancies found for 
prescribed medication other than that used in the management of chronic pain. 
Ninety-eight of the 102 prescribed medication discrepancies resulted from 
changes in therapy as recommended by the patients' GPs, but again no written 
record had been made in patients' notes. In total, 79 (82%) patients interviewed had 
102 other prescribed medication discrepancies. The most frequent types of 
discrepancies found were discontinuation of therapies (48%) and additions to 
therapy (30%). 
Four of the 102 discrepancies arose when patients admitted that they were not 
taking their medication as prescribed because of intolerable side effects (1 patient) 
or because they were unconvinced of the need for the treatment (3 patients). 
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3.5 Discussion 
It was reassuring to fmd that 3 of the top 4 most commonly prescribed 
NSAIDs in this study were those with lowest risk of gastrointestinal side effects 
(Committee on Safety of Medicines (CSM) 1994). However, indomethacin, 
piroxicam, and azapropazone were also prescribed, all of which have moderate to 
high risk of GI toxicity and use of which should be limited and especially 
discouraged in the elderly. Seven patients were prescribed 2 NSAIDs concurrently, 
3 of whom required referral to their GP because of gastrointestinal side effects and 
pain. Patients with chronic pain should be assessed regularly and concurrent use of 
more than one NSAID should be avoided to minimise potential serious side effects 
and maximise therapeutic outcome. 
The number of NSAIDs prescribed by a GP should be minimised, such that 5 
NSAIDs account for about 70-80% of prescriptions, to encourage familiarity of GP 
and patients with the NSAID and encourage adherence to CSM guidelines (Scottish 
Medicines Resource Centre 1995(A». In this study, 7 t012 different NSAlDs were 
used per practice, but as only a proportion of patients in each practice were included, 
the number of different NSAIDs prescribed may be an underestimate. 
NSAID prescribing in the OA group was high (77%). However, 5 of the 17 in 
this group prescribed NSAIDs used them as required, 3 of whom were using topical 
NSAIDs. Paracetamol prescribing in this group was much lower (18%) compared to 
the proportion prescribed an NSAID, which suggests that NSAlDs were 
overprescribed in this patient group. Some randomised trials have shown that for 
OA patients, paracetamol is as useful as NSAIDs (Bradley et a11991, Dieppe et al 
1993(A» and should be encouraged. In this study, very few OA patients at interview 
noted inflammation which is not a typical feature of osteoarthritis. Indeed, Swift and 
Rhodes (1992) have demonstrated that a large proportion of OA patients can be 
safely changed from NSAIDs to paracetamol without compromising efficacy. 
The use of prescribed topical NSAIDs in this study was restricted to 5 patients 
(2 with RA and 3 with OA). All prescribed topical NSAIDs were used as required, 
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not regularly, but one other OA patient was purchasing diclofenac gel for 
osteoarthritis of superficial joints and using it regularly instead of his prescribed oral 
NSAID. The rmding that 3 of the patients using topical NSAIDs were also using 
oral NSAIDs regularly and that 1 of the 3 was using 2 oral and 2 topical NSAIDs 
concurrently suggests that these patients were at high risk of gastrointestinal 
toxicity. None of the OA patients prescribed topical analgesics had used a simple 
rubefacient previously. Evidence suggests that chronic use of topical analgesics is 
similar in efficacy to 1200mg ibuprofen (Dickson 1991) i.e. an analgesic not an anti-
inflammatory dose of NSAID and is still associated with systemic gastrointestinal 
side effects. From this study, the use of topical NSAIDs, especially in OA patients, 
requires to be reviewed. Prescribers should be encouraged to use a rubefacient if 
needed and a single oral NSAID at an anti-inflammatory dose for a short course for 
soft tissue inflammation for ~A. Otherwise, OA pain and soft tissue injuries should 
be treated with paracetamol or dihydrocodeine. Dihydrocodeine was seldom used in 
this study. 
Combination analgesics were widely prescribed in preference to paracetamol 
in all groups. There is no significant evidence to suggest that combination analgesics 
are superior to individual analgesics of the combination if given alone (Li Wan Po et 
al 1997, Scottish Medicines Resource Centre 1995(C)). They also do not provide 
dosage flexibility, may encourage unnecessary use of an analgesic and are 
expensive. Cocodamol, the second most commonly prescribed combination 
analgesic in this study, with 8mg codeine and 500mg paracetamol per tablet, may 
cause patients, especially the elderly, to suffer opioid side effects such as 
constipation (see Chapter 6) with no additional analgesia conferred, but more 
problems associated with overdose treatment. 
Combination analgesics containing higher doses of opioid such as Tylex 
(paracetamol 500mg, codeine 30mg) which was also prescribed in this study, have 
been shown to be more effective than codeine alone, but not paracetamol (Bentley 
and Head 1987), and are more likely to cause dependence. A recent meta-analysis 
suggests that codeine provides a slight additive analgesic effect to paracetamol but 
use is limited by side effects (De Craen et al 1996). Coproxamol was the most 
commonly prescribed combination analgesic, a popularity demonstrated in other 
studies, which may be caused by habit rather than evidence of improved efficacy 
(Haigh 1996). Although dextropropoxyphene accumulation in chronic use may 
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contribute to coproxamol's enhanced efficacy (Sykes et aI1996), such chronic use 
should be discouraged, especially since overdoses can he quickly fatal. 
The review of drug therapy used in the management of patients with RA and 
with a combination ofRA and OA suggests that the usage ofDMARD agents is low. 
The low incidence of DMARD use can be partially explained by the fact that this 
study was performed prior to recent evidence suggesting that DMARDs should be 
initiated early on in the disease process (Egsmose et al 1995). Moreover, many RA 
patients had extensive joint disease, where DMARD therapy would be inappropriate 
and some patients had to discontinue DMARD therapy prior to the study due to side 
effects or lack of benefit. However, pharmacists should now be vigilant and identify 
newly diagnosed RA patients who may respond well to DMARD treatment long-
term (porter et aI1994). It was reassuring to fmd that no patient was prescribed or 
was using a DMARD as sole therapy. The lack of methotrexate use in this study, a 
DMARD now considered as frrst line DMARD treatment along with sulphasalazine 
(Felson et al 1990), reflects the time of the study at which time methotrexate was 
only just licensed for use in RA. 
Although the back pain group only consisted of 7 patients, it can be seen that 
NSAIDs and combination analgesics were largely prescribed. Simple analgesics 
should be encouraged in this group of patients wherever possible, with appropriate 
physical therapy, activity and biopsychosocial assessments (Clinical Standards 
Advisory Group 1994). 
An investigation of patients' usage of OTC and alternative medication was 
undertaken to identify whether patients were self-medicating and, if the OTC use 
was additional to or in preference to prescribed medication. Although a high 
percentage of the study patients believed that they should control their own pain, 
only 25 patients were using OTC analgesics and 26 were using alternative 
medication, which suggests that most patients were prepared to tolerate pain or 
adopt alternative management strategies. The latter is not obvious from the medical 
records, since only 57 patients had any documentation of other management 
strategies e.g. physiotherapy, occupational therapy, use of aids or a combination of 
approaches. Seventy-one study patients agreed or strongly agreed with the statement 
that 'Doctors know what is right for their patients', which suggests that most 
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patients preferred to use prescribed medication or other strategies suggested from 
their own doctor. 
The majority of patients using aTe analgesics were using them in addition to 
their prescribed therapy, with only 4 patients using aTe analgesics in preference to 
their prescribed analgesic therapy. The fmdings that RA patients were more likely to 
use aTe and alternative therapies may reflect not only the chronicity and 
pathophysiology of RA, but also patients' desires to fmd other therapies with 
perceived less side effects than their long-term prescribed medication (Donovan and 
Blake 1992), as self-medication is encouraged and publicised. It was unclear as to 
whether the patients who were taking aTe and / or alternative therapies not 
recorded in their medical notes had actually notified their GPs, emphasising the 
importance of an agreed and well defmed strategy of treatment between GP and 
patient. 
Age of patient did not influence the purchase of aTe or alternative therapies. 
The age of patients purchasing the latter therapies tended to reflect the mean age of 
RA patients in this study. Britten (1996) has investigated other factors which may 
influence the public's perception of herbal remedies or natural products and found 
that people with unorthodox views about medicines were more likely to be more 
positive about alternative therapies than prescribed medicines. Such patients were 
more likely to consider medicines as unnatural. In this study, 24 of the 25 patients 
who used aTe analgesics and 24 of the 26 patients who used alternative therapies 
agreed or strongly agreed that taking medicines was unnatural. 
Patients' understanding of their medication for chronic pain needs to be 
improved. The fmding that the majority of patients could identify the indications for 
all their prescribed medications is perhaps not surprising, since many of the study 
patients had been taking their therapies long-term. Some could also have been 
prompted to check their understanding prior to the pharmacist's scheduled visit. 
Fairbrother et al (1993) found that a similar percentage of patients knew the 
indications of their medications, but they were investigating a general group of 
elderly patients. 
It is encouraging that almost all patients could identify how many dosage units 
they took per dose but worrying to fmd that 40% could not identify the correct 
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strength. Pharmacists need to consistently check patients' awareness of dosage of 
medication, especially if on chronic therapy. 
Patient adherence to prescribed analgesic therapy was variable. Deviation from 
the prescribed dose was largely associated with a reduced analgesic usage due to 
patients' perception that they only took what was needed, pain was reduced or side 
effects limited use. These fmdings illustrated by a case study (Appendix 14) are 
similar to those of Donovan and Blake (1992), confrrming that patients' decisions to 
comply with therapy are based on their need to take control of their own disease 
management, after assessing the costs (side effects, stigma of drug-taking, drug 
regimen) and benefits (improved symptomatic and long-term pain relief, better 
quality of life) in relation to their own attitudes to their disease state and its 
management. 
The fmdings that nearly half of the study patients titrated their analgesic 
requirements to their own daily needs and tended to take no more than half of the 
daily dose of combination analgesic prescribed, suggest that patients are prepared to 
experiment with doses and timing of therapy in a similar manner to that observed by 
Donovan and Blake 1992, Dixon et al 1995. Some patients in this study 
demonstrated a reluctance to take the maximum daily dose of their prescribed 
analgesic or the dosages recommended by their GPs even when experiencing 
significant pain. 
Only five patients admitted to currently taking a higher dose of analgesic than 
their nonnal daily dose due to a recent increase in pain, despite 18 patients requiring 
referral because of poor pain outcomes. This suggests that some patients with 
chronic pain prefer to tolerate significant pain rather than increase analgesia (see 
Chapter 4). Deyo et al 1981, found that patients on DMARDs received better 
information than patients on other drugs and have identified the improved 
compliance with DMARD therapy as compared to other therapies in this study. This 
fmding emphasises the need for accurate and sufficient information about the 
rationale of therapy and monitoring requirements to be effectively communicated to 
the patient at a time convenient to him / her. Patients in the 'bereavement period' of 
a chronic illness do not respond well to information about their disease state 
(Donovan et 011989). 
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A high proportion of patients agreed with the statement that 'doctors know 
what is right for their patients', yet amended their medication taking according to 
their own pain experience and understanding of the treatment prescribed. These 
fmdings were similar to those of other investigators who have found that when 
patients were confident about their understanding of their treatment, they modified 
their own treatment regimes, yet perceived that this was not inconsistent with their 
GPs' recommendations (Blaxter and Britten 1997). (Chapters 4 and 5 discuss more 
fully the study patients' attitudes and perceptions of their chronic pain and its 
management. ). 
Only about 60% of the study patients were aware of the availability of 
information leaflets. More patients taking DMARDs were aware of this availability 
compared to patients on any other medication. This fmding may suggest some 
forgetfulness on the part of the patients, since most of the patients on DMARDs had 
been taking them for several years. Alternatively, this may also reflect a lack of 
communication and / or dissemination of information between rheumatologists and 
GPs, the latter acting in accordance with the consultants' recommendations and less 
familiar with the availability of information leaflets. Moreover, the study was 
undertaken prior to recommendations for all original packs to contain package insert 
leaflets. Assumptions may have been made by health professionals involved that 
patients already had leaflets or were not interested in obtaining further information 
as suggested by Donovan and Blake (1992). Many studies have found that patients 
want specific information about their disease state and its management in order to 
make informed decisions regarding their own medication-taking behaviour (Farmer 
and Peffer (1995), Donovan and Blake (1992)). 
Patients must be aware of the rationale for monitoring therapy outcomes and 
who is responsible for carrying out appropriate monitoring procedures. Pharmacists 
need to be proactive and identify those patients with chronic pain who will benefit 
from information leaflets in addition to verbal advice. Indeed, encouraging leaflet 
availability (Ghalamkari et al 1997(B)) can enhance patient perception of the skills 
of pharmacists. 
The high number of discrepancies between documented drug histories in 
medical records and that at time of interview found in this study was worrying, since 
few medical records of the study patients, especially those for RA patients actually 
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reflected their present prescribed medication regime. The fact that 60% of 
discrepancies were concerned with changes in drugs prescribed rather than just 
dosage or frequency changes, suggests that the risks of clinically significant 
interactions and side effects are increased, especially since no updated medical 
record is available for monitoring purposes. Potential toxicities could result as 
illustrated by Case Study 2 (Appendix 15). 
It was not possible to make a rapid assessment of patients' responses to 
therapy both therapeutic and toxic by appraising medical notes in this study. Such 
documentation is critical if adverse drug reactions are to be avoided and efficacy 
optimised. Indeed, four patients had discontinued therapy on their own accord due to 
intolerable side effects or lack of perceived benefit, none of which was documented 
in any record. 
No evaluation was made of the type or accuracy of medication records held by 
pharmacists in this study. Pharmacists are well placed to update patients' records as 
changes are made to patients' therapy and provide appropriate advice, provided 
these patients regularly attend the same pharmacy. OTC medication use can more 
easily be included in these records, whereas documentation in medical records was 
poor in this study. Pharmacists can then use the records to identify (1) any potential 
overuse of OTe analgesics in addition or in preference to prescribed therapy and (2) 
the development of any side effects attributed to analgesic therapy, discussing the 
situation with the patient and their GP (Briggs et aI1996). 
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Chapter 4 
Patient outcomes in terms of pain control 
4.1 Introduction 
Chronic pain associated with rheumatoid arthritis (RA), osteoarthritis (OA) 
and back pain is a longstanding problem which has often become a stable element in 
a patient's life. RA can cause both acute and chronic pain of varying intensity, 
arising from many sources including local joint inflammation, chronic changes in 
articular tissue, systemic problems, affective changes and side effects of medication 
(Reisner - Keller 1992). 
The perception of chronic pain is influenced by physical (age, tissue damage, 
drug toxicity), social (stress), psychological (depression, drug dependence) and 
emotional (fear, loss of dignity) factors (Reisner - Keller 1992). 
Elderly patients have demonstrated altered pain perception, partly due to 
altered nociceptive responses, such that they may not experience certain types of 
visceral pain. They also demonstrate altered psychological responses involving an 
unwillingness to label a noxious stimulus as painful, thus making chronic pain 
assessment difficult in the elderly (Gloth 1996). Moreover, age-related 
phannacodynamic changes and concurrent psychiatric illness can complicate pain 
control (Newman et a/1989). 
Patient attitude to pain is an important factor in pain perception and overall 
management, and can vary depending on severity of pain problems and duration of 
pain disease state. Older RA patients often present with fewer symptoms than 
younger patients and tend to report less pain (Deal et al 1985). Patient reporting of 
chronic pain may not be believed, their problem not fully appreciated or the patient 
can be mislabelled as a malingerer or 'addicted ' to medication, all of which damage 
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patient self-esteem and the patient-physician relationship (Weissman and Haddox 
1989). 
Studies suggest that analysis of medication usage cannot reliably predict the 
pain experienced by patients with chronic pain. Work in pain clinics suggests that 
certain patient groups will underestimate drug usage (Ready et a/ 1982), while 
patients with rheumatological diseases tend to deliberately limit their medication 
intake, preferring to tolerate pain (Donovan and Blake 1992). 
Patient satisfaction with medication is often closely associated with beliefs 
about the origin of their pain, with better outcomes being achieved when both 
physician and patient agree on a pain management strategy (Wooley et aI1978). 
Assessment of pain in arthritic patients is a critical factor in the determination 
of their medication usage, over and above any physical or psychological problems 
(Kazis et a/ 1983) and has a strong influence on general health assessment. The 
recommended pain scales used in patients with rheumatic diseases and other chronic 
pain states have been well reviewed (McDowell and Newell 1996). 
The McGill Pain Questionnaire (MPQ) is a well-validated tool for the 
assessment of pain, providing a qualitative profile of three major psychological 
dimensions of pain (sensory-discriminative, motivational-affective and cognitive-
evaluative). The MPQ has been shown to be reliable (Melzack 1975), although the 
extent of correlation between the three dimension scores depends on the type of pain 
being evaluated (perry et al 1988). Correlations between MPQ scores and VAS 
scores have been discussed in Chapter 1. Use of verbal descriptors within the MPQ 
can help classify patients into particular diagnostic groups (McDowell and Newell 
1996), but patients can misinterpret them. 
Researchers have mixed views as to whether the MPQ actually reflects the 
three proposed dimensions of the pain experience as reviewed by McDowell and 
Newell (1996). Turk and colleagues (1985) reassessed the factorial structure of the 
MPQ and confmned the three dimensions, although suggested that the total Pain 
Rating Index score is the recommended variable for research use. 
Few pharmacists have used validated pain assessment tools to evaluate chronic 
pain management in the community. Most studies by pharmacists investigating 
outcomes of patients with chronic pain have evaluated outcomes in terms of patient 
satisfaction with medication (Long and Wynne 1996) or medication usage (Briggs et 
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al 1996). Any pharmacist involved in the assessment of chronic pain perceived by 
patients should be encouraged to use a previously validated pain assessment tool to 
obtain a more accurate assessment of patients' pain and their perceptions of that pain 
over a period of time. The results could then be related to patients' medication 
taking behaviour to obtain a greater understanding of pain outcomes. 
4.2 Objectives 
The objectives of this part of the study were: 
1. To identify patients' expectations of pain relief compared to actual pain relief 
experienced. 
2. To investigate the pain experienced by the 96 patients at frrst interview and the 
differences, if any, between patient groups in terms of intensity, quality and 
description, using VAS and the McGill Pain Questionnaire. 
3. To measure any differences between pain experienced at initial and follow-up 
interview by those patients who had poor outcomes and were referred for 
. 
review. 
4. To identify patient attitude to pain and knowledge of pain management and 
differences, if any, between groups. 
5. To investigate the influence of age, duration and diagnosis of chronic pain, 
patient attitude and knowledge on pain perception. 
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4.3 Methods 
Patients' expectations of pain relief as compared to actual pain relief 
experienced were assessed using visual analogue scales (VAS) as described in 
Chapter 2, Section 2.1.6.3. 
The McGill pain questionnaire (MPQ), its verbal descriptors and visual 
analogue scales (VAS) (Appendices 8 and 9) were used to assess the quality and 
intensity of each patient's chronic pain during each interview as described in 
Chapter 2, Section 2.1.7. The mean time taken for each patient to complete the MPQ 
was 12 mins. 
Pain scores for each patient were calculated in terms of total PRI (S), total PRI 
®, NWC and PPI scores as described by Melzack (1975), and noted in Chapter 2 
Section 2.3.3. 
Visual analogue scales were also used to record each patient's subjective 
assessment of their 'ideal' analgesic and their perceived efficacy of prescribed 
analgesia. All VAS scales used were horizontal lines of 10cm. 
Patient attitude to pain and knowledge of pain management was assessed using 
attitude statements within the pain questionnaire as described in Chapter 2 Section 
2.1.7. 
The influence of age, duration and diagnosis of chronic pain on pain 
perception was assessed by correlating the patients' responses of age, duration and 
diagnosis of chronic pain with their respective total PRI pain scores. 
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4.4 Results: Evaluation of patients' pain control 
4.4.1 Patients' expectations of pain relief compared to pain relief 
experienced 
Table 4.1 shows the degree of pain relief which patients expected and achieved 
from their medication( s), assessed on a horizontal VAS scale where 0 = no relief and 
100 = complete pain relief (see questions 24 and 35 of Appendix 8). 
Expected pain Number of Cumulative Number of Cumulative 
relief patients who frequency patients who frequency 
(V AS scale 0-100) expected pain (%) achieved pain (%) 
relief relief 
0-30 1 1 4 4 
31-50 2 3 20 25 
51-70 24 28 32 58 
71-90 40 70 30 90 
91-100 29 100 10 100 
Total 96 96 
Mean (95% CI) 82.5 (79.4-85.6) 68.9 (64.9-72.9) 
Median (95% CI) 80 (80-90) 70 (60-75) 
Table 4.1: Patients' expected pain relief and that actually achieved 
Table 4.2 illustrates patients' expectations in tenns of goals of pain relief and 
that actually achieved (see questions 24 and 35 of Appendix 8). There were no 
differences of significance between pain diagnoses in tenns of expected goals or 
actual goals achieved, expected pain relief or actual pain relief achieved. 
Although 29 patients expected complete relief with their medication(s), only 9 
actually reported that they achieved 100% relief with 1 other reporting 95% relief. 
Sixty-nine patients (72%) expected at least 75% pain relief, yet only 40 patients 
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(42%) reported to have achieved that relief. The difference in expectations between 
patients with satisfactory outcomes at Interview 1, patients with poor pain control at 
Interview 1 and patients with poor outcomes at Interview 1 are shown in Table 4.3. 
Expectations of pain relief were significantly higher in the poor outcomes patient 
group as compared to those patients with satisfactory outcomes ('X: = 4.30, df= 1, P 
< 0.05). 
Goal of therapy No. of patients Cumulative No. of patients Cumulative 
(Rating on who expected frequency who achieved frequency 
numerical scale) goal of therapy (%) goal at first (%) 
Interview 
Provide complete 22 23 7 7 
relief (1) 
Relieve pain as 44 69 30 38 
much as possible (2) 
Relieve pain enough 21 91 44 84 
to cope with daily 
activities (3) 
Relieve pain enough 1 92 1 85 
to sleep (4) 
Other (5) 8 100 14 100 
Total 96 96 
Median (95% CI) (2) Relieve pain (3) Relieve pain 
as much as enough to cope 
possible with daily activities 
(2-2) (3-3) 
Table 4.2: Patients' expected goals of therapy and goals of therapy actually 
achieved 
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Expectations All patients at Patients with Patients with Patients 
of pain relief Interview 1 satisfactory poor pain control with poor 
outcomes at at Interview 1 outcomes at 
Interview 1 (V AS average Interview 1 
pain >75) 
(n=96) (n=68) (n=6) (n=28) 
Median VAS 80 70 85 90 
score 
(95% CI) (80-90) (70-80) (60-100) (80-100) 
Table 4.3: Patients' expectations of pain relief in terms of VAS scores for all 
patients and patient groups 
Patients were requested to rate how satisfied they were with their pain control. 
Six patients (6%) were completely satisfied, 41 (43%) were very satisfied, 44 (46%) 
were moderately satisfied and 5 (5%) were dissatisfied with their pain relief at that 
time. There was no statistical difference in patient satisfaction between pain 
diagnoses groups. 
4.4.2 Pain experienced in terms of intensity, quality and description using 
visual analogue scales (VAS) and the McGill Pain Questionnaire 
(MPQ) 
All 96 patients were asked to rate the intensity of their average pain at 
interview over the previous month, using horizontal VAS, (VAS average), the worst 
pain they had experienced (VAS worst), and the pain experienced at time of 
interview (VAS present) (Table 4.4). Compared with patients with satisfactory 
outcomes, patients with poor outcomes had significantly higher VAS average (X2 = 
9.08, df= 1, P < 0.01), VAS worst (X2 = 5.75, df= 1, P < 0.02) and VAS now scores 
(X2 = 13.41, df= 1, P < 0.001). 
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The results of pain outcomes measured using the MPQ are shown in Table 4.5. 
Patients with poor outcomes had significantly higher total PRI scale (X2 = 6.33, df = 
1, p < 0.02), total PRI rank (X2 = 8.18, df = 1, p < 0.01), NWC (X2 = 16.85, df= 1, P 
< 0.001) and PPI scores (X2 = 19.24, df = 1, P < 0.001) as compared with patients 
with satisfactory outcomes. 
Patient satisfaction demonstrated significant negative correlations with total 
PRI rank and scale scores (r = -0.34, r = -0.32, respectively, p < 0.001) and with 
VAS average scores (r = -0.57, P < 0.001) i.e. the higher the pain or VAS average 
scores, the lower the patient satisfaction. 
Table 4.6 summarises the MPQ scores in terms of patients' disease state(s). 
The total PRI® and PRI(S) scores for all patients are subdivided into the 4 MPQ 
categories i.e. sensory (S), affective (A), evaluative (E) and miscellaneous (M). 
Although the subgroup of back pain patients is small, this group had higher, but not 
statistically significant, PRI® and PRI(S) sensory scores as compared to the RA, RA 
and OA and OA groups. 
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Correlations between the scores of VAS average, NWC, PRI® total, PRI(S) 
total and PPI were calculated for all patients. A high correlation (p < 0.001) was 
found between the PRI(S) total and PRI® total scores (r = 0.98) and the number of 
words chosen (NWC) correlated highly with both PRI(S) total (r = 0.98) and PRI® 
total (r = 0.97). VAS average measurements demonstrated a poorer correlation with 
all of the other scores (range 0.41-0.69) as did the PPI scores. There were good 
intercorrelations between PRI rank and scale scores for all four categories (p < 
0.001). 
Intercorrelations between the 4 categories of each scoring system were also 
calculated (Table 4.7). Present pain intensity (PPI) significantly correlated with 
NWC and the PRI ® for each of the 4 categories (PRI sensory, affective, evaluative 
and miscellaneous) and the PRI® total, although the correlations were poorer than 
those between the total PRI rank and scale scores. The Pearson correlations (r) 
between PPI and each of the PRI categories were PRI® sensory = 0.32, PRI® 
affective = 0.44, PRI® evaluative = 0.50, PRI® miscellaneous = 0.41, PRI(S) 
sensory = 0.37, PRI(S) affective = 0.44, PRI(S) evaluative = 0.45 and PRI(S) 
miscellaneous = 0.37. 
The frequency of choice of each subclass within categories and words within 
subclasses were analysed in all patients. Patients used all subclasses at some stage. 
Only 8 out of the 78 verbal word descriptors available were not used at any time. 
The verbal word descriptors which were most commonly selected by patients were 
from the sensory subclasses i.e. throbbing (49 patients), aching (49 patients) 
gnawing (46 patients), sharp (30 patients) and shooting (25 patients). The most 
commonly selected verbal word descriptor overall was tiring ( 52 patients) from the 
affective category. Only 54 of the 96 patients (56%) chose a word in the evaluative 
subclass, the most common being 'annoying' (22 patients). 
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4.4.3 Pain control in 14 patients with poor outcomes before and after 
intervention by the study pharmacist 
Individual pain scores of the 14 patients who had poor outcomes as defmed by 
the pre-set criteria at Interview 1 and who were subsequently re-interviewed after 
pharmacist intervention are shown in Table 4.8. 
Patient VAS Average NWC PPI Total PRI® Total PRI (S) 
Code 
Int 1 Int 2 Int 1 Int 2 Int 1 Int 2 Int 1 Int 2 Int 1 
81 t 80 50 9 8 3 2 23 19 24.6 
76 t 60 40 3 5 2 2 4 8 6.2 
4 t 70 50 8 4 3 2 21 9 19.6 
40 <=> 30 30 7 7 2 2 13 13 14.9 
27 ,} 40 60 9 7 1 1 20 19 21.3 
28 t 50 50 17 15 2 2 35 31 43.6 
41 t 40 50 6 13 2 3 15 36 18.3 
46 ,} 60 90 10 7 2 4 21 18 25.9 
57 ,} 70 70 15 6 3 1 34 13 44.1 
39,}# 100 60 4 3 3 2 8 7 10 
78t# 20 50 8 8 2 2 19 20 20.5 
84 ,} 80 50 7 7 3 2 24 20 25.0 
52 t 80 60 15 14 3 3 37 36 39.5 
68 t 80 50 20 12 3 2 54 22 59.0 
Table 4.8: Patients' pain control prior to (Interviewl) and after pharmacist 
intervention (Interview 2) (n=14) 
(Int 1 = Interview 1, Int 2 = Interview 2) 
J, = decrease in pain scores at Interview 2 
t = increase in pain scores at Interview 2 
¢:> = no change in pain scores at Interview 2 
# = intervention was not accepted by the GP 
Int2 
21.1 
11.7 
9.2 
15.0 
19.2 
40.3 
40.5 
20.5 
14.0 
7.3 
21.6 
21.1 
39.0 
29.3 
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The Wilcoxon matched pairs signed rank sum test was used to investigate the 
within patient differences in pain scores obtained before and after intervention. The 
PRI rank, PRI scale and NWC scores all showed slight decreasing trends ( p < 0.1 n 
= 13, P < 0.1 n = 14, P < 0.1 n = 11 respectively). However, there was no statistically 
significant differences between VAS scores (p> 0.2, n = 11). When the pain scores 
of the 2 patients in whom the pharmacist's recommendations were not acted upon 
were excluded from analysis, changes in total PRI rank and scale and NWC scores 
were less significant (p < 0.2 n = 11, P < 0.2 n = 12 and p < 0.2 n = 9). VAS score 
changes were not statistically significant (p > 0.2 n = 9). 
In terms of clinical improvement, 10 patients demonstrated improvement in 
pain control after pharmacist intervention, as reflected by the reduced PRI rank and 
scale and NWC scores at Interview 2. Three patients perceived a decrease in pain 
control after intervention, as reflected by their increased scores at Interview 2, while 
1 patient perceived no change in pain control after intervention. 
The PPI scores were less sensitive to changes in pain before and after 
intervention than the respective PRJ and NWI scores. VAS scores were more 
sensitive to changes in pain than PPI scores. Decreases in VAS scores tended to be 
associated with decreases in NWC and PRJ scores, but some anomalies were found 
(Patients 27, 46 and 76 in Table 4.8). 
The consistency of choice of subclass and words within each subclass chosen 
from the MPQ was assessed for each of the 14 patients who were interviewed on 
two occasions. The median consistency of choice of subclass between Interviews 1 
and 2 was 75% (range 25-100%), whereas the median consistency of choice of 
words between Interviews 1 and 2 was 44% (range 22-83%). 
At Interview 2, 7 out of the 10 patients who had reduced pain (Patients 28, 46, 
52, 57, 68, 81 and 84), chose fewer or an equal number of verbal descriptors with 
lower scores from the same subclasses, as compared to those descriptors chosen at 
Interview 1. This fmding was reflected by correspondingly lower PRI rank or scale 
scores. The 3 other patients who perceived reduced pain (patients 4, 27 and 39) 
either selected new but fewer words of a higher score within the same subclass or 
selected new subclasses. Two of the 3 patients who demonstrated increased pain at 
Interview 2 had higher NWC scores, while one patient showed no change in the 
number of words chosen. 
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The most common verbal descriptors chosen in the 14 patients with poor 
outcomes and pharmacist intervention, correlated highly with those chosen by the 
total 96 study patients. This sub-group of 14 patients chose more words on average 
(median NWC= 8) at Interview 1 as compared to that for the total group (median 
NWC =6), but less than the sub-group who had poor pain relief (median NWC = 
10). The 14 patients at Interviews 1 and 2 used all subclasses. The most commonly 
used words included 'tiring' (13 patients), 'exhausting' (12 patients), 'throbbing' (12 
patients), 'aching' (12 patients) and 'sharp' (11 patients). Although the sensory 
subclasses were more frequently used by the 14 patients as compared to the affective 
or miscellaneous groups, 12 of the 14 patients chose a word from the evaluative 
group, the most commonly reported being 'miserable'. 
Expectation of pain relief of these 14 patients was similar to that for the total 
group (median VAS score 80), but scores were within a narrower range (65-100 as 
compared to 30-100 for the total group). Compared with the total group's pain 
scores prior to intervention, the group of 14 patients had higher median scores at 
Interview 1 for VAS worst, average and present pain (80, 65 and 50 respectively) 
and higher median total PRI rank and scale scores (21 and 23.0 respectively). After 
intervention, the intervention group's median VAS scores decreased to 70, 50 and 
40 respectively, and median PRI rank and scale scores decreased to 19 and 21 
respectively. After intervention, 2 patients were more satisfied, 9 were as satisfied as 
prior to intervention and 3 were less satisfied. All 3 patients who were less satisfied 
after intervention, had their therapy changed, but their arthritis had progressed as 
therapy changes were initiated. 
4.4.4 Influence of psychological, physical and treatment factors on 
patients' pain perception 
Patient knowledge and attitude to pain was investigated in the 96 patients to 
see if any differences existed between the diagnostic groups. The questions used to 
assess knowledge and attitude and the patient responses obtained are illustrated in 
Tables 4.9 and 4.10 respectively. 
The relationship of pain scores with QOL scores is discussed in Chapter 5. 
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The results investigating patient knowledge suggest that most patients 
(84,88%) believed that patients could become addicted to painkillers, although more 
patients with low back pain disagreed with or were uncertain about the statement. 
Moreover, comparatively more patients with back pain (5 out of 7) disagreed 
with the statement that 'exercise can help chronic pain'. Most of this sub-group did 
not perceive the benefit of drug therapy or exercise as demonstrated by specific 
comments: 
I don't take the tablets unless I'm desperate. 
I only take my tablets when I'm pushed to take them. 
I don't want to get dependent on them. 
I don't want to feel drowsy during the day, since I'm driving a lot and want to 
be alert - get the full benefit of painkillers when really needed. 
Chronic pain could dominate your life if you let it. You need to assess what 
activities you'll be able to achieve with the minimum amount of increased pain. 
Exercise aggravates my pain. (2 patients) 
Exercise makes my pain worse. (3 patients) 
Exercise is of no help to me. 
Gentle exercise helps stretch my spine. 
The statement 'pain can continue after healing has taken place' was used to 
investigate patients' understanding of the chronicity of the pain in the absence of a 
pathophysiological cause. In response to the latter statement, over a fifth of the study 
patients (20, 21 %) did not know. 
Three out of the 5 patients who disagreed with the statement that 'painkillers 
help you to cope with a normal life' patients had RA, with or without OA (Table 
4.10). Eighty-seven patients (91 %) agreed that taking painkillers was beneficial, yet 
most patients (84, 88%) agreed that patients should try to control their own pain. 
The results regarding attitude to medication-taking have been reported in Chapter 3. 
Older patients (greater than 70 years old) had significantly lower PRI scores 
(median total PRI scale score = 10.2) than the rest of the study patients ( median 
total PRI scale score = 15.9), (X2 = 7.49, df = 1, P < 0.01). Duration of chronic pain 
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and pain diagnosis did not influence pain perceived by patients (''I: = 5.47, df = 3, P 
< 0.2, X2 = 3.18, df = 3, p> 0.2 respectively). Mean duration of pain was 13.2 years 
(SD 10.2, range 1-53 years). 
No real assessment was made on the influence of patients' current medication 
on their current pain, since many of the patients in the study were undertreating their 
pain, as discussed in Chapter 3. 
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... .... 
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QI 
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Q 
..; Q ~ Eo-
People can be RA 26 5 1 42 
addicted to OA 21 1 0 22 
painkillers Back Pain 4 1 2 7 
RA+OA 23 2 0 25 
Total 84 9 3 96 
Persistent pain can RA 39 3 0 42 
make you OA 19 3 0 22 
depressed Back Pain 7 0 0 7 
RA+OA 24 1 0 25 
Total 89 7 0 96 
Exercise can help RA 33 8 1 42 
chronic pain OA 14 4 4 22 
Back Pain 1 5 1 7 
RA+OA 19 6 0 25 
Total 67 23 6 96 
Pain can continue RA 26 8 8 42 
after healing has OA 11 5 6 22 
taken place Back Pain 5 0 2 7 
RA+OA 15 6 4 25 
Total 57 19 20 96 
Table 4.9: Assessment of patient knowledge of chronic pain (n=96) 
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Statement Number of Patients 
lIP} 
.c = •• ~ D ~ lIP} •• 0 ~ u u CIS t ~ -f., = ~ u 1: ~ CIS ... ... ~ = ... 0 ~ ~ u CIS e CIS 0 CIS ... at < ~ WJ lIP} ~ •• ... 
= 
•• . . 
= 
CI.l 
= 
... 
= 
;:J CI.l 
Most patients RA 9 30 1 2 0 42 
benefit from OA 7 12 2 1 0 22 
taking painkillers Back Pain 0 5 1 1 0 7 
for pain RA+OA 9 15 0 1 0 25 
Total 25 62 4 5 0 96 
Taking medicines RA 10 8 2 17 5 42 
like painkillers is OA 6 5 2 9 0 22 
unnatural Back Pain 2 3 0 2 0 7 
RA+OA 2 10 2 10 1 25 
Total 20 26 6 38 6 96 
Patients should RA 17 21 0 4 0 42 
try to control OA 9 7 2 4 0 22 
their own pain Back Pain 4 2 1 0 0 7 
RA+OA 15 9 0 1 0 25 
Total 45 39 3 9 0 96 
Painkillers help RA 12 23 0 7 0 42 
you to cope with a OA 7 14 1 0 0 22 
normal life Back Pain 1 3 2 1 0 7 
RA+OA 10 11 1 3 0 25 
Total 30 51 4 11 0 96 
Taking painkillers RA 8 26 5 3 0 42 
for a long time OA 5 8 5 4 0 22 
can cause side Back Pain 0 4 3 0 0 7 
effects RA+OA 8 13 2 2 0 25 
Total 21 51 15 9 0 96 
Table 4.10: Assessment of patient attitude to chronic pain (n=96) 
- 100-
4.4.5 Case study - patients with poor pain outcomes on Interview 
requiring referral 
Although all 28 patients had inadequate pain control i.e. VAS average pain 
more than 50, only 6 of the 28 patients had a VAS average pain greater than 75 (one 
of the criteria defmed as a poor outcome in Chapter 2). Outcome details of all the 28 
patients reviewed by the phannacist are discussed in Chapter 7. 
In 14 of the 18 patients who had a second interview, recommendations were 
made by the pharmacist to the patient's GP and acted upon in 12 patients. Case 
study 3 in Appendix 16 illustrates the type and quality of poor pain outcomes 
experienced by the patients who required referral. 
4.5 Discussion 
The results indicate that patients' expectations in terms of expected pain relief 
and goals of therapy were much higher than those actually achieved. Fifty percent of 
patients expected that pain should be relieved as much as possible, yet in reality, half 
the study patients reported that pain was only relieved sufficiently to cope with daily 
activities. 
Patient satisfaction as a global measurement in this study was found to be 
relatively insensitive as an outcome measure, since patients after an intervention 
which improved pain control often rated satisfaction unchanged. This may reflect 
the narrow rating scale used, the high expectations of patients or may be explained 
by the fact that pain control is only one contributory factor towards patient 
satisfaction (Donovan and Blake 1992). Long and Wynne (1996) investigated 
patient satisfaction in arthritis, but only in global terms of symptomatic relief. They 
did not evaluate pain relief in terms of a numerical VAS scale or established pain 
scores as in this study. 
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The MPQ scores and VAS scores obtained show that pain perception was very 
variable both within and between groups of patients with different pain diagnoses. 
However, the high correlations found between MPQ scores for all study patients 
suggest an internal consistency among the different PRI categories and the three 
indices of the questionnaire i.e. PRI, NWC and PPI. Similar fmdings were found by 
Melzack (1975) using a much larger group of patients with diverse chronic pain 
diagnoses. 
This study's fmdings suggest that the indices of the MPQ are very valid tools 
to use in small groups of patients with chronic pain, as in this study, to assess pain 
intensity and quality, although there are limitations in scoring methods as discussed 
in Chapter 2. 
The high correlations between NWC and PRI® and PRI(S) are not surprising, 
since the scoring system operates such that the larger the number of words chosen, 
the higher the PRI. The correlation between PPI and PRI® categories is highest for 
the PRI® evaluative category in this study, a fmding also found by Melzack (1975), 
who suggested the reason for this was partly related to the PPIs' originating from a 
large number of evaluative descriptors (Melzack and Torgerson 1971). Moreover, 
the higher PPI correlation with the PRI® evaluative category suggests that the 
patient's past pain experience, mood or expectation of pain relief plays a larger part 
in the overall assessment of pain by patients, compared to the sensory and affective 
dimensions of pain. 
The lower correlations between PPI and NWC and PRI® categories suggest 
that a large part of the PPI variance may be explained by factors not directly 
suggested by the verbal descriptors of the PPI scale. One factor which may cause 
variance is the different interpretations of the same word descriptors by patients i.e. 
a PPI score of' l' (mild pain) in one person may be interpreted as '2' (discomforting 
pain) by another person (Melzack 1975, Read 1989). PPI has been influenced by 
psychological factors at the time of assessment including mood, anxiety and 
attention (Melzack 1973). In this study, such factors were not controlled, therefore 
patients may have demonstrated uncharacteristic moods, levels of attention or 
anxiety at the time of interview. 
The higher correlations between PPI and PRI scores for the affective category 
in either rank (r = 0.44) or scale (r = 0.44) scores compared to the correlations 
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between the same scores for the sensory category (r = 0.32, r = 0.37 respectively) 
suggest that pain intensity is influenced more by the affective rather than the sensory 
dimension. This suggestion is further supported by the fmding that the correlation 
between VAS average scores and PRJ® categories was highest for the affective 
category (r = 0.46) and lowest for the sensory category (r = 0.35). However, care 
must be taken when interpreting the PRJ scores for individual categories, rather than 
the total PRI score, especially when patients are grouped according to diagnosis, 
since the type of pain influences the correlation between the PRJ category scores 
(perry et aI1988). Moreover, subclassification is based on Melzack's proposal that 
chronic pain has three distinct dimensions (Melzack 1975), a proposal which is still 
under debate (McDowell and Newell 1996). 
Data obtained from the subgroup of 14 patients who had poor outcomes and 
who were followed up after intervention by the study phannacist suggests that the 
MPQ can be used to investigate the influence of a therapeutic intervention on pain 
perceived by patients. The trends in decreasing PRJ and NWC scores after 
phannacist intervention suggest that the MPQ may be able to be used by 
pharmacists to identify changes in intensity, chronicity and quality of the chronic 
pain experienced. 
The number-word categories of the PPI scale clearly meant different pain 
intensities and qualities to different patients, a fmding supported by Melzack (1975) 
using a much larger study group. These fmdings suggest that interpretation of PPI 
scores must be based on each individual patient's pain experience. 
Although the visual analogue scales in this study were more sensitive than the 
verbal rating scales in detecting changes in pain intensity, as previously found by 
Sriwatanakul et al (1983), patient understanding of their use can be a problem and 
may account for the anomalies found in this study. Patient 76 was slightly confused 
at Interview 2 and despite higher NWC scores and PRJ scores than previously, had a 
lower VAS score which may have indicated poor ability to use the VAS at the time 
of Interview 2. The particular word descriptors used by this patient suggested an 
increase in pain severity. 
Melzack (1975) has previously proposed that patients suffering from a specific 
type of pain state would be expected to show a considerable degree of consistency in 
the choice of subclasses which characterise that pain state. The consistency of 
- 103 -
subclasses chosen by the 14 study patients at both Interviews 1 and 2 was similar to 
that found by Melzack (1975) i.e. median consistency of 75% in this study as 
compared to a mean of 70% in the Melzack study. Although these studies were not 
directly comparable, the consistency suggests that the MPQ verbal descriptors are 
sufficiently sensitive to report changes in pain intensity and quality over a much 
longer period of study within a practical clinical setting. 
Re-testing using the MPQ after 4-6 weeks also minimised the risk that patients 
at Interview 2 would have remembered the verbal descriptors they had chosen at 
Interview 1. 
The consistency of word choice within subclasses between Interviews 1 and 2 
was lower, reflecting the diversity of pain quality and intensity experienced by 
patients even over 1 to 2 months. Moreover, almost all the words used within the 
MPQ subclasses were used by patients to describe their pain. Phannacists need to 
appreciate the diversity of patients' pain experiences, which they must be able to 
identify and act upon. 
Care needs to be taken when interpreting the NWC scores in this study, since 
the changes in PRJ scores were not necessarily reflected by a change in NWC. 
Patients who perceived decreases in pain tended to choose a less intense or highly 
scored word within that subclass rather than drop the subclass altogether, thus the 
NWC may not have changed but the change in word chosen influenced the PRJ 
scores. This rmding suggests that only partial relief may have been obtained in a 
large number of the 96 patients. Indeed only 6% of patients were completely 
satisfied with their pain control. The high correlation between the most commonly 
used verbal descriptors for the poor outcomes group, and the total group overall 
suggests that use of a similar MPQ verbal descriptor check list in practice could help 
to identify the type and intensity of pain perceived by patients. Such a checklist 
would be especially valuable for phannacists if patients could not adequately 
describe their pain, and in particular, it could identify those requiring acute 
intervention. Time taken for completion of the checklist might limit its uptake in 
practice. At least 1 hour per patient was required for satisfactory completion of the 
MPQ in this study. 
It is impossible to distinguish any specific influence of the phannacist in the 14 
patients in tenns of pain control, since many other factors may have contributed to 
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the outcome, including natural disease progression, influence of therapy and lack of 
wash-out period between therapy changes and psychological and social factors. It 
was however interesting to note that the median VAS scores for pain now at either 
interview were consistently lower than any other VAS scale measurement, which 
may reflect the influence of distraction and I or social interaction as a useful coping 
strategy perceived by patients. 
By visiting such patients in their homes and demonstrating specific interest in 
their needs, the pharmacist may be able to provide a therapeutic benefit. Long-term 
and regular evaluation of such patients, for at least 3-4 months would be needed to 
evaluate the influence of therapy changes on pain control, especially in patients 
using DMARDs. 
The results investigating patient attitude to and knowledge of chronic pain 
suggest that the majority of patients have a good understanding of the potential 
consequences of chronic pain and its treatment, which may reflect the duration of 
the chronic pain state, although the latter result was not of statistical significance in 
this study. 
Patients desired to manage their own pain yet recognised the therapeutic 
benefits of therapy, fmdings of which are consistent with those of other researchers 
(Donovan et al 1989). The fmding that patients with RA and I or OA were less 
likely to agree to the statement that painkillers help you to cope with a normal life, 
could reflect their awareness of potentially increased exposure to side effects 
associated with long-term medication including NSAIDs and DMARDs. Indeed, 
side effects were more likely to be reported by RA patients in this study (see 
Chapter 6). Patients are generally worried about the risk of side effects (Donovan 
and Blake 1992). Pharmacists need to provide accurate information to patients about 
the likelihood of serious adverse effects arising and encourage frequent monitoring 
of therapy and appropriate referral. 
Some patients, especially those with back pain, do not seem to perceive the 
benefit of therapeutic strategies such as exercise, which is worrying, since 
appropriate exercise and physiotherapy are important factors in management. Most 
of the patients who perceived little benefit from exercise, reported worse pain and 
were then less keen to persevere with the therapy. Indeed, the pain scores in Tab Ie 
4.6 suggest that patients with back pain were suffering more pain than patients with 
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other pain diagnoses. Pharmacists are well placed to confrrm and discuss with 
patients the rationale of established protocols for such chronic pain management 
(Kay 1997). 
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Chapter 5 
Patient outcomes in terms of quality of life measures 
5.1 Introduction 
Quality of life is a multidimensional concept, as discussed in Chapter 1, which 
needs to include at least three major components when understanding chronic pain 
(Van Riel and Van Lankveld 1993). Such components are often inter-related and 
include: 
1. disease related variables such as outcome variables (e.g. pain, functional 
status, drug side effects), process variables e.g. erythrocyte sedimentation 
rate (ESR). 
2. socio-demographic variables such as age, sex and social network. 
3. psychological processes such as adaptation and coping. 
Many quality of life studies in rheumatology have not utilised this 3 
component model and often measure just one component e.g. depression, often 
combined with one or more processes influencing quality of life. Initial health 
indices which were developed to measure quality of life either confused process 
with outcome measures or only focused on one outcome measure, instead of 
visualising a multidimensional concept (Carr et aI1996). 
Evaluation of health outcomes in rheumatic diseases has traditionally consisted 
of clinical measures, regarded as process measures e.g. the Arthritis Association 
Scale (Felson et al 1995) and outcome measures such as pain (Kazis et al 1983). 
Bowling (1995) has produced a full review of the quantitative outcome measures 
used in rheumatoid arthritis. 
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Measures of physical functioning and limitation of activity have been used 
extensively to assess the outcome of joint disorders. The wide range of functioning 
scales have been extensively reviewed by Bowling (1995), and their applicability, 
validity, reliability and sensitivity discussed by McDowell and Newell (1996) and 
Bowling (1997). However, such scales have not provided a sufficiently detailed 
assessment of functioning in everyday life in rheumatic diseases, failing to identify 
social, physical and emotional well being. 
Consequently, investigators have developed arthritis-specific functional scales 
such as the Health Assessment Questionnaire (HAQ) (Fries et al 1980) and the 
Arthritis Impact Measurement Scales (AIMS 1 and 2) (Meenan et a11980, Meenan 
et al 1990). These scales are often used in combination with a generic, non-disease 
specific scale to asses broader health status rather than just functional status, such as 
the Sickness Impact Profile (SIP), (Bergner et al1981) or the Short Form-36 Health 
Survey (SF -36) (Brazier et aI1992). 
The AIMS covers social, emotional and physical wellbeing and is one of the 
most widely used outcome measures in arthritis research, with well-established 
validity and reliability. Although widely used for research purposes, it is suitable for 
use in the clinical setting (Kazis et al 1990). Fries et al (1980) using the Health 
Assessment Questionnaire (HAQ), a tool which is extensively used with well proven 
validity and reliability (McDowell and Newell 1996), dermed the outcome of 
rheumatoid arthritis patients in terms of discomfort, disability, death, drug toxicity 
and cost. Researchers are increasingly using more patient-generated scales such as 
the Patient Generated Index (PGI) to obtain more patient-focused assessments of 
quality of life in arthritis and back pain (Ruta et alI994). 
Rheumatoid arthritis, osteoarthritis and back pain affect patients' quality of life 
largely by limiting activities due to pain and disability, which also significantly 
affects social activity (Newman 1996). Pain itself can be regarded as both a process 
and an outcome variable. 
Psychological processes such as depression and coping strategies can influence 
both pain and functional status such that correlations between functional status or 
pain with quality of life are poor. 
Depression can be a significant problem in patients with chronic pain, arising 
either as a consequence of the chronic disease or as a separate psychological 
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problem (Newman et aI1989). However, inappropriate tools have often been used to 
assess the influence of depression on quality of life of patients with chronic pain, 
ultimately overestimating its influence on quality of life 01 an Riel and Van 
Lankveld 1993). 
Patients with chronic pain can often feel that they are a burden to family and 
friends, that they have lost their independence, yet are detennined to cope without 
help and appear 'nonnaI' (Skevington 1990) thus making detennination of quality of 
life per se difficult. Coping strategies are employed by patients through time to 
minimise the stress associated with such chronic diseases such that in patients with 
stable disease, the duration of the diagnosis is correlated with patient well-being 
(Newman et aI1990). Coping strategies can be investigated by using validated self-
reporting disease-specific measures such as the London Coping with Rheumatoid 
Arthritis Questionnaire (Newman et a11990) or scales to assess coping with chronic 
pain itself (Rosenstiel and Keefe 1983). 
In this study, it was inappropriate in tenns of characteristics of QOL scales 
required and time available during each interview, to utilise both a generic scale 
such as SF-36 and a disease specific scale such as AIMS or the Medical Outcomes 
Study (MOS) Pain Measures (Sherbourne 1992). SF-36 psychological sub-scores, an 
important component of chronic pain, have been shown to be less sensitive to 
change compared to AIMS (McDowell and Newell 1996). The AIMS scale could 
not be used, since it is designed as an outcome measure for arthritis patients and not 
all patients included in this study had arthritis. Unfortunately, the MOS Pain 
Measures scale was not sufficiently validated for recommended use as a disease-
specific measure at the initiation of this study. Moreover, no patient generated index 
(PGI) had been published at the time of this study. 
Thus a QOL scale had to be created to assess the influence of chronic pain on 
activities of daily living, which could be easily used and could identify the physical, 
psychological, social and occupational factors which influenced pain. It would also 
need to be sufficiently sensitive to detect changes in quality of life over a short 
period of time. 
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5.2 Objectives 
The objectives of this part of the study were: 
1. To investigate the reliability, validity, and sensitivity of the quality of life 
scale used. 
2. To investigate the overall influence of pain on activities of daily living and 
mood, as experienced by the 96 patients at fIrst interview, and the 
differences between those with satisfactory and poor overall outcomes in 
total quality of life scores and / or scores for physical well-being, social, 
occupational and psychological status. 
3. To investigate the overall influence of pain on activities of daily living and 
mood as experienced by the 14 patients who had a second interview and 
the changes in total quality of life scores and / or scores for physical well-
being, social, occupational, and psychological status. 
4. To investigate the influence of phannaceutical intervention on quality of 
life in patients who had poor outcomes at the time of the fIrst interview. 
5. To investigate the influence of age, chronic pain duration, pain diagnosis, 
concurrent disease states, current medication, patient attitude and 
satisfaction on quality of life. 
5.3 Methods 
The reliability of the QOL scale used in the study was investigated using the 
Pearson correlation coefficient and by the detennination of split-half reliability using 
the Spearman-Brown 'prophesy' fonnula and Cronbach's alpha coefficient as 
described in Chapter 2 Section 2.3.5. 
Face and content validity was assessed during the initial piloting of the pain 
questionnaire as described in Chapter 2 Section 2.1.6.4. Construct validity of the 
QOL scale was assessed by proposing a working hypothesis that patients with 
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satisfactory outcomes should have lower QOL scores than those with poor 
outcomes. Sensitivity was assessed by investigating the differences if any, in 
patients' responses to individual statements and by investigating the influence of 
pharmacist's intervention on quality of life scores. 
Fourteen statements from a previously validated questionnaire (Williamson et 
al 1993) were incorporated into the pain questionnaire to assess the impact of 
chronic pain on patients' behaviour, mood and activities of daily living, as described 
in Chapter 2 Section 2.1.6.3 and Appendix 8. During each interview patients were 
free to describe unprompted any other aspect of daily living with which their chronic 
pain interfered. 
Two types of quality of life scores were created, a total QOL score and 
dimension scores to assess sensitivity and reliability of the scale and the influence of 
pharmaceutical intervention on quality of life, as discussed by Williamson et a11993 
and described in Chapter 2 Section 2.3.5. High scores indicated poor quality of life. 
The Wilcoxon matched pairs signed rank sum test and Chi-squared tests (2x2) 
were used to analyse results, as described in Chapter 2, Section 2.3.5. 
5.4 Results 
5.4.1 Reliability, validity and responsiveness of the QOL scale 
The reliability or homogeneity of the QOL scale used in 96 patients was 
investigated using the Pearson correlation coefficient as discussed in Chapter 2. 
Tables 5.1 and 5.2 show the correlations between the individual QOL statement 
scores (Table 5.1) and the QOL dimensions with total QOL scores (Table 5.2). 
Table 5.3 gives the correlations between individual statement scores and 
dimensions. Each individual quality of life statement correlated significantly with its 
total and specified dimension QOL score (p < 0.001) (Tables 5.1 and 5.3 
respectively) and significant correlations also existed between each dimension score 
and total QOL scores (p < 0.001) (Table 5.2). 
- 111 -
Split-half reliability using the Spearman-Brown 'prophesy' formula was found 
to be 0.87. Internal consistency, as determined by Cronbach's alpha was 0.87. These 
results suggest that that the QOL scale has good homogeneity and that the individual 
statements within the scale are well correlated with each other. The acceptable range 
for split-half reliability or internal consistency is 0.7-0.9 (Nunally 1978). Too high a 
result would suggest that 2 different constructs are combined. 
Individual QOL statements Pearson's correlation coefficient (r) 
(95% el) 
Walking 0.63 (0.49-0.74) 
Housework 0.64 (0.52-0.75) 
Sleeping 0.61 (0.45-0.71) 
Eating 0.65 0.51-0.75) 
Anxiety 0.70 (0.57-0.79) 
Depression 0.68 (0.54-0.77) 
Loneliness 0.50 (032-0.63) 
Frustration 0.67 (0.54-0.77) 
Enjoyment of life 0.73 (0.63-0.82) 
Daily activities 0.64 (0.52-0.75) 
Mobility 0.75 (0.67-0.84) 
Support to discuss problems 0.39 (0.22-0.56) 
Ability to plan activities 0.76 (0.67-0.84) 
Influence of pain on work 0.55 (0.4-0.68) 
Table 5.1: Pearson correlation coefficients of individual QOL statements with total 
QOL scores at Interview 1 (n=96, p < 0.001) 
QOL dimensions Pearson's correlation coefficient (r) 
(95% el) 
Physical 0.91 (0.87-0.94) 
Social 0.86 (0.80-0.90) 
Occupational 0.81 (0.73-0.87) 
Psychological 0.85 (0.79-0.90) 
Table 5.2: Pearson correlation coefficients of QOL dimensions with total QOL 
scores at Interview 1 (n=96, p < 0.001) 
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Individual QOL statement Dimension of Pearson's correlation 
QOL coefficient (r)(95% CI) 
Walking Physical 0.70 (0.58-D.79) 
Sleeping 0.71 (0.6()-{).80) 
Eating 0.74 (0.64-D.82) 
Mobility 0.76 (0.67-D.84) 
Enjoyment of life Social 0.74 (0.64-D.82) 
Friends I family support to 0.63 (0.49-D.74) 
discuss problems 
Ability to plan activities 0.82 (0.74-0.88) 
Housework Occupational 0.72 (0.61-D.80) 
Enough daily activities 0.61 (0.45-D. 71) 
Influence of pain on work 0.78 (0.69-D.84) 
Anxiety Psychological 0.83 (O.76-D.88) 
Depression 0.85 (0.79-D.90) 
Loneliness 0.68 (0.54-0.77) 
Frustration 0.69 (O.57-D.78) 
Table 5.3: Pearson correlation coefficients of individual QOL statements with QOL 
dimension scores at Interview 1 (n=96, p < 0.001) 
Initial piloting of the questionnaire assessed face and content validity. 
Construct validity was assessed by investigating if any correlations existed between 
the QOL scores and other relevant, previously validated health outcome measures 
i.e. MPQ outcome measures. Total QOL scores correlated significantly (p < 0.001) 
with total pain rating index scale scores (pRJ (S» (r = 0.39) and total pain rating 
index rank scores (pRJ®) (r = 0.38) for all 96 patients. 
A working hypothesis proposed to establish construct validity of the QOL 
scale was that patients with satisfactory outcomes should have lower QOL scores 
than those patients with poor outcomes. Table 5.4 shows that patients with 
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satisfactory outcomes compared with patients with poor outcomes had significantly 
lower total QOL (X2 = 10.41, df =1, P < 0.01), physical ("I: = 10.63, df = 1, P < 
0.01), social (X2 = 7.31, df= 1, P < 0.01) and psychological dimension scores (X2 = 
10.04, df= 1, P < 0.01). 
Sensitivity was assessed by investigating the differences if any, in patients' 
responses to individual statements and by investigating the influence of pharmacist's 
intervention on quality of life scores. The differences between total QOL, physical, 
social, occupational and psychological dimension scores for all patients and for 
subgroups can be seen in Table 5.4. 
Individual QOL statement scores in all 96 patients at Interview 1 and the 
changes in these individual scores in the 14 of the 28 patients who were interviewed 
after the pharmacist's intervention are shown in Table 5.5. The wide ranges of 
scores both before and after intervention, suggest that the QOL scores are sensitive 
to external and internal influences. 
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TotalQOL 28 24 48 44 50/63 
(95%, el) (23-36) (19-28) (32- 68) (36-57) (32-68/27-70) 
Physical 31 25 62 56 621 50 
dimension 
(95% el) (25-38) (19-31) (38-69) (31-62) (25-69/38-62) 
Social 25 25 33 33 40/62 
dimension 
(95% el) (17-33) (17-25) (38-50) (25-50) (25-67/25-75) 
Occupational 33 29 54 46 56/54 
dimension 
(95% eI) (25-33) (17-33) (17-92) (25-58) (17-83/26-67) 
Psychological 25 19 56 44 50/50 
dimension 
(95%, el) (19-31) (12-25) (19-69) (25-50) (25-69 / 19-75) 
Table 5.4: Summary of median quality of life scores and 95% confidence intervals 
of all patients and patient groups 
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Walking Physical 2 3 3 
0-4 0-4 1-4 
Sleeping Physical 1 2 3 
0-4 0-4 1-4 
Eating Physical 0 1 1 
0-4 0-3 0-3 
Mobility Physical 1 1 2 
0-4 0-4 0-4 
Enjoyment of life Social 1 2 3.5 
0-4 0-4 0-4 
Family support to Social 0 1 0.8 
discuss problems 0-4 0-4 0-4 
Ability to plan Social 1 2 2 
activities 0-4 0-4 1-4 
Influence of pain on Occupational 2 3 2 
work 0-4 0-4 0-4 
\ 
Housework Occupational 2 2 3 
0-4 0-4 1-4 
Daily activities Occupational 0 1 0.8 
0-4 0-4 0-4 
Anxiety Psychological 1 2 2 
0-4 0-4 0-4 
Depression Psychological 1 2 1 
0-4 0-4 0-3 
Loneliness Psychological 0 0 1 
0-4 0-3 0-4 
Frustration Psychological 1.5 3 2 
0-4 1-4 1-2 
Table 5.5: Median scores and ranges for individual QOL statements in all patients 
(n=96) and in those interviewed after pharmacist'S intervention (n=14) 
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5.4.2Influence of pain on quality of life 
5.4.2.1 Influence of pain on activities of daily living and mood in all patients 
In this study, a high QOL score implies a poor QOL and vice versa. Patients 
who had satisfactory outcomes at the time of Interview 1 had the lowest QOL scores 
in terms of total and dimension scores. Fourteen patients who had poor outcomes at 
Interview 1 and were interviewed after pharmaceutical intervention had the highest 
QOL scores in comparison to the other groups initially. Although they represent 
only half of the 28 patients with poor outcomes, total and dimensional QOL scores 
tend to reflect those of the whole group. 
The ranges of scores for both total QOL and QOL dimensions were very wide 
within and between patient outcome groups. However, the comparatively narrow 
confidence intervals for all patients at Interview 1 suggest that median QOL scores 
were not very variable, varying between 17 to 38% of the maximum QOL scores. 
Indeed, even among patients in whom a poor outcome had resulted at Interview 1, 
median QOL scores ranged from only 33-62% of the maximum achievable QOL 
score. 
The median scores in Table 5.4 suggest that at the time of Interview 1, 
occupational problems contributed most to the QOL scores of the total group, 
followed by physical, psychological and lastly social factors. Patients with 
satisfactory outcomes had higher occupational scores as compared to other 
dimensional scores while patients with poor pain outcomes had higher physical 
scores as compared to other dimensional scores. 
Patients' perception of quality of life in terms of individual QOL was again 
varied within and between patient groups as reflected by the wide range of QOL 
scores in Table 5.5. For the total patient group, the physical dimension results 
suggest that, patients in general identified a fair amount of difficulty in walking, a 
little difficulty in eating and in getting out the house more but did not generally fmd 
food unappealing. Within the occupational dimension of quality of life, most 
patients identified a fair amount of difficulty with household chores and with 
performance at work. The low median scores for the total patient group regarding 
enjoyment of life, planning of activities due to pain or family support, suggest that 
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the social dimension of quality of life was satisfactory for most patients. Frustration 
contributed most to the psychological problems of the 96 study patients. 
5.4.3Quality of life in 14 patients with poor outcomes before and after 
intervention by the study pharmacist 
The median scores of those patients who required pharmacist intervention 
were the highest of the patient outcome groups (Table 5.4). Physical problems 
contributed most to this group's total QOL scores, followed by occupational, 
psychological and lastly social factors. 
Table 5.5 demonstrates that, prior to intervention, patients who had 
pharmaceutical intervention after their fIrst interview had a lot of difficulty in 
walking (physical dimension), felt very frustrated (psychological dimension) and 
pain had greatly affected their work (occupational dimension). Patients also 
identified a fair amount of difficulty in sleeping, doing household chores, planning 
activities and felt fairly anxious and depressed. 
After pharmaceutical intervention in 14 patients, there were non-significant 
increases in total QOL scores, decreases in the median QOL scores for the physical 
and occupational dimensions, slight increases in median scores for the social 
dimension and no overall change within the psychological dimension (Table 5.4). 
Some of the changes in dimension scores post intervention (Table 5.4) did not 
reflect changes in individual statement scores (Table 5.5). Although the median 
physical dimension score decreased after pharmacist intervention, the median score 
for sleeping increased (Table 5.5). Slight decreases in the median occupational 
dimension score post intervention reflected increases in activity and a reduction in 
the influence of pain on work, yet the median score concerning the ability to do 
housework increased. Social problems increased after pharmaceutical intervention, 
which was reflected by a decrease in enjoyment of life, despite reduced family 
support problems. Patients perceived themselves after intervention to be less 
frustrated and depressed, but rated loneliness as slightly more of a problem (Table 
5.5). 
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Details of changes in total QOL and dimension scores, patient satisfaction and 
patient attitude in the 14 patients interviewed after pharmaceutical intervention are 
shown in Table 5.6. 
Within patient differences between Interviews 1 and 2 for total QOL scores 
and physical, social, occupational and psychological dimension scores were not 
statistically significant (p > 0.2 (n = 14), P > 0.2 (n =13), p > 0.2 (n = 11), P > 0.2 (n 
= 9), p> 0.2 (n = 14), Wilcoxon signed rank sum test). 
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In terms of patient outcome, 8 patients reported a decrease and 6 reported an 
increase in total QOL scores. In the 2 patients where the pharmacist's advice was 
not accepted, the total QOL score decreased in one but increased in the other (Table 
5.6). 
5.4.4 Influence of psychological, physical and social factors and quality of 
life 
5.4.4.1 Influence of patient attitude and satisfaction on quality of life 
Patients who demonstrated a high attitude score were regarded as having a 
good awareness of the rationale of therapy. Although each attitude statement used to 
create the attitude score was reasonably correlated with the overall attitude score ('r' 
ranged from 0.24 - 0.63), patient attitude to chronic pain did not correlate with QOL 
scores for either the total group (n = 96) or the sub-group interviewed on 2 occasions 
(n = 14). The distribution of the attitude scores for all 96 patients was heavily 
positively skewed (median 71 %, range 46 - 89). 
Satisfaction with overall pain management for the 96 patients was however 
significantly correlated with total QOL scores (r = -0.52, P < 0.001), with high levels 
of satisfaction being associated with low total QOL scores. 
5.4.4.2 Influence of pain, pain diagnosis, duration of pain, concurrent disease 
states, age and current medication on quality of life 
Total QOL scores for the 96 patients were positively correlated with all three 
McGill Pain Questionnaire pain parameters Le. total PRI rank scores (r = 0.38, P < 
0.001), total PRI scale scores (r = 0.39, p < 0.001) and VAS average scores (r = 
0.54, P < 0.001). The type of pain diagnosis and number of concurrent disease states 
were not related to total QOL scores. 
Duration of pain showed a weak positive correlation with patient attitude (r = 
0.24, p > 0.2), but no correlation with patient satisfaction or pain scores (r = 0.1). 
Total QOL scores were not influenced by age (r = 0.07) or duration of pain (r = 
0.12). 
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Since all patients were taking multiple medications, it was not possible to 
identify the influences, if any, of current medications on quality of life. 
S.4.SCase studies - patients with poor quality of life on interview 
requiring GP referral 
Appendices 17 and 18 illustrate two case studies in which patients had poor 
quality of life and required GP referral after intervention by the study phannacist. 
5.5 Discussion 
Phannacists in both primary and secondary care are being challenged to 
validate and ultimately use quality of life assessment tools to measure the impact of 
phannaceutical intervention on patients' quality of life (Williamson et al 1993, 
Salek and Walker 1995, Tully and CantrillI998). Quality of life instruments for use 
by phannacists in primary care need to be applicable, practical, sensitive and valid 
for the environment in which phannaceutical care is being delivered, the patient 
group(s) involved and intended purpose (Salek and Walker 1995, Tully and Cantrill 
1998). 
No one tool has yet been demonstrated by pharmacists to be ideal in tenns of 
measuring pharmaceutical influence on quality of life. Since health care 
professionals' and patients' perceptions of quality of life in chronic disease often 
differ (Weissman and Haddox 1989), researchers are increasingly investigating the 
validity and applicability of patient-generated scales, such as the Patient Generated 
Index (PGI) to obtain a more accurate assessment of the quality of life of patients 
with arthritis and low back pain (Tully and Cantrill 1998, Ruta et al 1994). 
However, Tully and Cantrill (1998), question the validity of the PGI, since areas of 
life described by patients as those most affected by their arthritis depended on the 
severity of their disease. Patients with severe arthritis described many areas of their 
lives which were affected, yet most often described the areas of life given as 
examples within the PGI. Patients with mild or inactive arthritis were much more 
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likely to describe different areas of their life which were affected and chose 
significantly fewer example areas of the PGI. 
Short-form generic instruments such as the Summary UKSIP may be useful in 
community practice to assess the influence of drug therapy on quality of life 
between different patient groups (Salek and Walker 1995). However, the Short 
Fonn-36 (SF-36) as a generic tool is insensitive to changes in drug therapy after 
implementing formulary changes (Stewart 1997). Patient-derived scales such as the 
PGI have also been used by pharmacists to assess quality of life in arthritis patients 
(Tully and Cantrill 1998) but such indices may need to be further refm~d to establish 
their validity prior to clinical use by pharmacists in practice. On the other hand, 
disease specific scales can be useful in measuring health outcomes resulting from 
therapy changes even with small sample sizes (Stewart 1997). 
The reliability of the QOL scale used was found to be within acceptable 
standards e.g. Cronbach's alpha coefficient of at least 0.85 (McDowell and Newell 
1996). However, it is important to consider that correlation coefficients fail to assess 
variability well (Deyo et al 1991). Ideally, intraclass correlations or a weighted 
kappa statistic should have been calculated to identify within-patient variations and 
explicitly dissociate between true variation and random error. Unfortunately, the 
lack of control groups in this study prevents such statistical analysis. 
The content and face validity of the quality of life tool are demonstrated by the 
facts that all individual QOL statements fell into at least 1 of the 4 physical, social, 
occupational or psychological dimensions and showed good correlations within their 
respective dimensions. The halo effect of patient rating of quality of life (Norman 
and Steiner 1995) was minimised by encouraging patients to assess their QOL in 
terms of individual statements rather than a global index or score. The wide range of 
responses for each individual statement and the individual comments made 
unprompted by patients suggest that the scale was able to identify most of the factors 
which influence the quality of life of patients with chronic pain. However, the scale 
did not investigate the influence of pain on sexual activity, which has been shown to 
be a significant problem (Skevington 1990). Such an omission may not have 
occurred had a patient-generated index been used to defme patient-perceived QOL 
problems (Ruta et aI1994). 
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Too few questions within each dimension with respect to the dimension's 
relative importance may also have limited the scale's content validity (Norman and 
Steiner 1995) and many have contributed to the anomalies seen in QOL statement 
scores after pharmacist intervention. In the scale used, although the physical and 
psychological dimensions were each allocated 4 questions as compared to the 2 
other dimensions, to reflect their greater contribution to the perception of chronic 
pain (Anderson et aI1985), the scale may have been too brief to ensure validity. 
Criterion validity was not assessed in this study. Ideally, the new scale should 
have been correlated with an already established QOL scale which assessed the 
impact of pain on activities of daily living e.g. the Medical Outcomes Study Pain 
Measures (Sherbourne 1992). 
The fmdings that patients who had satisfactory outcomes had statistically 
significantly lower QOL scores as compared to patients with poor outcomes, and 
that the QOL scores correlated positively and significantly with all validated McGill 
pain indices suggest that construct validity of the QOL questionnaire was 
satisfactorily investigated. If necessary, further exploration could involve 2 extreme 
groups, one group with chronic pain and the other healthy individuals. It would then 
be expected that the former group should score significantly higher on the QOL 
scale to provide further evidence of the QOL scale's construct validity. 
The statistically significant results from Interview 1 indicate that the QOL 
scale may be sufficiently sensitive to distinguish between patients with poor 
outcomes and those with satisfactory outcomes, using the pre-set criteria for poor 
outcome. This suggests that the QOL tool did contribute to identifying those patients 
most in need of help in terms of quality of life. Such a scale may be a useful 
screening tool in practice to help identify those patients who need health care 
intervention to improve symptoms in patients with chronic pain. However, it is 
important when using QOL scales for routine practice to be aware of each 
dimension score as each could be modified by intervention. 
The sensitivity of the scale in measuring changes in quality of life after 
pharmaceutical intervention appeared to be limited from the results obtained from 
tables 5.4 and 5.5. However, the small sample size here (14) and lack of control 
group precludes a valid assessment of sensitivity. The ranges of the dimension 
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scores before and after intervention were much more reflective of the resultant 
changes, if any, in scores as compared to median scores. 
Such fmdings again illustrate the lack of sensitivity of a generic scale to assess 
changes over a relatively short period of time, as in this study, especially when 
individual scores are compounded into a global score (Carr et al 1996). A more 
disease-specific scale would have been more appropriate as discussed earlier. 
Indeed, Stewart (1997) found that the generic SF-36 was less responsive to changes 
in health outcomes after implementing therapy changes in patients with peripheral 
vascular disease compared to the performance of a disease specific scale. 
The changes demonstrated in Table 5.5 after pharmaceutical intervention may 
reflect the unpredictable nature of the disease state, (especially since most of the 
patients who were interviewed twice had rheumatoid arthritis), the sub-optimal 
response of the revised therapy e.g. DMARDs and / or cross-over effects of 
treatment regimens between the interview times 1 and 2 (Fries et al 1997). Ideally, 
to asses the clinical contribution of a therapeutic change, this QOL scale would need 
to be used by patients regularly at appropriate 2 to 3 monthly intervals before and 
after therapeutic changes under controlled conditions. 
Patient bias in terms of demonstrating socially desirable responses, different 
interpretation of response scaling and attitude to management of their chronic pain 
may have also complicated results. However, careful wording of attitude and quality 
of life statements were designed to minimise response bias. The results 
demonstrated more bias to the left of the QOL scale i.e. low scores, rather than a 
skewed distribution in the middle of the scale as can often occur with patient rating 
scales (Norman and Steiner 1995). This finding may suggest that patients' response 
was reflective of their perceived quality of life with patients actually making a 
judgement rather than just marking the middle of the scale. 
In general within the group of 96 patients, patients identified more physical 
and occupational problems as compared with social or psychological problems. 
However, as with most QOL scales, this does not accurately reflect the individual 
patient perception of the relative influence of each factor on their QOL. Ideally, 
patients should have been asked to rank the statements in order of their perceived 
importance or to create their own patient-generated index to obtain a more realistic 
appreciation of patients' own problems (Ruta et aI1994). However, limitations have 
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also been found with this approach as discussed earlier in this chapter (Tully and 
Cantrill 1998). 
Although the results vary widely between patients, low median social scores 
for all groups suggest that patients have coping strategies to maintain enjoyment of 
life irrespective of the intensity of their pain. Coping strategies are well documented 
in patients with chronic pain and vary depending on many external and patient 
factors (Rosenstiel and Keefe 1983). For example, when patients were asked if they 
had difficulty in talking to their friends or relatives about their pain, some reported 
that they did not talk to their relatives about the pain, so it was not perceived as a 
problem by these patients. Although this was perceived by the study pharmacist as a 
coping strategy, it may have resulted in overestimating the extent of family and 
friend support which was provided to the study group and in underestimating the 
social problems of patients with chronic pain. 
It was interesting to note that although patients with satisfactory outcomes, as 
defmed by the pre-set criteria, had the lowest total QOL scores and the lowest QOL 
scores for all dimensions, the group still identified that their chronic pain caused 
problems including housework, planning activities and continuing their work. Their 
pain often resulted in changes in work practices, reflected by high occupational 
scores. They also identified problems in their ability to eat, sleep, walk and get out 
of the house. Such limitations have been well documented by Anderson et al (1985). 
These problems need to be appreciated by all health care professionals when 
assessing the wellbeing of patients with chronic pain, irrespective of perceived pain 
control. 
Patients with poor pain control reported the highest psychological scores as 
compared to the other groups, which may reflect the psychological distress 
associated with pain itself, a lack of coping strategies or may indicate that this group 
had separate psychological problems (Newman 1996), as illustrated by Case Study 5 
in Appendix 18. Further investigation of the psychological problems of such a 
patient group is needed using an appropriate tool to more accurately assess the 
influence of psychological problems such as depression and coping strategies on 
quality of life (Van Riel and Van Lankveld 1993). 
Patients who had poor outcomes and were interviewed on a second occasion 
after intervention, had the highest median total, physical and occupational dimension 
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scores and the highest individual statement QOL scores as compared to the other 
outcome groups. The large amount of frustration identified by this group (Table 5.5) 
may well have resulted due to problems of mobility and work, all of which can 
lower self-esteem (Newman et aI1989). 
Patient attitude to pain has been demonstrated to influence quality of life such 
that patients with a very negative attitude to chronic pain have reflected a poor 
quality of life (Van Riel and Van Lankveld 1993). In this study, the lack of 
correlation of overall attitude with quality of life may be partly explained by the 
positively skewed distribution of patient attitude in this group prior to intervention, 
the lack of sensitivity of the attitude score and the duration of chronic pain in the 
study group. Knowledge about chronic pain management in this group of patients 
was high (reflected by high attitude scores) and duration of pain was found to relate 
to attitude, marked changes in attitude would have been required to effect a change 
in overall score at Interview 2. The results also demonstrate the problem of 
potentially masking a change in an attitude statement by creating a global index 
attitude score from such statements (Norman and Steiner 1995). 
Although the type of chronic pain was not found to influence quality of life, 
pain intensity significantly influenced patients' overall quality of life. Pain in 
patients with RA, OA and back pain has been reported to be a significant factor in 
determining patients' quality of life (Reisner-Keller 1992, Kazis et al 1983). 
Pharmacists have an ideal opportunity to try to optimise pain relief where possible 
and so help to improve quality of life. 
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Chapter 6 
Side effects experienced by patients and documentation of 
monitoring parameters 
6.1 Introduction 
Patients with chronic disease states such as chronic pain are at high risk of side 
effects, since many of the patients are on multiple drug therapy, elderly, have 
concurrent disease and may be non-compliant with their medication. All of the 
above factors predispose to adverse drug reactions (Cadieux 1989, Kando et a11995, 
Col et aI1990). 
Patients prescribed long-term NSAIDs and DMARDs are at high risk of 
developing side effects (CSM 1994, Fries et al 1993) so need to be closely 
monitored to optimise efficacy and minimise toxicity. Indeed, NSAIDs are 
responsible for 25% of voluntary adverse effect reporting to the Committee on 
Safety of Medicines (CSM 1994). 
The incidence of adverse drug reactions (ADRs) in hospital ranges from 4 to 
30%, depending on the differences in methodology used to detect suspected 
reactions and the differences in the ADR defmition used (Bates et a11995, Seeger et 
al 1996). The few limited well .. designed studies of ADRs in the community which 
have been published, suggest an incidence of 2.6 to 40% (Martys 1979, Mulroy 
1973, Cunningham et aI1997). 
Mulroy (1973) prospectively investigated the number of GP consultations in a 
practice of 6,200 patients which were assessed as a direct result of iatrogenic 
disease. One consultation in every 40 was identified as the result of iatrogenic 
disease. This study had no control group and found problems in defming and 
measuring some of the side effects of medical treatment. Martys (1979) found a 
much higher incidence of ADRs in general practice (41%) in a 2 year prospective, 
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uncontrolled study, which involved more detailed patient interviews and follow-up 
as compared to the study of Mulroy (1973). Cunningham et al1997 found that over 
25% of hospital admissions in the elderly were due to drug related problems, and, 
unlike the previous researchers, utilised a review panel of health professionals to 
assess the type(s) of drug related problems and their contribution to the admission. 
Spontaneous reporting schemes of ADRs have, until recently, only been 
permitted for use by doctors, dentists, coroners and pharmaceutical companies via 
the 'YeHow card scheme'. Recent studies have demonstrated that under-reporting of 
ADRs in both hospital and general practice has occurred (Smith et al 1996). Both 
hospital and community pharmacists, in pilot studies, have been shown to have 
adequate resources and ability to participate in such schemes (Edwards et a11989, 
Wolfson et al 1993,Whittlesea and Walker 1996). Moreover, pharmacists have 
improved the reporting of serious drug reactions (Lee and Beard 1997). 
Consequently, all hospital pharmacists and some community pharmacists in pilot 
sites have been recruited recently into the scheme (CSM 1997). The pharmacist's 
roles in this scheme have been defmed recently by Lee and Beard 1997. The 
community pharmacist is actively encouraged to identify adverse effects associated 
with OTC medicines, alternative therapies and possibly generic medicines 
(Whittle sea and Walker 1996). Recent results suggest that ADR reporting by 
community pharmacists has been of good quality, but not as extensive as originally 
anticipated from the original response to involvement in the initial pilot study. 
Reduced uptake of the scheme may have reflected variations in the enthusiasm of 
the recruited pharmacists as the project proceeded. However the extent of ADR 
reporting is influenced by appropriate training programmes (Lewis 1998). 
Patients are becoming increasingly involved in making decisions about their 
drug therapy for rheumatological problems, and can be useful sources from whom 
adverse effects can be identified (Donovan et aI1989). However, attribution of the 
causality of symptoms to an ADR is difficult and limited (Lee and Beard 1997), 
especially since ADRs can often be masked by other concurrent diseases. Moreover, 
healthy people not taking any medication can report similar symptoms (Reidenberg 
and Lowenthal 1968). 
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Documentation and communication of an ADR to relevant healthcare 
personnel is vital to minimise further side effects and to maximise the therapeutic 
outcomes of potentially very toxic agents such as DMARDs and NSAIDs. 
Shared care protocols must be developed and agreed by both rheumatology 
consultants and general practitioners to clearly identify who is responsible for 
initiating and thereafter maintaining DMARD therapy and who is responsible for the 
monitoring of potential toxicity (Anekwe et a11997, Anon 1996). 
6.2 Objectives 
The objectives of this part of the study were: 
1. To identify patients' awareness of the potential side effects of their medication. 
2. To identify side effects reported by the study patients. 
3. To investigate the extent of documentation of monitoring parameters for efficacy 
and toxicity .. 
6.3 Methods 
The data collection form as described in Chapter 2 Section 2.1.6.1 and 
Appendix 7, was used to identify side effects which were both currently or 
previously experienced by patients and attributed to their medication for the 
management of chronic pain. These side effects were documented in the patients' 
medical notes. The question 'Have you ever experienced any problems which you 
think could be due to your medicine?' in the pain questionnaire (Appendix 8, 
question 36) was also used during each interview to identify patient awareness of 
side effects which they attributed to their medication for chronic pain management. 
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The same data collection form in Appendix 7, was also used to identify the 
extent of documentation of monitoring parameters for optimising efficacy and 
minimising toxicity ofNSAIDs, DMARDs, immunosuppressants and other therapy. 
6.4 Results 
6.4.1 Types and frequencies of side effects experienced and reported by 
study patients 
Seventy-three out of the 96 study patients (76%) reported that they had at some 
time since the diagnosis of their chronic pain experienced at least one side effect 
which they could attribute to their medication. One hundred and seventy five side 
effects were reported by the 73 patients, 158 during Interview 1 and 17 at Interview 
2, the latter attributed by patients to medication which was prescribed after 
Interview 1. 
Table 6.1 shows the number of RA, RA and OA, OA and back pain patients, 
who reported side effects. Table 6.2 describes the number of side effects reported 
related to type of drug therapy. 
Five of the 18 patients who had poor pain outcomes, as def~ed in Chapter 2, 
were referred to the GP because they were at high risk of or had developed side 
effects. 
No patients reported an ADR to an OTC medicine. 
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Interview Number of Number of patients who Chronic pain 
side effects reported side effects (0/0 disease state (total no. 
reported of pain group) of patients in group) 
1 76 35 (83) RA (42) 
21 13 (59) OA (22) 
53 20 (80) RAandOA (25) 
8 5 (71) Back pain (7) 
Total 158 73 (76) 96 
2 10 5 (62) RA (8) 
1 1 (33) OA (3) 
6 4 (80) RAandOA (5) 
0 (0) Back pain (2) 
Sub·total2 17 10 (56) 18 
Final Totals 175 83 
Table 6.1: Frequency of side effects reported by 73 study patients 
Type of drug Number of side effects Number of patients who 
reported (% of total) reported side effects (% of 
patients prescribed drug) 
NSAID 72 (41) 64 (90) 
DMARDsand 39 (22) 17 (93) 
Immunosuppressants 
Combination Analgesics 26 (15) 20 (42) 
Opioid analgesics 7 (4) 6 (75) 
Others 31 (18) 22 (67) 
Totals 175 (100) 
Table 6.2: Frequency of side effects reported by 73 study patients in terms of type 
of drug 
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6.4.2Types and frequencies of side effects attributed to NSAID therapy 
Table 6.3 lists the 72 specific side effects which 66 different patients attributed 
to their NSAID therapy. Eight of the 64 patients reported side effects which they 
attributed to NSAIDs prescribed since Interview 1. Seventy-one of the side effects 
reported with NSAIDs were known to be associated with NSAID therapy. The most 
common reported side effects were gastrointestinal side effects (74%). All patients 
who reported that they had a gastrointestinal bleed had no previous history of gastric 
ulceration prior to the bleed. Other NSAID side effects reported by 4 patients, 
included interstitial nephritis, nephropathy (induced by diclofenac), proctitis 
(indomethacin suppositories), and palpitations induced by etodolac. 
Type of side effect N umber of side Number of patients who 
effects reported reJ!orted the side effect 
Nausea 18 16 
Vomiting 3 3 
Diarrhoea 3 3 
Heartburn! indiE.estion 17 14 
Gastric or duodenal ulcer 8 8 
GI bleed 4 4 
Const~tion 1 1 
Dermatolo_gical 10 10 
Dizziness, eu~horia 3 3 
Others 5 4 
Total 72 66 
Table 6.3: Types and frequencies of side effects attributed to NSAID therapy by 
study patients 
6.4.3 Types and frequencies of side effects attributed to DMARD and 
immunosuppressant therapies 
Seventeen patients attributed 39 specific side effects to their DMARD or 
immunosuppressant therapies. The most commonly reported side effects included 
gastrointestinal problems (1 0 patients), rash (7 patients) and haematological 
problems ( 4 patients). Two patients on penicillamine reported that they had 
developed thrombocytopenia with their therapy, while 2 on sulphasalazine 
developed leucopenia. Proteinuria was reported by 1 patient on penicillamine and 2 
patients on gold. Two patients who had taken hydroxychloroquine in the past 
reported ocular side effects, fever, malaise and bone pain. 
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6.4.4 Types and frequencies of side effects attributed to combination 
analgesics, opioids and other therapies 
The frequency with which side effects were reported to combination 
analgesics, opioids and other therapies is shown in Table 6.2. 
The most commonly reported side effects of combination analgesics were 
constipation (12) and CNS side effects (9). Opioid therapy was reported to cause 
constipation in 5 patients, nausea in 2 patients and dizziness or drowsiness in 2 
patients. 
Thirteen of the 31 other side effects, reported by 7 patients, could not be 
attributed to any specific drug. The 18 other side effects, attributed to other therapy 
not associated with chronic pain management included gastrointestinal problems (7), 
side effects associated with cardiovascular therapy (8), night sweats with tamoxifen 
(1) and side effects associated with antibiotic therapy (2). 
6.4.SCase studies - patients requiring GP referral due to high risk or 
development of side effects 
Five of the 18 patients who had poor pain outcomes and who were 
consequently referred to the GP by the study pharmacist were at high risk of or were 
experiencing side effects to their prescribed medication. Appendices 19 and 20 
detail the case studies of 2 of the 5 patients who required GP referral due to the 
development of side effects. 
Four of the 5 patients were experiencing side effects which both they and the 
study pharmacist attributed to NSAID therapy. These NSAID side effects included 
gastrointestinal side effects (3 patients), ranging from dyspepsia to 'spitting blood' 
and dermatological side effects (1 patient). Two patients developed 
thrombocytopenia with penicillamine therapy, requiring GP referral, after which 
penicillamine therapy was discontinued in both cases. 
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6.4.6 Documentation of biochemical and other parameters to monitor the 
efficacy and toxicity of therapy 
There was very little documented evidence in medical records relating to the 
efficacy of treatment in terms of pain relief, either subjectively or objectively. 
Little documentation was made of the progression of rheumatoid arthritis in 
patients. Pain and joint scores were only documented in 1 patient's notes, erythrocyte 
sedimentation rates in 7 patients' notes and c-reactive protein levels in 1 patient. 
One patient with diagnosed iron deficiency anaemia had serum iron recorded post 
therapy, but no haemoglobin, mean cell volume or ferritin documented. 
Only 34 of the 96 study patients had any monitoring parameters actually 
documented in their medical records or on computer, which made it difficult for the 
study pharmacist to evaluate the potential efficacy or toxicity of patients' medication 
in terms of objective parameters. 
6.4.7 Documentation of parameters to assess the efficacy and toxicity of 
NSAIDs 
There was no routine monitoring of haematological parameters or renal 
function documented for any of the study patients. Only 2 patients had renal 
parameters monitored, which was due to underlying renal disease. 
6.4.8 Documentation of parameters to assess the efficacy and toxicity of 
DMARDs 
Out of the 16 patients who were taking DMARDs or immunosuppressants, 
only 10 patients had any monitoring parameters recorded. Three of the 5 patients 
prescribed gold, 2 of the 6 prescribed sulphasalazine and all 3 patients prescribed 
penicillamine had full blood counts documented. One patient prescribed 
hydroxychloroquine was due for an initial ophthalmology assessment and 1 
prescribed azathioprine had liver function and full blood tests documented. It is thus 
unclear if any monitoring was actually carried out in the patients with no 
documented results. No baseline serum biochemistry and haematology results were 
available to check baseline values prior to DMARD therapy. 
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Table 6.4 compares the documented monitoring parameters in the above 10 
patients with the protocol for monitoring DMARDs and immunosuppressants as 
defmed in Appendix 4. 
DMARD No. of No. of No. of Comments 
patients with patients records 
results prescribed which met 
recorded drug criteria 
Sulphasalazine 2 6 2 
Penicillamine 3 3 2 (a) 
Sodium 2 4 0 (b) 
Aurothiomalate 
Auranofin 1 1 0 (c) 
Hydroxychloroquine 1 1 1 (d) 
Azathioprine 1 1 1 (e) 
Totals 10 16 6 
Table 6.4: Comparison of documented monitoring for the DMARDs and 
immunosuppressants used in the study patients with data sheet monitoring 
recommendations and other published advice (Medicines Resource Centre 
1996) 
(a) Only I patient who developed thrombocytopenia had platelets recorded in OP medical 
notes after therapy was discontinued. 
(b) Two patients had no documented results, 2 had monthly full blood count results after 
injection, but no urinalysis. 
(c) No record of wee or urinalysis monitored. 
(d) Therapy just recently initiated, but ophthalmic check 2 weeks after initiation of therapy. 
(e) Liver function tests, full blood count monitored at 3 monthly intervals. 
6.4.9 Documentation of parameters to assess other disease states 
When blood pressure results were investigated for assessment of hypertension, 
it was found that in 7 of the 11 patients with documented blood pressure 
measurements, a clinical diagnosis of hypertension had been made. Only 1 of these 
patients had more than 2 blood pressure recordings documented. Three other 
patients who had blood pressure recorded had cardiovascular disease but were not 
hypertensive, while another patient had no diagnosis. One patient was diagnosed 
hypertensive yet no blood pressure measurements were recorded. 
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6.5 Discussion 
It is difficult to establish to what extent the study's side effect and adverse 
drug reaction reporting rates reflected their true incidence in this study group of 
patients. 
Side effect reporting may have included quite a number of false positives, 
since patients may have reported symptoms of concurrent disease which they had 
experienced, mistaking them for side effects of drug therapy, or may have been 
prompted to report a side effect which they were aware could potentially occur. 
Such information could have been obtained from patient information leaflets, or 
medication label warnings. Indeed, in this study, 39 of the 55 patients who 
identified that they had received information leaflets (see Chapter 3), reported that 
the leaflets were useful in helping patients identify potential side effects. Some 
researchers have found that specific information cards encouraging ADR reporting 
have prompted patients to report (Whittlesea and Walker 1996), while others suggest 
that written drug information alone does not improve patient reporting rate of ADRs 
(Kitching 1990). 
Although the question concerning side effects within the questionnaire was 
open, asking if patients had ever experienced any problems which they thought 
could be attributed to their medicines, some patients at interview did need some 
clarification about the term 'problem', which may have introduced bias. However, 
the reporting of adverse effects experienced by patients prescribed NSAIDs, 
DMARDs and immunosuppressants, was unprompted, suggesting that patient 
awareness of side effects was good. 
Conversely, some patients within the study may have under-reported side 
effects, since it is unclear if the 23 patients who reported no side effects actually had 
no problems or just had poorer recall. Portable documentation of patients' drug 
therapy, drug history and adverse drug reactions in the form of smart cards might 
improve the accuracy of ADR reporting by patients, by reinforcing their awareness 
of drug infonnation concerning their present and past disease states. 
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There was very limited evidence in the medical records of any minor side 
effects which may have been previously reported by patients in this study. 
Moreover, no evidence was available to indicate that any 'Yellow cards' had been 
submitted for any of the ADRs documented in the medical case notes. Since ADRs 
are frequently under-reported (Smith et al 1996), pharmacists have a crucial role to 
try to minimise this reporting problem, by accurately and consistently documenting 
and reporting potential and actual ADRs associated with a patient's therapy (CSM 
1997). 
The majority of side effects was reported by patients within the RA and RA 
and OA groups, associated with NSAID therapy (41 %) or DMARD therapy (22%). 
This fmding may reflect not only the toxicity profiles of the medications which they 
were currently or had been taking for their arthritis management, but also the side 
effects associated with concurrent medication and I or disease states. The majority of 
ADRs but not minor symptoms as reported by patients were verified in the past 
medical history or drug history of their respective notes. This latter fmding suggests 
that patients on long-term therapy can recall significant ADRs accurately and can be 
a useful source of drug history information relevant to the ADRs experienced, as 
demonstrated by O'Brien and colleagues (1990). However, the 2 case studies in 
Appendices 19 and 20 illustrate that patients may not always report significant 
ADRs to their GP. 
The side effect profiles of NSAIDs and DMARDs as reported by patients in 
this study reflect published data, with gastrointestinal problems most commonly 
reported with both types of therapy (CSM 1994, Lee and Morris 1997, Felson et al 
1990). It was interesting to note that all 4 patients who reported a gastrointestinal 
bleed had no ulcer previously diagnosed and had experienced little if any symptoms. 
All of these patients were elderly and taking high dose NSAIDs, risk factors now 
commonly recognised for the development of NSAID-induced ulcers (Lee and 
Morris 1997). Pharmacists need to be aware of the risk factors for NSAID-induced 
ulcers and develop strategies within their own practice to minimise NSAID-induced 
gastrotoxicity . 
Three patients attributed diarrhoea to misoprostol, mefenamic acid and 
diclofenac respectively, all of which have been reported previously (Lee and Morris 
1997). The renal adverse side effects reported may be an underestimate of the 
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problem in this study, especially since interstitial nephritis is a relatively rare ADR 
and only 2 patients had any renal function parameters documented. Since many of 
the patients in this study are elderly and on chronic NSAID therapy, such patients 
should have their renal function monitored regularly (Scottish Medicines Resource 
Centre 1995(B)}. 
The case studies demonstrate that patients with chronic pain want to be 
involved in making therapeutic decisions and they are often intentionally non-
compliant with their medication partly because of their perceptions of the side effect 
profiles of their prescribed drugs. 
Case 8 (Appendix 20) demonstrated medication-taking behaviour previously 
demonstrated by rheumatology patients (Donovan and Blake 1992) in that he took 
therapy for a short trial period as he thought fit, until side effects (dyspepsia) or lack 
of effect (no pain relief) occurred. The medication behaviour illustrated in Case 7 
(Appendix 19) was less intuitive and needed greater reassurance and information 
about the risk of side effects from the pharmacist. In both cases, neither patient was 
prepared to visit their GP despite experiencing significant ADRs. The risk of ADRs 
and their implications must be discussed with patients to ensure that maximum 
benefit of therapy is achieved with minimal toxicity, since more studies 
investigating chronic pain suggest that patients who are more worried about side 
effects are less likely to comply with therapy (Donovan and Blake 1992, Ward et al 
1993). 
Documentation of biochemical and other parameters in the medical case notes 
or practice computers was very poor. One explanation for the poor documentation of 
DMARD therapy is that the GPs were reluctant to be involved in the continued 
monitoring of second-line therapy. Alternatively, some patients may have had all 
their monitoring conducted at a local hospital. Blood pressure readings and other 
laboratory results may have been located in other nursing notes, but some 
verification of results should be made in the medical case notes. GPs should agree 
monitoring protocols with their local rheumatologists or health care team, depending 
on the parameters to be monitored (Anekwe et al 1997). Thereafter, whoever is 
responsible for the monitoring should carry it out as per protocol, act on the results 
and disseminate any results to relevant members of the healthcare team including 
patients (Anon 1996, Medicines Resource Centre 1996). 
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Hospital pharmacists are being encouraged to monitor the efficacy and toxicity 
of anti-rheumatic drugs (Kay 1997), but pharmacists in primary care are also well 
placed to carry out similar roles. The rmding that 5 of the 18 cases which required 
considerable pharmacist input and, ultimately, GP referral were associated with 
ADRs suggests that pharmacists in primary care especially, need to be vigilant to 
detect any signs or symptoms suggesting an ADR and refer proactively. The use of 
PMRs to detect and document ADRs with both prescribed and OTC medication is 
likely to be critical to the success of pharmacists' involvement in ADR reporting, as 
suggested by recent pilot studies in community pharmacies (Whittlesea and Walker 
1996, Briggs et a/1996). 
The results suggest that patient interviews via domiciliary visits provide very 
good opportunities to review patients' signs and symptoms, adherence, attitude and 
tolerance to both past and present prescribed and OTC medications. Much more 
detail regarding the type of side effect experienced, nature of onset and how the 
adverse effect was resolved was obtained by interview compared to information in 
medical notes. Patient reports could provide an additional resource to current ADR 
databases, as suggested by Jaremsiripornkul et al 1997. Such medication reviews 
could be carried out in the community pharmacy, but time available to both 
pharmacist and patient may limit outcomes. Such reviews must be interpreted in the 
light of up-to-date laboratory results and medical case note reports, all of which need 
to be readily accessible via, for example, computer links between pharmacies and 
local GP surgeries, to ensure efficient transfer and utilisation of information and 
optimum monitoring of therapy by all relevant members of the health care team. 
Community pharmacies may also need computer links with biochemistry and 
haematology laboratories to facilitate rapid retrieval of laboratory data, if results are 
not being sent effectively to and communicated from GP surgeries. 
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Chapter 7 
Pharmacist interventions and recommendations for patients with 
chronic pain 
7.1 Introduction 
Domiciliary visiting by pharmacists to review medication is becoming more 
common (Beech and Brackley 1996, Fairbrother et al 1993). Most studies have 
investigated medication review of the elderly as a general patient group (Dixon et al 
1995, Hawksworth 1996), since they are often on multiple medication supplied on 
repeat prescription (Cartwright1988), at high risk of adverse drug reactions (Royal 
College of Physicians 1997), and are often housebound with limited access to the 
primary health care team (Sommerville 1996). Recent national reports have 
supported these initiatives (Royal Pharmaceutical Society of Great Britain 1988, 
1992 and The Royal College of Physicians 1997). 
Few studies have however focused on pharmaceutical needs of patients with 
chronic pain. Dixon et al (1995) used chronic compound analgesic usage as a tool to 
investigate medicine usage of a wide range of patients in their homes. They 
determined patients' knowledge of their analgesics, but did not identify 
pharmaceutical needs associated with chronic pain management. Briggs et al (1996) 
investigated the influence of community pharmacists using prescription medication 
records on the use of analgesics by patients, but again did not investigate chronic 
pain management. 
Most of the studies on domiciliary visits have been pilot projects, with limited 
evidence to demonstrate the outcomes of such activities in terms of patient and GP 
benefits. Specific outcome measures must be identified and evaluated to appraise the 
feasibility and extension of such pharmaceutical services. However, specific and 
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sensitive outcome measures for pharmaceutical care are not easy to identify, as 
discussed in Chapters 4 and 5, so measures of process are often used instead of 
outcomes. 
Domiciliary visit outcomes from previous small studies have demonstrated 
patient, GP and carer satisfaction (Fairbrother et al 1993, Begley et al 1994), a 
reduction in the number of visits to the doctor (Hendrikson et al 1984), and reduced 
drug costs and hospitalisation rates by reducing drug usage, risk of side effects and 
increasing drug efficacy (Hawksworth 1996). No published work on pharmacists 
involved in domiciliary medicine management has utilised specific qualitative and 
quantitative indicators to evaluate the implementation of a pharmaceutical care plan 
on chronic pain management. 
Intervention reporting studies in community pharmacy have been used to 
justify developing the role of the pharmacist (Rogers et al 1994, Caleo et al 1996). 
Researchers involved in domiciliary visits have found that although the rate of 
doctors' acceptance of pharmacists' interventions is often high, the number of 
therapeutic interventions actually carried out by the prescriber is very variable (Rees 
et al 1995, Grymonpre et al 1994). Attitudes of members of the health care team 
towards the development of the pharmacist's role in chronic pain in primary care, 
have ranged from being very positive to negative (Begley et a/1994). This suggests 
that there is still a need to demonstrate that pharmacists can provide pharmaceutical 
care as an integral part of the primary health care team despite evidence that they 
have good analgesic knowledge (Briggs et a/1997). 
It is therefore important to record both process in the form of 
recommendations and outcomes, using appropriate measures, in the provision of 
pharmaceutical care. The willingness of GPs to implement recommendations 
generated by this new type of service is also important (Weir et a/1997). 
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7.2 Objectives 
The objectives of this part of the study were: 
1. To quantify the types of pharmaceutical care issues identified in patients with 
chronic pain in primary care. 
2. To quantify the pharmaceutical input needed to optimise chronic pain 
management in these patients. 
3. To assess the extent ofGP acceptance and therapeutic actions actually carried 
out as a result of the pharmacist's interventions. 
7.3 Methods 
The study pharmacist collected all relevant information from each patient's 
medical notes, 1 to 2 days prior to an interview in the patient's home using the pain 
questionnaire as described in Chapter 2, Section 2.1.7. The study pharmacist made a 
second visit if patients had a poor outcome on the frrst interview, as defmed in 
Chapter 2, Section 2.1.3. This second interview occurred 4 to 6 weeks after action 
was taken by the GP following the pharmacist's recommendations or 4 to 6 weeks 
after the frrst interview if the GP did not act on the pharmacist's advice, as described 
in Chapter 2, Section 2.1.9. 
GP referrals concerning problems with chronic pain management were 
considered separately from referrals due to other medical problems. All referrals 
were made directly by the study pharmacist by telephone or in discussion with the 
GP at his / her surgery within 2 days of the pharmacist's frrst interview. All requests 
from patients with chronic pain and the advice provided by the study pharmacist 
were collated in terms of type and frequency of pharmaceutical care issue as 
described in Chapter 2, Section 2.3.8. 
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The pharmacist's proposed solution(s) to a patient's problem were also 
categorised as reinforcement, clarification, correction or follow up with prescriber 
issues as described in Chapter 2, Section 2.3.8. 
Patient requests and pharmacist's solutions for those patients who had 
satisfactory outcomes were compared with those requests and solutions for patients 
who had poor outcomes. 
OP acceptance and implementation rates of pharmacist's recommendations 
concerning problems with chronic pain management were also assessed. 
7.4 Results 
7.4.1 Results: Types and frequencies of patient problems and 
interventions made by the study pharmacist 
Twenty-eight patients (29%) out of the 96 interviewed had poor outcomes 
requiring referral to their OP, although only 18 of these were re-assessed by a 
second interview. Out of the 28 , 6 patients had VAS average pain greater than 75, 5 
had or were at high risk of developing an adverse drug reaction,14 were generally 
dissatisfied with their chronic pain management, 5 of whom specifically requested 
alternative management. (Two patients demonstrated more than 1 poor outcome 
criteria). The 10 patients who did not receive a second interview to assess the 
outcomes of the pharmacist's intervention, were either unwilling or unavailable to 
be interviewed a second time despite agreeing to the study protocol at the outset (7 
patients), or were too ill to be interviewed twice during the study period (3 patients). 
In 14 of the 18 patients who were followed up, the pharmacist made 
recommendations to OPs concerning therapy changes. The remaining 4 patients had 
poor pain control at the frrst interview, but it was considered that no further 
recommendation could be made other than the surgical management currently being 
recommended by the patient's OP. All 14 patients required changes to their 
analgesic therapy due to reported poor pain control yet only 6 of these patients had 
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high VAS average pain scales (greater than 75) (see Chapter 4). GPs agreed with 
and carried out the pharmacist's recommendations in 12 of the 14 patients. Five of 
these 14 patients were also referred because of a high risk of the development of 
side effects (see Chapter 6). Table 7.1 summarises patient outcomes by pain 
diagnosis, referral rate to the GP and recommendation acceptance rate by GPs. 
A further 10 patients were referred to their GP by the study pharmacist due to 
inappropriate or duplicate therapy. These 10 patients did not have poor outcomes as 
defmed by the criteria of the study. 
Pain diagnosis RA OA RAand Back Total 
OA • no. of pain 
patients 
No. of patients with 32 17 14 5 68 
satisfactory outcomes 
No. of patients with poor 11 4 11 2 28 
outcomes 
No. of poor outcome 8 3 5 2 18 
patients reviewed by 
pharmacist at Interview 2 
No. of recommendations 5 3 3 1 12 
accepted by GP 
Table 7.1: Summary of patient outcomes in terms of disease state, referral rate to the 
GP and GPs' acceptance of pharmacist recommendations 
Table 7.2 details the problems identified by the study pharmacist and actions 
taken by the GPs in the 14 patients in whom recommendations were made. Pain 
scores in terms of total PRI rank and scale scores and NWC scores decreased in 10 
of the 14 patients, remained unaltered in 1 and increased in 3 patients (see Chapter 
4). 
Out of the 12 patients in whom the pharmacist's recommendations had been 
carried out, VAS average pain scores decreased in 6 patients (range of decrease was 
20-30mm), increased in 3 patients (range of increase was IO-30mm) and was 
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unchanged in 3 patients. Total PRI scale and rank scores decreased in 9 patients 
(range of decrease was 1-30.1), increased in 3 patients (range of increase was 0.7-
22.2) and was relatively unchanged in 1 patient. NWC scores decreased in 8 patients 
(average decrease was 4 words, range 1-9), increased in 2 patients (average increase 
was 4 words, range 2-7) and unchanged in 2 patients. 
The changes in overall mobility, psychological, patient satisfaction and 
attitude scores were strongly influenced by the changes in overall pain scores in 
most of the 12 patients after the second interview (see Chapter 5). 
In the 2 patients where the GP did not agree with the phannacist's 
recommendations, one patient's pain (patient 39 in Table 7.2) improved subsequent 
to surgery and the initiation of homeotherapy (VAS average pain score decreased 
from 100 to 60), while the other patient's pain (Patient 78) worsened with no change 
made in medication (VAS average pain score increased from 20 to 50). Total QOL 
scores for Patient 39 decreased while those for Patient 78 increased. However, 
psychological and social scores in both patients did reflect changes in pain control, 
while patient satisfaction was unchanged in both patients. 
During the fIrst interview, fifty-nine other patients required pharmacist advice 
on their current medication, but their problems did not fall under the category of a 
poor outcome as defmed in this study. Current medication included any medication 
(prescribed and OTC) used to treat their pain ( analgesic therapy) and other 
concomitant disease states (other therapy). 
Table 7.3 summarises the types and frequencies of problems encountered and 
the pharmaceutical actions required during the domiciliary visits. A total of 194 
pharmaceutical actions were implemented in these 59 patients in the form of advice 
and counselling for 84 problems. (50 patients (85%) required advice in at least 2 
categories.) 
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§- Problem identified by Action taken by GP ~ 
-~ G) pharmacist after pharmacist 00. = ~ --g u ~ r#l C2 = .~ ~ -C2 ~ = recommendations ..:. ~ ~ 
OA 4 NSAIDs prescribed. 1 NSAID continued. GI 
-30 -3.5 -.t 
81 Patient wanted to limit problems reviewed- no 
NSAID therapy and had ulcer. Misoprostol stopped 
dyspeptic symptoms. and aspirin monitored 
OA Stomach and arthritic pain - Diflunisal stopped, regular 
-20 +5.7 +4 
76 taking 2 NSAIDs cocodamol and Naproxen 
concurrently with possible continued. Haematemesis 
haematemesis. unconfirmed 
RA/OA Increased pain, requested DMARD changed. NSAID 
-20 -lOA -12 
4 alternative therapy - already re-introduced. 
on DMARD. NSAID ADR. 
RA Thrombocytopenia with Penicillamine ¢:) +0.7 ¢:) 
40 reduced peniciallamine discontinued. Analgesia 
dosage. Nose bleeds on changed to coproxamol 
steroids and NSAID. 
RA Patient keen to conceive and Penicillamine discontinued +20 -2.1 -1 
27 discontinue DMARD. Safflower therapy 
Requested safflower therapy commenced 
RA Very depressed due to RA Hydroxychloroquine ¢:) 
-3.3 -4 
28 and a recent death - reluctant commenced I social 
to start DMARD. support 
RA Reluctant to restart DMARD, Sulphasalzine and +10 +22.2 +21 
41 depressed, requested other restarted. Homoeopathy 
Rx. 
RA/OA Patient requested to try Existing therapy continued +30 -S.4 -3 
46 alternative therapy- on gold - trial of alternative Rx. 
injection I NSAID. 
RA Patient requested improved Sulphasalazine changed to <=> -30.1 -21 
57 pain relief and a change in penicillamine 
DMARD. 
Back Increased pain· patient Physiotherapy-coproxamol -30 -3.9 -4 
pain requesting alternative therapy changed to dihydrocodeine 
84 - on coproxamol. 
RA/OA Increased RA and GI pain - Omeprazole initiated - no -20 -0.5 -1 
52 on NSAID (GI history). ulcer. Ibuprofen started 
OA Poor pain control. Required Patient referred to -30 -29.7 -32 
68 physiotherapy. physiotherapy 
RA Awaiting hip surgery, Surgery performed. -40 -2.7 -1 
39 requested homoeopathy - on Homoeopathy started 
codydramol. 
RA/OA Increased pain - review No change to medication +30 +1.1 +1 
78 allopurinol. 
. . . 
- = decrease in pain scores at Interview 2 + = increase m pam scores at Intervtew 2 
¢::> = no change in pain scores at Interview 2 
U 
~ -~ ~ 
-1 
-1 
+2 ¢:) 
-4 -1 
¢:) <=> 
-2 ¢:) 
-2 <=> 
+7 +1 
-3 +2 
-9 -2 
¢:) -1 
-1 <=> 
-8 -1 
-1 -1 
<=> ¢:) 
Table 7.2: Problems identified by pharmacist, actions taken by GP and changes in 
pain scores in 14 patients with poor pain outcomes 
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Type of problem Type of action Total no. 
requiring action of actions 
Reinforcement Clarification Correction Follow up 
Chronic pain manageme1 1 7 3 0 11 
Therapy for pain 7 34 31 3 75 
Therapy for other disease 5 23 26 1 55 
states 
Side effect-pain therapy 5 15 20 5 45 
Side effects-other therap~ 1 1 1 1 4 
Management of other 0 2 2 0 4 
disease states 
Totals 19 82 83 10 194 
Table 7.3: Frequencies of problem areas and pharmaceutical actions implemented 
by the study phannacist during the domiciliary visits 
The problem areas in the different chronic pain groups are shown in Table 7.4. 
The majority of the actions were implemented within either the RA patient group or 
those with RA and OA. Analgesic problems required 131 of the total 194 care 
actions (68%). There was no significant difference in the type of problems between 
groups. 
Diseas. Type of problem 
State 
RA 2 
OA 4 
RA 1 
+OA 
Back 1 
Pain 
Totals 8 
11 
o 
7 
5 
23 
8 9 3 
4 5 o 
9 3 o 
4 4 o 
25 21 3 
Total Total no 
no. of of 
problems actions 
o 33 71 
1 14 27 
2 22 60 
1 15 36 
4 84 194 
Table 7.4: Types and frequencies of pharmaceutical actions identified by the study 
phannacist within each pain diagnoses. 
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7.4.2Results of patients with poor outcomes 
7.4.2.1 Case studies - pharmaceutical care of patients with poor pain outcomes 
Appendices 21 and 22 (Case studies 8 and 9 respectively), provide details of 2 
patients who required GP referral due to poor outcomes after fll'St interview. 
7.4.3 Results of patients with satisfactory outcomes 
Table 7.5 specifies the types and frequencies of pharmaceutical advice 
provided to patients who did not have poor outcomes by the study defmition, but 
still required advice to optimise efficacy of their treatment. 
Number of 
Type of problem patients with 
problem 
Poor pain control due to inappropriate use ofprn analgesia 6 
Patient taking 2 NSAIDs concurrently 1 
Poor understanding of DMARDs - taking it pm or stopped 4 
Poor understanding of DMARDs - taking it at wrong time 4 
Advice on other treatments to improve pain relief 4 
Compliance problems with analgesic therapy 12 
Advice to minimise the side effects of analgesic therapy 38 
Advice to improve efficacy of therallY for other disease states 14 
Advice to minimise the side effects of therapy for other disease stat 4 
Advice on other treatments to improve other disease states 6 
Compliance problems with other therapy 12 
Table 7.5: Types and frequencies of problems identified in patients with satisfactory 
outcomes but required advice 
7.5 Discussion 
The wide range of medication ... related problems identified by the study 
pharmacist is similar to those identified by other researchers who have investigated 
problems associated with chronic analgesic use (Briggs et al 1996, Dixon et al 
-149 -
1995). This indicates that pharmacists involved in the management of chronic pain 
via domiciliary visits must be prepared to discuss pharmaceutical problems, ranging 
from those related to the chronic pain including pain therapy, side effects, drug / 
drug or drug / disease state interactions to problems associated with other disease 
states or other pain management strategies. The pharmacist must be prepared to refer 
patients to other members of the health care team wherever appropriate. Only then 
will patients more readily perceive the pharmacist as a member of the health care 
team, not an isolated professional. 
The pharmaceutical actions required in this study were mainly advising 
patients (77%), but a substantial proportion of patients (38, 40%) needed GP referral 
with or without poor pain outcomes. The different types of advice given both to 
patients and GPs illustrate the complexity of patients' problems as well as the 
multiplicity of skills which pharmacists need to acquire and develop to optimise 
pharmaceutical care (Odedina and Segal 1996). 
The failure of 10 of the 28 patients with poor outcomes to agree to a second 
interview, reduces the value of the results. This lack of support can be partly 
explained by the unpredictably severe relapses of RA in some of the study patients. 
A longer follow up period, more selective patient criteria and more explicit 
information about the study implications may have helped improve patient follow-
up. 
Despite this, the study suggests that pharmacists have a valuable role in the 
assessment of and pharmaceutical care of patients with chronic pain. The study 
pharmacist made interventions in 14 patients, all of whom had poor pain outcomes. 
Moreover, 131 of the additional 194 pharmaceutical actions (68%) required were 
related to analgesic problems. The fmdings that 84% of these analgesic problems 
(110 out of 131) were clarification and correction issues and that 8 out of the 10 
patients without poor outcomes required GP referral due to analgesic problems, 
suggest that many patients are not achieving optimum pain management. This 
deficiency may be due to patients' reluctance to request a review of therapy or 
inappropriate GP prescribing. 
There were more problems identified in patients with RA as compared to those 
with OA or back pain, but no statistically significant difference in types of problems 
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between chronic pain groups. The fact that RA patients had more problems may be 
partly explained by the influence which RA has on other disease states. 
All available sources of information must be used prior to undertaking a full 
patient medication review as illustrated by Cases 8 and 9 in Appendices 21 and 22 
respectively. These should include the patient, medical notes and any patient 
medication records. Patient medication records were unavailable as a source of 
information in this study, but they have been shown to be very useful tools to help 
evaluate GPs' analgesic prescribing patterns (paes 1992), identify patients who 
require improvement in their pain management (Dixon et al 1995) and identify 
patients at risk of drug / disease state interactions with any OTC analgesics (Briggs 
et aI1996). 
Since most of the relevant laboratory data including biochemical and 
haematological parameters required to assess drug efficacy and toxicity was not 
available, little comment can be made about patient outcomes, particularly those 
with RA, in terms of standard clinical parameters. It was uncertain in the majority of 
cases whether GPs were aware of relevant laboratory and OTe drug use data and 
had just failed to document the details or whether they were unaware of the 
information. Pharmacists are well placed to aid in the monitoring process, having 
demonstrated appropriate skills in monitoring anticoagulant therapy outcomes in the 
community (Hall et aI1995). 
The acceptance rate of the pharmacist's recommendations by GPs (86%) was 
similar to that in previous studies (Lobas et al 1992, Dorevitch and Perl 1996). 
However, no external validation of the recommendations was made, which has been 
shown to help eliminate bias (Begley et al 1996). Ideally, the recommendations 
should have been validated externally, using an expert panel possibly consisting of a 
rheumatologist, GP and a pharmacist with a specific interest in chronic pain. 
In this study, all 12 of the recommendations agreed by the GPs were actually 
carried out. Other researchers including Rees et al (1995), found that, although 
acceptance rate by GPs was high, only 54% of pharmacists' recommendations were 
actually carried out. This study's higher rate of completed recommendations may be 
partly explained by the facts that the patient numbers involved were relatively small, 
that the study pharmacist was working closely with the GPs for a [mite period of 
time in a relatively academic capacity and had previously worked with 2 of the GPs. 
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Grymonpre and colleagues (1994) have suggested that the GP / pharmacist working 
relationship influences GP acceptance rate of intervention. However, Begley and 
colleagues (1994), found that young GPs were less willing to encourage the role of 
the pharmacist in chronic pain, and may perceive that community pharmacists do 
not possess the skills or knowledge to equip them for that role. The evidence of this 
study and that of Briggs et al (1997) suggest that pharmacists have a role to play in 
the management of chronic pain. 
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Chapter 8 
The role of the pharmacist in the management of chronic pain in the 
community 
8.1 Introduction 
There is currently extensive encouragement both by political and 
pharmaceutical bodies to develop the roles of the pharmacist within many primary 
care settings (SODoH 1996(A) and (B), Royal Pharmaceutical Society of Great 
Britain 1995, 1992). Pharmacists are now developing their skills and knowledge to 
provide services such as pharmacist-led clinics (MacGregor et a/1996, Radley and 
Hall 1994), GP formulary development and review (JenkinsI996) and medication 
review (Westwood and Hudson 1996). As deregulation of medicines increases, 
pharmacists are developing their advisory role to improve the appropriate use of 
medicines and the treatment of minor illnesses (Hassell et aI1996). 
Recent studies have demonstrated pharmacists' involvement in the 
management of chronic pain in the community (Dixon et al 1995, Briggs et al 
1995,1996,1997 and MacGregor 1996). Pharmacists have utilised patient medication 
records in community pharmacies or medical records in GP practices as useful 
sources to identify patients, enabling assessment of prescribed and ore analgesia in 
the light of patients' concurrent medication and their awareness and understanding 
of therapy, after which interventions were made to optimise efficacy of treatment 
(Briggs et a/ 1996, 1997). 
Data demonstrating improved outcomes in chronic pain control in patients 
after pharmacist involvement in the primary care setting is limited. However, the 
present study has shown that patients with chronic pain can benefit from 
pharmaceutical intervention to maximise the efficacy of drug regimes, reduce the 
risk of potential adverse effects and to make appropriate referrals to GPs and other 
members of the health care team. 
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Pharmacists in primary care need to be proactive if the outcomes of patients 
with chronic pain are to be maximised. Analgesics are the most widely used non-
prescription medicines, yet their use can often be inappropriate and potentially 
dangerous (Whitaker et aI1995). The elderly must be monitored closely, since they 
are a high-risk group in terms of analgesic use. This patient group is most likely to 
overuse analgesics (Whitaker et al 1995), is at greater risk of adverse drug reactions 
(O'Malley et aI1971), usually buys any OTe analgesics from a pharmacy but is less 
likely to ask for advice (Whitaker et aI1995). 
Most patients with chronic pain have benefited from management by a 
multidisciplinary team, based in hospital, which includes a pharmacist (Hardy and 
Hill 1990, Snell 1993). However, the majority of such patients are managed in 
primary care most frequently by their GPs who may not have such expertise in 
chronic pain management. Evidence of chronic pain clinics or an established chronic 
pain team in the community is limited, but a pharmacist-led clinic for neuropathic 
pain has been recently established (MacGregor 1996). A recent study has suggested 
that pharmacist involvement in the prescribing of analgesics is much needed and is a 
role requested by pharmacists themselves (Briggs et aI1997). 
The present attitudes of GPs, pharmacists and other members of the health care 
team to the developing roles of pharmacists need to be considered to encourage 
inter-professional communication, minimise duplication of services and enhance 
seamless care provision (Begley et al 1994). Previous studies have demonstrated 
that GPs and other health professionals are in favour of pharmacists' developing 
domicilliary services to encourage review of medication in high-risk patient groups 
and to provide appropriate drug information (Dixon et al 1995, Weir et aI1997). 
However, Begley et al (1994) found that although a large percentage of pharmacists 
were willing after training to provide domiciliary management of pain as a 
speciality, young GPs and nurses generally did not support this extended role for 
pharmacists. 
8.2 Objectives 
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The objectives of this part of the study were: 
1. To detennine the current clinical activities of community pharmacists and the 
extent of their clinical interaction with GPs. 
2. To evaluate general practitioners' and physiotherapists' experiences of 
pharmacists' contribution to patient care especially in chronic pain management. 
3. To detennine the views of community pharmacists, general practitioners and 
physiotherapists on the type(s) of patient, disease and management factors which 
can influence the management of chronic pain. 
4. To evaluate the attitudes of community pharmacists, general practitioners and 
physiotherapists towards the development of chronic pain teams and the 
responders' perceived role(s), if any, for the pharmacist within such a team. 
5. To identify the quantity, type of drug and disease state information requested by 
patients during domiciliary visits and to investigate the pharmacist's response to 
information requested. 
8.3 Methods 
Postal questionnaires incorporating attitude statements as described in Chapter 2 
Sections 2.2.1 and 2.2.2, were developed in November 1995.The questionnaires 
were fIrst piloted on 5 general practitioners, 5 community pharmacists and 5 
physiotherapists working in an area outwith the research areas between December 
1995 and January 1996 as described in Chapter 2 Section 2.2.3. Feedback from the 
pilot group revealed that completion of the questionnaire took an average of 5.5 
minutes to complete and also resulted in 2 of the original statements being removed 
from the fmal questionnaire due to their being ambiguous or leading. Slight 
modifications to the wording and layout of the questionnaires were made as 
described in Chapter 2 Section 2.2.3. 
100 GP practices, 100 community phannacies and 50 physiotherapy work 
bases were randomly selected in Aberdeen and Lanarkshire as described in Chapter 
2 Section 2.2.4. Only one practitioner was identified from each of the selected 
surgeries, pharmacies or physiotherapy sites. A revised questionnaire was then sent 
to each selected practitioner (see Appendices 11, 12 and 13 respectively), 
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accompanied by a covering letter (Appendix 10) as described in Chapter 2 Section 
2.2.5. 
Initially, 60 out of 100 GP practices, 57 out of 100 community pharmacies and 
30 out of SO community physiotherapist bases responded. Non-responders were 
identified by their code numbers. Subsequent response rate improved the fmal 
response to 63 GP practices, 59 community pharmacies and 33 physiotherapy work 
bases. 
The Kruskal-Wallis and Mann-Whitney U tests (if appropriate) were used as 
described in Chapter 2 Section 2.2.7. 
8.4 Results 
8.4.1 Professional details of GP, community pharmacist and 
physiotherapist responders 
Replies were obtained from 63 out of 100 GPs (63%) who had been sent a 
questionnaire, 34 (54%) of whom were from fundholding practices, with an average 
of 6 GPs (range 2.5 - 12 GPs) per practice. The number of patients per practice 
reflected the number of GPs per practice (range 3,200 .. 22,500). 
Fifty-nine out of the 100 pharmacists (59%) who had been sent a questionnaire 
responded. Fifty -six (95%) of the pharmacists worked full-time and 3 pharmacists 
(5%) worked part-time. Forty-eight of the responders were the sole pharmacist in the 
pharmacy, while 10 had 1 colleague and 1 had 2 colleagues working in the 
pharmacy at the same time. 
Replies were also obtained from 33 out of the 50 physiotherapists (66%) based 
in community practice who received a questionnaire. Limited access to community 
practice physiotherapists restricted the potential number of responders. 
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8.4.2 Responders' perceptions of present role(s) of the pharmacist in 
chronic pain management in primary care 
8.4.2.1 Current clinical activities of community pharmacists 
All community phannacists were asked to identify the areas of clinical activity 
in which they were currently involved. No responder identified specific involvement 
in the management of chronic pain. 
All pharmacists identified their traditional roles of provision of advice about 
prescribed medicines and over-the-counter (OTC) medicines. Ten pharmacists 
reported that they were currently involved in the development of treatment 
protocols, while 25 pharmacists identified the advising of GPs on their prescribing 
practices as a routine activity. Other clinical activities identified by 6 pharmacists 
included blood-pressure monitoring (3 pharmacists), stoma care advice (1 
pharmacist) and specific nutrition advice (2 pharmacists). Therapeutic drug 
monitoring activities included blood cholesterol monitoring (2 pharmacists). No 
pharmacist reported involvement in anticoagulant monitoring. 
8.4.2.2 Pharmacist assessment of clinical interaction with GPs 
Pharmacists were asked to provide a general estimate of the type and 
frequency of any clinical interventions made to GPs, to determine the extent and 
quality of clinical interaction between the pharmacists and their GPs (Table 8.1). 
Fifty-seven out of the 59 pharmacists (97%) who responded identified that they 
often requested information from GPs, to clarify a dosage or drug indication (39 
pharmacists identified that this was a common problem on most days or at least 2 to 
3 times a week). Forty out of the 50 pharmacists who did say that they proposed 
changes in therapy to try to improve patient outcome, did so infrequently i.e. once a 
month or less than monthly. Side-effect reporting to GPs was also an infrequent 
activity. Twelve out of the 50 pharmacists who identified that they reported drug 
interactions between prescribed and OTC medication did so at least 2-3 times a 
week. 
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Type of Intenrention most 2-3 once a once a less than Total number 
days times a week month monthly of 
week interventions 
Request information 27 12 12 2 4 57 
to clarify a dosing 
regime or drug 
indication 
. 
Propose a change in 0 3 7 14 26 50 
therapy to improve 
patient outcome 
Report a side effect 0 2 6 8 36 52 
Inform a GP about a 6 13 11 6 17 53 
patient request 
Report a prescribed 5 7 11 8 19 50 
medicine I OTC 
medicine drug 
interaction 
Total number of 38 37 47 38 102 262 
responses 
Table 8.1: Phannacist estimation of type and frequency of clinical interventions 
(n=59) 
All pharmacists communicated with their GPs by telephone, nineteen 
phannacists also visited their GPs personally, five communicated by letter as a third 
option, while 3 pharmacists used fax machines in addition to the three previous 
modes of communication. 
Fifty-eight of the 59 pharmacist responders (98%) described the feedback 
which they received from GPs. One responder did not complete this part of the 
questionnaire. Overall, pharmacists perceived that feedback from GPs was generally 
poor and sometimes non-existent. Forty pharmacists reported that the feedback 
which they requested from GPs indicated their recommendations were fully or 
mostly acted on, but eleven pharmacists said that only a few suggestions were 
accepted by their GPs. Seven pharmacists said that they did not know if their 
- 158-
suggestions were accepted or not. Comments regarding feedback from GPs were 
very variable (Table 8.2). Pharmacists who reported limited feedback from GPs 
were less likely to be currently involved in additional clinical activities (X2 = 6.85, df 
= 1, P < 0.01). 
Certain GPs refuse to answer any queries. 
Many GPs adopt the attitude that what they say "goes". GPs are nonnally happy with your 
advice at the time, but the advice is ignored in future. 
GPs feedback is not always prompt. Varies from genuine acceptance of advice and/or 
feedback to hostile resentment. 
GPs, even when they do not make any changes, nonnally thank you for pointing it out 
anyway. 
We do not suggest things to GPs. 
Ninety percent of them do not like it. From previous experience, only some suggestions 
have been received positively. 
Feedback from GPs especially is non-existent. 
Some GPs can be quite rude about our suggestions, while other GPs are extremely happy 
we get involved. 
Table 8.2: Pharmacists' comments regarding GP feedback 
8.4.2.3 GP assessment of pharmacists' contribution to patient care 
GPs were asked to identify if and how pharmacists were helpful to them, using 
a series of closed questions. Sixty-two out of the sixty-three GPs who responded 
(98%), identified that pharmacists were helpful. Fifty-three of the 62 (86%) 
recognised the pharmacist's role as a source of medication supply and drug 
information to patients while 46 (74%) and 49 (79 %) GPs respectively, identified 
that phannacists were very helpful in ensuring prescription legality and supply of 
medication to GPs. Twenty-two GPs (36%) were fmding pharmacists helpful in 
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encouraging patient compliance, but only nineteen and twelve GPs respectively 
had direct experience with pharmacists in discussing treatment options or general 
practice formulary development. Moreover, only six GPs had had experience or 
were at present gaining pharmacist input in GP practice research projects. 
8.4.2.4 Physiotherapist assessment of pharmacists' contribution to patient care 
No physiotherapist who responded had any direct involvement with a 
community pharmacist, so a physiotherapist assessment of the current role of the 
pharmacist could not be made. 
8.4.3 Factors influencing chronic pain management 
8.4.3.1Factors identified by responders which may influence the management of 
chronic pain 
Factors identified by responders which may influence the management of 
chronic pain are detailed in Table 8.3. All responders completed this section. 
There was a significantly greater number of GPs (31) as compared to 
pharmacists (17) «X2 = 5.29, df= 1, p < 0.05) who believed that patient expectation 
of pain control influenced management of chronic pain. There were no significant 
differences between groups with regard to the statement that poor compliance 
influenced management of chronic pain. Significantly more pharmacists (34) as 
compared to GPs (21) (X2 = 7.26, df = 1, P < 0.01) felt that limited access to pain 
specialists or pain clinics influenced patient outcome. Physiotherapists were more 
likely to identify that limited access to up-to-date drug information was an 
influencing factor as compared to either GPs (X2 = 16.62, df = 1, P < 0.001) or 
pharmacists (X2 = 10.92, df = 1, P < 0.001). Significantly more pharmacists (42) as 
compared with GPs (13) (X2 = 29.4, df= 1, p < 0.001) or with physiotherapists (15) 
(X2 = 4.90, df = 1, P < 0.05) identified that lack of opportunity limited chronic pain 
management. Pharmacists were more likely than GPs (X2 = 15.68, df= 1, P < 0.001) 
to identify lack of expertise in a multidisciplinary team as a limiting factor in pain 
management. 
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Factor No.ofGPs No. of No. of 
who said pharmacists who physiotherapists 
... : 
'Yes' (%) said 'Yes' (%) who said 'Yes' (%) 
<:.-.::: . 
.. 
'. 0' 
n = 63·:< .. ·: n=59 
. :.":." n =33 ,:-... 
Patient expectation of 31 (49) 17 (29) 20 (61) 
pain control 
Poor patient compliance 25 (40) 19 (32) 17 (52) 
Poor agreement of 13 (21) 5 (8) 2 (6) 
management with 
patient 
Limited access to pain 21 (33) 34 (58) 22 (67) 
clinics I specialists 
Limited access to up to 2 (3) 5 (8) 11 (33) 
date drug information 
Limited expertise in a 10 (16) 28 (48) 9 (27) 
multidisciplinary team 
Excessive workload 27 (43) 29 (49) 14 (42) 
Lack of opportunity for 13 (21) 42 (71) 15 (45) 
involvement in a 
multidisciplinary team 
Table 8.3: Factors which may influence the management of chronic pain. 
8.4.3.2 Attitude statement responses 
Table 8.4 summarises the responses to the attitude statements of the 154 
responders, since one physiotherapist omitted to tick any of the attitude statements. 
One hundred and forty-seven responders (95%) agreed or strongly agreed with 
the belief that compliance with a pain management strategy was better if patients 
understood the explanation. Moreover, almost two thirds of the study group (92, 
64%) thought that the majority of patients complied with their advice (24 (73%) of 
physiotherapists, 40 (64%) GPs and 35 (59%) pharmacists agreed or strongly 
agreed). However, when asked to indicate their response to the statement 'Some 
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patients want to control their own pain and don't comply with your advice', the 
responders were more uncertain. 
The majority of responders (133, 86%) recognised the negative influence of 
depression on pain control. Attitudes to patient perception of the pharmacist were 
significantly different between groups (X2 = 27.11, df= 2, P < 0.001). The majority 
of community pharmacists (41, 71 %) disagreed with the belief that patients 
generally regarded pharmacists as shopkeepers, but 27 (84%) physiotherapists 
agreed with the statement. Although 25 (40%) GPs disagreed with this statement, 20 
(32%) agreed with the statement and 18 (29%) were uncertain. 
Attitudes to treatment plans and guidelines were encouraging. However, there 
were significant differences between groups concerning the statement 'a treatment 
plan should be agreed by a multidisciplinary team' (X2 = 15.75, df= 2, p < 0.001). 
The statement about treatment guidelines disguises the fact that GPs as a group were 
least in agreement with this statement and were more uncertain than the other two 
groups in the benefits of treatment guidelines. Only 36 (57%) GPs agreed with this 
statement, as compared to 45 (76%) pharmacists and 24 (75%) for physiotherapists, 
but there was no statistical difference between groups «X2 = 5.46, df= 2, p > 0.1). 
These attitudes to guidelines were reflected in the results obtained when GPs 
and physiotherapists were asked about their actual use of treatment guidelines. 
Treatment guidelines were used by 14 of the 63 GPs (22%), while 17 of the 33 
(52%) physiotherapists used guidelines. GPs claimed to use the British National 
Formulary as a useful source while all 17 physiotherapists, who reported that they 
used guidelines, only used specific physiotherapy protocols. 
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Statement No. of responders 
who strongly 
agreel agree 
Most patients comply with 
your advice 
(0/0) 
99 (64) 
Patient compliance is 147 (95) 
increased if patients 
understand you explanation 
Some patients want to 92 (60) 
control their own pain and 
don't comply with your 
advice 
A patient with chronic pain 35 (23) 
exaggerates the pain which 
he I she feels 
Patients generally view 56 (36) 
pharmacists as shopkeepers 
More patients are self- 79 (51) 
medicating to improve 
control of chronic pain 
Patients with chronic pain 
who are depressed often 
have poor pain control 
Patients with chronic pain 
usually know very little 
about the management 
options for chronic pain 
A treatment plan for the 
control of chronic pain 
should be agreed by a 
multidisciplinary care team 
133 (86) 
108 (70) 
89 (58) 
Treatment guidelines 105 (68) 
improve cost-effective 
prescribing 
No. of 
uncertain 
responders 
(%) 
37 (24) 
6 (4) 
42 (27) 
66 (43) 
29 (19) 
52 (34) 
20 (13) 
31 (20) 
49 (32) 
37 (24) 
No. of responders 
who strongly 
disagreel disagree 
(8/0) 
18 (12) 
1 (1) 
20 (13) 
53 (34) 
69 (45) 
23 (15) 
1 (1) 
15 (10) 
16 (10) 
12 (8) 
Table 8.4: Summary of responses by 154 responders to all attitude statements 
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8.4.4 Responders' perceptions of future role(s) of the pharmacist in 
chronic pain management in primary care 
8.4.4.1 Responders' attitude to a multidisciplinary team approach to the 
management of chronic pain 
Attitudes to multidisciplinary care teams were encouraging. Overall, 89 (58%) 
responders agreed that treatment plans should be agreed by a multidisciplinary team. 
However GPs as a group were less positive about the merits of a multidisciplinary 
approach to pain control. 
These attitudes were reflected in the results obtained when GPs and 
physiotherapists were asked about their involvement in multidisciplinary care teams 
for chronic pain. Only seventeen of the GPs had a multidisciplinary team already 
established for the management of chronic pain at the time of study. The 
composition of the teams, as documented by the GP and physiotherapist responders, 
varied considerably with a nurse being the most frequently cited team member (14) 
after the GP (17), while pharmacists and physiotherapists were only involved in 2 
and 4 of these GP-Ied teams respectively. Two of the study physiotherapists were 
currently involved in a multidisciplinary care team, but other team members in each 
group were limited to a GP and a clinical psychologist. 
None of the pharmacists were involved in a multidisciplinary team themselves 
at the time of the study. When pharmacists were asked who they thought should be 
involved in the chronic pain team, 57 out of the 59 responders suggested a GP, 44 
suggested a pharmacist and 32 a physiotherapist. Ten responders suggested an 
anaesthetist, 19 an occupational therapist and 9 recognised the need for a nurse in 
the team. A patient or representative was suggested by 4 responders as an additional 
member of the team. 
Lack of money (14 responders), interest (17), time (31) and expertise (20) 
were reasons commonly given by GPs and physiotherapists for not establishing 
mUltidisciplinary care for patients with chronic pain. Twelve GPs suggested that 
there was a lack of need, either due to perceived lack of evidence of benefit (8) or 
adequate resources at present (4). Four GPs said that a chronic pain team had never 
been thought of within their practice, while 3 stated that it was not a high priority. 
- 164-
8.4.4.2. Responders' perceptions of the future roles of the pharmacist in chronic 
pain management 
All of the GPs and physiotherapists stated that pharmacists had a role to play 
in a multidisciplinary approach to managing patients with chronic pain. Thirty-five 
GPs (56%) and 21 physiotherapists (64%) recognised a dispensing role for 
pharmacists, 46 GPs (73%) and 29 physiotherapists (88%) identified the important 
role in provision of specific drug information to patients and 38 GPs (60%) and 25 
physiotherapists (76%) believed that pharmacists should be involved in medication 
. 
revIew. 
Other responders (8 GPs, 12 physiotherapists) suggested that pharmacists 
should be involved in drug history taking within a chronic pain clinic. Two 
physiotherapists and three GPs identified a need for pharmacists not only to act as 
facilitators to improve multidisciplinary care but also to actively educate health care 
professionals in the potential contributions which pharmacists can make to improve 
patient care. Two GPs requested more information from pharmacists regarding the 
clinical significance of drug interactions associated with chronic pain management. 
Three GPs suggested that pharmacists should be advising GPs more on substitution 
of prescribed medicines for pain with over-the-counter products where appropriate. 
Fifty-eight out of the 59 pharmacist responders (98%) identified that they 
wanted to develop their role in chronic pain management, but only thirty-three 
pharmacists (56%) were keen to become actively involved in pain clinics. Forty-
eight and 26 pharmacists respectively wanted to develop patient information 
services regarding OTe products and prescribed medication for chronic pain 
management. 
8.4.5 The role of the pharmacist as a provider of appropriate drug 
information to patients 
8.4.5.1 Information requested by patients during domiciliary visits 
A summary of the information requested by patients during domiciliary visits 
by the study pharmacist is tabulated in Table 8.5. 
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Table 8.5 shows that 35 different queries were made by 36 of the 96 study 
patients (38%) resulting in a total of 62 queries, the most frequent of which were 
about chronic pain. 
The requests were made by 14 (36%) of the RA group, 11 (44%) of the group 
with RA and OA, 7 (32%) of the OA group and 4 (40%) of back pain patients. 
The responses to these queries involved reassuring patients on 16 occasions 
that they were taking their medication correctly, clarifying 19 misunderstandings 
concerning medication, providing information to correct a potential or existing 
problem with medication on 14 occasions and referring 13 problems to the patients' 
GPs which were subsequently followed up. Reinforcement and clarification 
involved the pharmacist providing patients with written information to emphasise 
verbal recommendations. 
Pain Chronic Side Drug Other Total no. Total 
diagnosis pain effect info disease of no. of 
query query query state query different patients 
. :.' 
.. problems 
No. of No. of No. of No. of No. of 
queries queries queries queries queries 
RA 3 1 5 1 10 14 
RAand 3 6 5 0 14 11 
OA 
OA 3 1 1 2 7 7 
Back 3 1 0 0 4 4 
. paIn 
Total no. 12 9 11 3 35 36 
of types 
of queries 
Table 8.5: Types and frequencies of information requested by patients during 
domiciliary visits 
Total 
no. of 
. quenes 
18 
26 
12 
6 
62 
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8.5 Discussion 
8.5.1 Factors encouraging the development of the pharmacist's role in 
the management of chronic pain 
Analysis of the results from the questionnaire suggests that there are positive 
factors to encourage the development of the pharmacist's role in chronic pain 
management. These are the motivation of pharmacists to develop their role in 
primary care, current evidence of practice development and a common appreciation 
and agreement of the current and potential roles of pharmacists by GPs, 
physiotherapists and community pharmacists. Favourable relationships between GPs 
and pharmacists and a general enthusiasm to develop multidisciplinary teams to 
manage chronic pain in the community are also encouraging fmdings. 
An assessment of the study pharmacists' current and potential clinical 
activities suggests that all pharmacists recognised their roles in the provision of 
advice concerning both prescribed and non-prescribed medicines and were 
motivated to develop them. These roles need to be defmed and developed (Royal 
Pharmaceutical Society of Great Britain 1995, Hassell et aI1996). 
The fact that 98% of pharmacists wanted to develop their role in pain 
management was encouraging, even although no pharmacist identified his I her 
involvement in the management of chronic pain at the time of the study. No specific 
questions were asked to assess the number and frequency. of pharmacist 
interventions I advice to patients and GPs which related to chronic pain 
management, hence this perceived lack of involvement may be an underestimate of 
activity. The pharmacists in this study were keen to develop other strategies to 
improve pain management, especially drug information provision for both OTe and 
prescribed therapies for pain. Protocols must be developed to ensure that this 
provision of advice is appropriate, consistent and accurate for optimisation of patient 
care and the development of the pharmacist's role in chronic pain. 
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The questionnaire study demonstrated that communication between GPs and 
pharmacists, although not extensive and related largely to clarification of 
prescription information, was generally a positive influence on pharmacist role 
development. Although 50 pharmacists said that they recommended changes in 
therapy, only 10 pharmacists discussed therapy changes with their GPs at least 
weekly. Over 50% of the pharmacists reported that the incidence of drug 
interactions and patient requests which they discussed with GPs was only about one 
a month. This low reporting rate may be a true incidence of the number of clinically 
significant problems requiring intervention with a GP, but under-reporting due to 
lack of pharmacist awareness of a potential problem and / or poor documentation 
may be precipitating factors (Rogers et a/1994). 
The rmding that all three groups of health care professionals in the study 
strongly identified with the pharmacists' role as a provider of relevant drug 
information (pharmacists 81 %, GPs 73% and physiotherapists 88%) is a motivating 
factor towards development of a pharmacist'S advisory role. General practitioners 
have previously defended the development of this role of pharmacists in the areas of 
rational prescribing and formulary development (Hughes and McFerran 1995). The 
fact that physiotherapists in this study had no direct experience of pharmacists' 
contribution to the care of their patients within their workplace, might be partly 
explained by their lack of accessibility to pharmacists. The majority of 
physiotherapists were based within GP practices, while the pharmacists were largely 
based in community pharmacies not attached to a health centre. However, despite 
their lack of experience working with community pharmacists, they were very 
positive about the potential roles of pharmacists in the drug management of chronic 
. pam. 
The physiotherapists in our study may have had direct clinical contact with 
hospital pharmacists during their training, which, after qualification, may have 
influenced their perception of the pharmacist's potential role in the community. It 
was unclear as to the reason why physiotherapists were more likely than the other 
groups to identify lack of drug information as a limiting factor to control of pain. 
The result may reflect physiotherapists' need to gain more relevant analgesic drug 
knowledge (Stewart et al 1995). This rmding further validates the need for 
community pharmacists to establish links with community physiotherapists to 
identify their drug information needs. Pharmacists have been shown to provide 
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useful drug information to help physiotherapists appreciate the influence of 
analgesic therapy on their patient management strategies (Stewart et aI1995). 
The interest of pharmacists in domiciliary visiting and development of 
treatment protocols for chronic pain and the multidisciplinary support for 
pharmacists to undertake medication review in this study may reflect the developing 
roles of pharmacists in GP surgeries (Mason 1996). 
The large number of unprompted patient requests made during patient 
interviews and the pharmacist interventions made thereafter support the argument 
that pharmacists need to be readily available and accessible to patients in a location 
convenient to patients to optimise pharmaceutical care. Thirty-eight of the patients' 
requests were unrelated to chronic pain management, demonstrating the need for 
pharmacists to be aware of current therapeutic management strategies for all 
relatively common chronic disease states and to make appropriate recommendations 
and interventions. 
The fmding that 13 unprompted patient queries actually required follow-up 
with the relevant prescriber is significant, since the problems may not have been 
detected until symptoms and / or signs prompted the patient to refer them to his / her 
GP. Pharmacists thus need to be vigilant and utilise good open questioning, listening 
and other communication skills. 
Attitudes to mUltidisciplinary team management of chronic pain in this study 
were encouraging. Although only 17 of the GPs had a team at the time of study, and 
pharmacists were only involved in 2 teams, the majority of responders agreed or 
strongly agreed that a treatment plan should be agreed by a multidisciplinary team. 
The fmdings that pharmacists were more likely to identify limited access to pain 
specialists or pain clinics and lack of opportunity of pharmacist involvement as 
limiting factors to optimise pain control confrrms the study group's enthusiasm to 
develop the role in a specified environment within a multidisciplinary team. Chronic 
pain clinics led by pharmacists but facilitated by GPs and other health care team 
members are now being developed within a general practice environment 
(MacGregor 1996). 
The attitudes of the study groups to treatment guidelines for chronic pain 
management were variable and reflected their reported usage. Treatment guidelines 
were used by only 14 (22%) of the GPs involved in this study, while at least 50% of 
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physiotherapists utilised them. Patients with chronic back pain problems are often 
referred to physiotherapists who utilise well-validated exercise strategies for the 
effective control of pain (DiMaggio and Mooney 1987). Pharmacists must be aware 
of the importance of appropriate exercise and the limitations of pharmacological 
therapy in back pain management (Clinical Standards Advisory Group 1994). 
8.5.2 Factors limiting the development of the pharmacist's role in the 
management of chronic pain 
The results from the questionnaire study suggest that limited experience and 
skills of the study pharmacists, limited co-operation by GPs and varying attitudes of 
health care team members regarding chronic pain management and multidisciplinary 
team involvement, may limit the development of the pharmacist's role in the 
management of chronic pain. 
Significantly more pharmacists as compared to GPs identified lack of 
appropriate skills as a factor preventing development of their role. This fmding may 
suggest that pharmacists are becoming increasingly aware of the specific training 
needs required to develop advisory roles in clinical practice such as reporting of 
adverse drug reactions (Whittlesea and Walker 1996, Whittlesea et al 1995) and 
interpersonal skills (Hassell et al 1996). The latter is critical especially if pharmacist 
involvement in multidisciplinary teams is to develop, as this research would suggest. 
Community pharmacists need to be competent in the skills involved with adverse 
drug reporting, in order to fulfil this developing role, especially with respect to OTC 
products (CSM 1997) and potentially generic products (Whittlesea and Walker 
1996). If physicians perceive that pharmacists do not have the required skills, then 
role development of pharmacists will not be encouraged by other health care 
professionals (Begley et aI1994). 
A lack of feedback from GPs may be another factor contributing to the low 
intervention rates by pharmacists. Pharmacists who were not currently involved in 
additional clinical activities with their GPs were significantly more likely to have 
received limited feedback regarding the outcome of an intervention. The latter result 
suggests that good collaboration and communication between GPs and pharmacists 
is necessary to encourage mutual respect and development of roles in the primary 
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care team. However, clinical service development was not influenced by pharmacist 
perception of GP feedback, which suggests that other factors are of greater 
significance in service development. Recently, researchers have identified additional 
workload and lack of fmancial remuneration as deterrents to service progression 
(Bond et aI1997). 
Differences in attitudes to the development and roles of multidisciplinary 
teams may limit pharmacists' role development. GPs as a group were less positive 
about multidisciplinary management of a patient with chronic pain, which may 
reflect a fear that a treatment plan agreed by a team may confuse or jeopardise the 
patient-doctor relationship. Specification of defmed roles and responsibilities of 
each team member should alleviate such fears and optimise patient management 
(Hardy and Hill 1990). 
Pharmacists need to be aware of the varying attitudes of other health care 
professionals towards chronic pain management if their involvement in a pain team 
is to be valued. Too high patient expectation was identified as a limiting factor in 
pain control by significantly more GPs than pharmacists or physiotherapists. This 
fmding may reflect the environment in which GPs consult, such that within a 10 
minute clinic appointment, patients have limited time to discuss their expectations of 
treatment, which can result in patients' non-compliance with treatment and a lack of 
concordance about a treatment strategy established between patient and prescriber 
(Donovan et al 1989). Alternatively, this fmding may reflect the prescribing 
behaviour of GPs, since a recent study demonstrated that GPs' opinions of patients' 
expectations regarding medication influenced GPs' prescribing practices (Cockburn 
and Pit 1997). 
Pharmacists were less likely to identify too high patient expectation as a 
limiting factor, perhaps reflecting poorer probing skills and / or lack of awareness of 
potential patient non-concordance with medication in chronic disease (Donovan and 
Blake 1992). 
Lack of perceived benefit of a chronic pain team in the community may be a 
limiting factor to phannacist involvement. The professional and fmancial viability of 
a pharmacist working within the team must be evaluated carefully by each 
phannacist in consultation with his / her local GPs, phannacists and other health 
care professionals. 
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Physical resources such as the number of pharmacists working in a pharmacy 
at one time was not found to influence the type of clinical services provided. 
However, the sample size here was relatively small so the results may not be a true 
reflection of practice. Indeed, lack of resources, time and expertise were perceived 
to be more common reasons for lack of development of a pain team in this study, 
rather than lack of need. 
The fmding that GPs were less in agreement with the benefits of treatment 
guidelines in terms of cost-effectiveness, may reflect the GPs' personal experience 
of treatment guidelines actually increasing costs to the practice. Pharmacists need to 
be proactive in treatment guideline development and delivery where appropriate, as 
demonstrated in pharmacist-led neuropathic pain clinics, yet aware of the limitations 
of treatment guidelines and roles of the rest of the chronic pain team 
(MacGregor 1996). 
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Chapter 9 
General discussion 
Previous work investigating the role of the pharmacist in the management of 
chronic non-malignant pain in primary care focused largely on prescribed and OTe 
analgesic drug usage (Dixon et al 1995, Briggs et al 1996) or the influence of 
therapy on patient satisfaction (Long and Wynne 1996), with little reference to the 
effect on health outcomes. Dixon and colleagues only examined chronic compound 
analgesic usage using a domiciliary model to identify patients' medication 
knowledge rather than assessing pain management as a whole, whereas Briggs and 
colleagues assessed the need for pharmaceutical intervention and the risk of drug 
interactions between purchased and prescribed analgesics in community pharmacies. 
Both the latter studies were small and uncontrolled. The present study, although 
uncontrolled, aimed to investigate the potential for the pharmacist to improve health 
outcomes by assessing the effect of pharmaceutical intervention on pain control and 
activities of life. 
This study shows the need for pharmacists to undertake different types of 
activity such as prescribing advice, advice to patients and measurement of health 
outcomes. 
The study has identified that community pharmacists have a role in the 
provision of advice to GPs to encourage rational prescribing in chronic pain 
management especially with regard to NSAID prescribing, gastrointestinal 
prophylaxis and DMARD prescribing. In this study, primary care guidelines for 
chronic pain management were followed in only 41 (43%) of the 96 study patients. 
The incidence of NSAID prescribing in the study's OA patients was high in 
relation to those who had symptomatic inflammation, which has also been found by 
other researchers (Dieppe et al 1993(B». Hawker (1997) suggests that such 
inappropriate NSAID prescribing will continue to increase as life expectancy 
increases and thus the incidence of degenerative osteoarthritis will increase, with a 
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correspondingly increased risk ofNSAID toxicity. Indeed, as a result ofNSAID use , 
some OA study patients were placed at risk of side effects as demonstrated in case 
studies 6 and 7. 
Community pharmacists are well placed to assist in the development of 
treatment protocols for the use ofNSAIDs in OA patients and to recommend simple 
analgesics with or without a rubefacient as initial drug therapy if inflammation is not 
present. If inflammation is present , the community pharmacist could recommend 
short-term topical NSAID therapy e.g. ibuprofen in preference to oral therapy. 
Where NSAID use was appropriate, gastrointestinal prophylaxis was 
inappropriate in 12 patients in terms of drug choice and I or daily dosage prescribed 
of prophylactic therapy and non-existent in 8 other patients who fulfilled the 
necessary criteria. Moreover the study did not identify whether any of the study 
patients were H-pylori positive, recently identified as a potential risk factor in 
NSAID-induced gastrointestinal damage (Chan et aI1997). Community pharmacists 
could help to identify patients who had risk factors for the development of NSAID-
induced gastrointestinal ulceration and so encourage rational prescribing. 
This study was carried out just as initial research evidence encouraged early 
DMARD use in RA (Fries et al 1993). However, the use of DMARDs in patients 
with early onset RA or mild disease was limited in this study. Methotrexate, in 
particular, was not prescribed despite its increasing recognition as the DMARD of 
choice in Europe and the USA (Akil and Amos 1995(A), Cash and Klippel 1994). If 
the benefits of DMARDs on long-term health outcomes are to be elucidated, all RA 
patients must be commenced on early DMARD therapy, where appropriate, 
considering relevant drug, disease and patient factors to minimise toxicity and 
maximise efficacy. Community pharmacists are well placed to identify a patient 
presenting with inflammatory symptoms or signs and symptoms of chronic pain and 
to refer the patient appropriately to his I her GP. Ideally, more GPs should be 
encouraged to become specialists in rheumatology in primary care to encourage 
quick and accurate diagnosis and early DMARD treatment where appropriate. 
The results in Chapter 8 and the recent fmdings of Weir et al (1997), have 
demonstrated that GPs have identified a need for such advice from pharmacists, 
recognising pharmacists' roles in the provision of specific drug information to 
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patients and individual patient medication review. The results from this study 
demonstrate that the pharmacist can provide pharmaceutical care for patients with 
chronic pain in terms of rationalisation of medication and improvement in pain 
relief. 
The results have demonstrated that there is also a need for patient-centred 
activities. Chewning and Sleath (1996) discussed the need for a client-centred 
medication review, where patients should be encouraged to make their own 
decisions regarding treatment choices, frequency and the best times at which they 
should take their medication. Their own attitudes to medicines and management of 
their disease should be considered and outcomes fed back to their doctor to 
encourage patient concordance with therapy. In this study, patients' attitude to 
medicines and management including attitude to prescriber as described in Chapter 
3, were all important factors influencing the extent of patient concordance. The 
community pharmacist could act as a facilitator in this review process, since he / she 
does not 'own' the prescription. If decisions are not jointly agreed during a 
consultation between a doctor and patient, the patient-doctor relationship and fmal 
outcome of the consultation can be negatively influenced (Blaxter and Britten 1997). 
Community pharmacists should be responsible for ensuring that what the patient 
agrees to do is actually carried out and is involved in monitoring the outcome in 
terms of pharmaceutical care. 
These patient-centred activities need to follow a validated framework of 
activity before any analysis of their influence on health outcomes can be assessed. In 
Scotland, national guidelines providing standards for pharmaceutical care are in 
place for hospital practice (Clinical Resource and Audit Group 1996). New 
guidelines have yet to be produced to develop a framework for primary care 
practice. 
The information and advice provided by the pharmacist and that requested in 
this study suggest that patients with chronic pain are a high needs group in terms of 
drug and disease state information. The case studies in Chapters 4, 5, 6 and 7 
demonstrated that clarification and reinforcement of drug information was often 
needed, especially since such patients were often on multiple therapy with high risk 
of toxicity, had multiple chronic disease states and were taking concomitant OTC 
analgesics / alternative therapy. 
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The importance of an appreciation of patients' perceptions of their disease 
states and treatment is illustrated by the results particularly of the patients with back 
. pam. 
Although the group was small and perhaps not representative of the general 
back pain population, it did produce some interesting fmdings. Combination 
analgesics and NSAIDs were largely prescribed for this group, despite guidelines 
from the Clinical Standards Advisory Group 1994 suggesting that simple analgesics 
should be used fIrst line with NSAIDs only used short-term, where symptomatic 
inflammation is present. All 7 patients with back pain took less than the prescribed 
maximum daily dosage of their analgesic(s) largely due to fear of side effects e.g. 
drowsiness rather than describing feeling doped and constipation. The results in 
Chapter 4 suggest that patients with back pain suffered more pain than patients with 
other chronic pain states, yet were unwilling to agree with therapy recommendations 
and did not perceive the benefit of exercise. 
Moreover, these patients with back pain reported most of the highest 
psychological dimension scores in Chapter 5, which may reflect the large amount of 
psychological distress particularly associated with chronic back pain, a lack of 
coping strategies or separate psychological problems. 
These results suggest that this group of patients have significant needs which 
are not being fully addressed. Further study regarding not only the pharmaceutical 
needs but other health care needs of this group should be undertaken, using a larger 
sample size to identify if the results of this study represent those of the general 
chronic back pain popUlation. The community pharmacy may be the fIrst port of call 
for such patients seeking help. Community pharmacists must be able to identify the 
specific psychological and physical problems of such patients and refer them 
appropriately to specific health care personnel, depending on specific patients' 
health care needs. The views of the health care professionals as discussed in Chapter 
8 indeed reflect the perception that the community pharmacist is a valuable source 
of drug infonnation for not only patients but other health care professionals. 
The study has shown that there is a need for pharmacists to obtain information 
about patients in order to undertake medication review effectively. Drug history 
taking as part of the medication review process in this study was identified as a 
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major source of information which should be used by the phannacist to elicit an 
accurate history of patients' medicine .. taking behaviour, although patient medical 
records and pharmacy medication records can also be used as sources of 
information. In this study, pharmacy medication records were not used, but have 
been shown to be useful tools in the identification of potential medicine 
management problems (Rogers et al 1994). However, the large number of 
discrepancies between medical records and information obtained from patients, as 
demonstrated in Chapters 3 and 6, indicates that the former are not reliable. Beech 
and Brackley (1996) found similar problems when undertaking medication review of 
a small number of patients with multiple disease and medication problems. The 
discrepancies reported in Chapter 8 by pharmacists further support the fmding that 
pharmacists need accurate information about patients' therapy to undertake 
medication review. 
Community pharmacists could deliver a medication review service for patients 
with chronic pain within their community pharmacy as demonstrated by Rogers et al 
1994. However, the extent of patient assessment, in-depth patient discussion and 
patient confidentiality required within the community pharmacy for a medication 
review may well be limited by lack of pharmacist availability and / or skills and 
time. Other limiting factors might include lack of patient presence (a carer e.g. 
relative or home .. help may be collecting the prescription), limited privacy and lack 
of and accessibility to patient and medical information. 
The problems of skills training, manpower, remuneration and accessibility to 
patients and their medical records need to be addressed quickly to facilitate the 
development of pharmaceutical care of patients with chronic pain. A process of 
pharmaceutical needs assessment is essential to enable services to be provided to 
those patients who need the~ rather than those who demand them (Krska 1998). 
This study has adequately demonstrated a need for improved pharmaceutical 
services to patients with chronic pain. 
A high percentage of the study patients believed they should control their pain 
yet only 25% of patients were actually using OTC or alternative therapy and the 
majority of patients took less than the prescribed daily dosage of analgesic. These 
fmdings suggest that the study patients were prepared to tolerate pain, use only 
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medication which was prescribed and / or adopt alternative coping strategies. 
Although the study's results cannot be directly extrapolated to the general 
popUlation, the results would suggest that pharmacists need to be especially 
proactive when providing pharmaceutical care, especially the provision of 
pharmaceutical information to patients with chronic pain to optimise pain relief. 
Indeed, Donovan and Blake 1992, interviewed patients with rheumatoid arthritis 
prior to and following hospital consultations and found that patients with chronic 
pain were often deliberately non-compliant and developed their own pain 
management strategies, depending on their own lay beliefs, experiences and 
information obtained from pharmacists and other health care professionals. 
The results suggest that domiciliary visiting is an appropriate means by which 
health outcomes can be assessed and patient problems identified in an environment 
which is most convenient to patients, and not just a means of medication review as 
described by earlier researchers (Beech and Brackley 1996). The unprompted 
requests made by patients, as described in Chapter 7, after the pharmacist had 
discussed their present and past use of drug therapy, suggest that patients may have 
gained a better appreciation and acceptance of the pharmacist's role as the 
interviews proceeded. 
Domiciliary assessment of chronic pain in the community has demonstrated 
problems in terms of patient accessibility and consent to participate, appropriate 
skills training of the study pharmacist, time required to prepare for, undertake and 
intervene after a domiciliary medication review and the variable uptake of 
pharmacist's recommendations by GPs. These problems have been identified in 
earlier studies (Beech and Brackley 1996), using similar patient numbers and 
methodology. In this study, it was however, unanticipated that a number of patients 
would not want to participate after the frrst interview, despite the full support of the 
research pharmacist's activities by all the patients' GPs. Such a fmding suggests that 
these patients preferred being in control of their own pain and may have had limited 
beliefs or awareness of what the pharmacist could do to help improve outcomes. 
Although a number of patients with poor outcomes could not be interviewed on a 
second occasion due to unanticipated deterioration in their overall condition, the 
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number of patients who had a second interview was sufficient to demonstrate a 
statistical difference in pain scores. 
In this study, a longer study time and an improved communication strategy 
with patients may have improved the extent of initial patient uptake and continued 
commitment of patients who required a second interview. 
Another problem identified using this- model was the lack of documentation. 
The limited documentation of biochemical and haematological parameters and 
discrepancies in this study reinforces the need for accurate, regularly updated and 
easily available records to enable health care professionals such as GPs and 
community pharmacists to make informed decisions about the cost-effectiveness of 
therapy (Clinical Resource and Audit Group 1996). 
The fmding that documentation of relevant biochemical and haematological 
parameters for all patients on DMARDs was very limited suggests that patients on 
DMARDs in this study group are at risk of serious toxicities and that GPs may be 
reluctant to monitor therapy initiated in secondary care. Locally agreed protocols 
regarding monitoring schedules must be agreed by consultant rheumatologists and 
GPs to optimise patient outcome and minimise toxicity (Medicines Resource Centre 
1996). As community pharmacists develop their skills in adverse drug reporting, 
they will be ideally placed to playa role in the effective monitoring of DMARD 
therapy in the community (Committee on Safety of Medicines 1997), a role already 
developed by hospital pharmacists (Kay 1997). Indeed, it was encouraging to fmd in 
Chapter 8, that pharmacists were already involved in the development of treatment 
protocols and therapeutic monitoring before any directives from the Royal 
Pharmaceutical Society (1995) or Scottish Office Department of Health (1996(A) 
and (B» were publicised. 
If such a domiciliary model is to be extended to community pharmacy practice, 
then community phannacists should restrict this domiciliary service for example, to 
those patients with chronic pain who are housebound and / or elderly, a proposal 
recently endorsed by the Royal College of Physicians (1997). Such a service could 
be identified as a local priority to optimise the phannaceutical care of patients with 
chronic pain within the pharmacist's local health care co-operatives (LHCCs). 
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Measurement of health outcomes and the recording of these parameters would 
improve patient care, reinforcing the need for valid and sensitive health measures. 
The measurement of health outcomes provides an objective means of monitoring 
patient's progress over time. A disease-specific measure, the McGill Pain 
Questionnaire, MPQ, was able to detect small changes in pain intensity and quality 
whereas the generic QOL scale provided much broader measures of health related 
quality of life by assessing the influence of pain on physical, social, occupational 
and psychological dimensions. The use of a disease-specific measure combined with 
a generic measure has been recommended by McDowell and Newell 1996. 
Small sample size and relatively short duration time of the study limit 
extrapolation of the study's health outcome data. The large variability in MPQ, VAS 
and QOL scores both within and between patient groups demonstrates the need to 
identifY each patient's baseline scores when their chronic pain is relatively stable. 
This baseline data would encourage a truer evaluation of the significance of changes 
in pain control and quality of life in patients after a therapeutic intervention. Larger 
groups of patients are also needed to be able to extrapolate the results to the general 
chronic pain population in the community. Sources of variation such as current 
medication and medical problems were not controlled in this study. 
The study only looked at outcomes within a relatively short time span of 4 to 6 
weeks after a change in therapy or management was made or recommended and may 
have underestimated the chronic pain or quality of life experienced by patients. 
Some patients, particularly those with rheumatoid arthritis, may have been 
experiencing a time of remission and improved pain control during time of fIrst 
interview, yet experienced acute flare-ups over other times of the year. Moreover, no 
washout period was considered when patients were changed from one DMARD to 
another, thus the contribution of specific DMARDs to pain control in some patients 
cannot be determined. Further work needs to be carried out over a much longer 
period of time e.g. 4 to 6 months, to assess the chronicity of patients' pain and the 
impact of treatment changes on pain control and health related quality of life. 
In this study there was no assessment of any changes in pain or QOL scores in 
patients with satisfactory outcomes on medication review. Such analysis should be 
included if an estimate of the smallest clinically significant score difference is to be 
made (Guyatt et 011987). 
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The results of Chapter 5 demonstrate the continued difficulty in assessing 
quality of life when no gold standard tool for QOL assessment has yet been agreed 
and the limitations in using only part of a validated QOL scale. 
Correlation coefficients were used in this study as an assessment of reliability. 
Although the QOL questionnaire was found to have a high internal consistency and 
there were good correlations between pain outcome measures and QOL measures 
overall, alternative methods of assessing reliability could have been more 
appropriate. Correlation coefficients may not reflect some types of mismatch 
between scores such that replicated measurements may be systematically different 
yet highly correlated (Bland and Altman 1986). A more appropriate measure of 
reproducibility may be the intraclass correlation coefficient (ICC) (Deyo et a/1991), 
which not only assesses the strength of the correlation, but also whether the slope 
and intercept vary from those expected when measures are repeated. 
The results in Chapter 4 as compared to those in Chapter 5 suggest that the 
MPQ was the most valid and reliable of the two tools used in this study. The good 
correlations between pain rating index, number of word descriptors and visual 
analogue scale scores at Interviews 1 and 2 suggest that the MPQ can be used by 
pharmacists to investigate the influence of a therapeutic intervention. The MPQ has 
previously only been used in a clinical setting within a hospital environment, not 
within a community setting as used in this study. The consistency in choice of 
subclass by patients suggests that patients in the study could derme the quality of 
their pain well, differing more in intensity over time. However, the poor sensitivity 
of the PPI parameter suggests that pain intensity only partially reflects an 
individual's pain experience. 
Although Melzack (1975) found that the MPQ was capable of discriminating 
among different pain syndromes, individual patient responses were not related to 
pain diagnosis in this study. This fmding may be partly explained by the relatively 
smaller sample size as compared to Melzack's study in 1975, lack of consistency of 
use of pain language by patients and the difficulties in classification of patients into 
specific pain syndromes. The choice of scores used by the researcher can also 
influence the outcome (McDowell and Newell 1996). It must also be noted that the 
MPQ may not reflect Melzack's original pain theory. Since each word within a 
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subclass reflects both pain type and intensity, studies in factorial analysis of the 
MPQ may extract pain intensity factors, pain type factors or both (Leavitt et a/ 
1978). 
Despite the MPQ's limitations, a checklist for community pharmacists' use 
could be devised based on the MPQ to identify and assess the progress of patients 
with chronic pain. However, the time taken to carry out the MPQ (15 to 20 minutes 
in new patients) may be a limiting factor towards its general usability in community 
practice. The short-form MPQ (Melzack 1987), which takes 5 to 10 minutes to 
administer, is reliable, the scores of which correlate well with corresponding scores 
of the standard MPQ. This revised tool may be an alternative option for community 
use, having been shown to be sufficiently sensitive to demonstrate similar 
statistically significant differences in pain scores due to treatment compared with the 
standard MPQ. The short-form MPQ was not evaluated in this study, nor has it been 
extensively used in community settings. 
Consideration of the results and the QOL tool's limitations in reliability, 
validity and sensitivity, as previously discussed in Chapter 5, would suggest that the 
study's QOL tool may not be able to accurately assess quality of life after 
pharmaceutical intervention. The small sample size, lack of control group and lack 
of assessment of fluctuations of QOL in stable patients also limit the scale's 
sensitivity. In addition, while the QOL outcome measures used were evaluated for 
reliability and validity, only 14 statements out of the 50 statements originally 
validated by Williams et al (1993) were used in this study. Further work would need 
to be done using the same questionnaire on a much larger patient sample and 
assessing any differences between self-administered and assessor-led questionnaires, 
to identify any elements of bias and to investigate test-retest reliability. The 
responsiveness of the study's QOL measures would also need to be compared with 
established validated QOL instruments, such as AIMS (Meenan et a/ 1980). 
Despite the limitations of the QOL scale, the tool did discriminate between 
those patients who had satisfactory outcomes and those who had poor outcomes. 
Patients who had satisfactory outcomes had significantly lower QOL scores as 
compared to patients with poor outcomes, suggesting that the tool did help to 
identify those patients who were most in need of improvement in QOL. The results 
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in Chapter 5 suggest that patients had adopted various coping strategies to maintain 
quality of life irrespective of pain intensity. 
Ideally, an established disease-specific functional scale with proven reliability 
and validity should have been used to assess the impact of chronic pain on activities 
of daily living such as the Medical Outcomes Study Pain Measures (MOS) 
(Sherbourne 1992). The MOS covers pain severity in terms of pain intensity, 
frequency and duration of pain and records the impact of pain on patient behaviour 
and moods, which is useful for measuring functional outcomes. Although experience 
with this measure was very limited at the time of this study, McDowell and Newell 
(1996) suggest that it is suitable for surveys or for clinical settings when the goal is 
to assess the impact of pain on daily living rather than to provide a detailed 
assessment of the nature of the pain. Community pharmacists could use this tool to 
identify those patients whose chronic pain has significantly influenced their quality 
of life. 
Generic measures have been criticised in that they impose the choice of 
domains and attached values on the patient, which may not be considered to be most 
important (Ruta et al 1994). They have described a truly valid measure of health 
outcome as one which measured the effect of medical conditions on those aspects of 
life considered by patients to be most important, was reliable and responded to 
change over time. In addition, the measure needed to allow patients to rate the extent 
to which those aspects of life were affected and was adaptable, simple and brief. 
This resulted in the patient generated index (PGI) (Ruta et aI1994). Comparisons of 
PGI scores with the generic SF-36 and a validated clinical back pain questionnaire 
in 359 patients with low back pain, have demonstrated correlations with SF-36 
domains of bodily pain, social functioning, role limitation due to physical problems 
and the back pain questionnaire (Ruta et al 1994). However, recent work has 
suggested that outcomes using PGI tools need to be interpreted with caution (Tully 
and Cantrill 1998), since patients may be prompted to describe areas of life which 
are described as examples in a PGI , rather than thinking of their own specific 
situation. 
A similar measure, the 'measure yourself medical outcome profile' (MYMOP) 
has been described by Paterson (1996) and compared with the SF-36 in a sample of 
365 patients in primary care. Results suggest that the MYMOP is more sensitive in 
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detecting changes in acute rather than chronic conditions, so its use may be limited 
in chronic pain. However, further work needs to be performed by pharmacists, 
especially community pharmacists or pharmacists working in the community, to 
investigate the reliability of PGI measures as assessment tools of health related 
quality of life. 
However, as this study has shown, pharmacists are often working single-
handed in community practice and have limited opportunities to fully assess 
patients' needs. Patients may falsely report compliance or may request help 
indirectly through family or carers, resulting in sub-optimal appreciation by the 
pharmacist of patient outcomes (Hassell et al 1996). Communication between 
pharmacists and GPs in terms of personal relationships and reliable, extensive 
computer links need to be developed to improve understanding of each other's 
professional agendas, prescribing behaviours and information needs to optimise 
patient care. 
Financial resources need to be more readily available to encourage pharmacists 
to develop their skills in medication review of patients with chronic pain, the 
assessment of pain and its influence on their quality of life and in information 
provision to both patients and other members of the health care team. As 
professional links between practices and such skilled pharmacists develop, patients 
will be able to appreciate more readily the contribution which pharmacists can make 
in a chronic pain team in primary care. 
No pharmacist identified his / her involvement in the management of chronic 
pain at the time of the study, which suggests a lack of chronic pain management 
experience, although this may have been interpreted as meaning pharmacist 
involvement in a specific pain clinic. Indeed, appropriate training from and a 
structured information exchange network with other pharmacists and other health 
care professionals already involved in chronic pain management, in both primary 
and secondary care, should encourage pharmacists to become more involved in 
chronic pain management (Kay 1997). This strategy may involve training of 
community pharmacists by relevant members of the hospital chronic pain team or 
rheumatology team in pain management and seamless care strategies. 
- 184-
The fmdings of Chapters 7 and 8 are encouraging. Health care team members 
were found to both identify and appreciate the current and potential roles of the 
pharmacist in the management of chronic pain. The appropriate provision of drug 
information to both patients and other members of the healthcare team and the 
development of treatment protocols were well-appreciated roles which could be 
developed within a multidisciplinary team environment. 
The study's fmdings promote the extension of the role of the pharmacist in 
chronic pain from a pharmacist-led clinic for the management of patients with a 
specific type of chronic pain e.g. neuropathic (MacGregor 1996) to a domiciliary or 
community pharmacy based pharmaceutical management of other types of chronic 
pain such as arthritis and back pain. Indeed recent studies in asthma and 
anticoagulation have demonstrated the benefits of pharmacist-led clinics in primary 
care in terms of improved inter-professional co-operation, communication and 
patient care (Kennedy et a11994, MacGregor et aI1996). 
There are difficulties in measuring the impact of the pharmacist on chronic 
pain, although the inclusion of a control group would have been of benefit. The use 
of such a control group would have helped to derme more specifically the impact of 
pharmaceutical intervention on the management of chronic pain. The conclusions 
drawn from the study would have been more generalisable for the chronic pain 
population studied. However, creation of a matched control group for this study 
would be very difficult due to the multidimensional aspects of chronic pain itself 
and patients' mUltiple disease states and multiple drug therapy. In addition, the fact 
that the same pharmacist intervened and monitored the outcome may have biased the 
results. However, there was a clear willingness to involve pharmacists in the 
management of chronic pain both by GPs and physiotherapists, which will facilitate 
future developments. The extent of chronic pain in the community (50% of the 
population), (Smith 1998, verbal communication), suggests that there is a large, 
currently unmet need for such involvement. However, the inherent chronicity, 
variability and multidimensional aspects of chronic pain as perceived by patients 
would still render an analysis of the influence of medication change and advice 
provision on chronic pain difficult. 
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Selection of patients who were taking analgesics regularly or those with 
documented RA, involved the assumption that those who were not taking treatment 
were not suffering from chronic pain. This study may have underestimated the 
population who were suffering from chronic pain at the time of the study. Howie et 
al (1994), using random sample groups of 200 patients in Grampian and Tayside 
who had either shoulder, back, hip or neck pain identified that only about 50% of 
patients were prescribed analgesic therapy. Recent reports suggest that 2500 (50%) 
of a patient population within 29 Grampian GP practices suffered chronic pain and 
expressed a high need for analgesic therapy and GP consultation. 
An element of recall bias in terms of reported side effects and concordance 
with therapy may also have been present in the study. The presence of the study 
pharmacist in the patients' homes may have encouraged patients to report more 
adverse drug reactions and side effects. In addition, patients may have been 
genuinely inaccurate in their recall of drug information. Indeed, open and closed 
questions on drug use within the pain questionnaire did highlight within-patient 
discrepancies. Verbal reports were difficult to validate especially when 
documentation in patients' case notes regarding current OTe and prescribed 
medications, adverse drug reactions and monitoring was so limited. 
Despite these limitations, the study has shown both a need and a demand for 
pharmaceutical input into the management of chronic pain in the community. The 
value of using outcome measures to determine the impact of such input has yet to be 
fully determined. 
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9.1 Recommendations for the role of the community pharmacist in 
chronic pain 
9.1.1 Involvement in the development of treatment protocols for the 
management of rheumatoid arthritis, osteoarthritis and back pain with GPs, 
nurses, physiotherapists and other members of the primary health care 
team involved in chronic pain management 
9.1.2 Greater involvement in the review of repeat prescribing of analgesics 
(combination analgesics and NSAIDs) and disease modifying agents 
• Regular review with local GPs of NSAID use e.g. types of patient, 
types ofNSAID, appropriate GI prophylaxis 
• Provision of appropriate information to patients and health 
professionals regarding the appropriate use of topical NSAIDS and 
combination analgesics and OTC analgesia 
• Facilitation of or direct involvement in DMARD monitoring by 
developing seamless care strategies with the secondary care health 
team 
9.1.3 Development of domiciliary-based medication review involving the 
monitoring of patient outcomes, especially the efficacy and toxicity of 
disease modifying agents 
9.1.4 More extensive and consistent provision of specific drug information to 
patients with chronic pain including the development of a specific pain 
information service within community pharmacies concerning the rational 
use of and side effects associated with prescribed and OTC medications 
used for chronic pain 
9.1.5 Development of a formalised referral network for pharmacists to refer 
patients to relevant members of the primary care chronic pain team to 
optimise outcomes 
9.1.6 Development of a checklist for use by pharmacists incorporating MPQ and 
MOS Pain Outcome indicators to aid in the assessment of chronic pain 
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9.1.7 Increase involvement of patients in the primary care chronic pain team to 
encourage patient awareness of the importance of concordance with a pain 
management strategy and timely and accurate feedback to the primary 
health care pain team 
9.1.8 Development of a realistic remuneration system to encourage community 
pharmacists to participate in medication review of patients with chronic 
pain. The system would need to be sufficiently flexible to consider in 
particular, the pressures of limited resources especially time and manpower 
available to deliver such a service at the present time 
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Chapter 10 
Conclusion 
The study suggests that the role of the phannacist in the management of 
chronic pain in the community is a challenging one. This research has demonstrated 
not only the many pharmaceutical care needs of patients with chronic pain 
irrespective of pain relief obtained, but also the practical and patient-specific 
problems associated with domiciliary medication review. 
The study has identified that GP prescribing in the management of chronic 
pain in the community needs to be improved. Evidence based practices need to be 
implemented after which further research should be carried out to identify the 
benefits of pharmaceutical input in these practices. As primary care trusts (PCTs) of 
local health care co-operatives (LHCCs) in Scotland develop, some PCTs may 
identify the need to improve the management of chronic pain in primary care within 
their own local popUlation and to commission a local chronic pain team of at least 1 
GP, a consultant rheumatologist, a pharmacist, a nurse, an occupational therapist, a 
social worker, a clinical psychologist and possibly an osteopath depending on the 
type of chronic pain identified in the population. 
The study identified that the majority of patients with chronic pain made their 
own decisions regarding treatment choices, frequency and administration times of 
their prescribed medication such that documented medication records rarely 
reflected patient concordance with therapy. There is a need for improved 
documentation of and accessibility to medical records, better communication 
between primary and secondary health care professionals and between patients and 
health care professionals. Further research needs to be carried out to identify the 
most efficient methods of documentation and dissemination of such outcomes to 
both patient and all health care personnel involved in each patient's care. 
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The study also identified that more work needs to be carried out on the use of 
health outcome tools by pharmacists before they can be confidently used to assess 
the influence of pharmaceutical input on health outcomes such as quality of life. 
Further research using multi-centred studies should be undertaken to assess the 
applicability of existing pain measures such as the MPQ as tools to help identify 
pharmaceutical care needs of patients with chronic pain in domiciliary or 
community pharmacy environments. 
The study also identified both a need for pharmacists and a demand from 
pharmacists to develop their role in the management of chronic pain. Training needs 
of both hospital and community pharmacists may be extensive e.g. principles and 
practices of domiciliary medication review and medicines management in 
community pharmacies, documentation of care plans, monitoring of outcomes and 
communication skills. There is a need for further research using control groups to 
investigate the benefits of specific training schemes on pharmaceutical care 
outcomes. 
-190 -
References 
Akil M and Amos RS 1995(A). Rheumatoid arthritis - I: Clinical 
features and diagnosis. British Medical Journal 310, 587-590. 
Akil M and Amos RS 1995(B). Rheumatoid Arthritis - II: Treatment. 
British Medical Journal 310, 652-655. 
Altman DG 1991. Practical statistics for medical research. Chapman and 
Hall. London. 
Anderson KO, Bradley LA, Young LD, McDaniel LK 1985. 
Rheumatoid Arthritis: Review of psychological factors related to 
etiology, effects and treatment. Psychological Bulletin 98, 358-387. 
Anekwe J, Daly MJ, Martin MFR 1997. Give GPs more input on 
DMARD use. Pharmacy in Practice 1,241-244. 
Anon 1993. Slow-acting antirheumatic drugs. Drug and Therapeutics 
Bulletin 31, 17-20. 
Anon 1994. Rational use of NSAIDs for musculoskeletal disorders. 
Drug and Therapeutics Bulletin 32, 91-5. 
Anon 1995. Articular and periarticular injections. Drug and 
Therapeutics Bulletin 33, 67-70. 
Anon 1996(A). Second-line drug therapy in RA. Audit in General 
Practice 1,21-22. 
Anon 1996(B). What can be done about osteoarthritis? Drug and 
Therapeutics Bulletin 34, 33-36. 
Anon 1998. Modifying disease in rheumatoid arthritis. Drug and 
Therapeutics Bulletin 36, 3-6. 
Arkinstall W, Sandler A, Goughnour B, Babul N, Harsanyi Z, Darke AC 
1995. Efficacy of controlled-release codeine in chronic non-malignant 
pain: a randomised, placebo-controlled clinical trial. Pain 62, 169-178. 
- 191 -
Arnett Fe, Edworthy SM, Bloch DA et al 1988. The American 
Rheumatism Association 1987 revised criteria for the classification of 
rheumatoid arthritis. Arthritis and Rheumatology 31,315-324. 
Ash GM 1990. Depression in arthritis patients. The Arthritis & 
Rheumatism Council for Research. Arthritis and the Psyche. Conference 
Proceedings 9, 25 ... 29. 
Ashcroft J 1997. Arthritis: Understanding people's everyday needs. 
Arthritis Care. 
Audit Commission 1994. A prescription for improvement towards more 
rational prescribing in general practice. London. HMSO. 
Barnes J and White A 1998. Complimentary medicine: Acupuncture, 
Pharmaceutical Journal 260, 664-7. 
Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D et al 
1995. Incidence of adverse drug events and potential adverse drug 
effects. Journal of the American Medical Association 274, 29-34. 
Beech E and Brackley K 1996. Medicines Management. (1) Domiciliary 
based medication review for the elderly. Pharmaceutical Journal 256, 
620-622. 
Begley S, Livingstone C, Hodges N,Williamson V 1996. Evaluation of 
phannacist interventions during domiciliary visits. Pharmaceutical 
Journal 257 (Supplement 1), R41. 
Begley S, Livingstone C, Williamson V, Hodges N 1994. Attitudes of 
phannacists, medical practitioners and nurses towards the development 
of domiciliary and other community pharmacy services. International 
Journal of Pharmacy Practice 2, 223-8. 
Bensen WG, Bensen W, Adachi JD 1997. Back to the future: The 
pyramids of rheumatoid arthritis. Journal of Rheumatology 24, 1023-
1027. 
- 192-
Bentley KC and Head TW 1987. The additive analgesic efficacy of 
acetaminophen 1000mg, and codeine, 60mg in dental pain. Clinical 
Pharmacology and Therapeutics 42, 634-40. 
Bergner M, Bobbit RA, Carter WB, Gilson BS 1981. The Sickness 
Impact Profile: Development and fmal revision of a health status 
measure. Medical Care 19, 787-805. 
Bennan BM and Singh BB 1997. Chronic low back pain: an outcome 
analysis of a mind-body intervention. Complimentary Therapies in 
Medicine 5, 29-35. 
Bevan B 1996. Medicines management. (6) PACT data - avoiding the 
pitfalls. Pharmaceutical Journal 257, 25-30. 
Bland 1M and Altman DG 1986. Statistical methods for assessing 
agreement between two methods of clinical measurement. Lancet 1, 
307-310. 
Blaxter M and Britten N 1997. Lay beliefs about drugs and medicines 
and the implications for community phannacy. Phannacy Practice 
Research Resource Centre. Manchester. 
Boers M, Verhoeven AC, Markusse HM, Van de Laar MAP] et a/1997. 
Randomised comparison of combined step-down prednisolone, 
methotrexate and sulphasalazine, with sulphasalazine alone in early 
rheumatoid arthritis. Lancet 350, 309-18. 
Bond CM, Hickey FM, Matheson C 1997. Problems and pitfalls in 
practice research. Pharmaceutical Journal 258, 212-213. 
Bowling A 1995. Measuring disease: A review of disease specific 
quality of life measurement scales. Buckingham. Open University Press. 
Bowling A 1997. Research Methods in Health. Investigating Health and 
Health Services. Buckingham. Open University Press. 
- 193-
Boyce EG 1992. Chapter 28: Rheumatoid arthritis and its therapy. 
Clinical Pharmacy and Therapeutics 5th Edition. Eds. Herfmdal ET 
, 
Gourley DR and Hart LL. Baltimore. Williams and Wilkins. 
Bradley CP, Taylor RJ, Blenkinsopp A 1997. Developing prescribing in 
primary care. British Medical Journal 314, 744-7. 
Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI 1991. 
Comparison of an antiinflammatory dose of ibuprofen, an analgesic 
dose of ibuprofen and acetaminophen in the treatment of patients with 
osteoarthritis of the knee. New England Journal of Medicine 325, 87-91. 
Brazier JE, Harper R, Jones NMB, O'Cathain A, Thomas KJ, 
Usherwood T, Westlake L 1992. Validating the SF-36 health survey 
questionnaire: new outcome measure for primary care. British Medical 
Journal 305, 160-4. 
Breedveld FC 1997. Minocycline in rheumatoid arthritis. Arthritis and 
Rheumatism 40, 794-796. 
Briggs A, Scott EM, Steele K 1997. Analgesics: a comparIson of 
therapeutic knowledge and inter-professional liaison between general 
practitioners and community pharmacists. British Journal of General 
Practice 47, 378-379. 
Briggs A, Scott EM, Bradshaw JP 1996. Analgesic therapy: the need for 
community pharmacy intervention in the elderly. Pharmaceutical 
Journal 257 (Supplement 1), R20. 
Briggs A, Scott E, Steele K 1995. Analgesic drug use: an evaluation of 
professional knowledge and practice. Pharmaceutical Journal 255 
(Supplement 1), R4I. 
British League against Rheumatism 1997. Arthritis: Standards of Care. 
Towards meeting people's needs. Arthritis: getting it right. A guide for 
planners. 
British Medical Association and the Royal Pharmaceutical Society of 
Great Britain 1997. British National Formulary Number 33. London. 
-194 .. 
Britten N 1996. Lay views of drugs and medicines: orthodox and 
unorthodox accounts. Modem Medicine: Lay Perspectives and 
Experiences. Eds. Williams SJ and Calnan M. London. 
Broderick WM, Purves IN, Edwards C 1992. The use of biochemical 
screening in general practice - a role for pharmacists. Pharmaceutical 
Journal 249, 618-620. 
Buchanan NMM 1997. Is there a place for topical NSAIDs? 
Pharmaceutical Journal 259, 294-295. 
Buckley CD 1997. Science, medicine, and the future. Treatment of 
rheumatoid arthritis. British Medical Journal 315, 236-238. 
Cadieux RJ 1989. Drug interactions in the elderly. Postgraduate 
Medicine 86, 179-86. 
Caleo S, Benrimoj S, Collins D, Lauchlan R, Stewart K 1996. Clinical 
evaluation of community pharmacists' interventions. International 
Journal o/Pharmacy Practice 4, 221-7. 
Carmody JJ 1987. Opiate receptors: an introduction. Anaesthesiology 
and Intensive Care 15, 27-37. 
Carr AJ, Thompson PW, Kirwan JR 1996. Quality of life measures. 
British Journal o/Rheumatology 35,275-281. 
Cartwright A and Smith C 1988. Elderly people, their medicines and 
their doctors. Routledge. London. 
Cash 1M and Klippel JH 1994. Second-line drug therapy for rheumatoid 
arthritis. New England Journal 0/ Medicine 330, 1368-1375. 
Chan FKL, Sung JYJ, Chung SCS, To KF, Yung MY et al 1997. 
Randomised trial of eradication of Helicobacter pylori before non-
steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 
350,975-979. 
Chewning B and Sleath B 1996. Medication decision-making and 
management: a client-centred model. Social Science and Medicine 42 
(3), 389-98. 
.. 195 .. 
Chrischilles EA, Lemke JH, Wallace RB, Drube GA 1990. Prevalence 
and characteristics of mUltiple analgesic drug use in an elderly study 
group. Journal of the American Geriatric Society 38, 979-84. 
Clinical Resource and Audit Group 1996. Clinical Pharmacy in the 
Hospital Pharmaceutical Service: A Framework for Practice. The 
Scottish Office. National Health Service in Scotland. 
Clinical Standards Advisory Group 1994. Back pain. Report of a 
Clinical Standards Advisory Group Committee on back pain. HMSO. 
London. 
Cockburn J and Pit S 1997. Prescribing behaviour in clinical practice: 
patients' expectations and doctors' perceptions of patients' expectations .. 
a questionnaire study. British Medical Journal 315, 520-3. 
Col A, Fanale JE, Kronholm P 1990. The role of medication 
noncompliance and adverse drug reactions in hospitalizations of the 
elderly. Archives of Internal Medicine ISO, 841-845. 
Committee on Safety of Medicines 1994. Relative safety of oral non-
aspirin NSAIDs. Current Problems in Pharmacovigilance 20, 9-11. 
Committee on Safety of Medicines 1997. Involvement of phannacists in 
ADR reporting. Current Problems in Pharmacovigilance 23,3. 
Coombes GM and Bax DE 1996. The use and abuse of steroids in 
rheumatology. Practical Problems. Series Three. Reports on Rheumatic 
Diseases. The Arthritis and Rheumatism Council. 
Cunningham G, Dodd TRP, Grant DJ, McMurdo MET, Richards RME 
1997. Drug related problems in patients admitted to Tayside hospitals, 
methods of prevention and subsequent re-assessment. Age and Ageing 
26, 375-382. 
Daut RL, Cleeland CS, Flanery RC 1983. Development of the 
Wisconsin Brief Pain Questionnaire to assess pain in cancer and other 
diseases. Pain 17, 197-210. 
-196 -
Davidson W, Collett JH, Jackson C, Rees JA 1998. An analysis of the 
quality and cost of repeat prescriptions. Pharmaceutical Journal 260, 
458-460. 
De Bruin AF, De Witte LP, Stevens F, Diederiks JPM 1992. Sickness 
Impact Profile: the state of the art of a generic functional status measure. 
Social Science and Medicine 35, 1003-1014. 
De Brum-Femandes AJ 1997. New perspectives for nonsteroidal 
antiinflammatory therapy. Journal of Rheumatology 24, 246-8. 
De Craen AJM, Di Giulio G, Lampe-Schoenmaeckers AJEM et a11996. 
Analgesic efficacy and safety of paracetamol-codeine combinations 
versus paracetamol alone: a systematic review. British Medical Journal 
313,321-5. 
Deal C, Meenan D, Goldenberg J, Anderson R, Sack B, Pastan R, 
Cohen A 1985. The clinical features of early onset rheumatoid arthritis. 
Arthritis and Rheumatism 28, 987-94. 
Dean AD, Dean JA, Burton ill, Dicker RC 1990. Epi-Info, Version 5. A 
word processing, database and statistics program for epidemiology on 
microcomputers. Centers for Disease Control. Atlanta, Georgia. USA. 
Department of General Practice and Primary Care. University of 
Aberdeen 1998. General Practice Information Bulletin 3, 1-3. 
Deyo RA, Diehl AK, Rosenthal M 1986. How many days bed rest for 
acute back pain? New England Journal of Medicine 315, 1064-70. 
Deyo RA, Diehr P, Patrick DL 1991. Reproducibility and 
responsiveness of health status measures. Statistics and strategies for 
evaluation. Controlled Clinical Trials 12, 142S-158S. 
Deyo RA, Inui TS and Sullivan B 1981. Non-compliance with arthritis 
drugs. Journal of Rheumatology 8, 931-936. 
- 197-
Dickson DJ 1991. A double blind evaluation of topical piroxicam gel 
with oral ibuprofen in osteoarthritis of the knee. Current Therapeutic 
Research 49, 199-207. 
Dieppe PA, Cushnaghan J, Jasani MK, McCrae F, Watt I 1993(A). A 
two-year, placebo-controlled trial of non-steroidal anti-inflammatory 
therapy in osteoarthritis of the knee joint. British Journal oj 
Rheumatology 32, 595-600. 
Dieppe PA, Frankel SJ, Toth B 1993(B). Is research into the treatment 
of osteoarthritis with non-steroidal anti-inflammatory drugs 
misdirected? Lancet 341, 353-354. 
DiMaggio A and Mooney V 1987. The McKenzie Program; exercise 
effective against back pain. Journal of Musculoskeletal Medicine 4(12), 
63-74. 
Dixon NHE, Hall J, Hassell K, Moorhouse GE 1995. Domiciliary 
visiting: a review of compound analgesic use in the community. Journal 
0/ Social and Administrative Pharmacy 12, 144-151. 
Donovan J 1991. Patient education and the consultation: the importance 
of lay beliefs. Annals of the Rheumatic Diseases 50, 418-21. 
Donovan JL and Blake DR 1992. Patient non-compliance: deviance or 
reasoned decision-making? Social Science and Medicine 34,507-513. 
Donovan JL, Blake D~ Fleming WG 1989. The patient is not a blank 
sheet: lay beliefs and their relevance to patient education. British 
Journal o/Rheumatology 28,58-61. 
Downie WW, Leatham PA, Rhind VM et al 1978. Studies with pain 
rating scales. Annals o/the Rheumatic Diseases 37,378-381. 
Edwards C, Smith lM, Bateman DN et al 1989. Adverse drug 
monitoring in hospitals; study of pharmacy (green card) monitoring 
scheme in the Northern region. Pharmaceutical Journal 
243(Supplement 1), R48. 
- 198-
Egsmose C, Lund B, Borg G, Pettersson H et al 1995. Patients with 
rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup 
of a prospective double blind placebo controlled study. Journal oj 
Rheumatology 22, 2208-2213. 
Emery P, Salmon M, Bradley H, Wordsworth P et a11992. Genetically 
determined factors as predictors of radiological change in patients with 
early symmetrical arthritis. British Medical Journal 305, 1387-9. 
Fairbank JCT, Couper J, Davies JB et a11980. The Oswestry Low Back 
Pain Disability Questionnaire. Physiotherapy 66,271-273. 
Fairbrother J, Mottram D~ Williamson PM 1993. The doctor-
pharmacist interface, a preliminary evaluation of domiciliary visits by a 
community pharmacist. Journal of Social and Administrative Pharmacy 
10, 85-91. 
Fanner J and Peffer M 1995. Matching resources to needs: Drug 
infonnation for rheumatology patients. British Library Research and 
Development Report 6227. British Library Research and Development 
Department. 
Felson DT, Anderson JJ, Boers M et al 1995. American College of 
Rheumatology, preliminary defmition of improvement in rheumatoid 
arthritis. Arthritis and Rheumatism 38, 727-35. 
Felson DT, Anderson JJ, Meenan RF 1990. The comparative efficacy 
and toxicity of second-line drugs in rheumatoid arthritis: results of two 
metaanalyses. Arthritis and Rheumatism 33, 1449-1461. 
Ferrel BA 1995. Pain evaluation and management in the nursing home. 
Annals of Internal Medicine 123,681-687. 
Fisher B and Dunning M 1998. Implementing clinical effectiveness: 
making it happen in primary care. Pharmaceutical Journal 260, 24-25. 
Fitzpatrick ~ Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D 
1992. Quality of life measures in healthcare. I: Applications and issues 
in assessment. British Medical Journal 305, 1074-77. 
- 199-
Fletcher AE, Dickinson EJ, Philp I 1992(A). Review: Audit measures: 
Quality of life instruments for everyday use with elderly patients. Age 
and Ageing 21, 142-150. 
Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D 
1992(B). Quality of life measures in health care. 2: Design, analysis and 
interpretation. British Medical Journal 305, 1145-8. 
Fries 1F, Spitz P, Kraines RG, Holman HR 1980. Measurement of 
patient outcome in arthritis. Arthritis and Rheumatism 23, 137-45. 
Fries JF, Williams CA, Ramey DE, Bloch DA 1993. The relative 
toxicity of disease-modifying antirheumatic drugs. Arthritis and 
Rheumatism 36,297-306. 
Fries 1F, Williams CA, Morfeld D, Singh G, Sibley J 1996. Reduction in 
long-term disability in patients with rheumatoid arthritis by disease-
modifying antirheumatic drug-based treatment strategies. Arthritis and 
Rheumatism 39, 616-22. 
Fries 1F, Williams CA, Singh G, Ramey DE 1997. Response to therapy 
in rheumatoid arthritis is influenced by immediately prior therapy. 
Journal o/Rheumatology 24,838-844. 
Ghalamkari HH, Rees JE, Saltrese-Taylor A 1997(B). Evaluation of a 
pilot health promotion project in pharmacies: (2) Clients' initial views 
on pharmacists' advice. Pharmaceutical Journal 258, 314-317. 
Ghalamkari HH, Rees JE, Saltrese-Taylor A, Ramsden MA 1997(A). 
Evaluation of a pilot health promotion project in pharmacies: (1) 
Quantifying the pharmacist's health promotion role. Pharmaceutical 
Journal 258,138-143. 
Gloth FM 1996. Concerns with chronic analgesic therapy in elderly 
patients. American Journal 0/ Medicine 101{Supplement lA), 19S-24S. 
Goldstein R, Rivers P, Zakria A 1995. The integration of pharmaceutical 
care services within an elderly people's integrated care system: a pilot 
scheme. Pharmaceutical Journal 255 (Supplement 1), R26. 
- 200-
Goodyer L, Lovejoy A, Nathan A, Warnett S 1996. Medicines 
Management. (3) 'Brown bag' medication reviews in community 
pharmacies. Pharmaceutical Journal 256, 723-725. 
Grymonpre RE, Williamson DA, Huynh DH, Desilets LM 1994. A 
community-based care model for the elderly: report on a pilot project. 
International Journal o/Pharmacy Practice 2, 229-34. 
Guyatt G, Walter S, Norman G 1987. Measuring change over time: 
Assessing the usefulness of evaluative instruments. Journal 0/ Chronic 
Disease 40, 171-178. 
Guyatt G H, Feeny DH, Patrick DL 1993. Measuring health-related 
quality of life. Annals o/Internal Medicine 118, 622-629. 
Haigh S 1996. Twelve years on: co-proxamol revisited. Lancet 347, 
1840-1. 
Hall J, Radley AS, John S 1995. Community and hospital phannacist 
co-operation in an outreach anticoagulant clinic. Pharmaceutical 
Journal 255 (Supplement 1), R24. 
Hampal B 1997. Reviewing GP prescribing ofNSAIDs. Pharmaceutical 
Journal 259, 301-303. 
Hanlon JT, Fillenbaum GG, Studenski SA, Ziqubu-Page T, Wall WE 
1996. Factors associated with suboptimal analgesic use in community-
dwelling elderly. The Annals 0/ Pharmacotherapy 30, 739-744. 
Hardy PAJ and Hill P 1990. A multidisciplinary approach to pain 
management. British Journal o/Hospital Medicine 43, 45-47. 
Hassell K, Harris J, Rogers A, Noyce P, Wilkinson J 1996. The role and 
contribution of pharmacy in primary care. Summary Report. National 
Primary Care Research and Development Centre. Manchester. 
Hawker G 1997. Prescribing nonsteroidal antiinflammatory drugs -
what's new? Journal 0/ Rheumatology 24,243-5. 
Hawksworth G 1996. How to assist elderly patients. Pharmacy In 
Practice 1,272-274. 
- 201 -
Helliwell P, Dempsey 0, Faulkner P, Deacon A 1994. Treatment for 
non-inflammatory arthritis. Lancet 343, 1436. 
Hendrikson C, Lund E, Stromgard E 1984. Consequences of assessment 
and intervention among elderly people: a three year randomised 
controlled trial. British Medical Journal 289, 1522-4. 
Hepler CD 1997. Pharmaceutical care - a revised model. 
Pharmaceutical Journal 258, 899. 
Hepler CD and Strand LM 1990. Opportunities and responsibilities in 
pharmaceutical care. American Journal of Hospital Pharmacy 47, 533-
43. 
Hill J, Bird H, Harmer R 1997. Effectiveness of pain management in a 
nurse-led out-patient clinic. Journal of Rheumatology 24 (Supplement 
1), S328. 
Howie JGR, Heaney DJ, Maxwell M 1994. Evaluating care of patients 
reporting pain in fundholding practices. British Medical Journal 309, 
705-10. 
Hughes CM and McFerran G 1995. A survey of general practitioners' 
views on pharmacist involvement in formulary development. 
Pharmaceutical Journal 255 (Supplement 1), R38. 
Hulme H, Wilson J, Burrill P, Goldstein R 1996. Rationalising repeat 
prescribing: general practitioners and community pharmacists working 
together. Pharmaceutical Journal 257 (Supplement 1), R7. 
Hunt S, McEwen J, McKenna SP 1985. Measuring health status: a new 
tool for clinicians and epidemiologists. Journal of the Royal College oj 
General Practitioners 35, 185-188. 
Hutton CW 1995. Osteoarthritis - clinical features and management. 
Practical Problems. Series Three. Reports on Rheumatic Diseases. The 
Arthritis and Rheumatism Council. 
Jaeschke R, Singer J, Guyatt G 1989. Measurement of health status. 
Ascertaining the minimal clinically important difference. Controlled 
Clinical Trials 10,407-415. 
- 202-
Jaremsiripornkul N, Krska J, Richards RME, Capps PAG 1997. 
Pharmacist-assisted patient-reporting of adverse drug reactions. Abstract 
from the British Pharmaceutical Conference, Scarborough. 
Jenkins A 1996. Formulary development by community phannacists. 
Pharmaceutical Journal 256, 861-863. 
Jenner JR and Barry M 1995. Low back pain. British Medical Journal 
310, 929-932. 
Jensen MP, Karoly P, Braver S 1986. The measurement of clinical pain 
intensity: a comparison of six methods. Pain 27, 117-126. 
Jones AKP, Derbyshire SWG, Pearce S 1993. Reduced central 
responses to pain in patients with rheumatoid arthritis. British Journal oj 
Rheumatology 32 (Supplement 2), 20. 
Jones AKP 1997. Pain and its perception. Topical Reviews. Series 3. 
Reports on Rheumatic diseases. The Arthritis and Rheumatism Council. 
Kando JC, Yonkers KA, Cole JO 1995. Gender as a risk factor for 
adverse events to medications. Drugs 50, 1-6. 
Kay EA 1997. The role of the hospital pharmacist in rheumatoid 
arthritis management. Symposium: Rheumatoid Arthritis - Clinical 
management. British Pharmaceutical Conference, Scarborough. 
Kazis LE, Callahan LF, Meenan RF, Pincus T 1990. Health status 
reports in the care of patients with rheumatoid arthritis. Journal oj 
Clinical Epidemiology 43, 1243-53. 
Kazis LE, Meenan RF, Anderson JJ 1983. Pain in the rheumatic 
diseases. Investigation of a key health status component. Arthritis and 
Rheumatism 26, 1017-1022. 
Kennedy EJ, Blenkinsopp A, Purvis J 1994. A collaborative approach to 
asthma care. Pharmaceutical Jouma1253 (Supplement 1), R26. 
- 203-
Kirwan JR 1995. The Arthritis and Rheumatism Council Low-Dose 
Glucocorticoid Study Group. The effect of glucocorticoids on joint 
destruction in rheumatoid arthritis. New England Journal of Medicine 
333, 142-6. 
Kitching JB 1990. Patient information leaflets - the state of the art. 
Journal of the Royal Society of Medicine 83, 298-300. 
Kovar PA, Allegrante JO, MacKenzie CR, Peterson MGE et al 1992. 
Supervised fitness walking in patients with osteoarthritis of the knee. A 
randomised, controlled trial. Annals of Internal Medicine 116,529-34. 
Krska J 1998. Practice-based pharmaceutical needs assessment. 
Pharmacy World Congress. International Pharmaceutical Federation. 
The Hague. 
Leavitt F, Garron DC, Whistler WW, Sheinkop MB 1978. Affective and 
sensory dimensions of back pain. Pain 4, 273-81. 
Leavitt F and Sweet B 1986. Characteristics and frequency of 
malingering among patients with back pain. Pain 25, 357-64. 
Lee A and Beard K 1997. Pharmacovigilance and the Pharmacist. 
Pharmaceutical Journal 258, 592-595. 
Lee A and Morris J 1997. Drug-induced gastrointestinal disorders. 
Pharmaceutical Journal 258, 742-746. 
Lee A, Bateman DN, Edwards C, Smith 1M, Rawlins MD 1997. 
Reporting of adverse drug reactions by hospital pharmacists: a pilot 
scheme. British Medical Journal 315, 519. 
Levine JD, Lau W, Kwiat G, Goetzl EJ 1984. Leukotriene B4 produces 
hyperalgesia that is dependent on polymorphonuclear leukocytes. 
Science 225, 743-745. 
Levine JD, Moskowitz MA, Basbaum AI 1988. The effect of gold, an 
anti-rheumatic therapy, on substance P levels in rat peripheral nerve. 
Neuroscience Letter 87, 200-202. 
- 204-
Lewis AM, Archer lM, Bagley L, Wilson P 1998. The rapid 
development of a training programme to support the extension of the 
UK adverse drug reporting scheme to 10,000 pharmacists with early 
indicators of the impact on reporting levels. Abstract from the 3rd 
International Lifelong Leaming Conference, Denmark. 
Lewis AJ 1997. New drug targets and new drugs of promIse. 
Symposium: Rheumatoid arthritis. British Pharmaceutical Conference , 
Scarborough. 
Li Wan Po A 1990. Non-prescription drugs. 2nd edition. Oxford. 
Blackwell Scientific Publications. 
Li Wan Po A 1997. OTC oral analgesics. Pharmaceutical Journal 
Practice Checklist. Pharmaceutical Journal I Centre for Phannacy 
Postgraduate Education. University of Manchester. 
Li Wan Po A and Zhang WY 1997. Systematic overview of co-
proxamol to assess analgesic affects of addition of dextropropoxyphene 
to paracetamol. British Medical Journal 315, 1565-71. 
Lipowski EE 1996. Evaluating the outcomes of pharmaceutical care. 
Journal of the American Pharmaceutical Association NS36, 726-734. 
Lipsky PE and Isakson PC 1997. Outcome of specific COX-2 inhibition 
in rheumatoid arthritis. Journal of Rheumatology 24 (Supplement 49), 
9-14. 
Listing J, Alten R, Brauer D, Eggens U, Gromnica-Ihle E et al 1997. 
Importance of psychological well being and disease activity in 
termination of an initial DMARD therapy. Journal of Rheumatology 24, 
2097-2105. 
Lobas NH, Lepinski PW, Abramowitz PW 1992. Effects of 
pharmaceutical care on medication costs and quality of patient care in an 
ambulatory care clinic. American Journal of Hospital Pharmacy 49, 
1681-8. 
- 205-
Lohr KN, Aaronson NK, Alonso J et a11996. Evaluating quality-of-life 
and health status instruments: development of scientific review criteria. 
Clinical Therapeutics 18, 979-992. 
Long A and Wynne HA 1996. Patient satisfaction with arthritis 
medication. International Journal of Pharmacy Practice 4, 52-54. 
Lorig KR Mazonson PD, Holman HR 1993. Evidence suggesting that 
health education for self-management in patients with chronic arthritis 
has sustained health benefits while reducing health care costs. Arthritis 
and Rheumatism 36, 439-46. 
MacGregor SH 1996. Pharmaceutical care in the general practice 
surgery. Valuefor Money Update 2, 4-5. 
MacGregor SH, Hamley JG, Dunbar JA, Dodd TRP, Cromarty JA 1996. 
Evaluation of a primary care anticoagulant clinic managed by a 
pharmacist. British Medical Journal 312, 560. 
MacKeigan LD and Pathak DS 1992. Overview of health-related 
quality-of-life measures. American Journal of Hospital Pharmacy 49, 
2236-2245. 
Mackie CA 1997. Community pharmacists' role m clinical 
effectiveness. Pharmaceutical Journal 259, 557. 
Mahoney JM, Schmitz ML and Birge SJ 1992. Chapter 29 
Osteoarthritis. Clinical Phannacy and Therapeutics. 5th Edition. Eds. 
Herfmdal ET, Gourley DR and Hart LL. 
Maini RN1996. The role of cytokines in rheumatoid arthritis. Journal oj 
the Royal College of Physicians 30, 344-51. 
Malek M 1997. Pharmacoeconomics (2): Measuring quality of life 
impacts. Pharmaceutical Journal 258,22-24. 
Martys CR 1979. Adverse reactions to drugs in general practice. British 
Medical Journal 2, 1194-7. 
- 206-
Mason P 1996. A pharmacist in the surgery - what better prescription for 
the New Age? Pharmaceutical Journal 256, 192-195. 
McCallum A 1993. What is an outcome and why look at them? Critical 
Public Health 4, 4-9. 
McCormack HM, Horne DJdeL, Sheather S 1988. Clinical applications 
of visual analogue scales: a critical review. Psychological Medicine 18, 
1007-1019. 
McDaniel LK, Anderson KO, Bradley LA, Young LD, Turner RA, 
Agudelo CA, Keefe FJ 1986. Development of an observation method 
for assessing pain behaviour in rheumatoid arthritis patients. Pain 24, 
165-84. 
McDowell I and Newell C 1996. Measuring Health: A guide to rating 
scales and questionnaires. New York. Oxford University Press. 
McEInay JC and McCallion RC 1996. Non-prescription drug use by 
elderly patients. International Journal of Pharmacy Practice 4, 6-11. 
McQuay HJ, Moore RA, Eccleston C, Morley S, de C Williams AC 
1997. Systematic review of outpatient services for chronic pain control. 
Health Technology Assessment 1(6). 
Medicines Resource Centre 1996. Second-line drugs in rheumatoid 
arthritis. Medicines Resource Centre Bulletin 7, 9-12. 
Medicines Resource Centre 1997. Topical NSAIDs. Medicines Resource 
Centre Bulletin 8, 29. 
Meenan RF, Gertman PM, Mason JH 1980. Measuring health status in 
arthritis: the Arthritis Impact Measurement Scales. Arthritis and 
Rheumatism 23, 146-152. 
Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE 1992. 
AIMS 2: The content and properties of a revised and expanded Arthritis 
Impact Measurement Scales health status questionnaire. Arthritis and 
Rheumatism 35, 1-10. 
- 207-
Newman SP 1996. Psychological assessment in rheumatic diseases. 
Topical Reviews. Series Three. Reports on Rheumatic Diseases. The 
Arthritis and Rheumatism Council. 
Newman SP, Fitzpatrick R, Lamb R, Shipley M 1989. The origins of 
depressed mood in rheumatoid arthritis. Journal of Rheumatology 16, 
740-4. 
Nunally J 1978. Psychometric theory. New York. McGraw-Hill. 
O'Boyle CA, McGee H, Hickey A, O'Malley K, Joyce CRB 1992. 
Individual quality of life in patients undergoing hip replacement. Lancet 
339, 1088-91. 
O'Brien BJ, Elswood J, Calin A 1990. Perception of prescription drug 
risks: a survey of patients with ankylosing spondylitis. Journal of 
Rheumatology 17, 503-7. 
Odedina FT and Segal R 1996. Behavioural pharmaceutical care scale 
for measuring pharmacists' activities. American Journal of Health-
System Pharmacists 53, 855-65. 
O'Hara P 1996. Pain management for health professionals. Eds. 
Chapman and Hall. London. 
Oliver CW 1997. Role of surgery in patients with rheumatoid arthritis. 
Practical Problems Series 3. Reports on Rheumatic Diseases. The 
Arthritis and Rheumatism Council. 
O'Malley K, Crooks J, Duke E, Stevenson I 1971. Effect of age and sex 
on human drug metabolism. British Medical Journal 3, 607-609. 
Paes AHP 1992. Drug monitoring in community pharmacy. Journal of 
Social and Administrative Pharmacy 9, 29-34. 
Panayi GS and Welsh KI 1988. The immunogenetics of rheumatoid 
arthritis. Collected Reports on the Rheumatic diseases. Arthritis and 
Rheumatism Council for Research. Eds. Butler RC and Jayson MIV. 
- 208-
Panush RS, Carias K, Kramer N, Rosenstein ED 1995. Acute arthritis in 
the hospital: comparison of rheumatologic with non-rheumatologic care. 
Clinical Rheumatology 1, 74-80. 
Paterson C 1996. Measuring outcomes in primary care: a patient 
generated measure, MYMOP, compared with the SF-36 health survey. 
British Medical Jouma1312, 1016-1020. 
Perry F, Heller PH, Levine JD 1988. Differing correlations between pain 
measures in syndromes with or without explicable organic pathology. 
Pain 34, 185-189. 
Platt P 1997. Rheumatoid arthritis and its management. Pharmaceutical 
Journal 259, 298-301. 
Portenoy RK 1990. Chronic opioid therapy in nonmalignant pain. 
Journal of Pain and Symptom Management 5 (Supplement 1), S46-62. 
Porter D~ McInnes I, Hunter J, Capell HA 1994. Outcome of second 
line therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases 
53,812-815. 
Porter RW and Ralston SH 1994. Pharmacological management of back 
pain syndromes. Drugs 48, 189-198. 
Primary Care Rheumatology Society 1995. Partnership in Practice. The 
management of osteoarthritis. The Primary Care Rheumatology Society. 
Prouse PJ 1998. Management of early rheumatoid arthritis. Update (1), 
232-236. 
Puett DW and Griffm MR 1994. Published trials of nonmedicinal and 
noninvasive therapies for hip and knee osteoarthritis. Annals of Internal 
Medicine 121, 133-40. 
Pullar T 1995. Second-line drugs for arthritis: the reasons for early use. 
Practitioner 239, 387-390. 
- 209-
Pullar T, Capell HA, Millar A and Brooks RG 1982. Alternative 
medicine: cost and subjective benefit in rheumatoid arthritis. British 
Medical Journal 285, 1629-1631. 
Radley AS and Hall J 1994. The establishment and evaluation of a 
pharmacist-developed anticoagulant clinic. Pharmaceutical Journal 
252,91-92. 
Read RW 1989. The role of the pharmacist in the management of acute 
postoperative pain. MSc Thesis. University of Manchester. 
Ready LB, Sarkis E, Turner JA 1982. Self-reported versus actual use of 
medications in chronic pain patients. Pain 12, 285-294. 
Rees JK, Livingstone DJ, Livingstone CR, Clarke CD 1995. A 
community clinical pharmacy service for elderly people in residential 
homes. Pharmaceutical Journal 255, 54-56. 
Reidenberg MM and Lowenthal DT 1968. Adverse nondrug reactions. 
New England Journal of Medicine 279, 678-679. 
Reisner-Keller LA 1992. Chapter 50. Pain Management. Clinical 
Pharmacy and Therapeutics (Fifth edition) Eds. Herfmdal ET, Gourley 
DR and Hart LL. 
Roberts RI, Hampson JP, Morgan DA 1997. The Welsh Shared Care 
Prescribing Project. Pharmaceutical Journal 258, 415-416. 
Rogers PJ, Fletcher G, Rees JE 1994. Clinical interventions by 
community pharmacists using patient medication records. International 
Journal of Pharmacy Practice 3,6-13. 
Roins S, Benrimoj SI, Carroll PR, Johnson L W 1998. Factors used by 
pharmacists in the recommendation of the active ingredient( s) and brand 
of non-prescription analgesics for a simple, tension and migraine 
headache. International Journal of Pharmacy Practice 6, 196-206. 
- 210-
Rosenstiel AK and Keefe F J 1983. The use of coping strategies in 
chronic low back pain patients: relationship to patient characteristics and 
current adjustment. Pain 17, 33-44. 
Rowan K, Doyle D, Griffiths I 1997. The British League against 
Rheumatism. Arthritis: Standards of Care. Towards meeting people's 
needs. 
Royal College of General Practitioners 1996. Clinical guidelines on the 
management of acute low back pain. Royal College of General 
Practitioners. 
Royal College of Physicians 1997. Medication for older people (2nd 
edition). The Royal College of Physicians of London. 
Royal Pharmaceutical Society of Great Britain 1988. Report of a Royal 
Pharmaceutical Society Working Party. A domiciliary pharmaceutical 
service. Pharmaceutical Journal 241, 90-93. 
Royal Pharmaceutical Society of Great Britain 1992. Pharmaceutical 
care: The future for community pharmacy: Report of the joint working 
party on the future of the community pharmaceutical services. 
Royal Pharmaceutical Society of Great Britain 1995. Pharmacy in a 
New Age. Pharmaceutical Journal. London. 
Ruta DA, Garratt AM, Leng M, Russell IT, MacDonald LM 1994. A 
new approach to the measurement of quality of life: the Patient-
Generated Index. Medical Care 32, 1109-1126. 
Saag KG, Koehnke R, Caldwell JR et al 1994. Low dose long-term 
corticosteroid therapy in rheumatoid arthritis: an analysis of serious 
adverse events. American Journal of Medicine 96,115-23. 
Salek MS and Walker MD 1995. Quality of life assessment by 
community pharmacists: its practicality in providing pharmaceutical 
care. Pharmaceutical Journal 255 (Supplement 1), R28. 
- 211 -
Schnitzer TJ, Posner M, Lawrence ID 1995. High strength capsaicin 
cream for osteoarthritis pain: rapid onset of action and improved 
efficacy with twice daily dosing. Journal of Clinical Rheumatology 1, 
268-73. 
Scott DL and Symmons DPM 1986. The mortality of rheumatoid 
arthritis. Collected Reports on the Rheumatic diseases. Arthritis and 
Rheumatism Council for Research Eds. Butler RC and Jayson MIV. 
Scott J and Huskisson EC 1976. Graphic representation of pain. Pain 2, 
175-184. 
Scottish Medicines Resource Centre 1995(A). Non-steroidal anti-
inflammatory drugs - I. Appropriate use and choice in general practice. 
Scottish Medicines Resource Centre Bulletin 26, 99-102. 
Scottish Medicines Resource Centre 1995(B). Non-steroidal anti-
inflammatory drugs (NSAIDs) - II. Prevention and management of 
gastrointestinal side effects. Scottish Medicines Resource Bulletin 27, 
103-106. 
Scottish Medicines Resource Centre 1995(C). Combination analgesics. 
Scottish Medicines Resource Bulletin 25, 95-96. 
Scottish Office. Department of Health 1996(A). Choice and 
Opportunity. Primary Care: The future. London. HMSO. 
Scottish Office. Department of Health 1996(B). Primary care: delivering 
the future. London. HMSO. 
Scottish Office. Department of Health 1997. Designed to care -
renewing the National Health Service in Scotland. London. HMSO. 
Scottish Office. Department of Health 1998. Our healthier nation: a 
contract for health. London. HMSO. 
Seeger JD, Schumock GT, Kong SX 1996. Estimating the rate of 
adverse drug reactions with capture-recapture analysis. American 
Journal of Health-System Pharmacists 53, 178-181. 
- 212-
Shanks J and Frater A 1993. Health status, outcome and attributability: 
is a red rose red in the dark? Quality in Health Care 2, 259-262. 
Sherbourne CD 1992. Pain measures. Measuring function and well-
being: the Medical Outcomes Study Approach, Durham, North Carolina. 
Duke University Press. 
Silman A 1997. Rheumatoid arthritis: 'most important cause of major 
disability' . Pharmaceutical Journal 259, 510. 
Skevington S 1990.The psychosocial consequences of chronic pain. The 
Arthritis & Rheumatism Council for Research. Arthritis and the Psyche. 
Conference Proceedings 9, 35-40. 
Smith CC, Bennett PM, Pearce HM et al 1996. Adverse drug reactions 
in a hospital general medical unit meriting notification to the Committee 
on Safety of Medicines. British Journal of Clinical Pharmacology 42, 
423-9. 
Snell M 1993. Bristol's phannacist for rheumatology and self-
medication. Pharmaceutical Journal 251(Suppiement), HSI8-19. 
Sommerville H 1996. Medicines Management. (2) Medication review in 
nursing and residential homes. Pharmaceutical Journal 256, 648-650. 
Sriwatanakul K, Kelvie W, Lasagna L et a11983. Studies with different 
types of visual analogue scales for measurement of pain Clinical 
Pharmacology and Therapeutics 34, 234-239. 
Steele K, Mills KA, Gilliland AEW, Irwin WG, Taggart A 1987. Repeat 
prescribing of non-steroidal anti-inflammatory drugs excluding aspirin: 
how careful are we? British Medical Journal 295, 962-4. 
Stenstrom CH, Arge B, Sundbom A 1997. Home exercise and 
compliance in inflammatory rheumatic diseases - a prospective clinical 
trial. Journal of Rheumatology 24, 470-475. 
Sternbach RA and Timmermans G 1975. Personality changes associated 
with reduction of pain. Pain 1, 177-181. 
- 213-
Stewart D 1997. Implementing fonnulary recommendations in primary 
care: effect on patient outcomes. PhD Thesis. The Robert Gordon 
University. 
Stewart D, MacLeod E, Downie G, Munro K, Evans L 1995. A study to 
detennine which adverse effects of drugs may influence the work of the 
physiotherapist. Pharmaceutical Journal 255 (Supplement 1), R43. 
Stockwell Morris L and Schulz RM 1992. Patient compliance _ an 
overview. Journal of Clinical Pharmacy and Therapeutics 17,283-295. 
Streiner DL and Nonnan GR 1998. Health measurement scales. A 
practical guide to their development and use. Oxford University Press. 
Oxford. 
Swift GL and Rhodes J 1992. Are non-steroidal anti-inflammatory drugs 
always necessary? A general practice survey. British Journal o/Clinical 
Practice 46,92-94. 
Sykes N, Hanks GW, Forbes K 1996. Co-proxamol re-visited. Lancet 
348,408. 
Thompson JF, McGhan WF, Ruffalo RL et al 1984. Clinical 
pharmacists prescribing drug therapy in a geriatric setting: Outcome of a 
trial. Journal of the American Geriatrics Society 32,154-159. 
Timm KE 1994. A randomized-control study of active and passive 
treatments for chronic low back pain following L5 laminectomy. 
Journal of Orthopaedic and Sports Physical Therapy 20,276-286. 
Tugwell P, Pincus T, Yocum D et a11995. Combination therapy with 
cyclosporine and methotrexate in severe rheumatoid arthritis. New 
England Journal of Medicine 333, 137-41. 
Tully MP and Cantrill JA 1998. Validity assessment of the Patient 
Generated Index - a qualitative alternative. Abstract from the 4th Health 
Services Research and Pharmacy Practice Conference, Cardiff. 
- 214-
Turk DC, Rudy TE, Salovey P 1985.The McGill Pain Questionnaire 
reconsidered: ConfIrming the factor Structure and examining appropriate 
uses. Pain 21, 385-397. 
Turner JA, Calsyn DA, Fordyce WE, Ready LB 1982. Drug utilization 
patterns in chronic pain patients. Pain 12, 357-363. 
Tursky B, Jamner LD, Friedman R 1982. The Pain Perception Profile: a 
psychophysical approach to the assessment of pain report. Behavioural 
Therapy 13, 376-394. 
Van Riel PLCM and Van Lankveld WGJM 1993. Quality of life 3: 
Rheumatoid Arthritis. Pharmacy World and Science 15, 93-7. 
Waller PC 1992. Measuring the frequency of adverse drug reactions. 
British Journal of Clinical Pharmacology 33, 249-52. 
Ward SE, Goldberg N, Miller-McCauleyV, Mueller C, Nolan A, 
Pawlik-Plank D, Robbins A, Stonnoen D, Weissman DE 1993. Patient-
related barriers to management of cancer pain. Pain 52, 319-324. 
Watson M 1997. Management of patients with osteoarthritis. 
Pharmaceutical Journal 259, 296-297. 
Watson MC and Dieppe PA 1998. Issues in: (2) Rheumatoid Arthritis. 
Pharmaceutical Journal 260, 310-311. 
Weir LFC, Cromarty JA, Krska J 1997. Prescribing support from 
phannacists to general practitioners in Scotland. Pharmaceutical 
Journal 259 (Supplement 1), R27. 
Weinberger W, Tierney WM, Booher P, Katz BP 1989. Can the 
provision of information to patients with osteoarthritis improve 
functional status? A randomised, controlled trial. Arthritis and 
Rheumatism 32, 1577-83. 
Weissman DE and Haddox JD 1989. Opioid pseudo-addiction - an 
iatrogenic syndrome. Pain 36,363-366. 
- 215 -
Westwood P and Hudson SA 1996. Community phannacists' review of 
patients' medication. Pharmaceutical Journal 257 (Supplement 1), R8. 
Whitaker P, Wilson R, Bargh J, Chapman M and Dudley R 1994. 
Factors linking age and analgesic use in Somerset. Pharmaceutical 
Journal 253 (Supplement 1), R12. 
Whitaker P, Wilson R, Bargh J, Chapman M, Dudley R 1995.Use and 
misuse of purchased analgesics with age. Pharmaceutical Journal 254, 
553-555. 
Whittlesea CMC and Walker R 1996. An adverse drug reaction 
reporting scheme for community phannacists. International Journal oj 
Pharmacy Practice 4, 228-34. 
Whittlesea CMC, Chapman H, Walker R 1995. Community phannacists' 
knowledge of adverse drug reaction reporting. Pharmaceutical Journal 
255 (Supplement 1), R14. 
WHOQOL Group 1993. Measuring quality of life: The development of 
the World Health Organisation Quality of Life Instrument (WHOQOL). 
Geneva.WHO. 
Williamson CA, Ridler C, Sewell G 1993. A study to determine the 
quality of life of patients receiving low dose ambulatory chemotherapy. 
Hospital Pharmacy Practice 1, 197-204. 
Wolfson DJ, Booth TG, Roberts PI 1993. The community pharmacist 
and adverse drug reaction monitoring: (2) An examination of the 
potential role in the United Kingdom. Pharmaceutical Journal 251, 21-
24. 
Wood I, Bell D, Clark C 1998. Pharmaceutical care in patient medical 
records - putting a system of documentation into practice. 
Pharmaceutical Joumal260, 717-719. 
Wood KM, Mucklow IC, Boath EH 1997. Influencing prescribing in 
primary care: a collaboration between clinical pharmacology and 
clinical pharmacy. International Journal o/Pharmacy Practice 5, 1-5. 
- 216-
Wooley FR, Kane RL, Hughes CC, Wright DD 1978. The effects of 
doctor-patient communication on satisfaction and outcome of care. 
Social Science and Medicine 12, 123-8. 
Woolf CJ 1994. A new strategy for the treatment of inflammatory pain, 
prevention or elimination of central sensitisation. Drugs 47 
(Supplement 5), 1-9. 
Yaksh TL 1984. Multiple opioid receptor systems in brain and spinal 
cord: parts 1 and 2. European Journal of Anaesthesia 1, 171-243. 
Varon M 1995. Hormonal problems and rheumatic diseases. Topical 
Reviews. Series Three. Reports on Rheumatic Diseases. The Arthritis 
and Rheumatism Council. 
Yelin E, Henke C, Epstein W 1987. The work dynamics of the person 
with rheumatoid arthritis. Arthritis and Rheumatism 30, 507-512. 
Zwillich SH 1997. Outcome versus activity in rheumatoid arthritis: a 
focus blurred. Journal of Rheumatology 24, 826-829. 
- 217-
Appendix 1: Letter from GPs confirming approval of research 
Dr Janet Krska 
Lecturer in Clinical Phannacy 
SchoolofPhannacy 
The Robert Gordon University 
Schoolhill 
Aberdeen AB9 IFR 
Dear Dr Krska 
Strathaven Health Centre 
The Ward 
Strathaven 
Lanarkshire 
MLI06AS 
I confrrm, on behalf of Strathaven Health Centre practice, that we are willing to act 
as a collaborating establishment for the research study by Miss Rhona Park into the 
evaluation of the use and efficacy of analgesics in the management of chronic pain 
in the community. 
We are also willing to give permission for Miss Rhona Park to access appropriate 
medical notes and to interview selected patients in their homes. A suitable work area 
in the practice will also be provided for the period of the study. 
Yours sincerely 
Dr Carol Campbell 
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Appendix 2: Letter of consent from the Joint Ethical Committee of 
the Grampian Health Board and University of Aberdeen 
Ms Rhona Park 
Lecturer / Practitioner 
SchoolofPhannacy 
The Robert Gordon University 
Schoolhill 
Aberdeen AB9 IFR 
DearMs Park 
Clerk to the Committee: 
Mr Sandy Reid 
Headquarters Administration 
Grampian Health Board 
Summerfield House 
2 Eday Road 
Aberdeen AB9 IRE 
1 April 1993 
An investigation into the use and efficacy of analgesics in the management of 
chronic pain in the community 
The above project was considered at the Joint Ethical meeting on 25 March 1993. I 
am pleased to confrrm that ethical approval for this project has now been granted. 
With regards to medical indemnity, I enclose a form which should be completed and 
returned to either: (1) Dr J Hem, Clinical Director, Aberdeen Royal Hospitals NHS 
Trust, Foresterhill House, Ashgrove Road West, Aberdeen, (2) Dr R Scorgie, 
Medical Director, Grampian Healthcare NHS Trust, Westholme, Woodend Hospital, 
Aberdeen or (3) Clinical Director, Moray Health Services NHS Trust, 317 High 
Street, Elgin, as appropriate if you wish one of the above Trusts to accept liability 
for medical indemnity for this project. 
I also enclose a standard Joint Ethical Committee proforma for future use. 
Thank you for bringing this study to the Committee's attention. 
Yours sincerely 
SReid 
Clerk to the Committee 
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Appendix 3: Letter of consent from Lanarkshire Health Board 
Ethics of Research Committee 
Ms Rhona Park 
Lecturer I Practitioner 
School of Pharmacy 
The Robert Gordon University 
Schoolhill 
Aberdeen AB9 IFR 
DearMs Park 
Lanarkshire Health Board 
14 Beckford Street 
Hamilton 
Lanarkshire 
ML3 OrA 
10 October 1994 
An investigation into the use and efficacy of analgesics in the management of 
chronic pain in the community 
I refer to the above study which was submitted to the Ethics of Research Committee 
for consideration. 
Following discussion with the Chairman of the Committee, I can confmn that as the 
study is a multi-centre trial and it has been given approval by the Joint Ethical 
Committee of Grampian Health Board and the University of Aberdeen, Lanarkshire 
Health Board's Ethics of Research Committee has also approved the study. 
If you require any further information, please do not hesitate to contact me. 
Yours sincerely 
Mrs] Grant 
Assistant Secretary 
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Appendix 4: Monitoring schedules for commonly used DMARDs 
and Immunosuppressants (Medicines Resource Centre 1996) 
Drug Full blood count Renal Proteinuria 
Function 
Sodium Before each injection Before starting Before each injection 
aurothiomalate treatment 
Auranofin Before starting treatment, then Before starting Before starting treatment, 
at least every month treatment then at least ev~ty month 
Penicillamine Before starting treatment, Before starting Before starting treatment, 
weekly or fortnightly for first treatment. then weekly for first 8 
8 weeks and in week after any weeks and in week after 
dose increase. Every month any dose increase. Every 
thereafter month thereafter 
Antimalarials 
Azathioprine Weekly for first 8 weeks, at 
least every 3 months thereafter 
Cyclosporin At least twice 
before starting 
treatment, then 
every 2 weeks 
for frrst 3 
months. 
Monthly 
thereafter 
Methotrexate Before starting treatment. Before starting 
Every 1-2 weeks for 6-8 treatment. 
weeks or until dose stable. Annually 
Every month thereafter. thereafter 
Sulphasalazine Before starting treatment, then Before starting 
every month for frrst 3 treatment 
months. Every 3 months 
thereafter 
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Dru! Liver Function Other 
Sodium Before starting treatment 
aurothiomalate 
Auranofin Before starting treatment 
Penicillamine 
Antimalarials Eye examination at baseline. 
Data sheets advise 3-6 
monthly follow-up 
examination 
Azathioprine Monitor regularly e.g. at same time as full 
blood count 
Cyclosporin Monitor regularly if co-administering with Monitor blood pressure 
NSAIDs 
Methotrexate Before starting treatment. Every 2-4 
months during treatment 
Sulphasalazine Before starting treatment, then every 
month for fIrst 3 months. Every 3 months 
thereafter 
Blood count = Haemoglobin, differential white cell count and platelets. 
Renal function = Urea, electrolytes and creatinine 
Liver function = alkaline phosphatase, gamma-glutamyl transferase and aspartate (or 
alanine) transferase. 
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Appendix 5: Information leaflet sent to patients providing details of 
the project 
A survey of analgesic use in the treatment of chronic pain in the community 
Patient Information Leaflet 
People take painkillers prescribed by their doctors for many different reasons. We 
aim to fmd out how well your painkillers work for you and if there are ways to help 
you get better results from them. 
To do this, we need people who take painkillers to volunteer to take part in our 
study. 
This will involve one or two interviews (about 30 minutes each) asking you 
questions about: 
the type of painkillers you take 
how often you take them 
how you feel about your treatment 
any side effects you may have noticed 
Ifwe think that you may not be getting the best from your painkillers, your doctor 
and I will try to improve things. I will then come back to see you again to fmd out if 
they are working any better. 
Please don't worry. 
All information collected will be treated in the strictest confidence. There is no need 
for you to take part in the study if you don't want to. You can pull out at any time 
and there will be no effect on your future medical care. 
But it would be wonderful if you could help us. 
If you would like to help, please fill in the form giving your permission, which is 
attached. I will contact you again in a few days, to fmd out whether you do want to 
join the study. 
Thank you for your time. I look forward to meeting you, if you decide to volunteer. 
Rhona Park 
School of Pharmacy 
The Robert Gordon University 
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Appendix 6: Patient consent form for assessment of analgesic use 
and efficacy 
Name of Patient: 
Principal Investigator: Rhona W. Park 
I have read the Patient Infonnation Leaflet on the above study and have had the 
opportunity to discuss the details with Rhona Park and to ask questions. 
I understand that these questions are part of a research project to encourage better 
use of painkillers which has been approved by the Joint Ethical Committee. 
I also understand that my General Practitioner has agreed that I can participate in the 
study and that the study will not affect my continuing medical treatment in any way. 
I have agreed to take part in the study as it has been described to me, but I 
understand that I am completely free to withdraw from the study or any part of the 
study at any time if I wish. 
I hereby fully and freely consent to participate in the study which has been fully 
explained to me. 
Signature of Patient: Date: ____ _ 
I confmn that I have explained to the patient named above, the nature and the 
purpose of the questionnaires which will be used in the study. 
Signature of Investigator: _________ _ Date:_----
Patient number 
Address 
Telephone Number 
Sex 
Occupation 
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Appendix 7: Data Collection Form 
Male = 1 
Female= 2 
(if not working previous occupation) 
Marital status Single = 1 
Married = 2 
Divorced = 3 
Widowed= 4 
Separated = 5 
Occupation of Spouse 
Name of Doctor 
Education 
Pain Diagnosis 
Left school at 16 years = 1 
Completed school = 2 
College/ University experience = 3 
Other =4 
I=RA 
2=OA 
3= Back Pain 
4=RAandOA 
Concomitant disease states 
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Previous medical! surgical history 
Date Previous medical Date Previous surgical 
history history 
Prescribed analgesics and co-analgesics 
Name Formulation Dose and Route Date of initial 
Frequency prescription 
Documented OTC analgesia 
Name Formulation Dose and Route Date of initial 
Frequency prescription 
Present programme of treatment (other than drug therapy) 
Type of therapy Yes INo Details of therapy 
Physiotherapy 
Occupational 
therapy 
Surgery , 
I 
Psychological 
support I 
Other 
I 
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Previous programme(s) of treatment used (other than drug therapy) 
Type of therapy Yes/No Details of the~ Date oftheraJlj' 
Physiotherapy 
Occupational theraH 
Surgery 
Psycholo2ical sUJ!l!ort 
Other 
Previous alternative drug therapy used for chronic pain 
Name of Formulation Dose and Route Date of initial 
alternative Frequency prescription 
therapy 
Details of other prescribed medication 
Name Formulation Dose and Route Date of initial 
Frequency prescription 
Social history: _____________ ---------
Relevant Biochemistry 
Haematological Data Biochemistry Other data 
Date Date Date 
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Appendix 8: Pain Questionnaire 
ID Number: 
Date of interview: 
Time: 
Pain Diagnosis: 
Assessment of Pain 
McGill Pain Questionnaire (Melzack 1975) 
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McGi(~ Pain Questionnaire 
Patient's Nern _______________ _ 0". --_____ Tim. ____ A 
.""Jjm 
PAr: S A ---___ E 
(1-fO) -(11-1S) ---(-'e-)--- ... M-----_ PA!(Tl PPI_ (17-201 
\ FLICKERING 
OUWERING 
PU~S'NG 
THR08SING 
Be ATING 
POUNCING 
:2 JUMP'NG 
Fl.ASH'lfG 
SHOOTlHG 
3 PR'C~'NG 
BORING 
ORILLINO 
STAS!IHG 
~ SM-'RP 
CUTTeNQ 
l."CERA nNCl 
5 PINCH'NG 
P~~SSI"G 
GNAWING 
CRAMPINC 
CRUSHINQ 
6 TUGGING 
PUI..'-'NQ 
YlREWCHING 
7 ,",OT 
BURNING 
SCAt. alflG 
SE"ARIN'G 
8 TINGliNG 
ITCH't 
SM"RTINQ. 
STINGING 
e OULl. 
SORE 
WURTIMG 
"CHING 
WE""" 
'0 if:HDER 
7'-U1 
RASPING 
SPUrTING 
" TIRING 
EXWAUSTING 
1:Z SICI(ENIHG 
SUFFOCATING 
t3 FE'AAF'Ot. 
FRtGHrF'(Jt. 
TERArf"Y/HG 
,. PUNtS 11 1 "'Ci 
CiIlV~l.L1NQ 
CIIU£J. 
YICIOUS 
KIlLING 
'5 WRETCM(D 
8\.INO''''0 
f 6 ANNOl'ING 
TROUBl.ESOME 
INT£NSE 
IJNS£ARAlloE 
17 SPRE AOIHG 
FUDIATIHG 
PENETRATING 
PIERCING 
18 TlGHf 
NUMB 
DRAWING 
SOUEEZINQ 
TeARING 
19 COOl. 
COt-D 
"~EEZING 
20 NAGGING 
N'AUSE"TttfG 
AGONIZ.'NG 
DRE"OFV\. 
TORtUAINQ 
"PI 
o NO PAIN 
MILO 
2 DISCO .... FOATIHG 
3 OIS TRESS{HG 
• HORAl8\.£ 
5 EXCRVCIATING 
8R'EI" 
1.40 .... eNTARY 
TRA"SU:NT 
COMMENTS: 
Visual analogue scales - see Appendix 9 
RW\,THo\fIC 
PE"AIOOIC 
IHTERW/T'TEHT 
E : EXTERN",-
I = INTERNAL 
CONTINUOUS 
STEADY 
CONSTANT 
For the following questions, please indicate whether you STRONGLY AGREE, 
AGREE, are UNCERTAIN, DISAGREE or STRONGLY DISAGREE with each 
statement. 
Please circle the box containing your choice 
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2. Doctors know what is right for their patients 
Strongly 
agree 
Agree Uncertain 
3. Most patients benefit from taking painkillers for pain 
Strongly 
agree 
Agree Uncertain 
4. Taking medicines like painkillers is unnatural 
Strongly 
agree 
Agree Uncertain 
5. Medicines prescribed by your doctor are safe to take 
Strongly 
agree 
Agree Uncertain 
6. Patients should try to control their own pain 
Strongly 
agree 
Agree Uncertain 
7. Painkillers help you cope with normal life 
Strongly 
agree 
Agree Uncertain 
Disagree 
Disagree 
Disagree 
Disagree 
Disagree 
Disagree 
Strongly 
disagree 
Strongly 
disagree 
Strongly 
disagree 
Strongly 
disagree 
Strongly 
disagree 
Strongly 
disagree 
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8. Taking painkillers for a long time can cause side effects 
Strongly Agree Uncertain Disagree 
agree 
Strongly 
disagree 
Indicate how much the statements listed below apply to you over the past 4 weeks, 
using the scale below. 
Not a lot A little A fair amount A lot 
o 1 2 3 
9. I have difficult in walking 
10. I have difficulty doing household chores 
11. I have difficulty sleeping 
12. I fmd food unappealing 
13. I frequently feel anxious 
14. I frequently feel depressed / upset 
15. I frequently feel lonely 
16. I frequently feel frustrated 
17. My enjoyment of life is not what it was 
18. I do not have enough activities to fill the day 
19. I would like to get out of the house more 
20. I fmd friends / relatives have difficulty in talking to me 
about my pain 
Very much 
indeed 
4 
21. I have difficulty in planning activities because of my pain -----
22. My pain has greatly affected my work 
23. What do you think is the cause of your pain? 
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24. How effecti~e do you think a pain treatment should be in relieving pain? 
(Mark a pOint on each of the scales below which you feel best describes the 
amount of relief a painkiller should provide) 
No 0 
relief 
10 20 30 40 50 60 70 80 90 100% Complete 
pain relief 
1. Provide complete relief 
2. Relieve pain as much as possible 
3. Relieve pain enough top cope with daily activities 
4. Relieve pain enough to sleep 
5. Other 
25. What treatment are you receiving from your doctor for your pain? 
26. Do you use this treatment I medicine regularly or just when you feel that you 
need it? 
Medicine / Treatment Regular = 1/ As required = 2 
27. 
28. 
Do you always take the number of tablets I capsules I volume of syrup etc. 
per day that your doctor has prescribed? (for each treatment) 
Yes INo 
If' No', is it a higher dose you take? 
If 'No', is it a lower dose you take? 
Reasons for change in dose: 
Have you ever felt that you needed a dose much higher than the prescribed 
dose of painkiller? Yes / No 
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If ' Yes', reasons why: 
29. Have you ever forgotten to take your medicine or run out of it before you 
could get more? 
Yes / No 
If 'Yes', what happened? 
30. When do you take your medicine prescribed by your doctor? (in relation to 
food / time of day?) 
31. When you collect your medicine from the chemist, do you ever get an 
information leaflet? 
32. 
Yes / No 
If ' Yes' , did you read it? Yes / No 
If' Yes', how useful did you fmd it in providing information? 
Do you buy any medicines from your chemist to help pain relief, as well as 
your prescribed medicines? 
Yes / No 
If 'Yes', please specify 
If 'Yes', how often do you use this medicine? 
33. Do you buy any medicines from your chemist to help pain relief, instead of 
your prescribed medicines? Yes / No 
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If 'Yes', please specify 
If 'Yes', how often do you use this medicine? 
34. ~o you buy any alternative therapies e.g. herbal or homeopathic to treat 
your pam? ' 
Yes / No 
If 'Yes', please specify 
If ' Yes', how often do you use this medicine? 
35. How much relief do your pain treatments and / or medications provide? 
(Mark on the scales below how much relief you do receive) 
No 0 10 20 30 40 50 60 70 80 90 100% Complete 
relief pain relief 
1. Provide complete relief 
2. Relieve pain as much as possible 
3. Relieve pain enough top cope with daily activities 
4. Relieve pain enough to sleep 
5. Other 
36. Have you ever experienced any problems which you think could be due to 
your medicine? 
For questions 37-40, please c;rcleyour most appropriate answer 
37. People can be addicted to painkillers Yes / No / Don't know 
38. Persistent pain can make you feel depressed Yes / No / Don't know 
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39. Exercise can relieve chronic pain Yes / No / Don't know 
40. Pain can continue after healing has taken placeYes / No / Don't know 
41. Are there any other methods of treatment which you would like to fmd out 
about to help your pain control? 
Yes / No 
If 'Yes', please specify 
42. How satisfied are you with your pain control? 
Dissatisfied Very 
dissatisfied 
Completely Very Moderately 
1 2 3 4 5 
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Appendix 9: Visual analogue scales used to assess pain intensity 
Pain intensity 
I.Please rate your pain by placing a mark on the line at a point which represents 
your pain at its WORST in the last month (VAS worst) 
No Pain Pain as bad as you can 
imagine 
2. Please rate your pain by placing a mark on the line at a point which represents 
your pain on A VERAGE (VAS average) 
No Pain Pain as bad as you can 
imagine 
3.Please rate your pain by placing a mark on the line at a point which represents 
your pain RIGHT NOW (VAS now) 
No Pain Pain as bad as you can 
imagine 
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Appendix 10: Copy of the letter sent to each study pharmacist, GP 
and physiotherapist to assess the role(s) of the healthcare team in 
chronic pain management 
School of Pharmacy 
Faculty of Health and Food 
Schoolhill 
Aberdeen 
AB91FR 
24 January 1996 
Dear Colleague, 
I am currently investigating the role of the pharmacist in the management of chronic 
pain in the community, as part of my research into the management of chronic pain. 
Over the last two years, I have been working with GPs in Lanarkshire and Aberdeen, 
investigating GP management and patient perception of chronic pain. Patients with 
chronic pain were interviewed in their own homes after I obtained details of 
concomitant medical problems and relevant drug therapy details from medical notes. 
Twenty-eight of the 96 patients had poor pain control and / or quality of life. 
Recommendations were made to GPs concerning therapy changes in 14 patients, 12 
of which were acted on, after which pain control improved in nine patients. The GPs 
involved in the study, appreciated the pharmaceutical contribution to patient care, 
especially in the provision of drug information to patients. 
I am very interested to fmd out your views, regarding the present and potential 
clinical roles of pharmacists in the community, particularly with respect to the 
management of chronic pain. All information which you will provide will be kept 
strictly confidential. 
I would be grateful if you would complete the enclosed questionnaire and send it to 
me, in the stamped-addressed envelope provided, by 29 February 1996. 
I look forward to receiving your questionnaire. Thank you very much for your time 
and effort. 
Yours sincerely 
Rhona WRead 
Teacher- Practitioner 
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Appendix 11: Questionnaire sent to community pharmacists to 
assess the role(s) of the healthcare team in chronic pain 
management 
Section A Personal Information 
In which year did you register as a pharmacist? 
Do you work as a community pharmacist 
If part time, do you have other employment as a 
full time 0 
as a locum 0 
part time 0 
hospital pharmacist 0 
academic pharmacist 0 
How many phannacists work in your phannacy at anyone time? _____ _ 
Section B Your Pharmacy's Current Clinical Activities 
Please indicate by a tick which of the following services your pharmacy 
provides: 
Advice on prescribed 
medicines 0 
Development of treatment 
protocols 0 
Therapeutic drug 
monitoring 
o 
Advice on OTe 
medicines 0 
Anticoagulant monitoring 
o 
Involvement in a pain 
clinic 
o 
Advice to GPs about 
prescribing 0 
Involvement in an 
asthma clinic 0 
Other (please specify) 
Please indicate, by ticking, how often you contact a GP to : 
most 2-3 times once a once a less than 
days a week week month monthJy 
Clarify a dosing regime 
or dru2 indication 
Propose a change in 
therapy to improve 
patient outcome 
Report a side effect 
experienced by a patient 
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Inform GP about a 
patient's request 
Report a drug 
interaction between 
prescribed and I or OTC 
medications 
How do you usually contact a GP about patients' prescribed medicines? 
(please tick any method which you have used) · 
telephone o personal visit to surgery 0 letter 0 
How many of your suggestions have been received? 
always ignored 
acted on all 0 
o acted on a few 0 acted on most 0 
don't know whether action taken 0 
Please add any other comments you may have about GP's responses. 
fax 0 
Section C Increasing Your Pharmacy's Clinical Activities 
Please tick any of the factors listed below which you feel are preventing you 
from developing your role in the management of chronic pain 
Patient expectation of pain control 0 Limited access to 0 
up-to-date drug information 
Poor patient compliance 0 Limited expertise in a 0 
multidisciplinary care team 
Poor agreement with 0 
patient regarding pain management 
Excessive workload 0 
Limited access to pain clinics and / or 
pain specialists 
o Limited opportunity to get 0 
involved in a multidisciplinary 
care team 
Which, if any, of the following mechanisms of improving the treatment of 
patients with chronic pain, would you consider staff in your pharmacy could 
use? 
Advising patients on their prescribed medicines in the pharmacy 
Advising individual patients about OTe or other means of relieving pain 
o 
o 
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Advising individual patients about their use of medicines in their own homes 
Contributing to treatment protocols devised by local GPs 
Please indicate b! a tick in which of the following areas of pharmaceutical 
care you would lake to be more involved? 
o 
o 
Inhaler counselling and asthma advice 0 Drug management of chronic pain 0 
Involvement in an anticoagulant clinic 0 Patient compliance 
Nutrition o Other (please specify) 
Section D Your views on the management of chronic pain 
Who do you think should be involved in the management of chronic pain? 
(please tick as appropriate) 
GP 0 Anaesthetist 0 Pharmacist 0 Clinical Psychologist 0 
PhysiotherapistD Occupational Therapist 0 Other 
-------
o 
For the following questions, please indicate by a tick whether you STRONGLY 
AGREE, AGREE, are UNCERTAIN, DISAGREE or STRONGLY DISAGREE 
with each statement below. 
Most patients comply with your advice 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patient compliance is increased if patients understand your explanation 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Some patients want to control their own pain and don't comply with your advice 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
A patient with chronic pain exaggerates the pain which hel she feels 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patients generally view pharmacists as shopkeepers, not part of the health care team 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
More patients are self-medicating to improve control of chronic pain 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patients with chronic pain who are depressed often have poor pain control 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
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Patients with chronic pain usually know very little about the management options for chronic 
pain 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
A treatment plan for the control of chronic pain, should be agreed upon by a multidisciplinary 
care team 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Treatment guidelines improve cost-effective prescribing 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Thank you for completing this questionnaire 
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Appendix 12: Questionnaire sent to GPs to assess the role(s) of the 
health care team in chronic pain management 
Section A Personal Information 
How many GPs, in total, work in your practice at anyone time? (please specify 
number) 
How many patients are registered in your practice? (please specify number) 
Is your practice fundholding? Yes 0 No 0 
Section B Management of Chronic Pain 
Please tick any of the factors listed below which you feel are preventing you 
from optimising control of chronic pain 
Patient expectation of pain control 0 Limited access to 0 
up-to-date drug information 
Poor patient compliance 0 Limited expertise in a 0 
multidisciplinary care team 
Poor agreement with 0 Excessive workload 0 
patient regarding pain management 
Limited access to pain clinics and / or 0 ~imited opportuni~ .to ~e~ 0 
pain specialists mvolved m a multIdlSClplmary care team 
How often do you refer patients to a pain clinic? 
Never 0 Occasionally 0 Frequently 0 
Do you use treatment guidelines for the management of chronic pain within 
your practice? 
Yes 0 No 0 
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If 'Yes', which guidelines do you use? 
British National Formulary guidelines 0 Pain clinic guidelines 0 
Other (please specify) Local treatment protocol within your practice o 
Do y~u have a multidisciplinary team involved in pain control °thO practice? WI In your 
Yes 0 No o 
If 'Yes', who is involved in your team? (please tick as appropriate) 
GP 0 Anaesthetist 0 Pharmacist 0 Clinical Psychologist 0 
Physiotherapist 0 
Occupational Therapist 0 Other 
-------
If 'No', why is there no team involvement in the control of chronic pain? 
(please tick the most appropriate) 
Lack of expertise o Lack of interest 0 Lack of money 0 
No time to create a team 0 Other 
------
Section C The Role of the Pharmacist 
What role(s) ,if any, would a pharmacist have in a multidisciplinary team? 
(please select the most appropriate descriptor(s» 
Dispensing of medication 
Provision of drug information 
to patients 
Reviewing medication 
o No roleO 
o Drug history taking in a clinic session 0 
o Other 
-------
Please tick any of the professional situations below, in which you have you 
found a pharmacist helpful 
Ensuring the legality of a prescription 
o 
Supplying of medication for GP use 
o 
Discussion of treatment options 
o 
Development of GP formulary guidelines 
Cl 
Supply of medication or information 
o 
to patients 
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Practice research projects 
o 
Methods to improve compliance 
o 
Section D Your views on the management of chronic pain 
For the following questions, please indicate by a tick whether you STRONGLY 
AGREE, AGREE, are UNCERTAIN, DISAGREE or STRONGLY DISAGREE 
with each statement below. 
Most patients comply with your advice 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patient compliance is increased if patients understand your explanation 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Some patients want to control their own pain and don't comply with your advice 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
A patient with chronic pain exaggerates the pain which hel she feels 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patients generally view pharmacists as shopkeepers, not part of the health care team 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
More patients are self-medicating to improve control of chronic pain 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patients with chronic pain who are depressed often have poor pain control 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
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Patients with chronic pain usually know very little about the management options for chronic 
pain 
Strongly agree 0 Agree o Uncertain 0 Disagree 0 Strongly disagree 0 
A treatment plan for the control of chronic pain, should be agreed upon by a multidisciplinary 
care team 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Treatment guidelines improve cost-effective prescribing 
Strongly agre 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Thank you for completing this questionnaire 
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Appendix 13: Questionnaire sent to physiotherapists to assess the 
role(s) of the healthcare team in chronl-c pal-O management 
Section A Personal Information 
In which year did you register as a physiotherapist? 
Do you work within a GP practice? YesD No 0 
If 'Yes', how many GPs are in your practice? 
Is your GP practice within a health centre? Yes 0 No 0 
What is your major source of employment? 
Hospital Trust 0 (please state division) 
Employed by a GP practice 0 ---
Other 
-----
Section B Management of Chronic Pain 
Please tick any of the factors listed below which you feel are preventing you 
from optimising control of chronic pain 
Patient expectation of pain control 0 
Poor patient compliance 0 
Poor agreement with 0 
patient regarding pain management 
Limited access to 
up-to-date drug information 
Limited expertise in a 
multidisciplinary care team 
Excessive workload 
o 
o 
o 
Limited access to pain clinics and / or 0 
pain specialists 
Limited opportunity to get 0 
involved in a multidisciplinary care team 
Mr CF (46) is visiting his GP for the first time, having suffered from 
intermittent low back pain for the past 6 months. ( DO significant medical or 
surgical history). The pain has been increasing in intensity on bending and 
lifting over the past 4 weeks. He has been taking regular paracetamol with little 
effect_ 
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What management would you suggest? 
When should Mr CF be reviewed by you after initial GP referral? 
< 2 weeks o >2 < 4 weeks 0 > 4 < 8 weeks 0 > 8 < 12 weeks 0 
How often do you refer patients to a pain clinic? 
Never o Occasionally 0 Frequently o 
Do you use treatment protocols for the management of chronic pain? 
Yes 0 No o 
If 'Yes', which protocols do you use? 
Physiotherapy protocols 0 Pain clinic guidelines 0 
Local treatment protocol within your 0 
practice 
Other (please specify) 
Do you have a multidisciplinary team involved in pain control within your GP 
practice I health centre? 
Yes 0 No o 
If 'Yes', who is involved in your team? (please tick as appropriate) 
GP o Anaesthetist 0 Phannacist 0 Clinical Psychologist 0 
Physiotherapist 0 Occupational Therapist 0 Other ______ _ 
If 'No', why is there no team involvement in the control of chronic pain? 
(please tick the most appropriate) 
Lack of expertise o Lack of interest 0 Lack of moneyD 
No time to create a team 0 Other _____ _ 
What role(s), if any, would a pharmacist have in a multidisciplinary team? 
(please select the most appropriate descriptor(s» 
Dispensing of medication 
Provision of drug information 
Reviewing medication 
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o No role o 
o Drug history taking in a clinic session 0 
o Other 
Section C Your views on the management of chronic pain 
For the following questions, please indicate by a tick whether you STRONGLY 
AGREE, AGREE, are UNCERTAIN, DISAGREE or STRONGLY DISAGREE 
with each statement below. 
Most patients comply with your advice 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patient compliance is increased if patients understand your explanation 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Some patients want to control their own pain and don't comply with your advice 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
A patient with chronic pain exaggerates the pain which hel she feels 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patients generally view pharmacists as shopkeepers, not part of the health care team 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
More patients are self-medicating to improve control of chronic pain 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patients with chronic pain who are depressed often have poor pain control 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Patients with chronic pain usually know very little about the management options for chronic 
pain 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
A treatment plan for the control of chronic pain, should be agreed upon by a multidisciplinary 
care team 
Strongly agree 0 Agree o Uncertain 0 Disagree 0 Strongly disagree 0 
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Treatment guidelines improve cost-effective prescribing 
Strongly agree 0 Agree 0 Uncertain 0 Disagree 0 Strongly disagree 0 
Thank you for completing this questionnaire 
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Appendix 14: Case study 1 - Mrs RS (60 years) 
Patient concordance with therapy 
Diagnosis: Severe RA affecting most hand, knee, hip and shoulder joints. 
Concomitant problems: hypothyroidism, coeliac disease, dyspepsia / reflux, 
asthma, eye cysts and constipation. 
Previous adverse drug reactions: Sulphasalazine (nausea, vomiting and severe 
headaches), etodolac (palpitations), mefenamic acid (severe nausea, vomiting and 
diarrhoea), hydroxychloroquine (nausea, diarrhoea and increased muscle pain), 
penicillin ( severe diarrhoea). 
Current therapy for RA: Fenbufen capsules 300mg tid, coproxamol 2 pm (usually 
2 in the morning and 2 at night), traimcinolone injection 20-80mg intra-articularly 
three times a month if needed and prednisolone 7.5mg daily. 
Concomitant therapy: Docusate tablets 200mg nocte, Gastrocote tablets 2 pm, 
thyroxine 200mcg mane, Fybogel Orange 1 sachet twice daily, chloramphenicol eye 
ointment 1 % applied nightly to both eyes, gluten free products. 
Comments from Mrs RS: 'I have problems relating to my consultant - 1 feel that I 
have been badly treated. I'm worried about the side effects of the second line agents 
which he has recommended. 1 don't want to try sulphasalazine again. Doctors don't 
always know what is right for their patients. Taking medicines like painkillers is 
unnatural but 1 need them to relieve the pain. 1 strongly agree that patients should try 
to control their pain. 
1 usually take a lower dose of coproxamol than is prescribed to titrate the pain and 
reduce drowsiness and constipation. 1 have felt 1 needed a much higher dose of 
something at times when the pain is especially bad. 1 am keen to try some 
homeopathy products- I'm going to try them daily and get help with the foods I 
should try to avoid. 
Factors limiting adherence to GP recommendations: distrust of consultant, 
previous adverse drug reactions to NSAIDs and DMARDs, side effects of current 
therapy limiting compliance, keen to self-medicate, reduced dose of prescribed 
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therapy. 
Action by pharmacist: Provided more evidence-based information and reassurance 
regarding the pros and cons ofDMARDs in RA. Discussed the implications of 
starting homeopathic therapy and the evidence available to support its long-tenn use 
inRA. 
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Appendix 15: Case study 2 - Mr DF (38years) 
Analgesic discrepancies in medical records 
Diagnosis: RA associated with peripheral arthritis, ankylosing spondylitis, retinal 
vasculitis and panuveitis 
Concomitant problems: glomerulosclerosis. 
Adverse drug reactions: Interstitial nephritis (secondary to NSAIDs). 
RA therapy documented in medical notes: Naproxen 500mg bd, coproxamol 2 
every 6 hours, prednisolone IOmg daily and cyclosporin 500mg daily. 
RA therapy actually taken at time of interview: Coproxamol 1 in the morning and 
1 at night (2 as a stat dose caused drowsiness), cyclosporin 250mg daily and 
prednisolone 2.5mg daily. 
Reasons for discrepancies between medical notes and doses taken: Cyclosporin 
and prednisolone dosages reduced at last rheumatology clinic visit, but not updated 
in medical records. Patient's preferences regarding dosage and frequency not 
documented in records. Naproxen had been immediately discontinued after the 
diagnosis ofNSAID induced interstitial nephritis was made, but again drug details 
in medical notes were not updated. Both patient, GPs and rheumatologist involved in 
the patient's care were all aware of the amendments, but no record was available for 
any other health professional to use to review progress. 
Potential implications of the discrepancies: Restarting ofNSAID and potential 
exacerbation of renal disease. Continuation of high doses of cyclosporin and 
prednisolone associated with a risk of increased renal toxicity and 
immunosuppression. 
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Appendix 16: Case study 3 - Mrs MA (54 years) 
Pain disease states: RA, Cervical spondylosis. 
Duration of pain states: RA (4 years), Cervical spondylosis (9 years). 
Other relevant medical history: Thrombocytopenia (secondary to penicillamine therapy in 
1993), tinnitus (March 1993), tension headaches since 1973, anxiety. 
Relevant drug history: 
Salazopyrin from Aug 1990; Feb 1993 thereafter ineffective. 
Prednisolone from Aug 90- Aug 1992 for acute exacerbations. 
Penicillamine started in Feb 1993- rash and pruritus developed in March and Apri11993. Rash 
attributed to Nabumetone therapy- discontinued. Thrombocytopenia Oct 93 (penicillamine 
discontinued). Platelet count recovered- penicillamine restarted in Nov 1993. 
Intra-articular triamcinolone - July 93 for acute flare up. 
Risk factors to compliance: previous adverse drug reactions, otherwise none 
Risk factors which may prevent optimisation of pain control: anxiety, previous ADR 
to NSAID (rash), previous ADRs to penicillamine (dizziness, thrombocytopenia, rash), reduced 
steroid efficacy. 
Risk factors for the development of side effects: previous ADR history, hiatus hernia. 
Prescribed analgesia and co-analgesia: 
Penicillamine 250mg daily on an empty stomach with water, dihydrocodeine 30mg 2 three times a 
day and paracetamol 1-2 if required when dihydrocodeine is ineffective. Also uses hand splints 
periodically. (Used to take cod-liver oil capsules-discontinued a year ago). 
Other concurrent medication: 
Ranitidine 300mg nocte, Daktacort Cream- to be applied three times a day on rash (if needed), 
Altacite tablets 1 if required. 
Compliance with medication as reported by patient: All medicines as above, but 
sometimes took penicillamine after food. 
Assessment by study pharmacist at first interview 
Expectations of pain relief: Mrs MA thought that ideally a painkiller should provide complete 
pain relief, but that was unrealistic. She would consider 50% pain relief to be effective and that 
treatment should relieve pain enough to cope with daily activities. 
, I sometimes still get needling pain. Doctors can't do miracles- I can't expect miracles. The doctors 
are doing their best'. 
Actual pain relief experienced: Mrs MA complained of increasing pain over the past few 
months in both wrists, hands, shoulders and legs.' The pain has been bad over the past couple of 
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months-sometimes exercise helps. 1 can't feel 1 can control the pain at the moment. 1 can't sit in the 
bath- have to stand up in the shower- even that is difficult at times' . 
'I am moderately satisfied with my pain control. My pain treatments provided 30% pain relief- been 
good before this past bout. The painkillers have just taken the edge off the pain'. 
Attitude to pain 
'Patients benefit from taking painkillers for pain, but it takes too long and you get immune. You need 
painkillers to ease the pain. You have got to try them (the medicines) to ease the pain although you 
know the side effects. 1 would try to control the pain if 1 could'. 
Assessment of pain using VAS and MPQ at Interview 1 (median score for n=96) 
VAS av = 70 ( 40), VAS worst over last month = 80 (70), VAS right now = 70 (30), 
NWC = 8 (6), PPI = 3 (2), PRI® = 21 (14), PRIeS) = 19.6 (14.5). 
Verbal descriptors used to describe the pain were: throbbing, shooting, sharp, aching, tiring, 
miserable, freezing and nauseating. 
Patient perception of disease states and medication 
Mrs MA was unsure as to when to take her penicillamine, but was aware of the signs and 
symptoms of the adverse reactions associated with her past and present medication. Needed 
clarification regarding the consequences of further adverse drug reactions and the need to monitor 
therapy closely especially penicillamine. Mrs MA also requested information about eligibility for a 
car parking ticket. 
Monitoring efficacy and toxicity of treatment 
Full blood count results were regularly recorded from past rheumatology clinic visits after 
penicillamine therapy was initiated. Pain scores and joint count scores were recorded at yearly 
intervals between 1991 and 1993. 
Advice given to patient 
Advised Mrs MA to continue to take penicillamine before food and to avoid taking antacids 
at the same time as penicillamine or iron supplements within 2 hours of penicillamine administration. 
Advised Mrs MA to refer immediately to her GP again if she developed sore mouth, ulcers, bruising, 
fever, malaise or the rash developed again. 
Discussed possible implications of revisions to therapy e.g. change ofDMARD therapy due to 
worsening pain and ADR risks and I or cautious reintroduction ofNSAID (the latter to control the 
acute inflammation). Encouraged Mrs MA to rest more and to use her splints, especially her hand 
splints more regularly. Provided information re driving eligibility. 
Pharmacist's recommendations to the GP 
Increased pain 
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Made the GP aware that Mrs MA was complaining of increased pain recently and discussed: (1) the 
implications of changing her DMARD therapy in the light of her worsening pain and risk of 
thrombocytopenia and (2) introducing an NSAID e.g. diclofenac not nabumetone (previous ADR?) 
for a short time to control the acute inflammation, monitoring her gastrointestinal status carefully and 
risk of any rash re-occurrence. 
GP response to pharmacist's recommendations 
GP accepted all the pharmacist's recommendations and discussed them with the patient's 
rheumatologist. Penicillamine was discontinued and hydroxychloroquine commenced. Regular 
dihydrocodeine was continued and paracetamol could be taken regularly if required. 
Patient outcomes as reviewed by pharmacist at second visit 
Expectations of pain relief 
Mrs MA still reported that she considered pain relief between 50- 60% to be effective and that 
treatment should relieve pain enough to cope with daily activities. 
Current therapy for pain: Hydroxychloroquine 200mg /400mg on alternate days, 
dihydrocodeine 30mg qid and paracetamol 2 at night if required (only took a max of 4 lday if 
needed). 
Actual pain relief experienced 
'I am moderately satisfied with my pain control. My pain treatments provide about 60% pain relief, 
enough to cope with daily activities. The pain in my fmgers has reduced, but I am experiencing 
headaches a bit more now.' 
Assessment of pain using the VAS and the MPQ at Interview 2 (comparative 
score at Interview 1) 
V AS av = 50(70), VAS worst over last month = 80(80), VAS right now = 50(70) NWC = 4 (8) 
(group median = 7), PPI = 2(3) (group median = 2), PRI® = 9 (21) (group median = 19), 
PRI (S) = 9.2 (19.6) (group median = 20.8). 
Verbal descriptors used to describe the pain were: throbbing, gnawing, tingling and tiring. 
Attitude to pain 
Mrs MA's attitude to her pain was slightly more positive post intervention (attitude score 
increased from 77 to 80). 
Assessment ofQOL at Interview 2 (comparative score at Interview 1) 
Total QOL score 34% (57%), physical score 50% (62%), social score 33% (50%), occupational score 
33% (67%), psychological score 19% (50%). 
All of Mrs MA's QOL parameters improved and her satisfaction with pain control was unchanged 
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(moderate). Total number of medications was unchanged (5). 
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Appendix 17: Case study 4 - Mrs DB (56 years) 
Pain disease states: Systemic sclerosis with polyarthropathy, synovitis ofleft knee. 
Duration of pain states: Systemic sclerosis-7 years. 
Other relevant medical history: Breast carcinoma-right mastectomy 1983, depression, deaf, 
Raynaud's disease, neuralgia due to brachial nerve injury Feb 86. 
Relevant drug history: Penicillamine started in July 1990 and increased in December 1990. 
Rash developed which was treated with terfenadine, then penicillamine discontinued Jan 93.Intra-
articular triamcinolone (July 87) for acute flare ups in left knee and shoulders. 
Risk factors to compliance: previous ADR to penicillamine, worried about side effects. 
Risk factors which may prevent optimisation of pain control: recurring neuralgia, 
depression, recent bereavement, worry about side effects of therapy, family problems. 
Risk factors for the development of side effects: regular NSAIDs, previous rash with 
penicillamine 
Prescribed analgesia and co-analgesia: 
Codydramol2 tablets up to 4 times a day if required, nabumetone Ig at night. Mrs D.B. also uses 
hand splints. 
Other concurrent medication: none. 
Compliance with medication as reported by patient: 
Nabumetone as above, but Mrs D.B. tends to only take up to 6 Codydramol tablets daily. 
Assessment by study pharmacist at first interview 
Expectations of pain relief: Mrs DB thought that a painkiller should provide complete pain 
relief with no side effects. 
Actual pain relief experienced: Mrs DB complained of increasing pain over the past few 
months in both wrists, hands, shoulders and toes.' The pain has been bad over the past couple of 
months since my husband died. It can vary from distressing at worst to mild at best. I am moderately 
satisfied with my pain control. My pain treatments provided 50% pain relief enough to cope with 
daily activities.' 
Attitude to pain and pain management and influence of pain on activities of 
- 257-
daily living 
'I strongly disagree that doctors know what is right for patients. I strongly believe that patients 
benefit from taking painkillers, and they are generally safe to take, but I am worried about the side 
effects. When my consultant spoke to me about starting a new treatment, I didn't tell him or my GP 
about the worries I had about the possible side effects. My GP was more worried about my 
depression. 
I try to reduce my intake of codydramol according to my daily activities. If I am washing or ironing I 
need 8 a day, but if I am just sitting I take 4 a day. Once I take the painkillers, I can cope with the 
activity but feel very tired afterwards and further activity is still limited. I was made aware frorn the 
Relifex leaflet that it can cause constipation, which was helpful to know. 
Assessment of pain using VAS and MPQ at Interview 1 (median score for 0=96) 
V AS av = 50 ( 40), VAS worst over last month = 80 (70), VAS right now = 50 (30) 
NWC = 17 (6), PPI = 2 (2), PRI® = 35 (14), PRI (S) = 43.6 (14.5) 
Verbal descriptors used to describe the pain were: shooting, pricking, sharp, gnawing, searing, itchy, 
heavy, tender, exhausting, sickening, fearful, cruel, troublesorne, spreading, tight, freezing and 
naggmg. 
Assessment of QOL at Interview 1 (median score for n=96 as % of maximum 
score) 
Total QOL score 62% (28%), physical score 62% (31 %), social score 67%, occupational score 50% 
(33%), psychological score 69 (25%). 
'I feel pretty depressed at the mornent, since rny husband died just a few weeks ago. I would 
desperately like to get out of the house rnore - my family are a real worry to rne'. 
Patient perception of disease states and medication 
Mrs DB was very wary about restarting a second line agent despite her deteriorating signs and 
symptoms, unsure of the benefits of DMARD therapy and worried about their potential side effects. 
Advice given to patient 
Advised Mrs DB to continue to take her nabumetone after food and use up to 8 codydramol per day 
without undertreating her pain. 
Advised Mrs DB to follow her OP's advice and commence a DMARD therapy Discussed the 
monitoring of and the benefits and problems associated with DMARDs. Encouraged Mrs DB to rest 
more, contact her family and use her splints more. Provided information about bereavernent and 
support groups. 
Pharmacist's recommendations to the GP 
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Increased pain 
Made the GP aware that Mrs DB was less worried about co . 
mmencmg a DMARD therapy and had 
been given infonnation about local support groups. Discussed th. . 
e most SUitable DMARD m tenns of 
patient and disease factors. 
GP response to pharmacist's recommendations 
GP accepted all the pharmacist's recommendations after further discussion 
with the patient's rheumatologist. 
Hydroxychloroquine was commenced. 
Patient outcomes as reviewed by pharmacist at second visit 
Expectations of pain relief 
Mrs DB reported that she expected complete pain relief as at Interview 1. 
Current therapy for pain: Hydroxychloroquine 200mg / 400mg on alternate days, 
nabumetone 1 g at night and codydramol 2 qid pm. 
Actual pain relief experienced 
'I am moderately satisfied with my pain control. My pain treatments now provide me with about 50% 
pain relief .... as much as possible'. 
Assessment of pain using the VAS and the MPQ at Interview 2 (comparative 
score at Interview 1) 
VAS av = 50 (50) (group median = 40), NWC = 15 (17) (group median = 7), PPI = 2(2) (group 
median = 2), PRJ® = 31 (35) (group median = 19), PRJ (S) = 40.3 (43.6) (group median = 20.8). 
Verbal descriptors which had also been used to describe the pain at Interview 1 were: shooting, 
stabbing, sharp, gnawing, tingling, hurting, tender, exhausting, sickening, cruel, wretched, annoying, 
piercing, numb and nagging. (The tenns 'fearful' and 'wretched' were omitted during Interview 2). 
Attitude to pain 
Mrs DB's attitude to her pain was slightly more positive post intervention (attitude score increased 
from 63 to 71). 'I now see that doctors do know what is right for patients, but don't feel that 
prescribed medicines are always safe to take'. 
Assessment of QOL at Interview 2 (comparative score at Interview 1) 
Total QOL score 43% (62%), physical score 38% (62%), social score 67% (67%), occupational score 
50% (50%), psychological score 25% (69%). 
Mrs DB's overall QOL, physical and psychological status had improved, which was reflected in 
respectively lower total QOL, physical and psychological scores. 'I feel much less depressed at the 
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moment. The groups are helping me and my family is supporting me more. I don't seem to feel quite 
as frustrated at the moment and my walking has improved slightly. 
Mrs DB was moderately satisfied with her pain control (score of3 was unchanged), and her attitude 
to the pain was more positive (attitude score increased from 63 to 71% of maximum score). 
The total number of medications was increased from 2 to 3. 
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Appendix 18: Case study 5 - Mrs AT (62years) 
Pain disease states: Seropositive RA. 
Duration of pain states: Seropositive RA (2 years). 
Other relevant medical history: Acute closed angle glaucoma Dec 93, dry eye syndrome. 
Relevant drug history: Sulphasalazine E/C, Traxam gel, cocodamol and cimetidine started in 
Nov 92. Sulphasalazine daily dosage gradually increased to 2.5g daily as joint pain increased. Intra-
articular methyprednisolone (Feb 93) for acute flare up in left knee. 
Risk factors to compliance: large decrease in FBC at last clinic visit. 
Risk factors which may prevent optimisation of pain control: none. 
Risk factors for the development of side effects: Decreased FBC 
Prescribed analgesia and co-analgesia: 
Cocodamol dispersible tablets 2 tablets every 8 hours if required, nabumetone 500mg in the morning 
and Ig at night and sulphasalazine e/c 2.5g daily (500mg 5xday). 
Other concurrent medication: cimetidine 400mg nocte, Tears Naturale 1-2 drops both eyes 
pm, Pilocarpine 1 % 2 drops in right eye qid. 
Compliance with medication as reported by patient: As above. 
Assessment by study pharmacist at first interview 
Expectations of pain relief: Mrs A.T. thought that a painkiller should provide 80% pain relief 
to relieve pain as much as possible. 
Actual pain relief experienced: Mrs AT complained of increasing pain over the past few 
months in both wrists, hands, shoulders and toes.' The pain has been increasingly worse over the past 
few months. It can vary from horrible at worst to discomforting at best. I am dissatisfied with my 
pain control at the moment and need to get back to the RA clinic. My pain treatments only provide 
about 55% pain relief enough to cope with daily activities.' 
Attitude to pain and pain management and influence of pain on activities of 
daily living 
'I strongly agree that doctors know what is right for patients. Although I believe that patients benefit 
from taking painkillers, you don't always get relief during acute bouts. You need painkillers to help 
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the pain- they are not always safe to take. Some NSAIDs cause indigestion but R l' c. • OK 
e hex IS •••. now 
I have this blood count problem. People with RA know what to do but 1 don't think we should try to 
control our pain. 
Assessment of pain using VAS and MPQ at Interview 1 (median score for n=96 
) 
VAS av = 70 (40), VAS worst over last month = 90 (70), VAS right now = 60 (30) NWC = 15 (6), 
PPI = 3 (2), PRI® = 34 (14), PRIeS) = 44.1 (14.5). 
Verbal descriptors used to describe the pain were: throbbing, boring, sharp, gnawing, wrenching, 
burning, aching, exhausting, sickening, fearful, vicious, wretched, miserable, spreading and 
nauseating. 
Assessment of QOL at Interview 1 (median score for n=96 as % of maximum 
score) 
Total QOL 71% (28%), physical score 62% (31%), social score 67% (25%), occupational score 83% 
(33%), psychological score 75% (25%). 
'1 have been feeling generally unwell recently. 1 possibly need some changes in my therapy'. 
Patient perception of disease states and medication 
Mrs AT had a very good awareness of the rationale of treatment (patient attitude score 83% of 
maximum) and was aware of the deterioration in her symptoms especially pain control and the need 
to change her DMARD to improve efficacy and minimise any further drop in full blood count. 
Advice given to patient 
Advised Mrs AT to continue to take her nabumetone after food and use up to 8 codydramol per day 
to try to control pain while her DMARD therapy was being reviewed. 
Advised Mrs AT to report any sort of indigestion or gastric problems to her GP (no previous GI 
problems). 
Pharmacist's recommendations to GP 
Increased pain 
Made the GP aware that Mrs AT's symptoms were worsening and referral to Mrs AT's 
rheumatologist was needed to review DMARD therapy. Discussed the most suitable DMARD in 
tenns of patient and disease factors. 
GP response to pharmacist's recommendations 
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GP accepted aU the pharmacist's recommendations after discussm' g th 'th th ., em WI e patient s 
rheumatologist. Sulphasalazine was discontinued and d peru'cill . 
- amme was commenced. 
Patient outcomes as reviewed by pharmacist at second visit 
Expectations of pain relief 
Mrs AT reported that she expected 95% pain relief with treatment (slightly higher expectations than 
at Interview 1). 
Current therapy for pain: D-Penicillamine 500mg daily, nabumetone 500mg in the morning 
and Ig at night and cocodamol dispersible tablets 2 every 8 hoW'S pm. 
Actual pain relief experienced 
'I am now moderately satisfied with my pain control. I have pain all the time now, it's hard for me to 
describe how I feel- at the moment it's mild, thank goodness'. 1 couldn't do without the medication of 
Relifex and penicillamine. My rheumatologist frrst put me on them and I have been feeling a lot 
better. My pain treatments now provide me with about 80% pain relief .... as much as possible.' 
Assessment of pain using the VAS and the MPQ at Interview 2( comparative 
score at Interview 1) 
VAS av = 70(70) (group median = 40), NWC = 6 (15) (group median = 7), PPI = 1(3) (group median 
= 2), PRI® = 13 (34) (group median = 19), PRJ (S) = 14.0 (44.1) (group median = 20.8). 
Verbal descriptors used to describe the pain were: throbbing, boring, hot, aching, tiring and annoying. 
Attitude to pain 
Mrs AT's attitude to the pain was less positive (attitude score decreased from 83 to 77% of maximum 
score). 'I'm now not sure if doctors know what is right for their patients, but believe that the 
medicines they give you are safe to take--- you've just got to be careful with them long-term. We 
shouldn't try to control our own pain.' 
Assessment of QOL at Interview 2 (comparative score at Interview 1) 
Total QOL score 70% of maximum score (71%), physical score 56% (62%), social score 58% (67%), 
occupational score 42% (83%), psychological score 19% (75%). 
Mrs AT's mobility and psychological status had improved, which was reflected in respectively lower 
physical and psychological scores. Her improved pain control allowed her to do more activities. 
Mrs AT was more satisfied with her pain control (score was changed from 4 to 3). The total number 
of medications was unchanged (6). 
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Appendix 19: Case Study 6 - Mrs RW (65 years) 
Pain disease state: OA. 
Other relevant medical history: Frozen shoulder reactive hypom· dary 
, arua secon to surgery, 
anxiety, insomnia, constipation, ankle oedema. 
Risk factors to compliance: poor English, confusion, anxiety, multiple medication. 
Risk factors which may prevent optimisation of pain control: more than 1 NSAID 
prescribed on computer, concurrent CNS depressant therapy, confusion regarding maximwn dosage 
ofNSAID therapy, overweight, heavy smoker (more rapid clearance) easily stressed by family, 
insomnia. 
Risk factors for the development of side effects: patient use of more than 1 NSAID (GI 
problems), concomitant use ofCNS depressants (increased confusion), late diuretic use (diuresis at 
night), poor understanding of medication leading to overuse ofNSAID. 
Prescribed analgesia and co-analgesia: 
Naproxen tablets 500mg bd, diflunisal tabs 500mg bd, cocodamol2 daily, mianserin lOmg nocte, 
nitrazepam 5-10mg nocte, phenobarbitone 30mg bd. 
Other concurrent medication: 
Burinex K 1 bd, Senna 2 nocte, Canesten Cream-Apply as required. 
Compliance with medication as reported by patient: 
Naproxen 500mg bd regularly, Diflunisal500mg tablets (up to 8 daily ifrequirecL but not at the same 
time as naproxen!) and cocodamol (2 daily but sometimes up to 8 per day if needed). Rest of therapy 
as above. 
Assessment by study pharmacist at first inteniew 
Patient complained of poor sleep, which worsened pain control - need to review 
night sedation (nitrazepam) in view of long-term phenobarbitone use and need for twice-daily 
diuretic. Review serum biochemistry to encourage change from Burinex K to co-amilofruse if serum 
biochemistry required potassium maintenance. 
Patient described 'spitting blood' - Mrs RW said that she sometimes took up to 8 diflunisal 
tablets a day but never took naproxen at the same time as diflunisal. She admitted to taking naproxen 
'sometimes first thing on a empty stomach and last thing at night on little more than 1 piece of bread.' 
Patient perception of disease states and medication 
Mrs RW was confused about dosage and administration times of her analgesic therapy. Mrs RW did 
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recognise that diflunisal could cause heartburn if she took too many, but still admitted to exceeding 
NSAID daily dosage (as above). She felt that cocodamol had little effect on her p~ so only took 2 
tablets daily, despite knowing that she could take up to 8/day. 
She recognised that her legs got very swollen if she did not take her diuretic therapy. Mrs RW felt 
dependent on her phenobarbitone but requested increased sedation at night to improve sleep and pain. 
Monitoring efficacy and toxicity of treatment 
No serum biochemistry or haematological data were available in medical notes to assess electrolyte 
balance or haematologicaI status respectively. 
Advice given to patient 
Discussed the potential side effects ofNSAIDs (especially gastrointestinal symptoms), combination 
analgesics ( especially constipation) and side effects associated with long-term anxiolytic use. 
Stressed the importance of taking diflunisal as prescribed (not up to 8 per day) after food and 
discontinue use of naproxen. She was also advised to contact her GP if she coughed up any more 
blood or had further abdominal pain. 
Advised Mrs R W to avoid buying any OTe medication to help her constipation, but continue with 
her prescribed laxative, improve mobility and monitor fluid intake. Discussed the possibility that 
cocodamol could worsen her constipation and that her abdominal pain could be related to 
constipation. 
Discussed possible implications of revisions to therapy e.g. change in night sedation, change in 
diuretic therapy and NSAID dosage changes. Encouraged Mrs RW to avoid taking her diuretic any 
later than 6pm, since the diuresis may worsen her insomnia. 
Pharmacist's recommendations to GP 
Spitting of blood and abdominal pain 
Made the GP aware that Mrs RW was taking both naproxen and diflunisal concurrently, since both 
NSAIDs were still written up as repeat medications. 
Reported the recent spitting of blood and abdominal pain described by Mrs RW to the GP. Suggested 
that all NSAIDs be discontinued until Mrs R W was reviewed, and cause of abdominal pain identified. 
Thereafter, naproxen could be used as required, provided no GI problems were apparent. 
Regular combination analgesic should be encouraged to improve pain control. Laxative therapy may 
need to be reviewed to include a faecal softener. Haematemesis unconfirmed. 
Insomnia 
Discussed the rationale of nitrazepam use. Temazepam had been stopped after the capsule 
formulation had been discontinued and nitrazepam prescribed. 
Advised change back to temazepam (tablets) only for a short period until the acute exacerbation of 
her anxiety was resolved, then review need for anxiolytic / hypnotic. 
Ankle oedema 
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Suggested review use of Burinex K and check serum biochemistry. 
Suggested change therapy to coamilofruse if patient was hypokalaemic and diuresis was to be 
encouraged, and to review the need to administer the diuretic twi·ce daily espe ·all 1· 
, Cl Y as comp lance 
was a problem with Mrs RW. Possibility of reduced need for diuretic ifreduced need for NSAID. 
GP response to pharmacist's recommendations 
GP accepted all the pharmacist's recommendations. 
Diflunisal was discontinued and naproxen continued after the abdominal pain was diagnosed as 
constipation. Mrs RW was encouraged to take cocodamol and senna and Fybogel regularly. 
Temazepam was prescribed for a short course and nitrazepam was discontinued by a stepwise 
approach. 
Patient outcomes as reviewed by pharmacist at second visit 
Assessment of pain using the VAS and the MPQ at Interview 2 (comparative 
score at Interview 1) 
VAS av = 40(60) (group median = 40), NWC = 5 (3) (group median = 7), PPI = 2(2) (group median 
= 2), PRI® = 8 (4) (group median = 19), PRI (8) = 11.7 (6.2) (group median = 20.8). 
Mrs R W reported that her arthritic and abdominal pain, constipation and insomnia had decreased 
despite higher PRJ scores. 
Assessment of QOL at Interview 2 (comparative score at Interview 1) 
Total QOL score 54% of maximum score (70%), physical score 62% (81%), social score 67% (67%), 
occupational score 58% (83%), psychological score 31 % (50%). 
Mrs RW's mobility and psychological status had improved, which was reflected in respectively lower 
physical and psychological scores. Mrs R W was satisfied with her pain control (score of 2 was 
unchanged), and her attitude to the pain was more positive (attitude score increased from 71 to 74% 
of maximum score). 
The total number of medications was reduced from 9 to 7. 
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Appendix 20: Case study 7 - Mr CT (66 years) 
Pain disease state(s): OA of knees and shoulders. 
Other relevant medical history: Hypertension. 
Risk factors to compliance: multiple analgesic therapies, does not like taking tablets. 
Risk factors which may prevent optimisation of pain control: obesity (21 stone), 
recently bereaved, four NSAIDs concomitantly prescribed (3 oral and 1 topical), lack of perceived 
benefit of physiotherapy (aggravated joint pain). 
Risk factors for the development of side effects: more than 1 NSAID, smoker, long-term 
use ofNSAIDs, concurrent antihypertensive therapy. 
Drug history for chronic pain management: Evening primrose oil- took intermittently 
with some benefit for 3 years. Heat treatment and exercise since 1993. 
Variety ofNSAIDs (4) since 1983, Traxam gel 1988, coproxamol since 1988 and Arthrotec since 
October 1993. 
OTC medication: Snake oil (from South Africa) applied on knees, and Salmon oil capsules 1 
daily. Tiger Balm or Ralgex- applied as required to knees and shoulders. 
Prescribed analgesia and co-analgesia: Arthrotec 1 bd, coproxamol 2 as required (max 8 
per day), Brufen Retard tablets 2 at night for 7-10 days, Feldene gel apply to knee as required for 4 
days. 
Other concurrent medication: Aspirin 75mg one in the morning, coamilofruse 5/40 one in 
the morning and atenololl00mg daily. 
Compliance with medication as reported by patient: All as above including 
coproxamol4 per day. 
Assessment by study pharmacist at first interview: 
Patient complained of increased shoulder pain over past few days: reviewed 
rationale of Brufen Retard with Arthrotec, Feldene gel and daily aspirin. 
Patient reported dyspeptic symptoms - reviewed NSAID use in view of possible OJ 
problem(s) and potential change in analgesic e.g. Tylex. 
Control of hypertension: needed to reassure patient to comply with atenolol and co-amilofruse 
(if latter still appropriate). No documented indication for co-amilofruse. 
Monitoring efficacy and toxicity 
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No serum biochemistry or haematological data were available to monitor potential toxicity of co-
amilofruse or NSAID agents respectively. One blood pressure reading, 170/88 (systolic 
hypertension) taken Smonths prior to interview, was recorded in the medical notes. No other results 
were available to appraise hypertension control. 
Patient perception of disease states and medication 
Mr CT had a good awareness of the rationale of all his medication, but was worried about the 
potential GI side effects with his NSAIDs particularly after reading a patient information leaflet for 
his newly prescribed Brufen Retard and had recently experienced indigestion. He took his oral 
NSAIDs and Arthrotec after food. Mr CT decided to take Brufen Retard for a few days to relieve his 
shoulder pain, then return to his GP. He knew not to take any more than 8 coproxamol daily, but did 
admit to sometimes taking 4 coproxamol tablets at one time. 
Mr CT also worried about loss of efficacy of his antihypertensive therapy with concomitant NSAID 
therapy, having read his NSAID information leaflet. He admitted to forgetting his antihypertensive 
therapy occasionally, which had caused him to feel dizzy. 
Advice given to patient 
Emphasised the importance of continuing his antihypertensive therapy, stop smoking, watch his diet, 
try to lose weight and take moderate exercise. 
Advised Mr CT to discontinue Brufen Retard and continue taking aspirin and Arthrotec after food, 
unless dyspeptic symptoms got worse. Discussed the potential problems with topical NSAIDS, 
encouraging Mr CT to use only one sparingly. 
Discussed the need to comply with coproxamol dosing and avoid taking any more than 2 tablets per 
dose. Encouraged the appropriate use of joint exercises and referral to physiotherapy. 
Pharmacist's recommendations to GP 
Dyspeptic symptoms 
Advised discontinue newly prescribed NSAID in light of new dyspeptic symptoms and review other 
analgesia. 
Increased shoulder pain 
Encouraged physiotherapy referral. Discussed rationale of misoprostol after no ulceration diagnosed. 
Misoprostollater discontinued. 
Rationale of diuretic therapy 
d d· I . al ·ew ofMr CT including serum biochemistry to assess the need for and Encourage car 10 OglC revl 
the efficacy of coamilofruse. 
GP response to pharmacist's recommendations 
GP accepted all the study pharmacist's recommendations 
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Brufen Retard and misoprostol were discontinued. Physiotherapy was organised, instructions 
provided re use of coproxamol and sparing use of the topical NSAID. Mr CT was still moderately 
hypertensive on review - atenolol and coamilofruse were continued. 
Patient outcomes as reviewed by pharmacist at second visit 
Assessment of pain using the VAS and the MPQ at Interview 2 (comparative 
score at Interview 1) 
V AS av = 50(80) (group median = 40), NWC = 8 (9) (group median = 7), PPI = 2(3) (group median 
== 2), PRI® = 19(23) (group median = 19), PRI (S) = 21.1 (24.6) (group median = 20.8). 
Mr CT's shoulder pain improved after physiotherapy. 
Assessment of QOL at Interview 2 (comparative score at Interview 1) 
Total QOL score 54% of maximum score (57%), physical score 50% (62%), social score 42% (33%), 
occupational score 50% (50%), psychological score 69% (62%). 
Mr CT's mobility in his shoulder had improved, which was reflected in a slightly higher physical 
score. Mr CT was still moderately satisfied with his pain control (score of3 was unchanged), and his 
good attitude to the pain was unchanged (attitude score of 77%ofmaximum score was unchanged). 
Occupational score was unchanged since Mr CT was retired. 
The total number of medications was consequently reduced from 7 to 5. 
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Appendix 21: Case study 8 - Mr DM (67 years) 
Pain disease state(s): severe RA and ~A. 
Other relevant medical history: Ischaemic heart disease, hypertension, chronic obstructive 
aiIways disease, gastro-oesophageal reflux disease and cataracts (both eyes). 
Risk factors to compliance: lives alone, poor vision and multiple medication. 
Risk factors which may prevent optimisation of pain control: previous intolerance to 
NSAlDs (Indocid suppositories caused proctitis), proteinuria with gold, d-penicillamine and 
cyclosporin and bone pain with high dose hydroxychloroquine, physiotherapy too painful, patient 
perception that generic indomethacin was less effective than Indocid. 
Prescribed analgesia and co-analgesia: 
Paracetamol SOOmg-1 g qid pm, Indocid ® 50mg qid, Movelat gel 1 application at night, 
hydroxychloroquine 400mg daily (reducing dose). (RA clinic had prescribed Diclomax Retard one at 
night as well as Indocid, but Mr DM was not taking it). 
Other concurrent medication: 
Adalat Retard 20mg bd, isosorbide mono nitrate 40mg bd, bendrofluazide 2.Smg daily, ranitidine 
ISOmg bd, Flixotide Inhaler SOmcg qid, Volmax tablets 4mg bd, ipratropium bromide nebules 
2S0mcg bd via neubuliser, salbutamol nebules 2.5mg bd and hypromellose eye drops 0.3% 1 drop 
both eyes pm. 
Assessment by study pharmacist at first interview 
Patient complained of abdominal pain - needed to refer to GP in light of previous history 
and current NSAID use. 
Patient reported poor pain control- needed to review rationale for concurrent use of2 
NSAlDs (I oral and 1 topical) with GI history and Indocid use in hypertension. Limited alternative 
options, since poor tolerance to hydroxychloroquine and other slow acting agents. Patient wanted to 
avoid intra-articular steroid injections- worried about side effects. Provided reassurance re rationale 
of steroids in both RA and respiratory diseases. 
Monitoring efficacy and toxicity of treatment 
No biochemistry, blood gases or blood pressure measurements found in medical notes. No evidence 
of previous reports of proteinuria. 
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Patient perception of disease states and medication 
Mr DM had a good awareness of the rationale of all prescribed medications and was moderately 
satisfied with pain control with a positive attitude to his pain management. Aware of the need to 
continue NSAIO while altering hydroxychloroquine dosing, to monitor gastrointestinal side effects 
and need for regular eye examinations with hydroxychloroquine. Patient had good inhaler and 
nebuliser techniques - respiratory symptoms were stable. 
Advice given to patient 
Pharmacist discussed implications of possible revisions of therapy. 
Pharmacist's recommendations to GP 
Abdominal pain 
Advised discontinue NSAIDs, review gastrointestinal symptoms with the possible use of a proton 
pump inhibitor. (Barium meal had been recently performed and results needed chasing up). 
Pain control for RA and OA 
Advised a combination analgesic instead ofparacetamol and monitor bowel activity, Advised that the 
GP should discontinue NSAIDs and monitor efficacy and toxicity of hydroxy chloroquine- the latter 
could be carefully increased provided bone pain is monitored by patient, GP and RA clinic. 
GP response to pharmacist's recommendations 
GP accepted almost all pharmacist's recommendations apart from initiation of 
ibuprofen. 
Ranitidine was discontinued and omeprazole initiated to control GI symptoms (barium meal result 
was negative). Both indomethacin ® and diclofenac were discontinued. Mr DM was commenced on 
Brufen Retard thereafter and continued with the same dose of hydroxychloroquine. 
Patient outcomes as reviewed by pharmacist at second visit 
Assessment of pain using the VAS and the MPQ at Interview 2 (comparative 
score at Interview 1) 
VAS av = 60 (80) (group median = 40), NWC = 14 (15) (group median = 7), PPI = 3(3) (group 
median = 2), PRI® = 36 (37) (group median = 19), PRJ (S) = 39.0 (39.5) (group median = 20.8). Mr 
DM's abdominal pain had resolved. 
Assessment ofQOL at Interview 2 (comparative score at Interview 1) 
Total QOL score 65% of maximum score (60%), physical score 75% (69%), social score 67% (33%), 
occupational score 62% (62%), psychological score 56% (69%). 
Mr OM's mobility had become worse, which was reflected in a higher physical score. Mr OM was 
still moderately satisfied with his pain control (score of 3 was unchanged), but his attitude to the pain 
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was less positive (attitude score dropped from 66 to 60% of maximum score). Occupational score 
was unchanged since he was retired. The total number of medications was reduced from 12 to 10. 
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Appendix 22: Case study 9 - Mrs MD (49 years) 
Pain disease state(s): OA ankle and foot and cervical spondylosis. 
Other relevant medical history: Dyspepsia (gastric erosions in 1988 precipitated by OTC 
aspirin) and irritable bowel syndrome. 
Risk factors which may prevent optimisation pain control: Depressed because her 
orthopaedic surgeon could not offer any further treatment, perceived lack of benefit of physiotherapy 
and poorly fitting corset. 
Prescribed analgesia and co-analgesia: 
Solpadol caplets 1 - 2 every 8 hours as required (Mrs M.D. took 2 bd) 
Naproxen 500mg bd DHC Continus 120mg bd (up to 1 tid pm). 
Other concurrent medication: 
Omeprazole 20md bd (since 1992), Mucaine 5mls pm, Burinex K 1 in the morning as required for 
knee swelling, Ferrous Sulphate 200mg daily (since 1988) - no record of indication for use of iron. 
Compliance with medication as reported by patient: As above except Solpadol2 bd. 
Assessment by study pharmacist at first interview 
Patient reported poor pain control 
Mrs M.D believed that exercise did not help chronic pain, so was reluctant to continue physiotherapy. 
Poorly fitting orthopaedic corset prevented her wearing it, despite increasing pain. Advised not to sit 
for extended periods of time, yet walking also painful. Her consultant was very reluctant to review 
her opioid therapy - few other treatment options were left. 
Monitoring efficacy and toxicity of treatment 
No serum biochemistry or blood results were available to assess any electrolyte status or underlying 
anaemia. No problems with knee or ankle swelling -diuretic compliance poor. Her appetite was 
reasonable and she took a well balanced diet. 
Patient perception of disease states and medication 
Mrs MD had a reasonable awareness of the rationale of most of her prescribed medications and felt 
that her diuretic and iron supplement were unnecessary. She was moderately satisfied with pain 
control and had a reasonably positive attitude to her pain management.' I wouldn't be taking 
medicines if I didn't have to'. Mrs MD said that she always took her NSAID with or after food and 
had no recent stomach problems. 
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Advice given to patient 
The benefits in pain relief of appropriate exercise and a better fitting corset were discussed. 
Mrs MD was made fully aware by the pharmacist of the need to monitor and report dyspepsia, 
abdominal pain and the amount of antacid required while taking her Naproxen. 
Pharmacist's recommendations to GP 
Diuretic and iron therapies: 
Since there was no rationale for the treatments, the pharmacist advised the patient's GP to 
discontinue Burinex K® and iron therapies. 
Pain control: 
The pharmacist advised that a review of Mrs MD's opioid therapy be made after further referral to 
physiotherapy for appropriate exercise and corset alterations. 
GP response to pharmacist's recommendations 
GP accepted all the pharmacist's recommendations. 
Mrs MD was referred and seen by her physiotherapist, who discussed a revised exercise plan with 
Mrs MD and provided a new corset. 
GP reviewed the opioid therapy and suggested an increase in dihydrocodeine dosage but was unable 
to convince Mrs MD's orthopaedic surgeon of the benefit. 
Patient outcomes as reviewed by pharmacist at second visit 
Assessment of pain using the VAS and the MPQ at Interview 2 (comparative 
score at 
Interview 1) 
VAS av = 50(80) (group median = 40), NWC = 12 (20) (group median = 7), PPI = 2(3) 
(group median = 2), PRI® = 22 (54) (group median = 19), PRI (S) = 29.3 (59.0) (group median = 
20.8). 
Mrs MD reported that her arthritic pain had decreased. 
Assessment of QOL at Interview 2 (comparative score at Interview 1) 
Total QOL score 27% of maximum score (39010), physical score 38% (62%), social score 
25% (33%), occupational score 33% (42%), psychological score 12% (19%). 
The total number of chronic medications was consequently reduced from 8 to 6. 
Her mobility had improved as reflected in a decrease in her mobility problem score, she was still 
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moderately satisfied with her pain control (unchanged score of3) and her attitude to her pain was 
unchanged (attitude score remained at 69% maximum score). 
Text cut off in original 
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Potential roles of the pharmacist in 
r chronic pain management: a 
! multidisciplinary perspective in 
• prImary care 
RHONA W. READ and JANET KRSKA 
i Patients in the community with chronic pain may have poor pain control and use 
• both prescribed and alternative therapies, often inappropriately, to try to optimise 
pain relief. They may benefit from management by a multidisciplinary primary 
care team involving a pharmacist. This study used postal questionnaires to 
determine community pharmacists' attitudes to involvement in pain management 
and the perceptions of general practitioners and physiotherapists of the current 
and potential roles of the pharmacist within a chronic pain care team. The three 
professions' views on factors which could influence chronic pain management 
were also determined. Sixty-three GPs (63 per cent), 59 community pharmacists 
(59 per cent) and 33 physiotherapists (66 per cent) responded. None of the 
pharmacists was currently involved in chronic pain management, but 58 (98 per 
cent) wanted to develop such a role, especially within pain clinics. Pharmacists 
and physiotherapists were more likely than GPs to identify that limited 
opportunity for personal involvement and expertise within a pain team reduced 
the likelihood of achieving optimal chronic pain management. Only 17 of the 
GPs had an established multidisciplinary pain care team; two of these had 
pharmacist involvement. All GPs and physiotherapists agreed that pharmacists 
had an important role to play in chronic pain management, particularly in the 
provision of drug information to patients and medication review. 
THERE is currently extensive encouragement to 
develop the role of the pharmacist1,2,3 within 
many different primary care settings. Pharma-
cists are now extending their skills and knowl-
edge to provide services such as pharmacist-led 
clinics,4,5 medicine review,6 general practice for-
mulary development and review7 and health 
promotion.8 As more medicines are deregulated, 
pharmacists have also developed their advisory 
role to improve the appropriate use of medicines 
and the treatment of minor ailments.9 
i Analgesics are the most widely used non-pre-
I scription medicines, yet their use can often be in-
I appropriate and potentially hazardous,1o,ll 
I Along with non-steroidal anti-inflammatory 
. drugs (NSAIDs), analgesics are among the most 
commonly prescribed medicines,12 The elderly 
are most likely to overuse analgesics10 and are at 
greater risk of adverse drug reactions.13 NSAIDs 
, have been shown to contribute to hospital ad-
missions in the elderly.14 The elderly are more 
likely to obtain analgesia via prescription than 
purchase,lO although any analgesics for self-med-
ication are more likely to be bought from a phar-
macy than elsewhere,15 However, the elderly are 
less likely than younger patients to ask for ad-
vice,15 Inappropriate use of analgesic therapy 
may also lead to poor relief of symptoms,16 Con-
sequently, pharmacists must be proactive if the 
outcomes of patients with chronic pain are to be 
maximised. 
Controlled studies have shown that pharma-
cist input into the management of anticoagulant 
therapy results in improvement of patient out-
comes.4 Patients with chronic pain managed in 
the community can also benefit from pharma-
ceutical intervention to maximise the efficacy of 
drug regimes and reduce the risk of potential ad-
verse effects,16 Pharmacist referrals to general 
practitioners and other members of the health 
care team have been shown to result in an im-
provement in pain scores,16 
Many patients with chronic pain have benefit-
ed from management by a multidisciplinary pain 
team, based in hospital, frequently involving 
anaesthetists,17 Physiotherapists in particular 
have a large role to play in improving outcomes 
in patients with chronic, non-malignant pain, us-
ing well-validated manipulative techniques,lS 
and are a frequent referral point of GPs. They 
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are thus an important group of health profes-
sionals, dealing with substantial numbers of pa-
tients who are suffering from chronic pain. It has 
been estimated that 50 per cent of the popula-
tion aged 25 or over suffer from chronic pain 
lasting three months or more [W. C. S. Smith, 
personal communication]. The majority of these 
patients are managed in primary care by GPs us-
ing analgesic and NSAID therapy. 
Our previous work showed that large numbers 
of patients, for example those with rheumatoid 
arthritis, use non-prescription medicines and al-
ternative therapies to enhance the efficacy of 
their prescribed analgesia.16 There is therefore a 
potential need for pharmaceutical input into the 
treatment of patients with chronic pain in pri-
mary care,19 perhaps as part of a chronic pain 
team. GPs previously expressed mixed views on 
the role of the pharmacist in chronic pain man-
agement;20 however, recent work has shown that 
medication review by pharmacists was rated 
favourably.21 
The purposes of this study were to determine 
community pharmacists' current input into 
chronic pain management and to evaluate GPs' 
and physiotherapists' experiences of pharma-
cists' contribution to the care of patients with 
chronic pain. The views of all three professions 
on factors which limit the management of chron-
ic pain and the role(s) of the pharmacist, if any, 
within a multidisciplinary chronic pain care team 
were also determined. 
Methods 
Three postal questionnaires were developed to 
determine the current practice of GPs, commu-
nity pharmacists and community-based physio-
therapists in managing chronic pain. Each 
contained a list of attitude statements relating to 
chronic pain and factors potentially influencing 
its management, developed by discussion with 
academics and practitioners. All responders were 
also asked to indicate their level of agreement 
with the attitude statements, using a five-point 
Likert scale, and to indicate any of the factors 
they felt prevented them from optimising control 
of chronic pain. A range of potential roles for 
pharmacists in the management of chronic pain 
were given and responders asked to indicate 
which, if any, they considered appropriate. 
The questionnaires for GPs also requested 
practice details, the extent of current clinical in-
teraction with pharmacists and strategies used in 
the management of chronic pain. Questionnaires 
sent to pharmacists requested professional de-
tails, current clinical services provided, especial-
ly in chronic pain management, and the 
pharmacists' attitude to the development of their 
role in this area. Additional questions asked of 
physiotherapists requested professional details 
and information about their management strate-
gies used to control chronic pain. 
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The questionnaires were piloted by five vol-
unteers from each professional group and minor 
changes made as a result. None considered a 
need for changes to be made to the attitude state-
ments. Lists of GP practices, community phar-
macies and community-based physiotherapists 
were obtained from two health boards in Scot-
land. Questionnaires were sent to 100 GPs, 100 
pharmacists and 50 physiotherapists selected at 
random from these lists, while ensuring that no 
practitioners working in the same practice re-
ceived questionnaires. This represented approxi-
mately 50 per cent of all practices for each 
profession in the two boards. The first mailing 
took place in January, 1996. Prepaid envelopes 
were provided for return of the questionnaires 
and one follow-up reminder was sent. Data were 
analysed using EPI-info 5.0 statistical package. 
Chi-square and Kruskal Wallis tests were used to 
compare results between the professions. 
Results 
Demographic details Replies were obtained from 
63 GPs (63 per cent), 34 (54 per cent) of whom 
were from fund holding practices, with an aver-
age of six GPs (range 2.5-12) per practice. The 
practice list sizes (range 3,200-22,500 patients 
per practice) reflected the number of GPs per 
practice. Fifty-nine pharmacists (59 per cent) re-
sponded, 56 (95 per cent) of whom worked full-
time and the rest part-time. Forty-eight of the 
respondents were the sole pharmacist in the 
pharmacy, while 10 had one colleague and one 
had two colleagues working in the pharmacy at 
the same time. Replies were also obtained from 
33 of the 50 physiotherapists (66 per cent), all 
independent community practitioners, not asso-
ciated with general practices. 
Community pharmacists' current clinical activi-
ties and involvement with GPs and physiothera-
pists All pharmacists indicated that they 
provided advice about prescribed and non-pre-
scription medicines. No responder identified spe-
cific involvement in the management of chronic 
pain, but 25 (42 per cent) claimed to provide pre-
scribing advice to GPs and 10 (17 per cent) were 
involved in developing treatment protocols. 
Sixty-two GPs (98 per cent) identified phar-
macists as helpful, mostly (53 GPs) as a source 
of medication and drug information to patients. 
Twenty-two had found pharmacists helpful in 
encouraging patient compliance, but only 19 and 
12 GPs, respectively, had direct experience of in-
volving pharmacists in individualising treatment 
options or developing a practice formulary. 
No physiotherapist who responded had any 
direct involvement with a community pharmacist 
at the time of the study. 
Chronic pain management Factors preventing 
optimal management of chronic pain - The ex-
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,'T able 1: Extent of agreement with factors which may influence the management of chronic pain 
Factor Number (per cent) Number (per cent) Number (per cent) 
Patient expectation of pain control 
Poor patient compliance 
Poor agreement of management with patient 
Limited access to pain clinics/specialists 
Limited access to up-to-date drug information 
Limited [personal) expertise in a 
multidisciplinary team 
Excessive workload 
Lack of opportunity for [personal) involvement 
in a multidisciplinary team 
of GPs agreeing of pharmacists of physiotherapists 
(n=63) agreeing (n=59) agreeing (n=33) 
31 (49) 
25 (40) 
13 (21) 
21 (33) 
2 (3) 
10 (16) 
27 (43) 
13 (21) 
17 (29) 
19 (32) 
5 (8) 
34 (58) 
5 (8) 
28 (48) 
29 (49) 
42 (71) 
20 (61) 
17 (52) 
2 (6) 
22 (67) 
11 (33) 
9 (27) 
14 (42) 
15 (45) 
Table 2: Extent of agreement with attitude statements on chronic pain management (n=154) 
Statement Number (per cent) Number (per cent) Number (per cent) 
Most patients comply with your advice 
Patient compliance is increased if patients 
understand your explanation 
Some patients want to control their own pain 
and don't comply with your advice 
A patient with chronic pain exaggerates 
the pain which helshe feels 
More patients are self-medicating to improve 
control of chronic pain 
Patients with chronic pain who are depressed 
often have poor pain control 
Patients with chronic pain usually know very 
little about the management options 
for chronic pain 
A treatment plan for the control of chronic pain 
should be agreed by a multidisciplinary 
care team 
Treatment guidelines improve cost-effective 
prescribing 
who strongly who don't know who strongly 
agree/agree disagree/disagree 
99 ( 64) 
147 (95) 
92 (60) 
35 (23) 
79 (51) 
133 (86) 
108 (70) 
89 (58) 
105 (68) 
37 (24) 
6 (4) 
42 (27) 
66 (43) 
52 (34) 
20 (13) 
31 (20) 
49 (32) 
37 (24) 
18 (12) 
1 (1) 
20 (13) 
3 (34) 
23 (15) 
1 (1) 
15 (10) 
16 (10) 
12 (8) 
tent to which the three professional groups 
agreed with factors which may prevent optimal 
management of chronic pain is shown in Table 
1. A significantly greater number of GPs than 
pharmacists agreed that patient expectation of 
pain control influenced management of chronic 
pain (p<O.05;X2; df=l). More GPs than pharma-
cists also concurred with the statement that poor 
agreement with patients on a management strat-
egy was a limiting factor (p<O.05; X2; df=l). 
influence pain and its management. One physio-
therapist omitted to complete this section of the 
questionnaire, thus the total number of respon-
dents was 154. 
Few differences were found between the three 
professions in the extent of their agreement with 
these statements, the major difference involving 
the statement that treatment plans should be de-
veloped by a multidisciplinary team. Overall, 58 
per cent of responders agreed with this state-
ment; however, the proportion of GPs agreeing 
was lower than that of pharmacists or physio-
therapists. 
Ninety-five per cent of all responders agreed 
Pharmacists were more likely than GPs to 
agree that limited access to pain specialists/clin-
ics, lack of opportunity to be involved or lack of 
expertise within a multidisciplinary team limited 
chronic pain management (P<O.05; X2; df=l for 
all statements). Physiotherapists were more like-
ly than GPs to agree that limited access to pain 
specialists or clinics was an influencing factor, 
and more likely than the other two professions 
to indicate that lack of up-to-date drug informa-
tion was important (P<O.05; X2; df=l for both 
statements). 
Table 3: Extent of agreement with proposed roles for pharmacists in chronic 
pain management 
Proposed role 
Providing drug information 
to patients 
Medication review 
Attitudes to pain management - Table 2 shows Drug history taking in a 
the extent of agreement with a series of state- chronic pain clinic 
Facilitate chronic pain 
ments used to assess the attitudes of respondents management 
towards management strategies for chronic pain, Educate health care professionals 
compliance with therapy and other factors which about use of analgesics 
Number (per cent) of responders agreeing 
GPs Physiotherapists 
(n=63) (n=33) 
46 (73) 
38 (60) 
8 (13) 
3 (5) 
3 (5) 
29 (88) 
25 (76) 
12 (30) 
2 (6) 
2 (6) 
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or strongly agreed that compliance with a pain 
management strategy was increased if patients 
understood the strategy. While almost two thirds 
(64 per cent) agreed that the majority of patients 
complied with their advice, a similar number (60 
per cent) agreed that some patients prefer to con-
trol their own pain and do not comply. 
Current management of chronic pain - Treat-
ment guidelines for chronic pain were used by 14 
of the 63 GPs (22 per cent), while 17 of the 33 
physiotherapists (52 per cent) used guidelines. 
GPs claimed to use the British National Formu-
lary, while physiotherapists used specific physio-
therapy protocols. Only 17 of the GPs (27 per 
cent) had a multidisciplinary team already es-
tablished for the management of chronic pain at 
the time of study. 
The composition of the teams, as documented 
by the GP and physiotherapist respondents, var-
ied considerably, with a nurse being the most fre-
quently cited team member (13) after the GP; 
pharmacists and physiotherapists were only in-
volved in two and four of these GP-Ied teams, re-
spectively. 
Two of the study physiotherapists were in-
volved in a multidisciplinary pain team, but oth-
er team members in each group were limited to 
a GP and a clinical psychologist. None of the 
study pharmacists was involved in a team them-
selves. Lack of resources (30 respondents), time 
(31) and personal expertise (20) were reasons 
commonly given by GPs and physiotherapists for 
not establishing multidisciplinary care for pa-
tients with chronic pain, while 22 mggested that 
there was a lack of need. 
Development of the role of the pharmacist in the 
management of chronic pain - All 155 respon-
dents were asked to consider the potential 
role(s), if any, of a pharmacist in a chronic pain 
care team. There were no significant differences 
(p>0.05; X2) between the responses of GPs and 
physiotherapists (Table 3), all of whom agreed 
that pharmacists had a developing role to play in 
a multidisciplinary approach to managing pa-
tients with chronic pain. Further roles for phar-
macists suggested by GPs were help with 
understanding the clinical significance of drug in-
teractions (two respondents) and with the sub-
stitution of non-prescription products for 
prescribed analgesics (three respondents). 
Fifty-eight of the 59 pharmacist respondents 
(98 per cent) identified a desire to develop their 
role in chronic pain management. Forty-eight 
pharmacists wanted to develop further patient 
information services regarding non-prescription 
products and 46 pharmacists wanted to develop 
further patient information services for pre-
scribed medication in chronic pain management. 
Thirty-three pharmacists (56 per cent) indicated 
they would like to become actively involved in 
pain clinics. 
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Discussion 
All pharmacist respondents were currently pro-
viding advice concerning both prescribed and 
non-prescribed medicines, and some were also 
involved in providing prescribing advice to GPs 
and developing treatment protocols. Although 
98 per cent of pharmacists wanted to develop 
their role in pain management, the most common 
desire was to develop further the advice-giving 
role. 
Both GPs (73 per cent) and physiotherapists 
(88 per cent) also envisaged the pharmacist as a 
provider of drug information, but were encour-
aging more clinical and proactive roles for phar-
macists in addition. This was despite most 
previous GP contact with pharmacists involving 
the traditional supply role and the physiothera-
pist respondents having no direct contact with 
pharmacists, as is usual in primary care. There is 
a possibility that physiotherapists' views may 
have been influenced by beneficial contact with 
hospital pharmacists during training.22 
Sixty per cent of GPs and 76 per cent of phys-
iotherapists felt that pharmacists should under-
take review of medication in patients with 
chronic pain. More than 50 per cent of the phar-
macists were keen to review medication, either in 
pain clinics or via domiciliary visits, the need for 
which has been shown. 16 
While pharmacists claimed that limited access 
to pain clinics and the lack of opportunity for in-
volvement were limiting factors to optimising 
pain control, pharmacist-led chronic pain clinics, 
involving several health care professionals, are 
now being developed in primary care (5. Mac-
Gregor, personal communication). Meanwhile, 
there is still much that can be achieved in the 
community pharmacy. Pharmacists are currently 
able to use patient medication records to ensure 
that analgesic overuse does not occur. IO,23 Du-
plication of NSAIDs and paracetamol-containing 
preparations lO,1!,16 can easily be detected by 
pharmacists. 
Although only 17 of the GPs had a multidis-
ciplinary pain team at the time of study, and 
pharmacists were only involved in two teams, the 
majority of respondents felt that a treatment plan 
should be agreed by such a team. Drug history 
taking in pain clinics was identified by a number 
of GPs and physiotherapists in this study as a po-
tential role for the pharmacist. However, there is 
also a need for the development of local proto-
cols for both prescribed and non-prescription 
medicines. Recent work has shown that phar-
macists have a greater knowledge than GPs of 
analgesic therapy,24 which would be of benefit in 
developing treatment protocols and in the multi-
disciplinary management of chronic pain. 
The low usage of treatment guidelines for 
chronic pain management was disappointing, 
but indicates an opportunity for improvements 
in chronic pain management, which has been 
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dentified by other work. 16,25 The development 
of treatment guidelines for some chronic disease 
states has permitted GPs to delegate the opera-
tion of specific clinics to pharmacists4,5 and oth-
er health care team members,26 which has proved 
popular with patients.4 This should apply more 
frequently to chronic pain, given its high inci-
dence and potential for poor outcomes,16 
High patient expectations, poor compliance 
and poor patient agreement with a management 
strategy were all factors limiting pain control 
with which many respondents agreed. Minimal 
time for discussing patients' expectations of 
treatment and developing ownership of the man-
agement strategy may result in a reluctance to 
comply with treatment. This has been shown to 
be a problem in patients with arthritisP The 
move to concordance rather than compliance28 
and the involvement of health care professionals 
other than GPs who may be able to allocate more 
time to patients could also help to address these 
factors. 
Although the sample size of this study is rela-
tively small, primary health care team members 
were found both to identify and appreciate the 
current and potential roles of the pharmacist in 
the management of chronic pain. The results sug-
gest that there is greater willingness to involve 
the pharmacist in chronic pain management than 
was found previously,20 when many GPs and 
nurses were not supportive of pharmacist in-
volvement in domiciliary pain management. 
While fewer GPs than pharmacists and physio-
therapists agreed that a treatment plan should be 
agreed by a multidisciplinary care team in the 
present study, both GPs and physiotherapists 
agreed with many potential roles for pharmacists 
within such a team approach. 
The change in GP attitudes may be a reflection 
of the increasing co-operative working between 
pharmacists and GPs throughout the United 
Kingdom, and is in line with more recent find-
ings which suggest that GPs would welcome tar-
geted medication review by pharmacists. ll •21 
We have already shown that there is a need for 
pharmacists to integrate with the primary health 
care team, to provide advice and information 
about analgesic use, to help develop and imple-
ment treatment protocols for chronic pain man-
agement and to undertake medication review to 
improve the outcomes of patients with chronic 
pain.16 
The results of the present study suggest that 
these activities will be welcomed by those cur-
rently involved in chronic pain management. The 
opportunity for team approaches to the man-
agement of chronic diseases within the current 
developments in primary care should facilitate 
the extension of pharmacists' existing input. 
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Targeted medication review: patients 
in the community with chronic pain 
RHONA w. READ and JANET KRSKA 
Patients with chronic pain may be in need of improved pharmaceutical care 
because of lack of pain relief and lack of understanding of pain management, the 
potential for drug interaction and adverse effects. This study assessed the need 
for a pharmacist to review the medication of a population of patients with 
chronic pain in a domiciliary setting, using specific validated outcome measures 
to determine any benefits of pharmacist intervention. 
Ninety-six patients who had rheumatoid arthritis or were taking regular non-
steroidal anti-inflammatory drugs (NSAlDs) or combination analgesics were 
interviewed after reviewing their medical records. Expectations of pain relief and 
severity of pain were assessed using McGill pain questionnaire (MPQ), visual 
analogue scales (VAS) and verbal descriptor scales. Twenty-eight patients required 
referral to their GP as a result of meeting preset criteria for poor outcome from 
current therapy; these patients had higher expectations of pain relief than the 
remaining patients and also higher pain scores. Pain scores using the MPQ and 
VAS were generally well correlated with each other and both showed changes in 
the 14 patients who were re-interviewed after pharmacist intervention. A further 
59 patients required advice to optimise current therapy and 12 required referral 
concerning inappropriate therapy. Many patients' medicine use deviated from that 
prescribed, and a high proportion used alternative medicines in addition. The 
prescription of drugs for prophylaxis against ulceration was inappropriate in 17 
patients and evidence of monitoring in patients on NSAIDs and disease-modifying 
antirheumatic drugs (DMARDs) was poor. 
PHARMACISTS have increasingly begun to un-
dertake reviews of medication in patients living 
at home, which have resulted in the identifica-
tion of many medication-related problems.1.2 
Many workers have directed this service at el-
derly patients taking multiple medicines, al-
though younger patients and those taking fewer 
medicines may still be at risk of such problems. 
An alternative method of identifying patients for 
review is targeting by disease state or by drug 
group, for example, patients taking ulcer-healing 
drugs. 3 
Pain is the commonest symptom with which 
patients present to their GP, and analgesics, in-
cluding non-steroidal anti-inflammatory drugs 
(NSAIDs), are among the most commonly pre-
scribed medicines.4 Patients with chronic pain 
due to arthritis are also likely to use alternative 
therapies for pain, including non-prescription 
medicines.5,6 Not only could this lead to drug in-
teractions, it also suggests that patients are ex-
. periencing incomplete pain relief from their 
analgesics.7 
Patients with rheumatoid arthritis (RA) may i also be receiving treatment with disease-modify-
I ing antirheumatic drugs (DMARDs). Both 
NSAIDs and DMARDs have the potential for 
considerable toxicity, with NSAIDs being re-
sponsible for a substantial proportion of drug-re-
lated problems contributing to hospital 
admission. 8 Despite their toxicity, NSAIDs are 
over-prescribed in the United Kingdom.9 In ad-
dition, patients' knowledge about NSAIDs,lO 
analgesics ll ,12 and DMARDs13 has been shown 
to be poor. 
All of these factors suggest that patients with 
chronic pain may be in need of improved phar-
maceutical care, as has been identified in the 
United States. 14 
The purpose of this study was to identify pa-
tients with chronic pain living in the communi-
ty, to undertake a review of all their therapy for 
pain and concomitant conditions and to measure 
pain relief using standard instruments. A defini-
tion of poor outcome of therapy for chronic pain 
was set at the start of the study in order to quan-
tify the likely need for medication review in pa-
tients with chronic pain. Action was taken to 
address any medication-related problems identi-
fied during the process, thus enabling the type of 
action required to improve pain therapy to be 
quantified. 
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Method 
Three medical practices in two health board ar-
eas of Scotland agreed to participate in the study. 
Ethical approval was obtained from both health 
boards. From each practice all patients with a di-
agnosis of RA and a systematic random sample 
of every eighth patient receiving repeat prescrip-
tions for NSAIDs or combination analgesics 
were selected, using the practice computer sys-
tem (GPASS). Exclusion criteria were patients 
aged under 18, patients with malignant pain, pa-
tients considered by their GP to be unsuitable for 
inclusion and patients unwilling to participate. 
Information about medicines prescribed and 
medical problems were obtained from practice 
records. Patients were contacted by letter, fol-
lowed by a telephone call to determine whether 
they were willing to be interviewed (by RR) in 
their own home. Written consent was obtained 
from all patients who agreed to interview and re-
view of therapy. The study took place between 
July, 1993, and September, 1994. 
A structured interview was used to determine 
how the patients actually used their prescribed 
medicines, any non-prescription medicines which 
they used for pain relief and any complementary 
therapies used. Perceived adverse effects were de-
termined by asking about any problems ever ex-
perienced in relation to any medicines currently 
being used for pain. Any problems with admin-
istration of medicines were also determined dur-
ing the interview. Patients' knowledge of their 
medicines was determined without allowing ref-
erence to their medicine containers. Knowledge 
of side effects, disease states and the sources of 
medicines information used by the patient were 
also obtained by structured questioning. 
Pain relief was assessed using the McGill pain 
questionnaire (MPQ)15 and a horizontal visual 
analogue scale (VAS).16 The MPQ defines pain 
in terms of three major dimensions: sensory, af-
fective and evaluative and consists of 20 cate-
gories of words to describe the pain experience. 
Patients were asked to select the categories which 
they recognised as relevant to their pain at time 
of interview, and to circle the most appropriate 
word within each category. If none of the words 
within a category applied, none were chosen. 
The MPQ also asks patients to rate present pain 
intensity (PPI) on a 0 to 5 verbal descriptor scale 
where 0 = no pain and 5 = pain is horrible. This 
tool has been widely used and validated in pa-
tients with many different types of pain. 
Patients were asked to rate their expectations 
of pain relief, current pain and both average pain 
and worst pain over the previous month using 
the 1 OOmm VAS, where 0 = no pain and 100 = 
pain as bad as it could be. Expectations of pain 
relief and satisfaction with pain control were also 
assessed using a validated rating scale with spe-
cific verbal descriptors.J7 
A poor outcome of current therapy was de-
fined as one or more of the following problems 
at the time of interview: 
• pain greater than 7Smm on the VAS average 
• deliberate change in therapy by patient with-
out GP consultation 
• presence of potential adverse reaction(s) 
• dissatisfaction with therapy. 
Actions taken in patients identified as having 
poor outcomes took the form of providing in-
formation and advice or referral to the GP or 
other health care professional. Patients with sat-
isfactory outcomes but therapy considered to be 
inappropriate were also referred to their GP. Pa-
tients who had been referred due to poor out-
comes were subsequently revisited after an 
interval of four to six weeks to determine any 
changes in outcomes. 
The McGill pain questionnaire was analysed 
according to the method validated by Melzackl5 
and results expressed as: 
• Pain Rating Index (scale) score (PRI[S)): the 
sum of the weighted scale values for all the 
words chosen within a category or across all 
categories.18 A total PRI(S) score and a PRI(S) 
score within a category, eg, PRI(S) evaluative, 
was calculated. 
• Pain Rating Index (rank) score (PRI[R)): the 
weighted scale values were replaced by a val-
ue which indicated the ranking of the chosen 
word within a given category and summated 
to provide a Pain Rating Index score using 
rank values. A total PRI(R) score and a PRI(R) 
score within a category, eg, PRI(R) evaluative 
was calculated. 
• Number of Words Chosen (NWC): total num-
ber of words chosen (NWC) from the 20 cat-
egories within the MPQ were summated. 
• The Present Pain Intensity Score (PPI): score 
of 0 to 5 was also determined from the PPI 
verbal descriptor scale used within the MPQ. 
VAS scores were calculated by measuring the 
distance of each patient's mark from the lower 
end of the scale, measured in millimeteres, rang-
ing from 0 to 100. 
All data were analysed using Epi Info version 
5.0. Chi-square tests were used to compare pa-
tient subgroups and Pearson's correlation coeffi-
cient was used to compare pain scores. 
Results 
Patient population A total of 109 patients was 
identified from the three practices, of whom 96 
agreed to participate in the study. There were no 
differences between the 13 patients who refused 
to participate and those who agreed in terms of 
number of disease states or drugs prescribed. 
Of these 96 patients, 42 had RA, 22 had os-
teoarthritis (OA), 25 had both OA and RA and 
DECEMBER 1998, THE INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 
seven had low back pain. The mean age of the 
96 patients was 60.4 years (SD 13.8 years, range 
29-84 years). Twenty-eight of the 96 patients (29 
per cent) were male and 68 (71 per cent) were 
female. There was no significant difference in age 
between groups of patients with different chron-
ic pain diagnoses. The average number of medi-
cations currently taken by patients was 4.9 
(range 0-12) and the average number of concur-
rent disease states (excluding the chronic pain di-
agnosis) was 3.0 (range 2-9). 
Use of pain therapies Seventy-one patients (74 
per cent) were prescribed NSAIDs, 15 (16 per 
cent) DMARDs, 49 (51 per cent) combination 
analgesics, 27 (28 per cent) paracetamol and 
eight (9 per cent) an opioid. Other medicines re-
lating to pain, including immunosuppressants, 
hypnotics and anti epileptics, were prescribed in 
33 patients (34 per cent). The average number of 
medications taken by each patient group were: 
RA group 5.0 (range 0-12), OA group 5.2 (range 
2-9), back pain group 4.3 (range 2-9) and group 
with RA and OA 4.9 (range 0-12), with no sig-
nificant differences between groups. 
There was a substan~ial proportion of patients 
without RA who were prescribed NSAIDs, 
where their use was less appropriate. In 40 pa-
tients there was documented evidence in the 
records of use of additional therapies, such as 
physiotherapy, occupational therapy and herbal 
products, although only two patients were using 
these at the time of the study. No records of OTC 
medicines use were found in the majority of pa-
tients' notes, although in four there was mention 
of OTC medicines being used in preference to 
prescribed medicines. 
Comparing the information obtained from 
records with that obtained from the patients di-
rectly at interview, there were discrepancies re-
lating to therapy for chronic pain in 72 patients. 
Many patients' medicine use deviated from the 
regimens documented in medical records, al-
though patients claimed GPs were aware of these 
differences. This was particularly prevalent in 
patients with RA (54/67, 81 per cent of patients). 
The type of differences described were medicines 
having been discontinued (45 instances), dose 
changed (48 instances) or medicines added (49 
instances). Thirty-six patients voluntarily admit-
ted to recently modifying the dose of NSAID or 
analgesic taken from that prescribed themselves: 
31 of these had reduced their dose, while five re-
ported that they had increased their dose of anal-
gesic due to increasing pain. However, more 
specific questioning revealed that an additional 
10 patients used a lower dose than prescribed. 
Significantly more patients in the RA group re-
ported that they had at some time needed a high-
er dose of analgesic than that prescribed (P<O.05; 
xh df=3). 
The use of alternative therapies (homoeopath-
ic or herbal remedies) for pain was significantly 
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higher in patients with a diagnosis of RA (n=22, 
34 per cent) compared with the others (n=4, 12.5 
per cent) (P<0.05; X2; df=l). These patients also 
claimed to use allopathic non-prescription 
medicines more frequently than other patients 
(20 compared with five) although this difference 
did not reach statistical significance (P>O.05; X2). 
Duplication of NSAID use was found in seven 
patients, of whom four used two oral NSAIDs si-
multaneously, two used an oral and a topical 
product, and one used two oral and two topical 
products. One patient was taking two paraceta-
mol-containing combination analgesics concur-
rently and three prescribed an opioid were also 
prescribed a combination analgesic. Two pa-
tients were taking purchased paracetamol in ad-
dition to a prescribed combination analgesic 
containing paracetamol. 
Prophylaxis against NSAID-induced gastroin-
testinal ulceration Twenty-six patients were pre-
scribed prophylaxis against NSAID-induced 
gastrointestinal ulceration, as follows: misopros-
tol (3 patients), omeprazole (5), ranitidine (8), 
cimetidine (5) and antacids (7). Some had two 
medications. The daily dose of H -antagonist 
was too low in four patients, antaci;!s were used 
as sole prophylaxis in four patients and one pa-
tient was receiving a treatment dose of omepra-
zole. A further eight patients, six of whom were 
taking NSAIDs regularly or as required, had a 
previous history of gastrointestinal problems but 
were not prescribed any prophylactic therapy. 
Moreover, three patients prescribed prophylactic 
therapy were not taking it at the time of inter-
view, and two of these were continuing to take 
two NSAIDs concurrently. Elderly patients were 
no more likely to be receiving prophylaxis than 
younger patients. 
Monitoring Documentation of biochemical and 
haematological parameters in the GP records 
was very limited, although this information may 
have been available in hospital records. Only two 
of the 71 patients who were prescribed NSAIDs 
had any documentation of renal function testing 
(serum creatinine in both and urinalysis in one). 
Two of these 71 patients were also prescribed 
DMARDs (penicillamine and gold), one was pre-
scribed azathioprine and another patient had 
pre-existing renal impairment. No baseline urea 
and electrolyte and haematology results were 
available in the 15 patients who were taking 
DMARDs, and only eight of these patients had 
documented records of monitoring carried out 
after therapy was initiated. 
The study pharmacist needed to intervene in 
the care of one patient who developed thrombo-
cytopenia due to penicillamine therapy (see 
Table 2). 
Patient knowledge The extent of the patients' ba-
sic knowledge in relation to their therapy was 
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Table 1: Pain scores obtained using McGill pain questionnaire and visual analogue scales in 96 patient with chronic pain 
Patient group Median scores (95 per cent confidence intervals) 
V AS score for V AS score for V AS score for V AS score for PRJ scale PRJ rank NWC PPI 
expectations worst pain average pain pain now 
of pain relief 
All patients at 
80 70 40 30 14.46 14 6 2 interview 1 (n=96) 
(80-90) (60-80) (40-45) (30-40) (11.84-18.34) (10-17) (4-6) (2-2) 
Patients with 
satisfactory outcomes 
40 30 12.80 12 5 2 at interview 1 (n=68) 70 60 
(70-80) (60-70) (30-40) (30-40) (10.28-15.25) (10-14) (3-6) (2-2) 
Patients with poor 
outcomes at interview 1 
(n=28) 90 80 55 50 22.45 21 8 2 
(80-100) (60-90) (40-70) (30-60) (14.14-29.45) (15-26) (6-11) (2-3 
Patients with poor 
outcomes before 
intervention -
interview 1 (n=14) 85 80 65 50 22.96 21 8 2 
(60-100) (50-100) (40-80) (30-70) (14.94-43.57) (13-35) (6-15) (2-3 
Patients with poor 
outcomes after 
intervention -
interview 2 (n=14) 80 70 50 40 20.79 19 7 2 
(80-100) (70-90) (50-60) (30-60) (11.70-38.99) (9-31) (5-13) (2-3 
generally found to be good. Most (91 per cent) Thirty-nine reactions to DMARDs were iden-
identified all prescribed medication, its indica- tified by patients. Again gastrointestinal prob-
tion and dosing frequency correctly, 98 per cent lems were commonest (10 patients) followed by 
correctly identified the number of dosage units rash (seven patients) and blood abnormalities 
they should take, but 40 per cent did not know (four patients). Constipation was the commonest 
the strength of all their medication. All patients problem identified with opioids and combination 
taking paracetamol or combination analgesics analgesics, being cited by 17 patients, followed 
were aware of the maximum dose allowed. Six by dizziness or drowsiness (11 patients) and nau-
patients admitted to taking their NSAID on an sea (four patients). Side effects were reported by 
empty stomach, including one patient taking two significantly more patients with RA than those 
NSAIDs concurrently. Two patients took peni- with back pain or OA (55 compared with 18) 
cillamine after food. (P<0.05; X2; df=I), but this was not related to the 
A total of 57 patients (59 per cent) had re- number of drugs being taken, as the number did 
ceived an information leaflet about one or more not differ between patient groups. 
of their prescribed medicines, mostly from hos-
pital clinics or as package insens. Fifty-five of Pain measurement and satisfaction Using the 
these had read the leaflet; 28 patients had found MPQ, the most common words selected were 
it useful for finding out how their medicine from the sensory category, notably throbbing (49 
worked and 39 had found it useful for identify- patients), aching (49 patients), gnawing (46 pa-
ing potential side effects. tients), sharp (30 patients) and shooting (25 pa-
tients), but 52 patients also selected tiring from 
Adverse effects Of the 96 patients, 73 (76 per the affective category. Using the VAS, the medi-
cent) claimed to have experienced at least one an score for expectation of pain relief was 80 per 
side effect at some time which they attributed to cent (Table 1). Table 1 also shows median VAS 
their therapy. A total of 175 potential adverse ef- scores for average and worst pain over the pre-
fects were identified by the patients, a rate of 1.8 vious month and pain at time of interview, which 
per patient. Sixty-six patients claimed to have ex- indicate that patients did experience pain despite 
perienced an adverse effect to NSAIDs, citing 72 analgesic therapy. 
problems in total, of which the commonest were From the verbal descriptor scales, 29 patients 
gastrointestinal symptoms (74 per cent), includ- expected complete pain relief and 62 expected 
ing four bleeds. Only one of these 72 problems very good pain relief. However only 10 patients 
was not a reported adverse effect to NSAIDs. claimed to obtain complete relief and 36 at least 
The four patients who had experienced a bleed 75 per cent relief. Only six patients were com-
varied in age (range 49-80 years). The two old- pletely satisfied with their pain control, 41 were 
est of these four were still using NSAIDs, one still very satisfied, 44 were moderately satisfied and 
taking high doses of two NSAIDs concurrently five were dissatisfied. 
with no GI protection and the other using a top- Pain relief indices and number of words cho-
ical NSAID as required with antacid cover. sen from the MPQ (PRI[S], PRI[R], NWC) were 
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Table 2: Problems identified by pharmacist, actions taken by GP and changes in pain scores in 14 patients with poor pain outcomes 
Pain Problems identified by pharmacist: Action taken by GP VAS PRI(S) PRI(R) NWC PPI 
diagnosis changes changes changes changes changes 
OA Four NSAIDs prescribed, patient wanted to limit NSAID 
therapy and described dyspepsia: One NSAID continued, 
GI problems reviewed - no ulcer, misoprostol stopped, 
low dose aspirin monitored -30 -3.5 -4 -1 -1 
OA Stomach and arthritic pain, taking two NSAIDs concurrently, 
possible haematemesis: Diflunisal stopped, regular co-codamol 
nJc and naproxen continued, haematemesis unconfirmed -20 +5.7 +4 +2 
RNOA Increased pain, requested alternative therapy - already on 
DMARD, NSAID discontinued due to rash: 
DMARD changed, NSAID to be reintroduced cautiously -20 -lOA -12 -4 -1 
RA Thrombocytopenia with reduced penicillamine dosage, 
nose bleeds - on oral steroids and NSAID: 
Penicillamine discontinued, analgesia changed to co-proxamol nJc +0.7 nJc nJc nJc 
RA Patient keen to conceive and discontinue DMARD, 
requested safflower therapy: Penicillamine discontinued, 
safflower therapy commenced +20 -2.1 -1 -2 nJc 
RA Marked depression due to RA and recent bereavement-
not keen to start DMARD, on NSAID: Hydroxychloroquine 
commenced and a support group recommended nJc -3.3 -4 -2 nJc 
RA Reluctant to restart DMARD, depressed and keen 
to try alternative therapy: Sulphasalzine restarted and 
commenced on homoeopathy +10 +22.2 +21 +7 +1 
RNOA Patient requested to try alternative therapy - on gold 
injectionJNSAID: Existing therapy continued 
with a trial course of alternative therapy +30 -504 -3 -3 +2 
RA Patient requested improved pain relief and a change in DMARD: 
Therapy changed from sulphasalazine to penecillamine nJc -30.1 -21 -9 -2 
RA* Awaiting hip surgery, requesting homoeopathy, taking 
co-dydramol: No change in analgesia, surgery 
performed and homoeopathy started -40 -2.7 -1 -1 -1 
RNON- Increased pain, inappropriate allopurinol therapy: 
gout* No change was made to medication +30 +1.1 +1 nJc nJc 
Back Increased pain, requesting alternative therapy, 
pain on co-proxamol: Physiotherapy given, co-proxamol 
changed to dihydrocodeine 
-30 -3.9 -4 nJc -1 
RNOA Increased RA and GI pain, on NSAID, previous GI 
history: Omeprazole initiated - no ulcer, 
low dose ibuprofen commenced -20 -0.5 -1 -1 nJc 
OA Poor pain control, required physiotherapy: Referred 
to practice physiotherapist -30 -29.7 -32 -8 -1 
OA = osteoarthritis; RA = rheumatoid arthritis; - = decrease in pain scores at interview 2; + = increase in pain scores at interview 2; n/c = no change in pain scores 
at interview 2; 'GP did not fully implement pharmacist's recommendations in these patients 
highly correlated with each other (r2=0.941-
0.960, P<0.001), although the VAS scores and 
the PPI scores were less well correlated with each 
other and with the other three pain measures 
(r2=0.168-0.4 76, P<O.OOl). 
Patients with poor outcomes Twenty-eight (29 
per cent) patients had poor outcomes fulfilling 
one or more of the pre-set criteria. Six had poor 
pain control in terms of VAS average scores 
greater than 75mm, five were at high risk of or 
had developed side effects, 14 were generally dis-
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satisfied with their treatment and five specifical-
ly requested alternative management. Twenty-
one of the 28 had RA with or without OA, but 
there was no significant difference in frequency 
of poor outcomes between diagnostic groups. In 
these 28, both expectations of pain relief and the 
mean VAS pain scores and pain indices from the 
MPQ were high compared with those of patients 
with satisfactory outcomes at interview 1 (Table 
1). The six with poor pain control (VAS for av-
erage pain greater than 75 per cent) also had 
higher pain indices as measured by the MPQ. 
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Action taken by pharmacist Suggestions for 
changing therapy were discussed with the GPs 
for 24 of the 28 patients by the study pharma-
cist. The remaining four required surgical man-
agement rather than changes to medication. 
Twelve further patients were referred to their GP 
because of inappropriate or duplicated therapy 
(13 problems), despite not having poor out-
comes. In addition, advice was given to 59 pa-
tients by the pharmacist, the purpose being to 
improve efficacy of prescribed therapy (28 cas-
es), to improve compliance (24 cases), to min-
imise adverse effects (28 cases) or to improve 
knowledge of medicines (24 cases) or disease 
states (11 cases). 
Ten of the 24 who required follow-up to as-
sess the outcome of pharmaceutical intervention 
refused, were unavailable (seven) and too sick 
(three) for re-interview within the study period. 
The average pain scores for the 14 remaining pa-
tients before and after intervention are shown in 
Table 1. On follow-up, changes to therapy had 
been made in 12 cases, most being in line with 
the pharmacist's recommendations (Table 2). 
Pain scores (VAS, PRI[S] or PRI[R] scores) de-
creased in nine of these patients. 
Discussion 
Evidence-based guidelines are available for the 
management of patients with chronic pain asso-
ciated with RA, OA and back pain. 19-21 Howev-
er, many patients in this study were receiving 
treatment which was not in line with these guide-
lines. Only half of the patients who were receiv-
ing regular prescribed medication for these 
conditions were very or completely satisfied with 
their therapy. This was reflected in a high use of 
non-prescription analgesics (in 26 per cent of pa-
tients) and alternative therapies (in 27 per cent), 
particularly in patients with RA, and in poor 
pain scores measured using standard techniques. 
Other workers have also found that patients 
are increasingly buying non-prescription anal-
gesics in addition to, or in preference to, pre-
scribed analgesics7,22,23 or using alternative 
therapies,s suggesting that pain relief and/or pa-
tient satisfaction is less than optimal. The results 
obtained here confirm this suggestion. Patients 
with chronic pain who are referred to pain clin-
ics often under-report their consumption of anal-
gesics and have problems associated with 
inappropriate use of medicines, side effects, in-
teractions and dependency on analgesics.24,25 
Conversely, patients with RA often under-treat 
their pain.23 There is thus potential for pharma-
cist input into the management of these patients. 
A very high proportion of patients in this study 
claimed to have experienced side effects, yet 
there was also duplication of therapy in many 
cases, which is of concern. In addition, many pa-
tients reported they were following a different 
regimen from that documented in their medical 
records, which does not assist the review process 
and reduces the likelihood of poor pain control 
being recorded and being adequately managed. 
A further difficulty for medication review was 
the lack of information in the general practice 
records concerning monitoring of therapy. Al-
though this information may have been con-
tained in hospital records, evidence of 
monitoring having been carried out was scant. 
Explicit shared care schemes could help to ad-
dress these problems. 
NSAIDs are one of the groups of medicines 
identified as being over-prescribed in the UK.9 
The elderly, in particular, are at increased risk of 
gastrointestinal adverse effects and renal impair-
ment, yet the elderly are often prescribed these 
medicines for OAS with little evidence of review. 
Many patients claim to find benefit from 
NSAIDs,s but require protection from their ad-
verse effects.26 In this study, four patients were 
found to be taking two oral NSAIDs concur-
rently, of whom three experienced gastrointesti-
nal side effects and were referred to the GP, and 
many were prescribed these drugs for os-
teoarthritis with no evidence of inflammation 
identifiable at the time of interview. 
Despite extensive use of analgesics and other 
therapies, pain relief was less than optimal in a . 
substantial proportion of patients, with 29 per 
cent of patients requiring referral to their GP and 
61 per cent requiring advice. The pharmacist was 
able to provide information to optimise therapy 
in a high number of patients who did not require 
prescription changes, despite patients generally 
having a good basic knowledge of their 
medicines. Many of these patients had reduced 
their analgesic consumption and were not using 
their medicines regularly to obtain maximum 
benefit. A further 12 patients required referral 
because of inappropriate therapy. Thus the study 
demonstrates the potential value of pharmacist 
input into managing pain therapy whether or not 
patient outcomes were satisfactory. This was fur-
ther illustrated by the improvement in pain 
scores in a small number of patients who were 
reinterviewed after therapy changes were made. 
This could usefully be further investigated using 
a control group to minimise any effect of a domi-
ciliary visit and including an evaluation of out-
comes which is independent of the pharmacist 
making the interventions. 
Patients should be involved in treatment deci-
sions and need to agree on a therapeutic strate-
gyp particularly for conditions in which they are 
most able to monitor efficacy, such as chronic 
pain. For this to lead to optimal use of analgesics, 
patients need to be given information about the 
potential benefits of regular therapy and how to 
minimise adverse effects, and told which 
medicines can usefully be combined and which 
should not. Other work has shown that patients' 
knowledge of DMARDs is generally good, but 
only 54 per cent know why they have to under-
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go monitoring and 29 per cent could not name 
one potential side effect of their DMARD thera-
py.13 Despite this, many patients have voiced the 
desire for more information, particularly about 
side effects.28 
This study has demonstrated a need for phar-
maceutical input into the management of pa-
tients with chronic pain. The use of recognised 
methods of pain measurement enabled the iden-
tification of patients with poor outcomes in 
terms of pain control, of whom few expressed 
dissatisfaction with their therapy. Both the 
McGill pain questionnaire and the visual ana-
logue scales are simple to use and their reliabili-
ty has previously been shown. (While the MPQ 
may be limited in its usefulness in community 
pharmacy practice, a shortened version has been 
developed29 which remains to be validated in pri-
mary care settings.) Both were sensitive to 
changes in pain following changes in therapy ini-
tiated by the pharmacist. The use of such tools 
should be encouraged, to enable pharmacists to 
demonstrate their input into patient care on a 
routine basis. 
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